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Introduction 
 
1.1 General introduction and goal of the study 
1.2 Noncompaction cardiomyopathy 
Adapted from:  
Noncompaction cardiomyopathy 
Yvonne M. Hoedemaekers, Kadir Caliskan, Danielle F. Majoor-Krakauer. 
Textbook CLINICAL CARDIOGENETICS From basic science to clinical medicine. 
Springer 2010. 
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1.1 Introduction 
The first reports of familial cardiac disorders appeared over 60 years ago.1-3 Since then, 
knowledge on cardiogenetic disorders has increased tremendously. And now cardiogenetics is 
a rapidly expanding field, including the familial cardiomyopathies, arrhythmias, congenital heart 
diseases and cardiovascular disorders. Most of these disorders have an autosomal dominant 
inheritance pattern. In the last decade many genes involved in these disorders have been 
identified and more discoveries are sure to follow. 
The growing insight in the genetic conditions of the cardiovascular system has led to a 
substantial increase in the number of patients referred to clinical genetic departments for 
genetic counselling and DNA diagnostics. Close collaboration of departments of cardiology and 
genetics resulted in the initiation of multidisciplinary cardiogenetic outpatient clinics to provide 
the optimum care and facilitate family studies of hereditary cardiologic conditions. This way 
family studies of more and more adult patients could be initiated which led to increasing 
numbers of at risk relatives visiting the cardiogenetic units. Similarly, the cardiogenetic units 
were involved in counselling and family studies of the families of paediatric patients. Over the 
years the total number of cardiogenetic counselling sessions rose from 53 in 2000 to 482 in 
2008 at the department of clinical genetics of the Erasmus Medical Centre in Rotterdam (Figure 
1). In 2007 that number made up 12.6% of the total number of counselling sessions in 
Rotterdam. 
This is not only a local trend, it is observed nationwide. According to the numbers of the Dutch 
Society of Clinical Genetics (VKGN) the number of cardiogenetic counselling sessions rose 
from 538 in 2000, representing 4.5% of the total amount of counselling sessions, to 3216 in 
2008, rising to 11.8% of all counselling sessions (Figure 2). 
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 Figure 1. Amount of cardiogenetic and other counselling sessions at the department of clinical 
 genetics of the Erasmus Medical Centre in Rotterdam during the period 2000 – 2008. 
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Figure 2. Genetic counselling according to subject in the Netherlands during the period 2000 – 
2008. (Source: VKGN) 
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Since 2005 the most frequently counselled disorders at the cardiogenetic clinic are the 
cardiomyopathies, making up 71% of the cardiogenetic counselling sessions in Rotterdam in 
2007 with hypertrophic cardiomyopathy at a firm first place (HCM; 50%) and noncompaction 
cardiomyopathy  in second position (NCCM, 14%) (Figure 3). Approximately 27 % of the 
counselling sessions concern congenital structural heart defects in adults or children. The 
proportion of counselling sessions for familial arrhythmias, i.e. long QT syndrome (LQTS), 
Brugada syndrome, catecholaminergic induced polymorphic ventricular tachycardia (CPVT), 
Wolf-Parkinson-White syndrome (WPW), short QT syndrome (SQTS), idiopathic ventricular 
fibrillation, familial atrial fibrillation, atrial stand-still syndrome, familial conduction disease and 
sick-sinus syndrome, is smaller than the cardiomyopathies and structural heart defects,  
reflecting partly the lower prevalence of these disorders and perhaps also because there is less 
awareness of the genetic contribution to these disorders among the referring physicians. 
Genetic counselling and diagnostics of other cardiovascular diseases, like familial 
hypercholesterolaemia and familial thoracic and abdominal aneurysms complete the spectrum 
of disorders counselled at the cardiogenetic clinic. 
This dissertation focuses on genetic family studies of noncompaction and hypertrophic 
cardiomyopathy. 
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Figure 3. Different cardiogenetic subjects counselled in the period 2000-2008 at the Erasmus 
Medical Centre. 
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1.1.1 Goal of the study 
Noncompaction cardiomyopathy is a relatively newly discovered cardiomyopathy. Although 
several genes associated with NCCM have been identified and therefore the heterogeneity of 
NCCM, the exact genetic origin and heredity of NCCM are not as well established as those of 
hypertrophic cardiomyopathy. Since both diseases can co-occur within the same family, a 
common pathway might be expected. 
Identifying NCCM as a genetic disorder and finding the genes involved in the development of 
the specific features of NCCM is important because it enables accurate identification of 
relatives at risk of developing a cardiomyopathy, who may benefit from early monitoring and 
treatment to reduce morbidity and mortality. It is equally important that DNA diagnostics allow 
reliably excluding the familial predisposition in at risk relatives. This way relatives who are not at 
risk can be reassured and discharged from periodic cardiologic follow-up.  
Hypertrophic cardiomyopathy is genetically heterogeneous. Depending on the amount and 
choice of genes examined and the examined population, DNA diagnostic strategies may 
identify the genetic cause in over 60 - 70% of HCM cases, indicating that in approximately 30 - 
40% the genetic defect for HCM remains unidentified, and as a result presymptomatic DNA 
analysis of relatives is not possible.  
The genetic heterogeneity of both HCM and NCCM and the elaborate intrafamilial variability 
warrant genotype-phenotype relationship studies. This thesis aims to identify familial NCCM 
and its genetic causes, to find additional genes involved in hypertrophic cardiomyopathy and to 
establish genotype-phenotype relationships. 
 
1.1.2 Outline 
Part 1 of this thesis focuses on the genetic aspects of NCCM. Chapter 2 presents the first 
report of the identification of cardiac-myosin heavy chain (MYH7) defects in two families with 
noncompaction cardiomyopathy, linking non-compaction to hypertrophic, restrictive, and dilated 
cardiomyopathies. Chapter 3 describes the results of cardiologic family studies in a large 
cohort of NCCM patients, consisting of 49 adults and 9 children. The cardiologic family studies 
were performed according to the guidelines for family screening in HCM, as described in 
chapter 8. Chapter 4 presents the broad genetic spectrum as well as the mutation spectrum of 
NCCM yielded by investigating a large number of genes. Here the diagnostic implications of 
DNA analysis in NCCM are discussed as well. Focus on rare occasions of prenatal sonographic 
detection of NCCM is presented in chapter 5 of this thesis, reporting the first two prenatal 
NCCM cases with a known genetic defect and presenting a review of previously described 
sonographic prenatal diagnosis of NCCM. Chapter 6 describes the results of linkage analysis in 
a large NCCM family indentified by an aborted sudden cardiac death in the proband 
participating in the 2007 Rotterdam marathon. Next, chapter 7 deals with the subjects of 
compound heterozygousity for truncating mutations in the myosin binding protein C gene 
(MYBPC3) leading to NCCM. 
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In part 2 the focus shifts to the genetic aspects of hypertrophic cardiomyopathy. Chapter 8 
discusses the screening and genetic counselling as performed in the cardiogenetic outpatient 
clinic of the Erasmus Medical Centre in Rotterdam. In chapter 9, evidence is given for a more 
severe phenotype caused by MYBPC3 mutations than previously reported. Chapter 10 
discusses four-and-a-half-LIM domain (FHL1) gene mutations as a rare cause of familial 
hypertrophic cardiomyopathy. The FHL1 gene is known to be associated with myopathies.  
In literature a more severe phenotype is sometimes attributed to the co-occurrence of several 
genetic defects. In chapter 11 the results of screening for a second or third genetic sarcomere 
defect in a cohort of severely affected and in a cohort of mildly affected HCM patients are 
presented. Chapter 12 investigates the role of cardiac aldosteron as a modifying factor in HCM 
patients. Chapter 13 recapitulates the results described in this thesis and comments on their 
significance and implications for daily clinical practice. 
 
 
References 
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1.2 Noncompaction Cardiomyopathy 
 
Yvonne M. Hoedemaekers1, Kadir Caliskan2, Danielle F. Majoor-Krakauer1. 
1 Department of Clinical Genetics, Erasmus University Medical Centre, Rotterdam, the 
Netherlands. 
2 Department of Cardiology, Erasmus University Medical Centre, Rotterdam, the Netherlands. 
 
1.2.1 Introduction 
Noncompaction of the left ventricle or noncompaction cardiomyopathy (NCCM) is a relatively 
new clinicopathologic entity, first described by Feldt et al in 1969.1 NCCM is characterised by a 
prominent trabecular meshwork and deep intertrabecular recesses communicating with the left 
ventricular (LV) cavity, morphologically reminiscent of early cardiac development, and is 
therefore thought to be caused by an arrest of normal embryogenesis of the myocardium.2, 3 
Initial presentation includes congestive heart failure, thrombo-embolic events and (potentially 
lethal) arrhythmias, including sudden cardiac death. NCCM may be part of a more generalized 
cardiomyopathy, involving both the morphologically normal and the predominantly apical, 
abnormal LV segments. The cardiologic features of NCCM range from asymptomatic in adults 
to severe congenital forms.4-7 Recently, NCCM was classified by the American Heart 
Association (AHA) as a separate primary, genetic cardiomyopathy, based on the predominant 
myocardial involvement and genetic aetiology.8 The European Society of Cardiology (ESC) 
considers NCCM as unclassified, due to the lack of consensus whether NCCM is a separate 
individual cardiomyopathy or a non-specific morphological trait that can be found solitary or in 
combination with other forms of cardiomyopathy like hypertrophic cardiomyopathy (HCM), 
dilated cardiomyopathy (DCM) or with congenital heart disease.9 The majority of NCCM 
diagnosed in adults is isolated. Non-isolated forms of NCCM are more frequent in childhood 
and may co-occur with congenital heart malformations, or may be part of a malformation or 
chromosomal syndrome.7 The combination of NCCM and neuromuscular disorders is observed 
in adults as well as in children.  
The majority of NCCM, isolated and non-isolated, is hereditary and NCCM appears to be 
genetically heterogenous.10, 11 An important proportion of isolated NCCM in children and adults 
has been associated with mutations in the same sarcomere genes, that are involved in HCM, 
DCM and restrictive cardiomyopathy (RCM).10 Not finding a genetic defect does not preclude a 
genetic cause of NCCM. In approximately half of familial NCCM the genetic defect remains 
unkown.11 Shared sarcomere defects and the occurrence of HCM and DCM in families of 
NCCM patients indicate that at least some forms of NCCM are part of a broader 
cardiomyopathy spectrum. 
 
The literature differentially refers to this form of cardiomyopathy as left ventricular 
noncompaction (LVNC), noncompaction cardiomyopathy (NCCM), noncompaction of the left 
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ventricular myocardium (NCLVM), left ventricular hypertrabeculation (LVHT), spongiform 
cardiomyopathy, embryonic myocardium, honeycombed myocardium, persisting myocardial 
sinusoids, myocardial dysgenesis, ventricular dysplasia or spongy myocardium. In analogy with 
the nomenclature of hypertrophic (HCM) and dilated cardiomyopathy (DCM), the term 
noncompaction cardiomyopathy is preferable. Therefore noncompaction cardiomyopathy, 
abbreviated as NCCM, will be used in this thesis to denote this entity. 
 
Definition 
NCCM is defined by prominent trabeculations on the luminal surface of the left ventricular apex, 
the lateral wall and rarely the septum in association with deep recesses that extend into the 
ventricular wall but which do not communicate with the coronary circulation. It is associated with 
a clinical triad of heart failure, arrhythmias and / or thrombo-embolic events.12, 13 Diagnosis of 
NCCM relies on two-dimensional transthoracic echocardiography and / or cardiac magnetic 
resonance imaging (MRI) (Table 1). Improvements in cardiac imaging techniques have led to 
increased recognition and diagnosis of NCCM. Figure 4 displays echocardiographic and cardiac 
MRI images of two NCCM patients, showing the abnormal segmental trabeculations as the 
hallmark of this new entity.  
Features of noncompaction observed in cardiologic patients and normal controls illustrate the 
necessity of defining criteria in order to differentiate accurately normal physiological 
trabecularisation from NCCM.14 
 
Table 1. Echocardiographic diagnostic criteria for NCCM. 
Ι. Chin et al.2 
Focussing on trabeculae localised at the LV apex on the parasternal short axis and apical views and 
and on LV free-wall thickness at end-diastole NCCM is defined by a ration of X/Y ≤ 0.5 with: 
X = distance from the epicardial surface to the trough of the trabecular recess 
Y = distance from the epicardial surface to the peak of the trabeculation 
ΙΙ. Jenni et al.12 
1. An excessively thickened left ventricular myocardial wall with a two-layered structure consisting of a 
compact epicardial layer (C) and a noncompacted endocardial layer (NC) of prominent 
trabeculations and deep intertrabecular recesses 
2. A maximal end-systolic NC/C ratio > 2, measured at the parasternal short axis 
3. Colour-Doppler evidence of deep perfused intertrabecular recesses 
4. Absence of coexisting cardiac anomalies 
ΙΙΙ. Stollberger et al.15 
1. More than three trabeculations protruding from the left ventricular wall, apical to the papillary 
muscles and visible in a single image  
2. Perfusion of the intertrabecular spaces from the ventricular cavity visualised on colour-Doppler 
imaging 
 
In 1990 the first diagnostic criteria for NCCM by Chin et al. were derived from the observations 
made in eight NCCM patients.2 These diagnostic criteria defined NCCM by the ratio of the 
distance from the epicardial surface to the trough of the trabecular recess (X) to the distance 
from the epicardial surface to the peak of the trabeculations (Y), with ratio X/Y ≤ 0.5. 
More than a decade later Jenni et al. proposed new diagnostic criteria for isolated NCCM, 
consisting of four echocardiographic features: 1) an excessively thickened left ventricular 
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myocardial wall with a two-layered structure consisting of a compact epicardial layer (C) and a 
noncompacted endocardial layer (NC) of prominent trabeculations and deep intertrabecular 
recesses; 2) a maximal end-systolic NC/C ratio > 2, measured at the parasternal short axis; 3) 
colour-Doppler evidence of deeply perfused intertrabecular recesses; 4) absence of coexisting 
cardiac anomalies.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B A 
 
 
Figure 4. Cardiac MRI (A) and echocardiography (B) of a 43-year-old patient illustrating a two-
layered  myocardium with prominent intertrabecular recesses.  
In 2002 Stollberger et al. proposed other diagnostic criteria for NCCM, wherein the diagnosis 
was a function of the number of trabeculations (> 3) protruding from the left ventricular wall, 
apically to the papillary muscles and visible in a single image plane with obligatory perfusion of 
the intertrabecular spaces from the ventricular cavity visualised on colour-Doppler imaging.15 
More recently MRI criteria for NCCM introduced by Petersen et al. indicated that a 
noncompacted / compacted ratio (NC/C) of >2.3, measured in end-diastole, can differentiate 
with sufficient sensitivity between the normal variation of noncompaction of the LV in the 
population, noncompaction in other cardiovascular disorders and NCCM.16 
The most recent classification system of NCCM as proposed by Belanger et al. (2008) included 
dividing noncompaction into four categories (none, mild, moderate and severe) according to 
noncompaction to compaction ratio and the size of the noncompaction area.13 This new 
classification scheme used the following criteria: 1) absence of congenital heart disease, 
hypertrophic or infiltrative cardiomyopathy and coronary artery disease; 2) evidence of 
prominent trabeculations in the apex in any view (noncompacted to compacted ratio does not 
require to be >2); 3) concentration of the noncompacted area in the apex; 4) blood flow through 
the area of noncompaction. 
The Jenni criteria have been the most convenient to work with in daily clinical practice and have 
been most widely applied in studies. However, further efforts to reach universal consensus with 
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respect to the diagnosis of NCCM are clearly needed. A disparity in diagnosis has been 
observed when comparing the application of three different sets of NCCM criteria (Chin, Jenni 
and Stollberger) in a cohort of 199 heart failure patients; 79% fulfilled the Chin criteria, 64% 
fulfilled the Jenni criteria and 53 % the criteria proposed by Stollberger. In only 30% of patients 
there was consensus among the three criteria on the diagnosis. Moreover, 8.3% of normal 
controls fulfilled one or more criteria with a higher prevalence in black controls.14 
For now, it is disputable whether any of these diagnostic criteria are sufficiently sensitive to 
diagnose patients with mild noncompaction, and identify patients who may benefit from careful 
surveillance. For instance, in NCCM family studies a substantial proportion of (mostly 
asymptomatic) relatives showed mild to moderate features of NCCM.11 Longitudinal studies of 
mild forms of NCCM will be needed to determine whether the current diagnostic criteria are 
suitable for diagnosis of family members in familial NCCM, or should be adapted in analogy to 
the criteria proposed for diagnosis of attenuated forms of familial HCM in relatives. 
 
Pathology 
Macroscopy 
The noncompacted endocardial layer of the myocardium is comprised of excessively numerous 
and prominent trabeculations with deep intertrabecular recesses that extend into the compacted 
myocardial layer. The apical and midventricular segments of the left ventricular inferior and 
lateral wall are predominantly affected.17, 18 
In a pathoanatomical study of NCCM, Burke et al. described the morphology and microscopy of 
14 paediatric NCCM cases.18 The macroscopic appearance varied from anastomosing 
trabeculae to a relatively smooth endocardial surface, with narrow openings of the recesses to 
the ventricular cavity. Three types of recess patterns were distinguished: 1) anastomosing 
broad trabeculae; 2) coarse trabeculae resembling multiple papillary muscles; 3) interlacing 
smaller muscle bundles or relatively smooth endocardial surface with compressed 
invaginations, identified primarily microscopically (Figure 5). In this study no morphological 
differences were found between isolated and non-isolated NCCM.18 
Jenni et al described pathology of seven adult NCCM cases.12 The pathoanatomical localisation 
of the noncompacted myocardium corresponded to the echocardiographic findings. Two 
patients also showed involvement of the right ventricular apex.12 
In a review of published pathology of NCCM Stollberger et al. distincted three particular 
morphologic features of NCCM in adults and children: 1) Extensive spongiform transformation 
of the LV. 2) Prominent coarse trabeculations and deep recesses, covered with endocardial 
tissue and not communicating with coronary arteries. 3) Dysplastic thinned myocardium with 
excessive trabeculations.19 The first morphology was frequently associated with other cardiac 
malformations, compared to the second and third. 
In 1987, in an autopsy study of 474 normal hearts of all ages, it was found that prominent 
trabeculations may be observed in as many as 68% of the hearts, although more than three 
trabeculations were only identified in 3.4%.20 
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 Figure 5. NCCM gross pathology with a variety of NCCM patterns: 
A. Anastomosing broad trabeculae 
 B. Coarse trabeculae resembling multiple papillary muscles 
 C. Interlacing smaller muscle bundles resembling a sponge 
D. Trabeculae viewed en face  
E. Subtle NCCM on gross section, requires histological confirmation 
  
 Reproduced with permission from “Left ventricular noncompaction: a pathological study of 14 cases; Burke 
Human Pathology 2005;36;403-411” 
 
et al; 
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Microscopy 
Two patterns of myocardial structure in the superficial noncompacted layer in NCCM have been 
described by Burke et al.:1) anastomosing muscle bundles forming irregularly branching 
endocardial recesses with a staghorn-like appearance; 2) multiple small papillary muscles, 
resulting in an irregular surface appearance (Figure 6).18 In most patients, these patterns 
overlapped. Endocardial fibrosis with prominent elastin deposition was found in all 14 cases 
and subendocardial replacement fibrosis, consistent with microscopic ischemic infarcts, was 
present in 10.18 Right ventricular involvement was identified in 6 cases.18 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Histological features in NCCM 
The ratio of noncompact versus compact myocardium is larger than two. 
 A. Relatively smooth endocardial surface (left) with anastomosing broad trabeculae. 
 
B. Polypoid pattern of trabeculae; prominent fibrous band separating the noncompact from the compact 
myocardium. 
  
 
 
Reproduced with permission from:  “Left ventricular noncompaction: a pathological study of 14 cases; 
Burke et al; Human Pathology 2005;36;403-411” 
Histological examination in another study showed that ventricular endocardium covered the 
recesses in continuity with the LV cavity and identified ischaemic lesions in the thickened 
endocardium and the prominent trabeculae.12 Interstitial fibrosis ranged from absent to severe. 
No fibre disarray was identified in any of these cases. Signs of chronic inflammation and 
abnormalities of intramyocardial blood vessels were present in some patients.12 
In one adult case report abundant extracellular matrix and myocardial fibre disarray were 
reported.21 
Freedom et al. proposed two criteria for the pathological diagnosis of NCCM: 1) absence of 
well-formed LV papillary muscles and 2) histological verification of more than 50% penetration 
of invaginated endocardial recesses toward the epicardial surface. The endothelium that covers 
the recesses extends close to the surface of the compact layer. The recesses neither 
communicate nor connect with the coronary circulation.22 
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1.2.2 Epidemiology  
Estimates of prevalence of NCCM were derived from large retrospective studies of patients 
referred for echocardiography. Population studies for NCCM have not been performed. In 1997 
Ritter et al identified NCCM in 17 of 37555 (0.045%) patients who had an echocardiographic 
exam.23 Similarly, in 2006 Aras et al reported a prevalence of 0.14% in over 42000 patients and 
in 2008 Sandhu identified definite or possible NCCM in 13 / 4929 (0.26%) patients referred for 
echocardiography.24, 25 Prevalence was much higher (3.7%) in patients selected for a LV 
ejection fraction ≤ 45%.25 Depending on the diagnostic criteria applied, even higher prevalence 
of NCCM (15.8% by Belanger; 23.6% by Kohli) were reported recently, indicating that NCCM 
may be more prevalent than previously indicated.13, 14 In line with this are the observations that 
a substantial proportion of patients are asymptomatic, suggesting that true prevalence of NCCM 
may be higher, because asymptomatic patients may go unnoticed in the studies of cardiologic 
patients.11, 13 In a large study on childhood cardiomyopathies, NCCM was the most frequent 
cardiomyopathy after DCM and HCM, with an estimated prevalence of 9% in paediatric 
cardiomyopathies.26 
 
1.2.3 Aetiology and molecular genetics 
The aetiology of NCCM is rapidly being unravelled as more and more genetic defects in 
different genes are found, indicating that NCCM is genetically heterogeneous. Causes for 
acquired NCCM are scarce. One report suggested that candida sepsis was associated with 
cardiologic features mimicking NCCM.27 Currently, genetic defects are identified in 41% of 
NCCM patients (35% of adults and 75% of children).10 Most genetic defects are inherited as 
autosomal dominant traits (Table 2), with exception of rare genetic causes of syndromal NCCM, 
predominantly diagnosed in children. A small proportion of patients has a de novo mutation. 
However, absence of a genetic defect does not exclude a genetic aetiology. By performing 
systematic cardiologic family studies it was shown that no genetic defect could be found in 
approximately half of the familial forms of NCCM, indicating that further studies are needed to 
find additional genetic causes for NCCM.11 
There is evidence that some forms of NCCM are part of a spectrum of cardiomyopathies, 
including hypertrophic, dilated and restricted cardiomyopathy. A shared genetic aetiology 
consisting of genetic defects in the same sarcomere genes, sometimes even with identical 
mutations, has been found in these types of cardiomyopathy. Co-occurrence of NCCM, HCM 
and DCM within families endorses a shared genetic susceptibility to these different forms of 
cardiomyopathy.10, 11 The phenotypic variability of cardiomyopathies within families, including 
variability in age at onset and severity of clinical features, might be explained by additional 
modifying factors, additional genetic variants or defects, or may depend on yet unidentified 
exogenous or systemic factors. 
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Molecular defects in NCCM 
Isolated NCCM has been associated with mutations in 14 different genes (Table 2). Defects in 
sarcomere genes have been identified to be the most prevalent genetic cause occurring in 32% 
of all patients with isolated NCCM.10 In two DNA studies in cohorts of approximately 60 isolated 
NCCM patients mutations were identified in 17 to 41% of the patients depending on the number 
and choice of analysed genes.10, 28 In the study by Dooijes et al of 56 patients the yield was 
slightly higher 41% in all and 50% in case of confirmed familial disease.11 In children with 
isolated NCCM the yield of testing for sarcomere genes was as high as 75%.10, 11 
Over 40 different mutations in sarcomere genes encoding thick (MYH7), intermediate 
(MYBPC3) and thin filaments (TNNT2, TNNI3, TPM1, ACTC) have been described. In particular 
in MYH7, the most frequent NCCM-associated gene, accounting for up to 20% of isolated 
NCCM (19% in adults and 25% in children).10, 28 Fifty percent of the MYH7 mutations currently 
associated with NCCM cluster in the ATP-ase active site of the head-region in the N-terminal 
part of MYH7.10 This is an evolutionary well-conserved region of MYH7. As the ATP-ase active 
site is required for normal force production, impaired force generation might play a role in the 
aetiology of NCCM. Mutations in this region have been associated with NCCM with or without 
Ebstein anomaly.28, 29 Other MYH7 mutations (30%) were found in the C-terminal rod-region of 
the MYH7 protein that plays an important role in the formation of the core of the thick filament. 
Mutations in this region of the gene are more commonly associated with skeletal myopathies. 
Relatively few cardiomyopathy mutations are situated in this region. 
Sarcomere mutations were common causes for NCCM in adults as well as in children.10, 11 
Multiple or compound / double heterozygous mutations were identified in 25% of the children 
and in 10% of the adult NCCM patients.10 HCM complex genotypes have been described in 
7%.30 In HCM, double heterozygousity for truncating sarcomere mutations have been 
previously associated with severe congenital forms mostly inherited in an autosomal recessive 
mode.31-33 In NCCM double mutations were associated with severe disease in two children and 
were also observed in adults.10 Non-sarcomere genetic causes for isolated NCCM include 
mutations in the calcium-handling genes calsequestrin (CASQ2) and phospholamban (PLN), in 
taffazin (TAZ), α-dystrobrevin (DTNA), lamin A/C (LMNA) and LIM domain binding 3 (LDB3), 
potassium voltage-gated channel (KCNH2) and sodium channel type 5 (SCN5A) genes.34-36 
However, mutations in these genes were only rare causes of NCCM in single families.37 
The absence of a mutation in approximately half of familial NCCM could be explained by 
phenotype assignment errors, the involvement of other yet unidentified genes, the presence of 
mutations in non-analysed gene sequences and incomplete sensitivity of the methods used.10 
1.2.4 Pathogenesis 
Mutations in different genes associated with NCCM affect different mechanisms in the 
cardiomyocyte leading to changes that may individually cause NCCM or lead to a common 
cellular disturbance resulting in NCCM. 
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Mutations in sarcomere genes may have their effect through defective force generation (either 
by a dominant negative mechanisms where the mutant protein acts as a “poison polypeptide” or 
by haploinsufficiency); mutated cytoskeletal proteins may lead to a defective force transmission; 
myocardial energy deficits may be the result of mutations in ATP-regulatory genes and a fourth 
possible mechanism is abnormal calcium homeostasis either due to changes in calcium 
availability or myofibrillar sensitivity for calcium.38 
The development of NCCM features might be a compensatory response to dysfunction in one 
of these mechanisms. 
The variable phenotypic expression of (sarcomere) gene mutations leading to different types of 
cardiomyopathy has not been explained. The localisation of the mutations may partly explain 
phenotypic diversity. Another theory is “dose-effect”; the extent of the defective mechanism may 
determine which phenotype develops. Thirdly, there might be independent pathways leading to 
the different cardiomyopathies. Finding identical mutations in different phenotypes suggests a 
role for additional factors, either environmental or molecular. 
 
Isolated NCCM 
The first hypothesis on the pathogenesis of NCCM stemmed from observations that the 
morphology of NCCM was reminiscent of the embryonic stages of cardiac development. 
Consequently it was postulated that NCCM could be the result from an arrest of compaction of 
myocardial fibers.39 Figure 7 illustrates the striking resemblance between NCCM and the 
physiological embryonic noncompaction in the 8th – 10th embryonic week. However, the 
possible mechanisms causing the arrest remain unclear. Epicardium derived cells are thought 
to play an important role in myocardial architecture and in the development of 
noncompaction.40, 41 Mutations in genes involved in myocardial genesis like peroxisome 
proliferator activator receptor binding protein (PBP), jumonji (JMJ), FK506 binding protein 
(FKBP12), transcription factor specificity protein (Sp3), homeobox factor NKX2.5, bone 
morphogenetic protein 10 (BMP10), lead to congenital NCCM in knock out mice.42-46 However, 
in human NCCM no mutations in these genes have been described. 
Until now, there is very little insight in factors that influence the variability in age at onset and 
severity of symptoms of NCCM, or any other familial form of cardiomyopathy. 
In the majority of patients NCCM is diagnosed in adulthood, similar to HCM and DCM, which 
are rarely congenital.47, 48 Of course it could be that in NCCM the lesions detected in adult 
patients were present from birth on, but remained unnoticed until symptoms developed and 
high-resolution cardiac imaging techniques were applied. However, the detection of sarcomere 
defects in NCCM patients may suggest otherwise, since mutations in sarcomere genes are 
known to cause late onset HCM and DCM. Similarly, sarcomere mutations might lead to late 
onset NCCM. Longitudinal cardiologic studies of unaffected carriers of pathogenic mutations 
are necessary to provide insight whether noncompaction may develop later in life. The 
pathogenetic mechanism(s) of sarcomere defects in cardiomyopathies are not fully understood. 
It is possible that the pathological myocardial changes in the adult onset sarcomere related 
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cardiomyopathies are caused by a compensatory response to impaired myocyte function 
resulting from mutations in the sarcomere genes.38, 49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Human embryos at Carnegie stage 16 (A), 
stage 18 (B) and after closing of the embryonic 
interventricular foramen (C). 
During development there is an extensive trabecular layer 
forming the greater part of the ventricular wall thickness 
compared to the extent of the compact layer. 
The trabecular layer becomes compacted and forms the 
papillary muscles of the atrioventricular valves (asterisks). 
 
Reproduced with permission from “The morphological 
spectrum of ventricular noncompaction; Freedom et al; 
Cardiology in the Young 2005;15:345-364” 
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Non-isolated NCCM 
NCCM has been observed in a number of neuromuscular disorders, metabolic and 
mitochondrial disease, congenital malformations and chromosomal syndromes. 
Some of these disorders may share pathogenetic mechanisms with NCCM. Alternatively NCCM 
might be secondary to other cardiac malformations or other malformations or even vice versa. 
Another possibility is that the co-occurrence is coincidental. Congenital heart malformations for 
instance are relatively frequent (birth prevalence 0,008) and may therefore occasionaly coincide 
with NCCM without a mutual aetiology. 
 
Congenital heart disease 
The co-occurrence of congenital heart disease and noncompaction is predominantly observed 
in children. Tsai et al. showed that 78% of 46 children with NCCM had a congenital heart 
defect.7 The large number of structural heart malformations reported in association with 
noncompaction are presented in Table 3, indicating that septal defects, patent ductus arteriosus 
and Ebstein’s anomaly are the most prevalent congenital heart defects in NCCM. 
Increasingly, congenital cardiac malformations (septal defects, Ebstein anomaly, patent ductus 
arteriosus, Fallot’s tetralogy, aortic coarctation and aortic aneurysms) are being reported in 
familial cardiomyopathies (HCM, DCM and NCCM) linked to sarcomere mutations, suggesting 
that these specific sarcomere defects may have been involved in cardiac morphogenesis.11, 29, 
50-54 But since there is rarely more than one patient with a congenital heart defect, even in 
families with multiple cardiomyopathy patients, the association of sarcomere defects and heart 
defects still demands further exploration. 
 
Neuromuscular disease 
Similar to HCM and DCM, NCCM has been associated with neuromuscular disorders. 
Stollberger and Finsterer identified NCCM-like morphological features in Duchenne and Becker 
muscular dystrophy and in myotonic dystrophy.55-58 The gene mutated in Duchenne and Becker 
muscular dystrophy, is part of the dystrophine complex, a complex of muscle membrane 
associated proteins, connecting the cytoskeleton to the surrounding extracellular matrix and 
may also play a role in cell signalling. The dystrophine gene is expressed in skeletal and 
cardiac myocytes. A large proportion of patients and also female carriers have cardiac 
symptoms, including DCM.59, 60 Other genes previously associated with neuromuscular 
disorders, like adult onset myofibrillar myopathy (LDB3 or Cypher/ZASP), limb girdle muscular 
dystrophy (LGMD) (LMNA), scapuloperoneal myopathy (MYH7), myosin storage distal 
myopathy (MYH7) and Barth syndrome (TAZ), have recently been associated with isolated 
NCCM (Table 1 and 4). ZASP, lamin A and C, β-myosin heavy chain and taffazin are all 
expressed in cardiac and in skeletal muscle tissue. ZASP has a function in cytoskeletal 
assembly. Mutations in ZASP can lead to DCM and to skeletal myopathy. Lamin A and C, 
proteins situated in the nuclear membrane, play an important role in maintaining nuclear 
architecture. LMNA mutations have been described in three NCCM patients.11, 61, 62 In one of 
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Table 3. Congenital heart disease associated with NCCM. 
Proportion of CHD Congenital heart disease in NCCM 
In NCCM studies* Case reports
References 
Aberrant origin of right / left subclavian artery 1 / 12 (8%) 1 146, 147 
Absent aortic valve  1 148 
Anomalous pulmonary venous return 2 / 26 (8%)  18, 146 
Aortic coarctation 6 / 204 (3%)  7, 11, 113, 146, 149 
Aortico-left ventricular tunnel  1 150 
Aortic stenosis 2 / 46 (4%) 2 7, 22, 151 
Aortopulmonary window 1 / 21 (5%)  113 
Atrial septal defect 22 / 135 (16%) 3 7, 11, 29, 113, 152, 153 
Atrio-ventricular diverticulum  1 154 
Bicuspid aortic valves 3 / 64 (5%) 3 7, 113, 119, 155 
Bicuspid pulmonary valve 1 / 14 (7%)  18 
Cardiac aneurysms  4 81, 156-158 
Coronary ostial stenosis 1 / 14 (7%)  18 
Cor triatriatum 1 / 46 (2%)  7 
Dextrocardia 2 /58 (3%) 1 1, 7, 146 
Dextro malposed great arteries 1 / 12 (8%)  146 
Dextroversion  1 159 
Double inlet left ventricle 1 / 46 (2%)  7 
Double orifice mitral valve  4 160-162 
Double outlet right ventricle 1 / 54 (2%)  149 
Ebstein’s anomaly 6 / 117 (5%) 10 7, 11, 153, 163-168 
Fallot's tetralogy 1 / 71 (1%) 1 11, 147 
Hypoplastic left heart syndrome 3 / 54 (6%)  149 
Hypoplastic right ventricle 3 / 58 (5%)  7, 146 
Isomerism of the left atrial appendage 4 / 66 (6%) 8 22, 146, 149, 169 
Left sided superior vena cava 1 / 46 (2%)  7 
Mitral valve atresia  1 148 
Mitral valve cleft 2 / 54 (4%) 1 149, 158 
Mitral valve dysplasia 2 / 14 (14%)  18 
Mitral valve prolaps 1 / 46 (2%)  7 
Patent ductus arteriosus 16 / 182 (9%) 1 7, 11, 149, 153 
Persistent left superior vena cava 1 / 14 (7%) 1 18, 157 
Pulmonary atresia 6 / 125 (5%) 1 11, 149, 153 
Pulmonary stenosis 4 / 97 (4%) 1 11, 18, 146, 153 
Pulmonary valve dysplasia 2 / 14 (14%)  18 
Single ventricle 1 / 12 (8%) 1 146, 170 
Subaortic membrane 2 / 55 (4%)  149 
Transposition of the great arteries 1 / 46 (2%) 1 7, 171 
Tricuspid atresia 2 / 54 (4%)  149 
Tricuspid valve dysplasia 1 / 14 (7%)  18 
Ventricular septal defect 23 / 218 (11 %) 3 1, 7, 11, 18, 113, 146, 149, 151, 157 
Legend. *Cumulative number of NCCM patients with congenital heart defect (CHD) described in one or 
more NCCM studies 
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them there was familial LGMD as well as DCM.11 Over 200 mutations have been described in 
LMNA, causing over 20 different phenotypes, including isolated DCM, limb girdle muscular 
dystrophy (LGMD), Emery–Dreifuss muscular dystrophy, Hutchinson–Gilford progeria, partial 
lipodystrophy and peripheral neuropathy. For many of the phenotypes there is no clear 
genotype-phenotype correlation, phenotypes may overlap and different phenotypes are 
associated with single mutations.62 Up to 25% of patients with a LMNA mutation may remain 
cardiologically asymptomatic.63 The β-myosin heavy chain is part of type II myosin that 
generates the mechanical force needed for muscle contraction. Tafazzins have no known 
similarities to other proteins. Two regions of the protein may be functionally significant, one 
serving as a membrane anchor and soluble cytoplasmic protein and the other may serve as an 
exposed loop, interacting with other proteins. 
Table 4 presents a list of neuromuscular disorders in which NCCM has been identified. In 
addition one case of noncompaction in a patient with Friedreich ataxia has been reported.64 
Friedreich ataxia is associated with symmetric, concentric, hypertrophic cardiomyopathy. 
 
Table 4. Neuromuscular disorders associated with NCCM / hypertrabeculation. 
Neuromuscular disorders Gene Inheritance Features Ref. 
Adenosine Monophosphate 
Deaminase 1 
(MADA deficiency) 
AMPD1 AD Exercise-induced myopathy, muscle 
weakness, cramps; prolonged fatigue 
after exertion; benign congenital 
hypotonia 
172 
Becker and Duchenne 
muscular dystrophy 
DMD XR Muscle weakness and wasting; 
hypotonia; waddling gait; 
pseudohypertrophy; cognitive 
impairment; cardiomyopathy; 
respiratory failure 
55-57, 132, 
173, 174 
Charcot-Marie-Tooth 1A 
(HMSN 1A) 
PMP22 AD Distal limb muscle weakness and 
atrophy; distal sensory impairment 
175 
Myotonic dystrophy I DMPK AD Myotonia; weakness; muscle wasting; 
adult cognitive deterioration; cataract; 
arrhythmia 
58, 176, 177 
Myotonic Dystrophy II ZNF9 AD Muscle pain; myotonia; weakness 
(proximal / deep finger / neck flexor); 
cataract; cardiac conduction 
abnormalities; palpitations; 
tachycardia; hypogonadism; frontal 
balding 
178 
Infantile epilepsy-
encephalopathy syndrome 
(Ohtahara syndrome) 
ARX XR Age-dependent epileptic 
encephalopathy with “burst-
suppression” on EEG; physical and 
mental retardation 
179 
Limb girdle muscular 
dystrophy 1B 
LMNA AD Muscle weakness and wasting 
restricted to the limb musculature, 
proximal greater than distal 
11, 132 
Succinate dehydrogenase 
deficiency 
 AR Encephalomyopathy; 
cardiomyopathy; generalised muscle 
weakness; cerebellar ataxia; optic 
atrophy; tumour formation in 
adulthood  
180 
Legend. AD: autosomal dominant; XR: X-linked recessive; AR: autosomal recessive. 
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Syndromes 
NCCM can occur as part of a syndrome in combination with dysmorphic features and other 
congenital malformations. When there are other congenital defects or when there are 
dysmorphic features in a patient, one of the chromosomal defects listed in Table 5 or one of the 
syndromes in Table 6 could be considered in the differential diagnosis. 
 
Mitochondrial 
Mitochondrial disorders often lead to multi-organ disease, including central and peripheral 
nervous system, eyes, heart, kidney and endocrine organs. One of the cardiac features 
observed in mitochondrial disease is noncompaction cardiomyopathy. Cardiac features may be 
the first or only feature in patients suffering from a mitochondrial disorder. In a study of 113 
paediatric patients with mitochondrial disease NCCM was identified in 13%.65 Pignatelli et al 
showed that five of the 36 paediatric NCCM patients who underwent a skeletal muscular 
biopsy, had morphologic and biochemical evidence for a mitochondrial defect, including a 
partial deficiency of complex I-III of the mitochondrial respiratory chain.66 Mutations in 
mitochondrial DNA (mtDNA) and in nuclear DNA have been identified in the mitochondrial 
disorders associated with NCCM.67-69 MtDNA mutations are maternally transmitted, whereas 
nuclear DNA genes involved in oxidative phosphorylation are transmitted as Mendelian traits 
with an autosomal dominant or recessive inheritance.  
 
Miscellaneous 
NCCM has been described in patients with heterotaxy with polysplenia, polycystic kidney 
disease, congenital adrenal hyperplasia, nefropathic cystinosis and myelofibrosis.11, 66, 70-74 
Whether these co-occurrences are coincidental or represent shared aetiologies with NCCM is 
unknown.  
Among the possibly acquired forms of NCCM there are reports about an infectious cause.27 
Recently, an aetiologic role for macro- and microvascular abnormalities was suggested.75-84 
NCCM has also been described in patients with coronary heart disease.85-87 Since coronary 
artery disease is a frequent disorder, this association may well be coincidental. Aortic elasticity 
was significantly altered in a group of 20 NCCM patients (aortic stiffness index of 8.3 ± 5.2).78 
Microvascular abnormalities in NCCM including decreased coronary flow reserve with wall 
motion abnormalities in more extended regions of the myocardium than the noncompacted area 
have been observed.77 In addition, several case studies reported hypoperfusion of the non-
compacted region in NCCM patients using myocardial perfusion SPECT, positron emission 
tomography, Thallium myocardial imaging or MRI.75, 76, 79, 80, 82, 83 It is thought that fibrosis, 
thrombus formation, hypokinesis and necrosis may be the underlying mechanisms of 
hypoperfusion.76, 79, 80  
Other pathogenic hypotheses for NCCM include adaptation to changes in the cardiovascular 
and / or haemodynamic climate; myocardial dissection or tearing of the inner layer of the 
cardiac muscle due to dilatation.19, 22 
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1.2.5 Clinical aspects 
Heart failure is among the most frequent presentations of NCCM, followed by supraventricular 
and ventricular arrhythmias, including sudden cardiac death, and thrombo-embolic events. 
However, as in other cardiomyopathies, there is a great variability in presentation, even within 
families, ranging from a fully asymptomatic course to severe heart failure necessitating cardiac 
transplantation. The age of presentation is also highly variable varying from prenatal and 
neonatal diagnosis to diagnosis at the age of 94 years.6,11, 88-93 Prenatal diagnostic imaging 
detects more often bilateral ventricular hypertrophy / hypertrabeculations than the typical left 
ventricular morphologic changes observed postnatally and in adults (own observation). The 
fourth to fifth decade of life is the median age for diagnosis in adult isolated NCCM, constituting 
a relatively young population in adult cardiologic practice. Many patients remain asymptomatic 
and may be detected due to an asymptomatic heart murmur, or by chance by pre-operative 
cardiac evaluation or medical assessment for insurance or jobs or because they participated in 
cardiologic family screening, after a relative had been diagnosed with NCCM.11, 13 Symptomatic 
patients may present clinical symptoms of dyspnea, fatigue, (atypical) chest pain and / or (pre) 
syncope. NCCM may also present as a peripartum cardiomyopathy.11, 94-96 Review of the 
literature revealed a male to female ratio of almost 2 to 1.19 This gender difference can not be 
fully explained by the occurrence of already known X-linked forms of NCCM. 
Different arrhythmias and conduction disorders may occur in NCCM patients (Table 7). None of 
these arrhythmias is characteristic or pathognomonic for NCCM. Thrombo-embolic events may 
include stroke (cerebrovascular event or transient ischemic attack), peripheral embolism and 
mesenterial thrombosis. 
 
Table 7. Arrhythmia and conduction disorders associated with NCCM. 
Arrhythmia / conduction disorders associated with NCCM Reference 
Atrial fibrillation 15, 113, 203 
Atrioventricular nodal re-entrant tachycardia 204 
Bigemini ventricular extra systole 146 
Complete atrioventricular block 1, 158, 205, 206 
Complete left bundle branch block 109, 146 
Giant P-waves and focal atrial tachycardia 207 
Long QT syndrome 2 135 
Narrow QRS complex 106, 107, 110 
Persistent atrial standstill 208 
Sick sinus syndrome 209 
Sinus bradycardia 153, 210 
Supraventriular tachyarrhythmia 7, 113, 130, 146, 211 
Ventricular fibrillation 106, 205, 212 
Ventricular tachycardia 7, 79, 106, 109, 210 
Wolff-Parkinson-White syndrome 2, 7, 146, 210, 213 
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1.2.6 Differential diagnosis 
The definitive diagnosis of NCCM relies on the morphological features of the LV myocardium, 
as defined by an imaging modality, like echocardiography, MRI, CT or LV angiography. The 
variability in the extent of physiological trabecularisation may complicate distinction of NCCM 
from normal physiological left ventricular trabeculations. Especially in the area around the base 
of the papillary muscles of the mitral valve more trabeculations may be present.  However, in 
the normal heart there is no excessive segmental thickening (due to hypertrabeculation) like in 
NCCM and the thickness of these physiological trabeculations does not exceed the thickness of 
the compact layer. Also the area of noncompaction is larger in NCCM than in physiological 
trabeculations.13  
Secondary forms of (acquired) NCCM may be the result of hypertension, chronic volume or 
pressure overload,97 ischemic heart disease or extreme physical activity (i.e. athletes), leading 
to NCCM like abnormalities. These are referred to as pseudo-noncompaction cardiomyopathy 
or a NCCM look-a-like. Hypertensive patients are diagnostically challenging, because of the 
occurrence of LV hypertrophy due to hypertension. Further studies are needed to confirm 
whether excessive trabeculation is more prevalent in specific ethnic groups, as suggested by 
one study.14 
Furthermore dilated, hypertrophic and ischemic cardiomyopathy may be mistaken for NCCM or 
vice versa, due to prominent trabculations and or abnormal myocardial thickening. Candida 
sepsis with intramyocardial abscesses and intramyocardial haematoma may mimic NCCM.27, 98, 
99 
The neuromuscular disorders, syndromes and chromosomal abnormalities mentioned earlier 
(Table 3-5) should be considered in the differential diagnosis of non-isolated NCCM, especially 
when NCCM occurs in patients with dysmorphism, growth retardation or skeletal muscle 
weakness. 
 
1.2.7 Therapy, follow-up and prognosis 
 
Therapy and follow-up 
Current guidelines for heart failure, arrhythmias, cardiac resynchronisation therapy and ICD 
implantation for primary and secondary prevention are applied for NCCM.100-102 β-Blockers and 
Angiotensin-converting-enzyme (ACE) – inhibitors are the cornerstones of treatment in the 
presence of LV dysfunction and/or arrhythmias. Establishing an expert consensus rapport, 
similar to HCM, based on case reports, small cohorts and clinical registries would be 
recommended since no randomized trials or studies on management of NCCM have been 
conducted, and clear-cut evidence-based clinical guidelines for this disorder are therefore 
missing.103 
An important issue is the use of prophylactic anticoagulants, in view of frequent thrombo-
embolic events. The early case reports and case series emphasised the high risk of thrombo-
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embolism and advised routine anticoagulation therapy. However, a review of 22 publications 
addressing the issue concluded that thrombo-embolic events are rare in NCCM.104 Fazio et al. 
came to the same conclusion.105 Currently, in our hospital anticoagulation therapy is advised 
only in patients with an ejection fraction less than 40% (cut off arbitrary), paroxysmal or 
persistent atrial fibrillation and/or previous thrombo-embolic events. 
Successful cardiac resynchronisation therapy has been described in several NCCM patients, 
leading to left ventricular reverse remodelling and an increase in left ventricular function.106-110  
Heart transplantation has been performed in some NCCM patients with severe heart failure.3, 11, 
23, 111-117 Left ventricular restoration surgery has been reported successful in a single patient.118 
Treatment with an implantable cardioverter defibrillator (ICD) will be discussed further on. 
The indication for cardiologic follow-up depends on individual symptoms and cardiac 
abnormalities. In asymptomatic patients with preserved LV function, annual or biannual 
cardiologic follow-up is recommended, including ECG and echocardiography. If necessary, 
these could be extended with 24-hour-Holter monitoring and exercise-testing. When EF is 
below 50%, β-blocker therapy and ACE-inhibitors should be prescribed, especially when NCCM 
is accompanied by hypertension or arrhythmias. 
 
Prognosis  
Initially, NCCM was reported to have a grave prognosis.2,3,12,19,23,119-125 However, the application 
of new imaging techniques allowing diagnosing NCCM in asymptomatic individuals, suggests 
that the first observations were influenced by selection of the most severely affected individuals. 
It has become clear that prognosis of NCCM is as variable as the prognosis in other 
cardiomyopathies. Even in those with presentation in early childhood, gradual improvement in 
cardiac function may be observed, although in others evolvement to severe heart failure 
requiring heart transplantation does occur.6,88,90,92,126,127 Similarly in some adult patients a rapid 
deterioration of heart function occurs, whereas in others the disease remains stable up to old 
age.89 Malignant arrhythmias leading to sudden cardiac death and heart failure are the main 
indicators of poor prognosis. The establishment of appropriate risk stratification will be an 
important issue in the near future in order to identify patients at risk and to help prevent sudden 
cardiac death. 
 
1.2.8 Risk stratification and indication for ICD 
Patients at highest risk for sudden death are patients who previously experienced (aborted) 
cardiac arrest, ventricular fibrillation and sustained VF. Family history of sudden death, 
unexplained syncope (especially during exercise), abnormal blood pressure response during 
exercise tests, frequent premature ventricular beats on the resting ECG and / or non-sustained 
ventricular tachycardia on Holter monitoring and significantly impaired left ventricular function 
may be considered risk factors. The results from longitudinal studies and the understanding of 
underlying disease mechanisms will hopefully help to gain more insight in the risk factors and 
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allow more appropriate risk stratification.128 Consensus and guidelines for prophylactic ICD 
treatment in NCCM patients are also needed. Regular ICD indications include primary and 
secondary prevention. For secondary prevention, i.e. after a previous episode of aborted 
cardiac death or collapse due to sustained VT or VF, current ICD guidelines advise ICD 
implantation. In the Rotterdam NCCM cohort of 67 patients, an ICD was indicated in 42% 
according the current ICD guidelines (n=28: 21 primary and 7 for secondary prevention). After 
long-term follow-up, appropriate ICD therapy occurred only in patients with secondary 
prevention (n=3). Inappropriate ICD therapy occurred in 33% of the patients with primary 
prevention and in 29% of the patients with secondary prevention.129 In another study, follow-up 
of 12 patients who received an ICD showed overall appropriate therapy in 42% in primary and 
secondary prevention combined.130 In primary prevention 25% of ICD therapy was appropriate 
opposed to 50% in secondary prevention.130 This accentuates the need for further research of 
appropriate risk stratification of sudden cardiac death in patients with NCCM. 
 
1.2.9 Cardiogenetic aspects 
 
Molecular and cardiologic family screening  
Familial NCCM has been estimated to occur in 18 - 71% of adults with isolated NCCM, mostly 
consistent with an autosomal dominant mode of inheritance, indicating the importance of 
informing and examining relatives of patients with isolated NCCM.2, 11, 24, 66, 120, 131-133 Since 
extensive family studies showed that the majority of affected relatives are asymptomatic, 
cardiologic evaluation should include all adult relatives irrespective of medical history. 
Obviously, taking a family history is by itself insufficient to identify familial disease, given the 
high frequency of asymptomatic disease in families.11 In families where a pathogenic mutation 
has been identified, relatives can be offered predictive DNA analysis. In families without a 
pathogenic mutation cardiac family screening remains the method of choice to identify relatives 
at risk of developing symptomatic cardiomyopathy, who may benefit from early treatment. 
Introducing patients to the probability that their disease is genetic and explaining the 
significance of DNA testing especially in those who are unaware of familial disease, requests 
genetic counselling. It is important to explain and discuss risks for relatives and to provide 
support tailored to individual needs and situations. Whether presymptomatic testing is based on 
genetic information or cardiac evaluation makes no difference in this respect. Informing 
relatives includes discussing possible medical, as well as psychological and socio-economical 
consequences of predictive testing (particularly in countries where genetic discrimination by 
insurance companies or employers is not prohibited). Asymptomatic relatives, not anticipating 
to be affected, have to be prepared to cope with a cardiomyopathy or the risk of developing a 
cardiomyopathy and transmitting the genetic predisposition to their offspring. On the other 
hand, patients and at risk relatives need to be informed about possible benefits of early 
diagnosis including suitable treatment and life-style recommendations. 
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Apart from NCCM other cardiomyopathies may co-occur within families, like hypertrophic and 
dilated cardiomyopathy, so cardiac screening should aim at identifying all cardiomyopathies. 
Cardiac screening of relatives may show minor abnormalities not fulfilling NCCM criteria, which 
may be difficult to differentiate from normal physiologic trabecularisation. Hypothetically these 
minor abnormalities might develop into NCCM eventually. Longitudinal studies of patients with 
mild NCCM features are needed to investigate the natural history of these forms of 
noncompaction. 
 
Genotype-phenotype correlations 
Molecular studies of NCCM have thus far shown that there are few recurrent mutations.10 
Therefore it is difficult to establish genotype-phenotype correlations. Additionally, intrafamilial 
phenotypic variability complicates predictions based on an identified mutation. Multiple 
(truncating) sarcomere mutations appear to result in a more severe phenotype with childhood 
onset.10, 11 Multiple mutations identified in adults, mostly also comprise involvement of a non-
sarcomere gene. Adult patients with multiple mutations seem to have more symptoms than 
adults with a single mutation.10, 11 These observations may indicate that the combination of a 
sarcomere mutation and a non-sarcomere mutation causes a less severe phenotype than when 
a patient has two sarcomere mutations. Mutations in DTNA and TAZ seem to transfer the 
strongest predisposition to childhood onset NCCM. 
 
Molecular strategies  
The proposed strategies for the molecular and cardiologic evaluation of NCCM are depicted in 
the flow chart in Figure 8. Extensive genetic screening may lead to the identification of a 
molecular defect in over 40% of isolated NCCM patients and in half of these patients an MYH7 
mutation is found.10 MYH7 gene sequencing should be considered as initial approach, being 
the most prevalent cause for NCCM in adults and children. Further molecular analyses of the 
other genes within the NCCM spectrum, which quantitatively have a relatively modest 
contribution to NCCM morbidity, may be considered when no mutation in MYH7 can be 
identified. Sarcomere gene analysis is also warranted in paediatric patients, given the high 
percentage of sarcomere mutations in this group.10 When an adult or paediatric patient is 
severely affected, screening for a second molecular defect is advised, given the high frequency 
of multiple mutations in NCCM. 
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 Figure 8. Flow chart for family screening in NCCM 
Legend. * including unclassified variants; ** if clinically indicated; *** earlier when symptomatic  
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Summary 
NCCM is a relatively new, genetically heterogeneous, cardiomyopathy. Clinical presentation 
and prognosis range from asymptomatic disease with no or slow progression, to severe 
disabling, rapidly progressive cardiac failure. Initial presentation includes the triad of heart 
failure, (potentially lethal) arrhythmias and /or thrombo-embolism. In adults the majority of 
NCCM is isolated. 
The first clinical presentation of NCCM may occur at all ages, even prenatally. In childhood, 
clinical features are often more severe and NCCM is frequently associated with congenital heart 
defects. The echocardiographic diagnostic criteria as proposed by Jenni et al. are convenient in 
daily practice and currently the most widely applied. The general cardiac guidelines for chronic 
heart failure and ICD’s are suitable and applicable to the NCCM population. 
In as much as 41% of isolated NCCM molecular testing may yield a genetic defect, mostly in 
sarcomere genes. The MYH7 gene is the most prevalent disease gene. The non-isolated forms 
of NCCM are caused by a range of different (rare) genetic defects. Until now in half of familial 
isolated NCCM the genetic defect remains unknown. Genetic defects in a large number of 
sarcomere and other cardiomyopathy genes and in genes primarily associated with skeletal 
myopathies indicate that NCCM may result from a wide range of pathophysiologic mechanisms. 
Shared genetic defects and familial aggregation of NCCM, HCM and DCM indicates that NCCM 
may be part of a broad spectrum of cardiomyopathies. 
The genetic aetiology of NCCM requires that patients and their relatives are offered genetic 
testing and counselling. This may include (predictive) molecular analysis of relatives, when 
applicable, and/or cardiac evaluation of at risk relatives, even when they are as yet 
asymptomatic. 
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1.3 Hypertrophic cardiomyopathy 
1.3.1 Introduction 
Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy in the 
absence of predisposing cardiac conditions (e.g. aortic stenosis) or cardiovascular conditions 
(e.g. long-standing hypertension). It is usually asymmetric and involves the intraventricular 
septum.1 The right ventricle is occasionally also hypertrophic. 
HCM manifestation ranges from asymptomatic disease to progressive heart failure and sudden 
cardiac death. Symptoms vary from individual to individual even within the same family. 
Common symptoms include shortness of breath (particularly with exertion), chest pain, 
palpitations, orthostasis, presyncope, and syncope. HCM frequently manifests during 
adolescence or young adulthood, although it may also develop in infancy, childhood or later in 
life. 
 
History 
In 1958 Teare was one of the first to describe asymmetrical hypertrophy in nine cases of 
sudden death at a young age (14-45 years). Two of these cases were siblings.2 In 1964 
Braunwald et al gave a detailed description of the disease based on a thorough analysis of 64 
cases, both familial and non-familial.3 Braunwald characterised idiopathic hypertrophic 
subaortic stenosis (IHSS) by marked hypertrophy of the left ventricle, involving in particular the 
intraventricular septum (IVS) and the left ventricular outflow tract. Obstruction of left ventricular 
outflow tract was observed and the hypertrophy was most often asymmetric, although 
occasionally concentric hypertrophy could be identified. The papillary muscles were often 
enlarged and the hypertrophy of the IVS often led to deformation of the mitral valve with a 
thickened anterior leaflet. His cohort showed an uneven distribution between the sexes, but in 
familial disease distribution was approximately equal. The women were significantly older than 
the men. Braunwald concluded that at least in some instances IHSS was congenital, although 
the disease could also be acquired. Not all patients were symptomatic; the most common 
symptoms were dyspnoea, chest pain, dizziness and syncope. Heart failure was present in 22% 
of the patients. Braunwald considered IHSS a slowly progressive disease, although sudden 
death may occur at any age. Analysis of the familial cases showed that IHSS transmitted as an 
autosomal dominant trait.3 
Simultaneously Morrow issued a paper on operative treatment of the disease, describing 
ventriculo-myotomy in five patients and ventriculomyotomy combined with resection of a portion 
of the hypertrophied IVS in an additional five patients.4 All 10 patients came from the Braunwald 
cohort. Success rate was 90%, although two patients needed a pacemaker. One patient died 
suddenly, probably due to arrhythmia, eight days post-surgery.4 
The development of M-mode echocardiography in the 1970s facilitated imaging of the anterior 
septum and the posterior free wall, and lead to recognition of the asymmetry of the disease, 
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that was now often called asymmetric septal hypertrophy (ASH). In 1976 Maron was the first to 
describe a cohort of 46 children suffering from ASH.5 31% of the patients died suddenly with an 
annual mortality rate of 4%. Sudden death could not be predicted by evaluating 
symptomatology, electrocardiographic (ECG) abnormalities, heart size, left ventricular ejection 
or upstroke time, magnitude of outflow gradient, or left ventricular end-diastolic pressure. Maron 
concluded that the clinical and haemodynamic spectrum of ASH in childhood is broad.5 
Cross sectional echocardiographic imaging, available since the early 1980s, identified 
hypertrophy in other ventricular segments than the anterior septum.6, 7 
It was Spirito et al that suggested in 1989 that prognosis in HCM may be less grave than 
previously considered.8 Spirito based this suggestion on a study of an outpatient cohort of 25 
patients, comparing them with 3404 patients from 78 studies from referral institutions.  
 
 
Terminology 
Since 1958 different terminology to describe HCM has been used. After muscular hamartoma, 
idiopathic hypertrophic subaortic stenosis (IHSS), muscular subaortic stenosis, asymmetric 
septal hypertrophy (ASH) and hereditary ventricular hypertrophy, eventually hypertrophic 
cardiomyopathy (HCM) is the preferred name. In case of obstruction of the left ventricular 
outflow tract (LVOT) the term hypertrophic obstructive cardiomyopathy (HOCM) is applicable. 
 
 
Diagnosis 
Probands 
Conventional two-dimensional echocardiography is reliable in diagnosing HCM by identifying 
left ventricular hypertrophy (LVH). LVH is often asymmetric but also a diffuse or segmental 
pattern of LV wall thickening associated with a non-dilated and hyperdynamic LV independent 
of presence or absence of LV outflow tract obstruction, can be demonstrated.9 Absence of 
another cardiac or systemic disease (e.g. hypertension, congenital heart disease or exposure to 
drugs known to cause cardiac hypertrophy) is required. HCM was thought to be predominantly 
non-obstructive, only 25% of patients had a sizable resting outflow tract gradient.10-13 With 
exercise though, this percentage increases to 70%.14 
Left ventricular wall thickness (LVWT) smaller or equal to 12 mm is considered normal in adults; 
LVWT of 13-15 mm is generally classified as borderline LVH. LVWT greater than or equal to 15 
mm is enough to establish the clinical diagnosis of HCM in adults.9 In children diagnosis is 
made based on a LVWT two or more standard deviations above the normal population mean 
for body surface area.15, 16 
Apart from establishing LVH, its degree and its location, echocardiography can also provide 
details of the atrial cavities, the mitral valve anatomy and function and can assess systolic and 
diastolic cardiac function. Systolic anterior motion (SAM) of the mitral valve can also be an 
echocardiographic finding.  
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Four types of hypertrophic cardiomyopathy can be distinguished:  
Type 1: hypertrophy is confined to the anterior segment of the ventricular septum;  
Type 2: hypertrophy of both the anterior and the posterior segments of the ventricular septum;  
Type 3: involvement of both the ventricular septum and the free wall of the left ventricle; 
Type 4: involvement of the posterior segment of the septum, the anterolateral free wall, or the 
apical part of the septum.1 
 
Cardiac magnetic resonance imaging (cMRI) is increasingly used in HCM, especially in patients 
with poor echocardiographic imaging. Delayed gadolinium hyperenhancement can be used to 
detect and establish the degree of intramyocardial fibrosis.17 Figure 9 displays an 
echocardiographic and a cMRI image of HCM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The disease process is not confined to cardiac muscle alone. Primary malformations of the 
mitral valve apparatus, such as enlargement and elongation of the mitral leaflets and 
anomalous papillary muscle insertion directly into the anterior mitral leaflet, may lead to 
dynamic LVOT obstruction and/or muscular midcavity obstruction and are present in at least 
two thirds of patients.18, 19 
 
Adult relatives 
Pedigree analysis has revealed that in some families with hypertrophic cardiomyopathy adult 
relatives who carry the familial pathogenic mutation do not always fulfil conventional 
echocardiographic criteria.20 Echocardiographic changes may be mild, sometimes only ECG 
abnormalities are identified and these relatives are often asymptomatic.21 Adult carriers may 
even have a completely normal phenotype. 
In 1997 McKenna et al proposed revised diagnostic criteria in members of families with 
hypertrophic cardiomyopathy, including major and minor criteria based on symptoms, and 
A B 
Figure 9. Cardiac MRI (A) and echocardiography (B). 
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electrocardiographic and echocardiographic abnormalities.22 The criteria are listed in Table 8. 
Presence of one major criterion, or two minor echocardiographic criteria, or one minor 
echocardiographic plus two minor electrocardiographic criteria fulfils the diagnosis of HCM in 
adult relatives of HCM patients. 
 
Table 8. Diagnostic criteria for HCM in adult relatives adapted from McKenna et al.22 
Major criteria 
Echocardiography 
Anterior septum or posterior wall ≥ 13 mm 
Posterior septum or free wall ≥ 15 mm 
Severe systolic anterior motion of the mitral valve (septal-leaflet contact) 
Electrocardiography 
Left ventricular hypertrophy and repolarisation changes 
T-wave inversion in leads I and aVL (≥ 3 mm), V3-V6 (≥ 3 mm), or II, III, aVF (≥ 5 mm) 
Abnormal Q (> 40 ms or >25% R wave) in at least two leads from II, III, aVF, V1-V4 or I, aVL, V5-6 
Minor criteria 
Echocardiography 
Anterior septum or posterior wall 12 mm 
Posterior septum or free wall 14 mm 
Moderate systolic anterior motion of the mitral valve (no septal-leaflet contact) 
Redundant mitral valve leaflets 
Electrocardiography 
Complete bundle branch block or (minor) interventricular conduction defect (in LV leads) 
Minor repolarisation changes in LV leads 
Deep S in V2 (> 25 mm) 
Diagnosis is made when one major criterion or two minor echocardiographic criteria or one minor 
echocardiographic in combination with two minor electrocardiographic criteria are present. 
 
Children 
Charron et al evaluated ECG and echocardiography in the diagnosis of familial HCM in 
genotyped children.23 They concluded that HCM was diagnosed in approximately 50% of 
genetically affected children using conventional ECG and/or echocardiographic criteria (LVWT 
>95% confidence interval on echocardiography; abnormal Q waves, LVH (voltage >95th 
percentile), or marked ST-T changes on the ECG).23 They identified four relevant additional 
diagnostic criteria (QRS axis, left atrium dimension, intraventricular septum/posterior wall ratio, 
E/A wave ratio) so that nearly all children considered as healthy carriers of a mutation (based 
on conventional criteria) could be identified with excellent specificity.23 
 
Pathology 
Macroscopy 
Macroscopically HCM is characterised by cardiomegaly and either asymmetric or symmetric left 
ventricular hypertrophy.24 Figure 10 shows gross pathology of HCM. Many patients show LVH 
that is diffusely distributed, affecting any part of the left ventricle. In approximately 33% 
however, mild wall thickening is localised to a single segment, including the apical form.6, 25-27 
The apical form was first described in Japanese HCM patients, recently it is increasingly 
diagnosed in Western HCM patients as well.28, 29  
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In the classical form, the basal anterior septum bulges 
beneath the aortic valve, leading to narrowing of the 
LVOT.2 Anterior displacement of the papillary muscles 
and the mitral leaflets is seen and beneath the aortic 
valve formation of a sub-aortic mitral impact lesion of 
endocardial fibrosis occurs.30 Few HCM patients show 
symmetric concentric hypertrophy of the left ventricle 
combined with a small ventricular cavity.6, 7, 25 
 
About 5-10% of HCM patients develop resemblance 
to dilated cardiomyopathy with LV wall thinning, 
enlargement of the LV cavity and systolic dysfunction, 
leading to irreversible heart failure.31-33 
 
 
 Figure 10. HCM gross pathology. 
(Source: univadis.nl) Microscopy 
The triad of myocyte hypertrophy, disarray and interstitial fibrosis is pathognomonic for HCM.24, 
30 Myocyte disarray tends to be regional, with oblique and perpendicular myocyte arrangement 
around patches of interstitial collagen, the arrangement pattern can be either pinwheel-like or 
herringbone-like and has no prognostic significance.30 Figure 11 shows myocyte disarray in 
HCM. There is hypertrophy, pleomorphism, and hyperchromasia of the myocyte nuclei. 
Disorganisation of the myofibrillary architecture within the myocyte itself leads to loss of the 
usual parallel alignment of myofibrils.30 
Apart from the triad of hypertrophy, disarray and interstitial fibrosis, arterial dysplasia is also a 
pathological feature seen in HCM. Smooth muscle cell hyperplasia leads to thickening of the 
wall and narrowing of the lumen of the intramural coronary arteries (Figure 12).30 Small vessel 
disease may ultimately lead to fibrosis and may facilitate development of dilated end-stage of 
HCM.31 
1.3.2 Epidemiology 
HCM is the most common genetic cardiac disorder with an estimated prevalence of 1 in 500 
(adult) individuals.34, 35 In routine cardiologic practice however, HCM is relatively uncommon, 
affecting approximately 1% of outpatients.36 
HCM is the leading cause of sudden cardiac death in young athletes in the Unites States, 
accounting for 25 to 33% of these deaths.37 
In a United States paediatric population HCM made up 42% of cardiomyopathy cases, 
corresponding with an annual incidence of 0.47 per 100,000.38 In Australia 25.5% of paediatric 
cardiomyopathies can be attributed to HCM, with an annual incidence of 0.32 per 100,000.39 
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Figure 11. Myocyte disarray in HCM. E 
Myocytes are arranged obliquely and 
perpendicularly around foci of interstitial c
in a: 
ollagen 
A. pinwheel or;  
B. herringbone pattern; 
C. increased interstitial fibrosis (Modified 
Masson’s); 
D. Hypertrophy and distinct nuclear changes 
(hypertrophy, pleomorphism and 
hyperchromasia) of the myocytes;  
E. Myofibrillar disorganization and intersecting of 
myofibrils within individual myocytes 
(Phosphotungstic acid haematoxylin stain). 
 
 
Reproduced with permission from: “The pathology of hypertrophic cardiomyopathy; Hughes; Histopathology 
2004; 44; 412-427.” 
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1.3.3 Aetiology and molecular genetics 
HCM is mainly a disease of the cardiac sarcomere and Z-disc; with mutations in 24 genes, 
mostly coding for sarcomere or Z-disc proteins, it is genetically heterogeneous. Currently, 
genetic defects are identified in 60 - 70% of HCM patients.40 Most genetic defects are inherited 
as autosomal dominant traits.  
Since sarcomere and Z-disc gene mutations are identified in HCM but also in other 
cardiomyopathies, such as dilated cardiomyopathy (DCM), noncompaction cardiomyopathy 
(NCCM) and restrictive cardiomyopathy (RCM) and the occurrence of different types of 
cardiomyopathy within the same family, caused by the same familial mutation, these 
cardiomyopathies might be part of a spectrum with a shared genetic susceptibility to these 
different phenotypes. Additional modifying factors, genetic variants or defects, or yet 
unidentified exogenous or systemic factors might explain the phenotypic variability of 
cardiomyopathies within families, including variability in age at onset and severity of clinical 
features. 
 
Figure 12. Intramural coronary artery dysplasia in 
HCM.  
 
 
 
 
 
 
 
 
 
There is marked medial hypertrophy and narrowing of 
the lumen of the intramural coronary arteries with 
associated myocardial fibrosis (Elastic van Gieson). 
 
Reproduced with permission from: “The pathology of 
hypertrophic cardiomyopathy; Hughes; Histopathology 
2004; 44; 412-427.” 
 
Molecular defects in HCM 
HCM has been associated with mutations in 24 different genes (Table 9). Defects in these 
genes (mostly sarcomere and Z-disc genes) are the most prevalent genetic cause occurring in 
approximately 60-70% of HCM patients.40 
In a study of 84 paediatric HCM patients, 55% had a mutation in one of the genes MYH7, 
MYBPC3, TNNT2, TNNI3, TPM1, MYL3, MYL2, ACTC, PRKAG2 and LAMP2.41 
Over 500 different mutations in sarcomere genes encoding thick (MYH7), intermediate 
(MYBPC3) and thin filaments (TNNT2, TNNI3, TPM1, ACTC) have been described. Most 
mutations are single point missense mutations or small deletions or insertions. Mutations in the 
MYH7 and MYBPC3 genes are the most prevalent, accounting for up to 45 - 65% of HCM in 
adults and over 75% in children.40, 41 
In a cohort of 80 HCM patients 5% had multiple gene mutations which may result in a more 
severe clinical phenotype because of a ‘‘double dose’’ effect.42, 43 Double heterozygousity for 
truncating sarcomere mutations has been associated with severe congenital forms leading to 
cardiac death in early infancy.44-46 
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MicroRNA 
Recently the role of micro-ribonucleic acids (microRNAs, miRNAs or MiRs) in cardiac 
development and (hypertrophic) heart disease is under investigation. MiRNAs are single-
stranded RNA molecules with a length of 21 to 23 nucleotides. They regulate gene expression 
at the posttranscriptional level by targeting messenger RNA (mRNA). Almost all miRNAs and 
especially the miRNA critical region for binding to mRNA (the seed region, spanning 2 to 8 
nucleotides from the 5’ end of the RNA molecule) are highly conserved in closely related 
species.47  
MiRNAs play an important role in cardiac development as well as in orchestrating 
organogenesis and early embryonic patterning processes.48, 49 They also seem to play an 
important role in cardiac remodelling and development of hypertrophy.50-53 Expression of MiR1 
and MiR133 was decreased in patients with HCM.51 
1.3.4 Pathogenesis 
Mutations in different HCM genes affect different mechanisms in the cardiomyocyte, thus 
leading to changes that may individually cause HCM or may lead to a common cellular 
disturbance resulting in HCM. Mutations in sarcomere / Z-disc / Calcium-handling genes may 
have their effect through defective force generation (either by a dominant negative mechanisms 
where the mutant protein acts as a “poison polypeptide”; by domination of a gain of function of 
the mutated protein over normal function; or by haploinsufficiency).54 The mutant protein may 
interfere with normal spatial myofibrillar arrangement; changes in this arrangement may lead to 
misshapen cardiomyocytes.55 Any defect in genes encoding for contractile proteins supports 
this myofibrillary dysgenesis theory. A similar hypothesis is that the genetic defect, being the 
primary abnormality, alters myocardial function. This alteration triggers several growth 
responses leading to myocyte hypertrophy and proliferation of fibrocytes. Environmental and 
other genetic factors may further enhance this process.54 
1.3.5 Clinical aspects 
There is a great variability in presentation, even within families, ranging from a fully 
asymptomatic course to sudden cardiac death and severe heart failure necessitating cardiac 
transplantation. The age of presentation is also highly variable with prenatal and neonatal 
diagnosis to diagnosis at a high age.31 HCM most commonly presents during adolescence and 
young adulthood.56  
A lot of HCM patients are asymptomatic and may be detected due to a heart murmur, or by 
chance by pre-operative cardiac evaluation or medical assessment for insurance or jobs or 
because they participated in cardiologic family screening.31 Symptomatic patients may present 
with dyspnea, fatigue, (atypical) chest pain, palpitations and / or (pre) syncope.  
Exercise intolerance and dyspnoea, dizziness, presyncope and syncope usually occur despite a 
preserved systolic function and a non-dilated LV. Diastolic dysfunction with impaired filling due 
to abnormal relaxation and increased chamber stiffness appear to cause symptoms, and may 
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lead to elevated left atrial (LA) and LV end-diastolic pressures with reduced stroke volume and 
cardiac output, pulmonary congestion, and impaired exercise performance with reduced oxygen 
consumption at peak exercise.9 Diastolic dysfunction does not appear to play a role in causing 
symptoms in patients with LVOTO. They appear to be disabled by elevated LV pressures and 
coexistent mitral regurgitation, as the often dramatic symptomatic improvement after 
therapeutic reduction of the outflow gradient proves.9 Chest pain can present as typical or 
atypical angina pectoris and is probably due to myocardial ischaemia due to arterial dysplasia, 
as the identification of reversible myocardial perfusion defects, scarring on cMRI or at autopsy 
prove.  
Although 75% of HCM patients do not demonstrate left ventricular outflow tract obstruction 
(LVOTO) under resting (basal) conditions, provocation of LVOTO by exercise or stress leaves 
only 30% of HCM patients without obstruction.11-14 Classic signs indicating LVOTO consist of 
dynamic systolic ejection murmur, increasing during the Valsalva manoeuvre, and a bifid pulse. 
“End-stage” disease with systolic dysfunction, dilation of the LV and heart failure occurs in 
approximately 10% of HCM patient that already have severe symptoms.57 In a large study 
comprising 1259 patients, 3.5% characterised as end stage disease with systolic dysfunction 
(EF <50% at rest); developing at a wide age range (14 to 74 years), with 45% of patients ≤40 
years old.58 
 
Arrhythmias 
Re-entrant tachycardias, bradyarrhythmias and supraventricular or ventricular tachyarrhythmias 
may occur in HCM patients, probably due to disruption of the cellular architecture which creates 
an unstable pro-arrhythmic electrical environment.59, 60 Atrial fibrillation (AF) is the most 
common arrhythmia observed in HCM.61 It occurs in 20-25% of HCM patients and is linked to 
left atrial dilatation and advanced age.61, 62 AF in HCM is associated with progressive heart 
failure, stroke and disease progression.62 Other supraventricular arrhythmias include 
tachycardias (SVT), AV block, sinus bradycardia and Wolf-Parkinson-White (WPW). Ventricular 
arrhythmias include premature ventricular depolarisations, ventricular couplets, non-sustained 
ventricular tachycardia (NSVT).63 Ultimately arrhythmias may lead to sudden cardiac death. 
 
1.3.6 Differential diagnosis 
 
Acquired LVH 
Several cardiovascular conditions can lead to left ventricular hypertrophy, for instance 
hypertension, aortic valve stenosis or chronic increase of circulatory volume. In children 
Kawasaki disease can also lead to LVH. 
Physiologic hypertrophy can be caused by LV remodelling due to trained endurance (athlete’s 
heart). Deconditioning of sport activities however should lead to regression of the increased LV 
mass.64  
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Other conditions leading to acquired LVH are obesity, pulmonary disease, infections, drug 
abuse or toxicity of medication, radiation, malignancy, connective tissue or granulomatous 
disease and immunologic or endocrine disease. 
 
Neuromuscular diseases 
Muscular dystrophies, myopathies (congenital and/or metabolic) and ataxias can be associated 
with several types of cardiomyopathy, like HCM, DCM and NCCM. Table 10 represents a list of 
the neuromuscular disorders that can be identified in HCM patients. 
 
Metabolic diseases  
The mechanisms through which metabolic disease can lead to HCM are infiltration (storage 
disease), defective energy metabolism and cardiotoxicity of intermediary metabolites. They are 
listed in Table 11. 
 
Syndromes 
Several syndromes can be accompanied by HCM. They are listed in Table 12 together with 
their dysmorphic and congenital traits.  
 
 
Table 10. Neuromuscular disorders associated with HCM. 
Neuromuscular disorders Gene Inheritance 
Muscular dystrophies   
Becker muscular dystrophy DMD XR 
Duchenne muscular dystrophy DMD XR 
Emery-Dreifuss muscular dystrophy FHL1 XD 
Myotonic dystrophy DMPK XD 
Myopathies   
α-B Cristallinopathy (myofibrillar myopathy with cataract) CRYAB AD 
Distal myopathy MYH7 AD 
Minicore-multicore myopathy SEPN1 AR 
Myofibrillar myopathy DES AR / AD 
Myopathy with postural muscle atrophy FHL1 XR 
Nemaline myopathy ACTA1 AD 
Ataxias   
Combined Charcot-Marie-Tooth peroneal muscular atrophy 
and Friedreich ataxia 
 XR 
Friedreich ataxia FXN AR 
Refsum disease PAHX / PEX7 AR 
Legend. XR, X-linked recessive; XD, X-linked dominant; AD, autosomal dominant; AR, autosomal 
recessive 
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1.3.7 Therapy and prognosis 
 
Therapy 
Treatment of HCM patients depends on the presence of symptoms, LVOTO and risk for SCD. 
Figure 13 shows a treatment algorithm for HCM. 
 
 
HCM 
 
 
 SymptomsNo symptoms High risk SCD
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No medication 
Follow-up 
LVOTO 
(at rest or 
provoked) 
No LVOTO 
(at rest or 
provoked) 
Medication: 
Beta-blocker 
Calciumantagonist 
Diuretica 
Medication: 
Beta-blocker 
Calciumantagonist 
Disopyramide 
 
PTSMA 
 
 
Surgery 
 
Decreased Adequate LVF
Standard 
heartfailure 
treatment 
ICD 
 
Atrial fibrillation 
 
Anticoagulants 
Paroxysmal Chronic 
Therapy resistent 
 Beta-
blockers Amiodarone 
 Calcium 
antagonists 
AV node 
ablation 
 
Heart 
transplant Pacemaker 
Figure 13. Treatment algorithm or HCM. Treatment depends on symptoms and severity of disease.  
Legend. 
HCM = hypertrophic cardiomyopathy; 
LVOTO = left ventricular outflow tract obstruction; 
SCD = sudden cardiac death; 
ICD = implantable cardioverter defibrillator; 
PTSMA = percutaneous transluminal septal myocardial ablation. 
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Most asymptomatic patients do not require treatment, although dilemmas may occur when the 
patient is very young and / or has substantial hypertrophy or other risk factors for SCD. So far 
no evidence is given for prophylactic therapy in asymptomatic HCM patients or in genotype 
positive - phenotype negative carriers. 
In symptomatic patients the initial therapeutic approach is pharmacological, to relieve dyspnoea 
and to improve exercise tolerance. It is the only available treatment option for patients without 
LVOTO and consists of β-blocking agents and calcium antagonists. 
A small group of patients with non-obstructive HCM develops systolic dysfunction and heart 
failure, displaying wall thinning and LV dilatation, due to LV remodelling. Their pharmacological 
therapy differs from patients without heart failure and comprises conversion to afterload 
reducing agents such as ACE inhibitors or angiotensin II-receptor blockers or diuretics, digitalis, 
beta-blockers or spironolactone. Ultimately, patients with end-stage heart failure may become 
candidates for a heart transplant. 
In presence of LVOTO and failure of pharmacological therapy to relieve symptoms the options 
of myectomy or percutaneous transluminal septal myocardial ablation (PTSMA) remain. 
Approximately 5% of all HCM patients in non-referral centres qualify for surgery, whereas in 
tertiary referral centres 30% do.9 LVOT gradients are equal to or higher than 50 mm Hg, 
decreasing to less than 10 mm Hg after surgery. During surgery mitral valve abnormalities can 
also be corrected. Operative mortality is approximately 1-2% and there is over 40 years of 
follow-up of this technique.9  
PTSMA is more recent, first reported in 1995 by Sigwart et al, who injected a small amount of 
absolute alcohol into the first septal branch of the left anterior descending artery to induce a 
small localised myocardial infarction and so producing a chemical myectomy without open heart 
surgery.65 It decreases the LVOT gradient to less than 25 mm Hg and improves exercise 
capacity with a comparable mortality rate to surgery, 1-2%.9 The need for postoperative 
pacemaker therapy is higher than in conventional myectomy, 5-10% opposed to 1-2%.9  
Atrial fibrillation (AF) can be treated pharmacologically with amiodarone, β-blockers and 
calcium antagonists and with cardioversion. AV-node ablation is an option when 
pharmacological therapy fails, as is placement of a pacemaker. As AF can cause thrombo-
embolic events, anti-coagulant therapy should be given if there are no contra-indications. 
 
Pregnancy 
Pregnancy is usually well tolerated by HCM patients. Maternal mortality is low, occurring mainly 
in women with high risk clinical profiles.66 These women should be well monitored throughout 
their pregnancy and specialised obstetrical care should be provided. Most pregnant HCM 
patients however can have an uneventful pregnancy and normal vaginal delivery. 
 
Prognosis  
Life threatening events in HCM consist of sudden cardiac death, embolic stroke and heart 
failure. First reports on prognosis mainly concerned HCM populations from tertiary referral 
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centres with a more severe phenotype and were consequently more pessimistic than 
nowadays, when more reports of large unselected HCM patients are being described. Currently 
the overall annual death rate in HCM is estimated to be approximately 1% a year; risk rate for 
obstructive HCM is approximately 2% per year, with a four-fold greater risk of stroke than in 
HCM patients without obstruction.9, 31, 67 
HCM patients with high LVOT gradients are also at higher risk for severe heart failure.68 
A significant proportion (up to 25%) of HCM patients achieve normal life expectancy (≥ 75 
years).69-72 However, presentation in infancy and young childhood tends to give an 
unfavourable prognosis.9 
Patients presenting with a normal ECG at the time of diagnosis often display a less severe 
phenotype and tend to have better outcomes.73 Apical HCM appears to have a better prognosis 
than other HCM types, although it can be complicated by apical ischemia or infarction with 
aneurysm formation.27 
 
1.3.8 Risk stratification and indication for ICD 
(Aborted) SCD may be the first symptom of HCM in a previously asymptomatic “healthy” 
individual. Often there are no signs of warning. SCD may occur at all times, during sleep, early 
after awakening, in rest or during (or shortly after) physical activity. SCD is more frequent in 
adolescents and young adults (≤ 35 years) but may also occur above that age. HCM is the most 
common cause of SCD in young people.74 Several risk factors and possible risk factors have 
been identified in HCM; they are listed in Table 13. Having two or more of these risk factors 
qualifies as a high risk profile; ICD implantation is advisable in these patients. However, 
approximately 3% of SCD in HCM occurs in patients without any of these risk factors.75 
 
 
Table 13. Risk factors for sudden cardiac death in hypertrophic cardiomyopathy adapted from 
Maron et al. and Sen-Chowdry et al.9, 127 
Major Risk Factors Possible Risk Factors Gene 
Previous cardiac arrest / VF Co-existent obstructive CAD 
Spontaneous sustained VT LVOTO in rest 
Family history (≥1) of SCD Microvascular ischemia 
Non-sustained VT on Holter Previous PTSMA 
Abnormal blood pressure response in exercise "Burnt out" disease 
Unexplained syncope Diffuse late gadolinium enhancement on cMRI 
Maximal LV wall thickness ≥ 30 mm High risk mutation 
 AF 
 Intense physical exertion 
Legend. AF = atrial fibrillation; CAD = coronary artery disease; cMRI = cardiac magnetic resonance 
imaging; LV = left ventricle; LVOTO = left ventricular outflow tract obstruction; PTSMA = percutaneous 
transluminal septal myocardial ablation; SCD = sudden cardiac death; VF = ventricular fibrillation; VT = 
ventricular tachycardia. 
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Risk stratification in HCM patients should take place annually or when there is a change in 
clinical status and should consist of a thorough personal and family history, two-dimensional 
echocardiography (assessment of LVH and LVOTO), 24-hour ECG monitoring (Holter), and 
exercise ECG for blood pressure response.9 
 
ICD implantation is important in primary (based solely on non-invasive risk factors) and 
secondary (following cardiac arrest or spontaneous and sustained ventricular tachycardia) SCD 
prevention. In a multi-centre retrospective study, ICDs appropriately detected and automatically 
aborted potentially lethal ventricular tachyarrhythmias by restoring sinus rhythm in almost 25% 
of a high-risk cohort, during a three-year period.76 In primary prevention appropriate device 
interventions occurred at a rate of 5% per year and in secondary prevention at 11% per year.76 
ICD functions consist of detecting arrhythmia and delivering appropriate electrical therapy 
accordingly, but they also provide diagnostic information and antibradycardia pacing. A dual-
chamber ICD is therefore preferred in patients with sinus node dysfunction, SVT precipitating 
VT/VF or AF.77  
 
Children 
Several studies to identify risk factors for SCD in paediatric HCM patients have been 
performed. Ostman-Smith et al described SCD in 12.5% of 128 patients and determined that 
ECG voltages (sum of the R and S waves > 10 millivolts) and septal thickness > 190% of the 
95th centile for age were independent predictors of sudden death. Noonan’s syndrome and a 
ratio of the LVW to its cavity in diastole > 0.30 were independent predictors of death due to 
cardiac failure.78  
In a population of 91 paediatric HCM patients Decker et al retrospectively assessed whether 
reported adult risk factors for sudden death are predictive in children with HCM. During a 20-
year follow-up four patients had a heart transplant and seven patients died, of which three died 
suddenly. Extreme LVH and an abnormal blood pressure response to exercise were predictive 
of non-SCD. Survival analysis predicted an 82% survival over a 20-year period.79 Since non-
SCD was more common than SCD in children, they concluded that the identification of risk 
factors for non-SCD is at least as important in children as identifying risk factors for SCD. ICD 
implantation in children to help prevent SCD is safe and has a good medium-term outcome; the 
occurrence of inappropriate shocks is the most serious problem.80 
 
1.3.9 Cardiogenetic aspects 
 
Molecular and cardiologic family screening  
Isolated HCM is familial in the majority of cases. Family history is therefore very important. Not 
only should there be focus on cardiomyopathies and cardiac symptoms such as heart failure, 
sudden unexplained death, conduction disorders or arrhythmia and thrombo-embolic disease 
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e.g. stroke, but also on skeletal muscular symptoms, like myopathy, muscle weakness or wheel 
chair dependence. 
Inheritance mode is autosomal dominant in the majority of cases (exceptions are listed in 
Tables 10, 11 and 12), informing and examining relatives is advisory. Recently Dutch guidelines 
for genetic diagnostics and genetic counselling in HCM were published.81 Age of onset and 
severity of symptoms are highly variable, ranging from prenatal presentation with heart failure to 
asymptomatic disease at a high age.31, 82, 83 Since the age of onset is so variable, a single 
cardiologic examination does not suffice to exclude HCM in a relative. Regular follow up is 
recommended (Table 14). The proposed strategies for family screening in HCM are depicted in 
the flow chart in Figure 14. In families where a pathogenic mutation has been identified, 
relatives can be offered predictive DNA analysis. In families without a pathogenic mutation or in 
relatives who refuse DNA analysis cardiac family screening remains the method of choice to 
identify relatives at risk of developing HCM. 
 
Table 14. Screening guidelines for healthy family members adapted from Maron et al.56 
Age Screening guidelines (physical examination echocardiography and ECG) 
< 12 years Optional 
 Highly recommended when: 
 Positive family history of paediatric onset of HCM / early HCM-related death or other complications 
 Child participates in competitive sports with an intense training program 
 Symptoms are present 
 Other clinical findings that suggest early LVH are present 
12-18 years Regular evaluation with intervals of 12 - 18 months 
> 18 years Regular evaluation with intervals of 3 - 5 years 
 Adjust intervals according to clinical findings and presence of symptoms 
Legend. ECG, electrocardiography; HCM, hypertrophic cardiomyopathy; LVH, left ventricular hypertrophy 
 
When identifying HCM in a relative additional diagnostics (exercise-ECG and 24-hour Holter 
monitoring) should be performed to determine the risks of complications.  
Similar to all genetic disorders, cardiac or other, genetic counselling is vital to explain patients 
that their disease is genetic and to explain the importance of DNA testing to reliably identify 
relatives at risk. Equally, relatives should be well informed about the disease, its risks and 
possible complications, its heredity and the possibilities for testing, either through DNA analysis 
when a familial mutation is known or through cardiac screening. Medical, psychological and 
socio-economical consequences of predictive testing should be discussed elaborately in order 
for relatives to make a well-informed decision. Apart from HCM other cardiomyopathies may co-
occur within families, like noncompaction and dilated cardiomyopathy, so cardiac screening 
should aim at identifying all cardiomyopathies.  
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 Figure 
 Legend. Multidisciplinary
14. Flow chart for family screening in HCM.128 
 doctors (un
 
 approach by cardiologist (dashed boxes), clinical genetic nurses and medical 
-dashed boxes); X-ECG = exercise electrocardiography; 24 H Holter = 24 hour Holter 
monitoring. 
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Genotype-phenotype correlations 
After detecting pathogenic mutations that cause HCM, scientists have tried to establish 
genotype-phenotype correlations. Early observations lead to the belief that specific mutations in 
the same gene  are malignant, while others are benign.75, 84-90 HCM due to MYBPC3 was 
thought to be slowly progressive, with a higher age of onset and milder symptoms, whereas 
TNNT2 related HCM was associated with a higher incidence of sudden death, revealing a 
higher extent of myocyte disarray, although hypertrophy was less severe.85, 86, 91-93 The major 
shortcoming of all of these observations was the fact that they were coming form small cohorts 
of patients originating from a few large families. Genotype-phenotype studies in large cohorts of 
unrelated patients have indicated that caution is required when assigning particular prognostic 
significance to any particular mutation.94-96 Mutations previously thought to be benign were 
shown to lead to a severe clinical phenotype and “malignant” mutations did not necessarily lead 
to a severe clinical course. It was also demonstrated that HCM due to MYBPC3 and MYH7 may 
display a similar phenotype, although age of onset may vary.97, 98 In a large cohort of unrelated 
Italian HCM patients risk of cardiovascular death, non-fatal stroke, and progression of disease 
was compared between patients with a genetic defect in one of the genes coding for 
myofilament proteins and patients without a known causative mutation. In patients with a 
mutation risk was significantly increased.99 Several studies have indicated that compound or 
double heterozygousity, identified in up to 5% of familial HCM, leads to a more severe 
phenotype with earlier onset and an increase in sudden death, which suggests that a gene-
dosage effect might contribute to disease severity.42, 43, 45, 100  
 
Molecular strategies  
Extensive genetic screening may lead to the identification of a molecular defect in 
approximately 60-70% of HCM patients, with an MYH7 or an MYBPC3 mutation in the majority 
of cases.40, 98, 101  
MYBPC3 and MYH7 gene sequencing should be considered as initial approach, being the most 
prevalent cause for HCM in adults and children.41 Further molecular analyses of the other 
genes within the HCM spectrum (Table 9), which quantitatively have a relatively modest 
contribution to HCM morbidity, may be considered when no mutation in the MYBPC3 or MYH7 
gene can be identified.81 When an adult or paediatric patient is severely affected, screening for 
a second molecular defect is advised, given the possibility of compound or double 
heterozygousity in HCM. 
 
Summary 
HCM is the most frequent cardiogenetic disorder and is genetically heterogeneous. Clinical 
presentation ranges from asymptomatic disease, with no or slow progression, to severe, 
disabling, rapidly progressive cardiac failure. HCM displays a high intra- and interfamilial 
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variability. It can present with (symptoms of) heart failure or arrhythmias and even SCD. A 
substantial proportion of HCM patients is asymptomatic. HCM occurs at all ages, from prenatal 
presentation to onset at a high age.  
In up to 70% of HCM molecular testing may yield a genetic defect, mostly in the MYBPC3 and 
MYH7 genes. The genetic aetiology of HCM requires genetic counselling and testing of patients 
and their relatives, who are offered (predictive) molecular analysis and/or cardiac evaluation.  
HCM may also be caused by mitochondrial defects and is associated with several syndromes 
and neuromuscular disorders.  
HCM can have important clinical consequences and may lead to premature death in some 
patients while a normal life expectancy is reached by many other patients, having mild or no 
disability. Not all HCM patients require treatment, their prognosis is favourable. When treatment 
is needed, pharmacological therapy is the first option, followed by myectomy or PTSMA when 
medication is insufficient to relieve symptoms. Adequate risk stratification is important to 
determine who will benefit from ICD implantation in order to prevent sudden cardiac death. 
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Abstract 
Background 
Noncompaction cardiomyopathy (NCCM) is a distinct cardiomyopathy featuring a thickened 
bilayered left ventricular wall consisting of a thick endocardial layer with prominent 
intertrabecular recesses with a thin, compact epicardial layer. Similarly to hypertrophic (HCM) 
and dilated cardiomyopathy (DCM), NCCM is genetically heterogeneous and was recently 
associated with mutations in sarcomere genes. In order to contribute to the genetic 
classification for NCCM a systematic cardiologic family study was performed in a cohort of 58 
consecutively diagnosed and molecularly screened patients with isolated NCCM (49 adults and 
nine children). 
 
Methods and results 
Combined molecular testing and cardiologic family screening revealed that in 67% NCCM is 
genetic. Cardiologic screening with electrocardiography and echocardiography of 194 relatives 
from 50 unrelated NCCM probands revealed familial cardiomyopathy in 32 families (64%), 
including NCCM, HCM and DCM. Sixty-three percent of the relatives newly diagnosed with 
cardiomyopathy were asymptomatic; of 17 asymptomatic relatives with a mutation, nine had 
NCCM, in eight non-penetrance was observed, explaining that 44% (14/32) of familial disease 
remained undetected by ascertainment of family history prior to cardiologic family screening. 
The molecular screening of 17 genes identified mutations in 11 genes in 41% (23/56) tested 
probands; in 35% (17/48) adults and 75% (6/8) children. In eighteen families single mutations 
were transmitted in an autosomal dominant mode. Two adults and two children were compound 
or double heterozygous for two different mutations. One adult proband had three mutations. In 
50% (16/32) of familial NCCM the genetic defect remained inconclusive. 
 
Conclusions 
NCCM is predominantly a genetic cardiomyopathy with variable presentation ranging from 
asymptomatic to severe. Accordingly, the diagnosis of NCCM requires genetic counseling, DNA 
diagnostics and cardiologic family screening. 
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Introduction 
Noncompaction cardiomyopathy (NCCM) is a cardiomyopathy featuring segmental thickening of 
the left ventricular (LV) wall with a thin, compact, epicardial layer and an excessively thickened 
endocardial layer with prominent, deep intertrabecular recesses. Application of the 
echocardiographic diagnostic criteria for NCCM as postulated by Jenni together with advances 
in cardiological imaging techniques have enhanced awareness and diagnosis of NCCM.1 
Consequently NCCM was incorporated in the most recent classification of cardiomyopathies as 
a genetic disease.2 
Prevalence of NCCM, estimated from retrospective studies, ranges from 4.5 to 26 per 10,000 
adult patients referred for echocardiography.3-5 NCCM was diagnosed in 3.7% of patients with a 
LV ejection fraction ≤ 45% suggesting that NCCM might not be a rare disorder in adults.5 In 
paediatric series NCCM is the most frequent cardiomyopathy after DCM and HCM, comprising 
approximately 9% of childhood cardiomyopathies.6 Clinical features include heart failure, 
arrhythmias and thrombo-embolic events.3, 7 Familial disease was estimated to occur in 
approximately 18 - 50% of adults with isolated NCCM, mostly consistent with an autosomal 
dominant mode of inheritance.3, 8-13Intrafamilial phenotypic variability, including NCCM, 
hypertrophic cardiomyopathy (HCM) and/or dilated cardiomyopathy (DCM) suggests that these 
cardiomyopathies may be part of a broader cardiomyopathy spectrum. The first association of 
isolated NCCM with mutations in the cardiac β-Myosin Heavy Chain gene (MYH7) was reported 
in two unrelated Dutch families.14 NCCM was also associated with mutations in other 
sarcomere genes (cardiac Troponin T (TNNT2) and cardiac α-Actin (ACTC1)) in 17% of 63 
adult NCCM patients,15-17 linking NCCM to defects in MYH7, TNNT2 and ACTC1, genes 
encoding sarcomere components that are frequent causes of HCM and DCM, provides 
additional evidence for a shared genetic susceptibility to NCCM, HCM, and DCM. Reports of 
mutations in Lamin A/C (LMNA), α-dystrobrevin (DTNA), Cypher/ZASP or Lim Domain Binding 
3 (LDB3) and Sodium Channel Type V alpha (SCN5A) expanded the genetic spectrum of 
NCCM.18-20 Other genetic causes, characteristically in complex childhood NCCM with 
congenital heart defects or (metabolic) syndromes, include Barth syndrome with mutations in 
the Tafazzin gene (TAZ)21, 22 and rare chromosomal defects and loci.23-30 The current study 
investigates the heredity of NCCM, the spectrum of clinical features and the genetic aetiology of 
NCCM by combining systematic cardiological family studies with extensive molecular analysis. 
 
Methods 
Study population 
The study comprised 58 unrelated patients with isolated NCCM; 53 were diagnosed 
consecutively from 2005-2008 in the Cardiogenetics clinic of the Erasmus MC in Rotterdam, 
and five in other tertiary referral centres in the Netherlands. All fulfilled the four 
echocardiographic diagnostic Jenni criteria: a) excessively thickened LV myocardial wall with a 
two-layered structure comprising a compact epicardial layer (C) and a noncompacted 
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endocardial layer (NC) of prominent trabeculations and deep intertrabecular recesses; b) 
maximal end-systolic NC/C ratio > 2 measured at the parasternal short axis; c) colour-Doppler 
evidence of deep perfused intertrabecular recesses; d) absence of coexisting cardiac 
anomalies.1 Subsequently, all patients were referred for genetic counselling, DNA analysis and 
to initiate family studies as depicted in Figure 1. 
 
Cardiologic family study and molecular analysis 
Family studies were initiated by ascertainment of family histories and inviting initially first- and 
second-degree relatives for genetic counselling. When possible, ‘cascade screening’ for 
cardiomyopathies was pursued.  Participation of 50 families of probands allowed inclusion of 
194 relatives (Table 1). Relatives were referred for cardiologic screening, unless a familial 
pathogenic mutation had been detected. In that case only mutation positive individuals and 
relatives refusing DNA testing were examined cardiologically. Informed consent was requested 
to review medical records from 31 relatives who had cardiologic examinations in other 
hospitals. Similarly, information was retrieved from the medical records of 13 deceased 
relatives reported to be affected. Details of the family studies of the probands identified with a 
genetic defect are presented in the addendum. 
 
Cardiologic Family Study 
Cardiologic screening of relatives was performed by two cardiologists (K.C. and M.M.), and 
included a review of the medical history, physical examination, electrocardiography (ECG; 
Mortara Portrait, Milwaukee, USA) and two-dimensional echocardiography (iE33 system with a 
S5-1 transducer; Philips Medical Systems, Best, the Netherlands). If the imaging quality was 
poor, especially at LV apical or mid-ventricular walls, magnetic resonance imaging (MRI; 1.5 
Tesla scanner; Signa CV/l, GE Medical systems, Milwaukee, USA) was performed (n=26). 
Measuring the maximal NC and C with electronic callipers in end-systolic parasternal short axis 
or apical four-chamber view assessed extent and severity of noncompaction. Relatives were 
diagnosed with NCCM when complying to the Jenni criteria and were diagnosed with DCM or 
HCM when meeting the current definitions.31  When ECG and echocardiography were normal in 
relatives, NCCM or another cardiomyopathy was excluded. Other cardiologic findings observed 
in relatives possibly associated with cardiomyopathy included ECG with pathological Q’s (>40 
ms or >25% of R-waves in at least two leads), left ventricular hypertrophy (LVH), complete 
bundle branch block, other intraventricular conduction or repolarisation abnormalities. 
 
Molecular study 
DNA analysis was performed in 56 probands at the department of clinical genetics and 
consisted of direct sequencing of all coding regions and intron-exon boundaries of the following 
genes: MYH7, Myosin Binding Protein C (MYBPC3), cardiac Troponin C (TNNC1), TNNT2, 
cardiac Troponin I (TNNI3), cardiac-regulatory Myosin Light Chain (MYL2), cardiac-essential 
Myosin Light Chain (MYL3), ACTC1, α-Tropomyosin (TPM1), Cysteine- and Glycine-rich  
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protein (CSRP3), Theletonin 
(TCAP), Calsequestrin (CASQ2), 
Calreticulin (CALR3), 
Phospholamban (PLN), TAZ, 
LDB3 and LMNA. One proband 
declined DNA analysis and no 
DNA was available from one 
patient who died aged 11 days. 
The parents of this patient were 
cardiologically unaffected and did 
not have a mutation. 
The mutations previously 
associated with cardiomyopathy 
(NCCM or HCM) were regarded 
as pathogenic. Novel mutations 
were considered to be pathogenic 
when they were either truncating, 
splice-site or de novo mutations or 
fulfilled the following three criteria: 
1. segregation with disease in a 
family, 2. Absence on 384 
ethnically matched healthy control 
chromosomes and 3. were likely 
pathogenic according to prediction 
software (SIFT and PolyPhen).32 
DNA variants not fulfilling these 
criteria were considered 
unclassified variants (UV). 
Figure 1. Flow chart for NCCM family screening 
Table 1. Descriptives of the NCCM family study. 
 Total Men 
Age of 
onset/screening 
mean yrs ± SD 
(range) 
Women 
Age of 
onset/screening 
mean yrs ± SD 
(range) 
Probands 58 30 39 ± 17 (0 – 63) 28 37 ± 19 (0 – 66 ) 
Adults 49 26 44 ± 12 (19 – 63) 23 43 ± 13 (19 – 66) 
Children 9 4 7 ± 8 (0 – 17) 5 6 ± 6 (0 – 16) 
Participating relatives 194 89 41 ± 21 (0 – 77) 105 43 ± 20 (0 – 78) 
Parents 40 20 55 ± 15 (23 – 74) 20 56 ± 15 (23 – 78) 
Siblings 64 27 38 ± 18 (3 – 66) 37 43 ± 17 (0 – 71) 
Children 41 22 23 ± 15 (0 – 56) 19 33 ± 15 (11 – 47) 
Second-degree relatives 43 18 51 ± 19 (15 – 76) 26 48 ± 21 (6 – 74) 
Third-degree ≥ 6 2 38 ± 1 (37 – 39) 4 41 ± 13 (5 – 55) 
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Statistics 
Statistical analyses were performed by SPSS for Windows 15.0 (SPSS Inc., Chicago, IL). 
Unpaired student’s t-test analysis was used for continuous variables. Descriptive data for 
continuous variables were presented as mean ± one standard deviation. Chi-square analysis 
was used for categorical variables. A p-value of <0.05 was considered to be significant.  
Results 
The cardiologic screening of relatives and the molecular analysis of probands and relatives 
combined showed that at least 67% (39/58) of NCCM is genetic (Table 2 and 3). The 
cardiologic family study identified 64% (32/50) of isolated NCCM as familial. Genetic defects 
were identified in 50% (16/32) of cardiologically confirmed familial NCCM. In 50% (16/32) of 
familial disease the genetic defect remained unknown. With extensive DNA screening we found 
a mutation in 41% (23/56) of all tested probands. These results clearly indicate the importance 
of combining cardiologic family screening for cardiomyopathy with genetic testing of NCCM 
patients. 
 
Table 2. Cardiologic family studies and genotyping of 58 NCCM probands. 
Proband Cardiologic family screening Total 
 Positive De novo Inconclusive Not performed  
With mutation 16† 1† 3† 3† 23 
Without mutation 15†  13 5 33 
Without DNA analysis 1†  1  2 
Total 32  18* 8 58 
Legend. * including the family of the de novo proband, † genetic NCCM (total 39) 
 
Family histories reported by probands before DNA testing and cardiologic family studies were 
performed, failed to identify 44% (14/32) of familial disease. Only nine (53%) of the 17 adult 
patients with a mutation reported familial disease prior to DNA testing and cardiologic family 
evaluation. Familial disease was reported correctly by 8/14 (57%) adults without a mutation, 
and by none of the parents of children with NCCM. Mutations were observed in 6/8 children 
with NCCM and in 17/48 (35%) of adult probands. NCCM was associated with defects in six 
sarcomere, two Ca2+-handling, the LMNA, LDB3 and TAZ genes in this study. Mutations in 
sarcomere genes, in particular in MYH7, were the most frequent genetic defects: 9/57 adults 
and 2/9 children (addendum families 1-9 and 18-19). None of the MYH7 mutation carriers had 
neuromuscular symptoms. Eighteen (32%) probands (14 adults and four children) had a single 
mutation consistent with an autosomal dominant mode of inheritance. Two de novo mutations 
were observed: one in the asymptomatic father of an affected newborn and one in a young 
patient (addendum families 20-21). Multiple pathogenic mutations occurred in 9% (5/56) of the 
probands. Two (22%) children (diagnosed at age 4 months and at 7 years) had respectively 
mutations in TNNI3 and TPM1 and two different MYBPC3 mutations (Figure 2; addendum 
families 22-23). Complex genotypes in adults constituted respectively of mutations TNNT2 – 
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Table 3. Overview of the family studies in families with and without mutations. 
Proband Mutation Participating relatives (n) 
Cardiologically 
affected 
relatives (n) 
Cardiologically 
unaffected 
carriers (n) 
Deceased 
affected 
relatives (n) 
Adult 1 + 12 9  1 
 2 + 6 4 2 1 
 3 + 3 1   
 4 + 2 0  1 
 5 + 2 3 1 2 
 6 + 4 0 1  
 7 + 0    
 8 + 1 1   
 9 + 7 3  1 
 10 + 1 0 1 1 
 11 + 1 0  1 
 12 + 2 1   
 13 + 1 0   
 14 + 6 2   
 15 + 0    
 16 + 9 4  2 
 17 + 2 1   
Child 18 + 1 1   
 19 + 0    
 20 + 4 1   
 21 de novo 2 0   
 22 + 10 3 2  
 23 + 9 0 4  
Adult 24 - 5 4   
 25 - 8 4  1 
 26 - 3 1   
 27 - 5 3   
 28 - 7 2  2 
 29 - 3 1   
 30 - 1 1   
 31 - 10 5   
 32 - 4 4   
 33 - 4 2   
 34 - 3 1   
 35 - 5 3   
 36 - 3 1   
 37 no DNA 1 1  1 
Child 38 - 3 1   
 39 - 5 1   
Adult 40 - 1 0   
 41 - 1 0 Continued on next page 
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Table 3. Continued. 
Proband Mutation Participating relatives (n) 
Cardiologically 
affected 
relatives (n) 
Cardiologically 
unaffected 
carriers (n) 
Deceased 
affected 
relatives (n) 
Adult 42 - 3 0   
 43 - 1 0   
 44 - 5 0   
 45 - 3 0   
 46 - 3 0   
 47 - 3 0   
 48 - 3 0   
 49 - 3 0   
 50 - 3 0   
 51 - 4 0   
 52 - 3 0   
Child 53 no DNA 3 0   
Legend. Numbers 1-23 correspond to families 1-23 and 24-26 to paragraph 1C in the addendum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. MYBPC3 p.Gly148Arg and c.2373dupG mutations in one family. 
 
 
 
 
Compound heterozygousity for two different MYBPC3 mutations in a NCCM patient diagnosed at age 
seven years from a family where one grandparent was previously diagnosed with HCM (addendum 23). 
Family studies identified a spectrum of cardiomyopathies: the asymptomatic parents were carriers, NCCM 
in the father and HCM in the paternal grandfather associated with the p.Gly148Arg mutation, and HCM in 
the maternal grandfather associated with c.2373dupG. The arrow indicates the proband. († = deceased; 
CVA = Cerebrovascular Accident; ND = Not determined, i.e. no cardiologic and/or molecular testing; SIDS 
= Sudden Infant Death Syndrome; CoAo = Coarctation of the Aorta; HTX = Heart transplant). 
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LDB3 and LMNA – LDB3. One adult proband had two TNNT2 mutations and a CASQ2 
mutation. In five families UV’s were observed. Family studies are ongoing to determine the 
segregation in families and the phenotypic effect of multiple mutations, or UV’s especially in 
families where affected relatives were observed with single mutations (addendum families 14, 
16 and 22). 
DNA analysis was performed in 61 relatives from 20 families, confirming previous clinical 
diagnosis of 16 relatives: 12 with NCCM, two with HCM and two with DCM. Four symptomatic 
relatives (presenting with palpitations, fatigue and shortness of breath) had a mutation and were 
diagnosed with NCCM by subsequent cardiologic exams. Predictive DNA testing identified a 
mutation in 49% (17/41) of asymptomatic relatives. Cardiologic evaluation revealed that 53% 
(9/17) of the asymptomatic carriers had NCCM and eight carriers showed non-penetrance. 
Results of DNA analysis in relatives endorsed the pathogenicity of the mutation in 17 families. 
In three families with mutations only unaffected carriers were identified and in three families no 
cardiologic or DNA family studies have been performed yet (Table 2). 
 
Cardiologic studies 
There was no difference in age at diagnosis in adult probands with respect to gender (p=0.4), 
between adults with one or multiple mutations and those without a mutation (p=0.4) or between 
the probands and affected relatives (p=0.2). In families with a mutation unaffected adult carriers 
of a mutation were approximately the same age as the affected carriers (p=0.2). Fifty-six 
percent of unaffected carriers were older than 40 years, indicating non- or age-dependent 
penetrance of NCCM. 
Similar proportions of adult probands with a single mutation and without a mutation were 
asymptomatic when diagnosed (29% and 16%; p=0.3) (Table 4). All adult patients with multiple 
mutations presented with NYHA class II and III. These differences cannot be attributed to a 
selection bias because clinical diagnosis of NCCM preceded DNA testing. 
In nine children NCCM was diagnosed; in four before age one year; in three between 1-10 
years and in two between 10 -18 years. The two children with multiple mutations were severely 
affected with cerebral infarctions and one had a heart transplant at age seven years (Figure 2). 
All the children were the first in their families to be diagnosed with cardiomyopathy, cardiologic 
screening and DNA testing indicated familial NCCM in 89% (8/9) of their families; NCCM was 
diagnosed in 3/17 (18%) parents, and 3/15 (20%) were unaffected carriers. Figure 3 displays 
cardiac features in an affected asymptomatic parent. 
In total cardiologic screening was performed in 145 first-degree, 43 second-degree and six 
more distantly related relatives (Table 1). Of the 69 (35%) relatives diagnosed with 
cardiomyopathy 47 had NCCM, five had HCM, 15 DCM and two congestive CM (Table 4). The 
majority (63%) of the relatives diagnosed with cardiomyopathy was asymptomatic. Severe 
complications in affected relatives (heart failure, arrhythmia and thrombo-embolic events) were 
observed more frequently (23%) in families without than in families with a mutation (13%) (OR 
2.01, p= 0.36). This may be explained by the fact that we examined two large families without  
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Table 4. Cardiologic features in NCCM families. 
Mutation* No Mutation* 
Probands (23) Relatives (39) Probands (35) Relatives (49)  
≥ 18 yrs 
(17) 
< 18 yrs 
(6) 
Affected 
(34) 
Other† 
(5) 
≥ 18 yrs 
(32) 
< 18 yrs 
(3) 
Affected 
(35) 
Other† 
(14) 
Age ± SD (yrs) 41 ± 11 6 ± 6 41 ± 21 43 ± 15 46 ± 13 6 ± 10 43 ± 15 48 ± 16 
Men 8 2 21 2 19 3 15 8 
Presentation         
Asymptomatic 4  25 3 3  24 14 
Heart failure 6 6 5  18 2 6  
Arrhythmias 5    6 1 1 1 
Thrombo-
embolism 1    3  1  
Other‡ 1  2  3  1  
NYHA   I 5  21 2 5  24 15 
II 7  10 1 19  9  
III 5  2  8    
IV         
NC/C ratio ≥ 2 17  25  32  22  
NC/C ratio 1.0–1.9    3    9 
ECG abnormal    1    8 
LVH 1  4  4   9 
Abnormal 
repolarisation 4    8    
Abnormal Q 1  1  1   1 
Bundle branch 
block 4    9  2  
AV-block   4      
T-wave 
inversion 1  1  4  1  
Diagnosis         
NCCM 17 6 25  32 3 22  
HCM   2    3  
DCM   6    9  
Congestive CM   1    1  
Family history of 
CM§ 9 0   8 0   
Familial 
screening║ 15 5   27 3   
Familial CM  13 4   14 2   
Congenital heart 
defect in relative# 2 2   3 1   
Legend.  Families with and without mutation; † Other include NC/C ratio between 1.0-1.9 and/or ECG 
anomalies; ‡ Chest pain (n=4); enlarged heart on X-ray; pre-operative screening; prenatal sonography; 
cardiac screening before Ritalin use; § Prior to cardiologic family studies; ║ Cardiologic screening / DNA 
analysis;   Ebstein malformation; Fallot’s tetralogy; Atrial septal defect type II (ASDII) and ventricular 
septal defect (VSD); aortic coarctation in four families with a mutation. Valvular pulmonic stenosis; ASDII, 
VSD, pulmonic atresia; patent ductus arteriosus and aortic coarctation in four families without mutation. 
NYHA = New York Heart Association classification; NC/C ratio: Ratio of noncompacted to compacted 
wall; LVH = Left Ventricular Hypertrophy; NCCM = Left ventricular noncompaction; HCM = Hypertrophic 
Cardiomyopathy; DCM = Dilated Cardiomyopathy; CM = Cardiomyopathy 
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 Figure 3. Cardiac MRI (A) and echocardiography (B) illustrating a two-layered myocardium with 
rominent intertrabecular recesses in the asymptomatic father from Figure 2 with an MYBPC3 
utation.  
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mutation with recurrence of a severe phenotype; affected relatives in these families had been 
diagnosed prior to this study. 
In 34% (11/32) of familial disease, familial aggregation of NCCM, HCM and DCM was 
observed. HCM and/or DCM were diagnosed in four families with a mutation (Figure 2; 
addendum families 8, 10, 16, 23) and in seven families without a mutation (Table 4). 
In seven families congenital heart malformations were diagnosed. In one family with an MYH7 
mutation, NCCM was associated with Ebstein’s anomaly and in two families with MYBPC3 
mutations one relative with the mutation had Fallot’s tetralogy without NCCM and one had an 
aortic coarctation but did not have a DNA test. (Figure 2; addendum families 1, 10 and 22). In 
three families without a mutation NCCM occurred together with a valvular pulmonic stenosis, 
ventricular septal defect, atrial septal defect type II, pulmonic atresia, patent ductus arteriosus 
or aortic coarctation in six relatives. 
Discussion 
The approach of this study was to combine cardiologic family studies with extensive genetic 
testing to establish a genetic classification of NCCM. The results showed that isolated NCCM is 
predominantly (67%) a genetic condition, including HCM and DCM in 11 families (34%). The 
molecular screening of a large number of genes in this study allowed expanding the genetic 
spectrum of NCCM with novel genetic defects. 
Genetic defects were identified in 41% of all patients and in 50% (16/32) of the cardiologically 
confirmed familial forms and consisted of one or more mutations in 11 different genes, 
indicating that further studies are needed to find causes for the remaining familial forms of 
NCCM. Molecular diagnosis of NCCM is important because it offers reliable identification of 
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asymptomatic relatives at risk. In absence of an identified genetic cause for NCCM, or when 
relatives decline DNA testing, cardiologic screening remains the appropriate method to identify 
familial disease.  
The proportion of familial disease in this study is higher than reported previously (18%-50%) by 
studies investigating the prevalence of genetic defects in adult patients or ascertaining family 
histories of cardiomyopathy.3, 8-13 The systematic cardiologic family screening showed that the 
majority (63%) of the affected relatives were asymptomatic, explaining that family histories 
without cardiologic family studies, failed to identify 44% of familial disease. Intrafamilial 
variability and incomplete penetrance, including asymptomatic disease, as well as small family 
size, may contribute to underestimation of familial disease. Therefore cardiologic evaluation of 
at risk relatives of all NCCM patients is recommended to enhance detection of familial disease, 
in accordance with the current expert consensus for family screening in HCM.31 Familial 
screening for cardiomyopathies is important because early diagnosis in relatives may prevent 
severe complications. Nevertheless, predictive DNA testing and/or cardiologic evaluation 
should only take place after relatives have been well informed about possible medical benefits 
of early diagnosis including suitable treatment and life-style recommendations, as well as 
psychological and socio-economical consequences of predictive testing (particularly in 
countries where genetic discrimination by insurance companies or employers is not prohibited). 
Similar to other familial cardiomyopathies, familial NCCM showed intrafamilial phenotypic 
variability, including HCM and/or DCM, reduced expression and reduced penetrance (ie. clinical 
symptoms not expressed).3, 12, 33, 34 In this study non-penetrance was observed in eight relatives 
with a mutation ranging in age from 12 to 72 years. The implications of non-penetrance include 
pursuing cardiologic follow up of unaffected relatives (as depicted in Figure 1). And for families 
without a mutation, the consequences are that cardiologic screening is recommended. 
Improved imaging by echocardiography and cardiac MRI has enhanced diagnosis and 
awareness of NCCM. However, establishing the extent to which physiologic trabeculations are 
pathologic remains difficult.35  
Mutations in the sarcomere genes were found in 6/8 tested affected infants and in 17/48 adult 
probands. Although the number of children included in this study is to small to draw conclusions 
on the aetiology of childhood disease, molecular testing of sarcomere genes and systemic 
cardiologic evaluation of first-degree relatives are recommended in early onset NCCM, 
especially in absence of dysmorphic features or metabolic defects. Congenital heart 
malformations in NCCM patients should not refer from analysing sarcomere genes. Our results 
endorse that co-occurrence of NCCM and congenital heart defects with and without sarcomere 
gene defect is not rare, warranting careful evaluation of the validity of the fourth of the Jenni 
diagnostic criteria.15, 17, 36-38 
Two severely affected children and three adults were compound / double heterozygous, 
indicating that multiple mutations appear to be more prevalent in NCCM (22%) than in HCM 
(7%) (p=0.15).39 In HCM double heterozygousity for truncating sarcomere mutations have been 
associated with severe congenital forms of HCM, inherited in an autosomal recessive mode.40-
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42 In this study double mutations were also observed in adults with NCCM. The complex genetic 
defects in adults involved the combination of a sarcomere gene with another gene, suggesting 
that two sarcomere mutations may cause a more severe phenotype than the combination of a 
sarcomere mutation and a non-sarcomere mutation. The epigenetic effect of multiple mutations 
may depend on the specific defects involved. Further studies are needed to investigate the role 
of additional mutations and determine whether they play a role in the phenotypic variability. 
For now, the evidence that sarcomere defects are an important cause for NCCM, together with 
the occurrence of NCCM, HCM and DCM within families, suggests that these cardiomyopathies 
represent phenotypic variability within a spectrum and thus require comparable approach with 
respect to family screening. 
The results of cardiological follow-up of families will help to understand the natural history of 
NCCM, to determine whether NCCM represents a congenital endomyocardial defect or may 
develop later in life, and eventually to attain recommendations for follow-up of relatives based 
upon accurate risk classification.43 The perspective of new studies investigating modifying 
genetic effects or genome-environment interactions to explain variability and age dependent 
penetrance of this phenotype is challenging. 
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Addendum: Description and pedigrees of the families of 
NCCM probands with a gene defect. 
 
1. Adult probands 
 
 
1A. Adult probands, single mutation 
 
Cardiac β-Myosin Heavy Chain (MYH7) 
 
Family 1 
NCCM was diagnosed in a 27-year-old woman presenting with progressive dyspnea, 
fatigue and oedema. In 1993 her sister died aged 27 years of a peripartum 
cardiomyopathy six days after giving birth to her third child. Cardiological screening of 
seven asymptomatic siblings revealed NCCM in five: two sisters aged 35 and 30 years, 
and two brothers aged 34 and 49 years. NCCM was also diagnosed in the 62-year-old 
father who was in NYHA class II and in the 24-year-old asymptomatic daughter of the 
eldest brother. DNA analysis showed the p.Leu301Gln mutation in the MYH7 gene in all 
tested affected relatives and was excluded in four asymptomatic and cardiologically 
unaffected relatives. Two asymptomatic children (aged 12 and 15 years) of one of the 
affected relatives had NCCM, the 12-year-old girl was also diagnosed with an Ebstein 
malformation; both had the MYH7 mutation. 
 
Family 2 
A 35-year-old man was hospitalised with symptoms of congestive heart failure (extreme 
fatigue, dyspnea, orthopnoea and palpitations). He was diagnosed with NCCM and severe 
systolic left ventricular (LV) dysfunction. He had a large thrombus in the left ventricle, 
which resolved completely with anti-coagulant treatment. Treatment of heart failure was 
successful and after four-and-a-half years of follow-up he remains asymptomatic with 
moderate LV dysfunction. In childhood, he had been treated for lymphoblastic leukaemia 
with chemo- and radiotherapy (cytosine, arabinoside, methotrexate and prednisone). 
Cardiological family studies revealed NCCM in his asymptomatic son, brother, father and 
a paternal aunt. The medical records of a paternal uncle who died at age 70 years also 
indicated NCCM. All the living affected relatives had the p.Asp545Asn and p.Asp955Asn 
double mutations in cis in the MYH7 gene. Additionally, predictive DNA analysis found 
both mutations in the asymptomatic and unaffected 15-year-old daughter of the proband 
and in the unaffected son of the deceased uncle of the proband, confirming the uncle to 
have been an obligate carrier of the double mutations. 
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Family 3 
A 32-year-old woman with persistent dyspnea following an episode of influenza was 
diagnosed with heart failure and NCCM. She had the p.Glu1350del mutation in the MYH7 
gene. Her asymptomatic mother had the MYH7 gene mutation but did not show features 
of NCCM, although LV function was slightly impaired (Fractional shortening 27%) and her 
mother had a grade II aortic insufficiency. The asymptomatic father did not carry the 
mutation and did not show any signs of cardiomyopathy. The asymptomatic brother, an 
athlete, showed extensive trabeculation of the apex and his ECG showed a non-specific 
intraventricular conduction delay. Exercise ECG and 24-hrs ECG were normal. He did not 
have the familial mutation. His cardiac abnormalities are possibly related to athletic 
performance, or they may indicate involvement of another so far unidentified genetic 
cause for NCCM in this family. 
 
Family 4 
In 2005 NCCM and an MYH7 mutation (p.Arg1925Gly) were diagnosed in a 50-year-old 
asymptomatic woman. She was referred for cardiological screening after the sudden 
death of her brother at age 48 years due to congestive cardiomyopathy confirmed at 
autopsy. The MYH7 mutation was excluded in an asymptomatic and cardiologically 
unaffected 55-year-old sister and the asymptomatic 77-year-old mother of the patient. The 
father died of lung cancer at age 65 years. The family history suggested that the mutation 
was inherited from the paternal side because of a reported sudden death at age 64 of one 
of the paternal aunts. One of her sons showed apical trabeculation at age 37 years, not 
fulfilling the Jenni criteria and his ECG showed voltage criteria for left ventricular 
hypertrophy, he refused molecular analysis. 
 
Family 5 
Cardiac screening of an asymptomatic 22-year-old woman identified NCCM and an MYH7 
mutation (p.Asn1918Lys). Her father had died aged 59 years after developing a sepsis. 
He was diagnosed previously with heart failure. The father’s sister was also diagnosed 
with heart failure, and died at the age of 30 years. Three brothers of the father died 
suddenly, two at age 50 and one at age 63 years. An asymptomatic son and daughter of 
one of these brothers were diagnosed with NCCM at age 30 and 27 years respectively. 
They had the MYH7 mutation. The sole surviving paternal uncle who was diagnosed with 
NCCM at age 61 years also had the MYH7 mutation. The asymptomatic sister of the 
proband had the MYH7 mutation, showing non-penetrance at age 27 years. 
 
Family 6 
A 41-year-old man presented with progressive dyspnea caused by congestive heart failure 
due to NCCM. An ICD was implanted. DNA analysis showed the p.Tyr1488Cys mutation 
in MYH7. His asymptomatic 9-year-old and 12-year-old sons were screened by a 
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paediatric cardiologist and found normal, as were his asymptomatic mother and brother. 
The eldest son carried the MYH7 mutation, the youngest didn’t. The mother and brother 
refused DNA testing. 
 
Family 7 
In 2005 a 61-year-old man had complaints of palpitations and chest pain. 
Echocardiography showed left ventricular hypertrophy. Two years later NCCM was 
diagnosed on MRI. He had the p.Leu658Val mutation in MYH7. Family history was 
negative for cardiac disease or sudden death; so far no relatives participated in cardiologic 
screening or DNA analysis. 
 
Family 8 
ECG showed left ventricular hypertrophy which could not be confirmed by 
echocardiography in a 21-year-old man who had a syncope while jogging. MRI at age 33 
years showed evident NCCM with a non-compact to compact (NC/C) ratio of 4.2. After this 
diagnosis his father, previously diagnosed with HCM at age 17 years, also after syncope 
while jogging, had an MRI and was subsequently diagnosed with NCCM (NC/C ratio 2.2) 
at the age of 60 years. He died three years later. Family history reported that the probands 
paternal grandmother died at 40 years of age and that a sudden death during exercise 
occurred in a 17-year-old paternal uncle and in a 21-year-old paternal aunt. Cardiologic 
screening of another paternal uncle shortly before he died at age 64 years showed no 
abnormalities. The proband and his affected father both had the p.Ile818Asn mutation in 
MYH7. 
 
Family 9 
Standard prenatal ultrasound at 20, 22 and 23 weeks gestation showed cardiomegaly with 
increased wall thickness. Advanced prenatal ultrasound at 23+3 weeks gestation showed 
cardiomegaly, decreased contractility and increased apical myocardial wall thickness. A 
foetal cardiomyopathy was suspected, prenatal follow up showed a stable condition of the 
pump function. Subsequent cardiologic screening identified NCCM in the 34-year-old 
Turkish father who suffered from fatigue and excessive perspiration. The asymptomatic 
Turkish mother was unaffected. Their eldest (asymptomatic) son, aged 14 years, was also 
unaffected; the youngest son, aged 10 years who was also asymptomatic, had NCCM. 
The paternal mother had been diagnosed with NCCM after having chest pain 
approximately one year earlier in another medical centre. One of her sisters suffered a 
sudden cardiac death at the age of 38 years. A pathogenic splice-donor site MYH7 
mutation was identified (c.732+1G>A) in the affected father. At gestational age 37+4 
weeks their son was born. DNA analysis confirmed the presence of the MYH7 mutation. 
Echocardiography showed evident NCCM with cardiomegaly. Left ventricular function was 
not impaired and he was discharged form the hospital one day later. Follow-up will take 
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place at the paediatric cardiology department. The two affected sons both had the MYH7 
mutation. The asymptomatic 28-year-old brother of the father was unaffected, he refused 
DNA testing; two unaffected sisters of the father, aged 30 and 45 years, did not have the 
MYH7 mutation. 
 
Myosin Binding Protein C (MYBPC3) 
 
Family 10 
NCCM was diagnosed in a 56-year-old woman. In 1980, at the age of 30 years she was 
diagnosed with an unspecified cardiomyopathy. In 2000 on echocardiography a dilated 
cardiomyopathy was diagnosed, with a slight mitral valve insufficiency. In 2001, aged 51 
years, she suffered a mesenterial thrombosis. She was also diagnosed with myelofibrosis. 
She had several transient ischemic attacks and a cerebral infarction at age 53 years 
confirmed by MRI. DNA analysis identified the truncating HCM founder mutation 
c.2373dupG in the MYBPC3 gene. She died from progression of myelofibrosis at the age 
of 59 years. Her father died of a peritonitis aged 87 years. At autopsy his heart showed 
signs of hypertrophy and dilatation of the left and right ventricle and the founder mutation 
was confirmed in autopsy tissue. The proband’s asymptomatic son inherited the founder 
mutation. He has Fallot’s tetralogy, which was surgically corrected at the age of 14 months 
and cardiological screening at the age of 31 years did not show features of 
cardiomyopathy. 
 
Phospholamban (PLN) 
 
Family 11 
After successful resuscitation due to ventricular tachycardia a 48-year-old woman was 
diagnosed with NCCM (NC/C ratio was 2.5). She had the p.Arg14del mutation in the PLN 
gene. Her father died aged 62 years. Post mortem analysis showed cardiomyopathy with 
a thrombus in the left ventricular apex. DNA analysis of the deceased father could not be 
performed. Cardiologic screening of an asymptomatic 47-year-old sister, without the PLN 
mutation, was normal. 
 
Calsequestrin (CASQ2) 
 
Family 12 
A 53-year-old man from Surinam had exercise intolerance and was scheduled for an 
oesophageal-jejunostomy due to complications of a gastrectomy. The gastrectomy, six 
months previous, was due to gastric necrosis, caused by an arterial thrombo-embolism. 
Preoperative physical examinations revealed severe LV dysfunction due to NCCM. DNA 
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analysis identified the p.His244Arg mutation in CASQ2. His asymptomatic mother (aged 
77 years) and sister (aged 53 years) both had NCCM and the CASQ2 mutation. 
 
 
 
1B. Adult probands, multiple mutations or unclassified variants 
 
MYBPC3 and a UV in cardiac α-Actin (ACTC1) 
 
Family 13 
A 50-year-old man from Surinam presented with shortness of breath and palpitations, 
especially during stressful events. Cardiological evaluation detected non-sustained 
ventricular tachycardia and severe LV dysfunction. He was diagnosed with NCCM and 
received an ICD. DNA analysis identified the mutation p.Ala216Thr in MYBPC3 and 
unclassified variant *22C>T in ACTC1. Cardiologic examination of an asymptomatic 
daughter showed no anomalies, she did not have the MYBPC3 mutation, the ACTC1 UV 
has not been tested yet. 
 
Cardiac Troponin T (TNNT2) and Lim Domain-Binding 3 (LDB3)  
 
Family 14 
In 2003 a 45-year-old woman of Moroccan descent presented with exercise related chest 
pain. Echocardiography showed apical hypertrophy and contrast echocardiography 
showed typical features of NCCM in the apex of the LV. DNA analysis identified the 
p.Pro87Leu mutation in TNNT2 and the p.Asp117Asn mutation in LDB3. She had six 
asymptomatic children who were screened cardiologically. NCCM was diagnosed in two 
sons (aged 22 and 27 years respectively). One of these sons had the TNNT2 but not the 
LDB3 mutation. The other children declined DNA testing. A third son had supraventricular 
tachycardia and apical ventricular hypertrophy with trabeculation with a NC/C ratio <2. No 
signs of cardiomyopathy were detected in three children (aged 18 to 31 years).  
 
TNNT2 and CASQ2 
 
Family 15 
A 35-year-old woman from Curacao was diagnosed with NCCM during pregnancy. 
Ejection fraction was approximately 20%. She had two mutations in TNNT2 (p.Arg161His 
and p.Val225Leu) and one in CASQ2 (p.His244Arg). So far no relatives have participated 
in the family study. Therefore it was not possible to determine whether the two TNNT2 
mutations are allelic or not. 
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Lamin A/C (LMNA) and LDB3 
 
Family 16 
This patient had palpitations at age 30 and was previously diagnosed with limb girdle 
muscular dystrophy type IB. At age 42 years he was admitted with atrial fibrillation, non-
sustained VT’s and a total AV block. Cardiac MRI diagnosed NCCM. He received an ICD. 
He had the c.1608+5G>C mutation in LMNA and the p.Asp117Asn mutation in LDB3. 
Family history was positive for dilated cardiomyopathy (two daughters of his paternal 
grandmother’s sister; both confirmed LMNA mutation carriers; a son and daughter of one 
of these daughters; a son and grandson of another sister of the paternal grandmother) 
and sudden cardiac death (the proband’s sister at age 39; the probands father at age 59; 
a paternal uncle at age 43 and a son of the first sister of the paternal grandmother at age 
40 years). The asymptomatic brother of the proband had both mutations, cardiologic 
evaluation showed a first-degree AV-block with frequent ventricular extrasystoles and left 
ventricular hypertrophy on ECG. Echocardiography and MRI did not show signs of NCCM, 
MRI showed an ejection fraction of 47%. One of his sisters, who reported palpitations, 
carried only the LMNA mutation but not the LBD3 mutation. ECG showed sinus 
bradycardia and a first-degree AV-block. Echocardiography did not show signs of 
cardiomyopathy. 
 
Tafazzin (TAZ) and a UV in LMNA 
 
Family 17 
In 2007 a 57-year-old Surinam woman was diagnosed with cardiomegaly on X- ray after 
referral for persisting coughing. Echocardiography showed NCCM. She had the UV 
c.1968+26A>G in LMNA and the p.Phe128Ser mutation in TAZ. One of her sisters was 
reported with a sudden death at the age of 57 years. Her two sons were asymptomatic, 
one declined DNA analysis and cardiologic screening; the other was unaffected and didn’t 
have either mutation. A 71-year-old sister, suffering from dyspnea and fatigue, showed 
significant cardiac enlargement on an X-ray made in Surinam. She had the UV in LMNA; 
the results of the TAZ gene analysis are not known yet. 
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1C. Adult probands with unclassified variants 
Three families had only unclassified variants. Although these NCCM families did not 
have pathogenic mutations they were added here to complete the overview of the 
results. 
 
UV in CASQ2 
Preoperative cardiologic screening revealed NCCM in a 56-year-old asymptomatic 
woman. Cardiologic screening identified NCCM in her asymptomatic 16-year-old son, two 
asymptomatic brothers, aged 54 and 57 years respectively and in the 20-year-old 
asymptomatic daughter of the youngest brother. In childhood she was diagnosed with an 
aortic coarctation that was surgically corrected at the age of four years. She also had a 
duplicate frontal mitral valve slip. An unclassified variant was identified in CASQ2 
(p.Asp398del) in the proband. This variant did not co-segregate with NCCM in the family.  
 
UV in CASQ2 
This patient presented with a CVA in the right hemisphere at age 38 years. Following the 
young-stroke-protocol she had a cardiological examination that revealed NCCM. Her 
sister was diagnosed with dilated cardiomyopathy at age 21 years. She was one of the 
first patients in the Netherlands to receive an ICD. She died aged 23 years of 
complications of an ICD infection. The 66-year-old mother was diagnosed with NCCM 
after diagnosis was made in her eldest daughter. She had been suffering from dyspnea. 
Her 65-year-old asymptomatic brother and his 40-year-old asymptomatic daughter were 
also diagnosed with NCCM; her 55-year-old asymptomatic sister was diagnosed with 
DCM. Family history further mentioned a paternal nephew who has an ICD, his brother 
died suddenly at the age of 40 years. The UV p.Asp398del in CASQ2 has been identified 
in the mother of the proband but didn’t segregate with disease in the family. 
 
UV in LMNA and LDB3 
A 48-year-old man presented with chest pain. Catheterisation showed trabeculation and 
left ventricular dysfunction. NCCM was confirmed by echocardiography. During admission 
telemetry showed non-sustained VT’s and he received an ICD. DNA analysis showed the 
unclassified variants c.1968+26A>G in LMNA and p.Val118Met in LDB3. His 24-year-old 
daughter, who suffered from syncope, showed LV trabeculation on echocardiography. 
MRI confirmed NCCM. She has the LMNA UV, but not the LDB3 variant. Her 22-year-old 
asymptomatic sister was unaffected and carried the LMNA UV; the unaffected 53-year-old 
sister of the proband did not carry the LMNA UV. The LDB3 variant was not tested. 
 
 
NCCM family studyg 111
2 Childhood probands 
 
 
2A. Childhood probands, single mutations 
 
MYH7 
 
Family 18 
A four-year-and-nine-month-old girl was diagnosed with NCCM when a cardiac murmur 
was detected at a paediatric consultation because of her congenital agenesis of the 
thyroid gland and urinary reflux. DNA analysis identified a nonsense mutation in the MYH7 
gene (p.Tyr266X). The mutation was also identified in the 35-year-old asymptomatic 
father, who was subsequently screened and diagnosed with NCCM. His father had died 
suddenly in his sleep aged 60 years. 
 
Family 19 
A ten-year-old boy, experiencing persistent fatigue and dyspnea after having had the flu, 
was diagnosed with heart failure and NCCM. DNA analysis revealed the p.Arg369Gln 
mutation in MYH7. Under medication his left ventricular function improved. Both parents 
and his twin sister are asymptomatic; they declined molecular and cardiologic testing. 
Recently, the MYH7 mutation p.Arg369Gln was also found as a de novo mutation in a 
paediatric NCCM patient presenting with heart failure (Dellefave et al., Circ Cardiovasc 
Genet. 2009; 2:442-449) 
 
Cardiac α- Actin (ACTC1) 
 
Family 20 
NCCM was diagnosed in a six-week-old girl examined because of failure to thrive and 
feeding problems. Her heart showed mid-ventricular noncompaction with apical dilatation 
of the left ventricle and a dilated left atrium with bulging of the atrial septum to the right. 
Under treatment of an ace-inhibitor and digoxin her condition improved. DNA analysis 
showed a mutation in the ACTC1 gene, p.Met271Val. Her asymptomatic father had this 
mutation and was diagnosed with a dilated LV and RV, with apical, lateral and septal 
thickening without any evident crypts on echocardiography. On MRI NCCM was evident 
with a NC/C ratio of 15/3. The paternal grandparents did not have the mutation, identifying 
it as a pathogenic de novo mutation in the father of the proband. 
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α-Tropomyosin (TPM1) 
 
Family 21 
A 16-year-old girl was suspected of liver failure. On chest X-ray she had an exceptionally 
large heart and echocardiography showed a poor cardiac output. She was diagnosed with 
NCCM. She received a left ventricular assist device before she had a heart transplant at 
age 17 years. DNA analysis identified the pathogenic de novo p.Arg160His mutation in 
TPM1: the mutation was excluded in both parents. Cardiologic screening of her mother 
was normal; her father had developed ischemic DCM after a major heart infarction eight 
years earlier, not related to the TPM1 mutation in the proband. 
 
 
2B. Childhood probands, multiple mutations 
 
Compound heterozygousity of two mutations in MYBPC3 
 
Family 22 
A 7-year-old girl presenting with fatigue and vomiting was diagnosed with severe dilated 
cardiomyopathy. X-ray and ECG showed signs of left ventricular hypertrophy. Four 
months after diagnosis she had a heart transplantation. The pathological exam of the 
heart showed a two-layered structure of the left ventricle with excessive trabeculations 
consistent with NCCM. She suffered a cerebral infarction shortly after being diagnosed 
with NCCM. DNA analysis revealed two MYBPC3 gene mutations, the Dutch HCM 
founder mutation c.2373dupG and a novel mutation, p.Gly148Arg. The founder mutation 
was identified in the asymptomatic mother, without signs of cardiomyopathy. The maternal 
grandfather, diagnosed with HCM had the c.2373dupG mutation. The asymptomatic father 
had the p.Gly148Arg mutation and was subsequently diagnosed with NCCM. The paternal 
grandfather, suffered from hypertension and atherosclerosis, was diagnosed with HCM at 
age 76 years and had the p.Gly148Arg mutation. One asymptomatic paternal uncle (age 
49 years) had the p.Gly148Arg mutation; cardiologic examination did not show signs of 
cardiomyopathy. The asymptomatic paternal grandmother and a paternal uncle without 
the mutation had no signs of cardiomyopathy. Screening of two asymptomatic brothers 
(ages four and nine years) of the proband did not show signs of cardiomyopathy. The 
eldest brother had an aortic coarctation which was surgically corrected at age nine years. 
 
Double heterozygousity of mutations in cardiac Troponin I (TNNI3) and TPM1 
 
Family 23 
In 2004 a four-month-old girl was admitted because of failure to thrive, dyspnea and 
excessive perspiration. Echocardiography diagnosed NCCM. She suffered a cerebral 
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infarction in the medial cerebral artery area at the age of four months. At age four years 
and 10 months she died waiting for a heart transplant. 
DNA analysis revealed the novel mutations p.Asp180Gly in the TNNI3 gene and c.241-
12_241-11delinsTG in the TPM1 gene. The TPM1 mutation was detected in her 
asymptomatic, cardiologically unaffected father (age 39 years). Her mother (age 37 years) 
who was also asymptomatic and cardiologically unaffected had the mutation in the TNNI3 
gene. The paternal grandparents were asymptomatic and unaffected. The paternal 
grandfather had the TPM1 mutation. This mutation was excluded in the paternal 
grandmother and an unaffected aunt. In the asymptomatic unaffected maternal 
grandparents, the TNNI3 mutation was identified in the grandmother and excluded in the 
grandfather. A maternal aunt, a professional athlete who did not have the TNNI3 mutation, 
had features of noncompaction of the left ventricle with a ratio <2 and a normal ejection 
fraction. It is unclear whether the attenuated form of trabeculation was primarily related to 
physical activity or indicates another yet unidentified genetic cause for NCCM in this 
family. 
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Table 5. Family studies of genotyped patients. 
Probands Relatives 
 Affected Unaffected 
Family* Gene Mutation With mutation No mutation With mutation No mutation 
1 MYH7 p.Leu301Gln 5   2 
2 MYH7 p.Asp545Asn / p.Asp955Asn 4  2  
3 MYH7 p.Glu1350del  1 1  
4 MYH7 p.Arg1925Gly    2 
5 MYH7 p.Asn1918Lys 4  1  
6 MYH7 p.Tyr1488Cys   1 1 
7† MYH7 p.Leu658Val     
8 MYH7 p.Ile818Asn 1    
9 MYH7 c.732+1G>A 2   2 
10 MYBPC3 c.2373dupG 1  1  
11 PLN p.Arg14del    1 
12 CASQ2 p.His244Arg 2   1 
13 MYBPC3 p.Ala216Thr (A)‡    1 
 ACTC1 c.*22C>T (B)‡     
14 TNNT2 p.Pro87Leu (C)‡ 1    
 LDB3 p.Asp117Asn (D)‡  1   
15† TNNT2 p.Arg161His (E)‡     
 TNNT2 p.Val225Leu (F)‡     
 CASQ2 p.His244Arg (G)‡     
16 LMNA 1608+5G>C (H)‡ 3  2 1 
 LDB3 p.Asp117Asn (I)‡  3 1 2 
17 TAZ p.Phe128Ser (J)‡    1 
 LMNA 1968+26A>G (K)‡ 1    
18 MYH7 p.Tyr266X 1    
19† MYH7 p.Arg369Gln     
20 ACTC1 p.Met271Val 1   2 
21 TPM1 p.Arg160His    1 
22 MYBPC3 c.2373dupG (L)‡ 1  1  
 MYBPC3 p.Gly148Arg (M)‡ 2  1 3 
23 TNNI3 c.241-12_241-11delinsTG (N)‡  1 2 1 
 TPM1 p.Asp180Gly (O)‡   2 2 
Legend. * Family number corresponds with pedigree number in Figure 4; † No family studies were 
performed in probands 7, 15 and 19; ‡ Capitols in brackets refer to capitols in Figure 4. 
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Figure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Pedigrees of genotyped families.  
Numbers correspond with numbers in the description of the families.  
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Abstract 
Background 
Noncompaction cardiomyopathy (NCCM) is characterised by an excessively thickened 
endocardial layer with deep intertrabecular recesses. Despite partial overlap in causal genes 
between NCCM and other cardiomyopathies, a genetic classification of NCCM is currently 
lacking.  
 
Methods and results 
Seventeen genes (MYH7, MYBPC3, TNNC1, TNNT2, TNNI3, ACTC1, MYL2, MYL3, TPM1, 
CSRP3, TCAP, LDB3, CASQ2, CALR3, PLN, TAZ and LMNA) were completely analysed in a 
cohort of 56 NCCM patients (48 adults and 8 children). These genes encode proteins of the 
sarcomere, Z-disc, Calcium-handling system and cellular matrix which, when mutated, cause 
cardiomyopathy.  
Twenty-nine mutations, including twenty-one new ones, were identified in 41% of the patients in 
MYH7 (11), MYBPC3 (4), TNNT2 (3), TNNI3 (1), TPM1 (2), ACTC1 (1), CASQ2 (2), PLN (1), 
TAZ (1), LDB3 (2) and LMNA (1). Thirty-five percent of the adult patients had a mutation. 
Seventy-five percent of the paediatric patients had a sarcomeric mutation. Eighteen probands 
had a single mutation, four had two and one had three mutations. Prognosis in families with an 
identified mutation was worse compared to prognosis in non-genotyped families. 
 
Conclusions 
We identified MYBPC3, TNNI3, TPM1, PLN and CASQ2 as novel NCCM genes. Genetically, 
NCCM classifies primarily as a sarcomeric disease and part of a spectrum including 
hypertrophic and dilated cardiomyopathy. The high frequency of mutations in adult- and 
childhood-onset NCCM warrants genetic counselling and molecular analysis, starting with 
MYH7.  Identification of the genetic cause allows accurate identification of relatives at risk for 
cardiomyopathy. 
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Introduction 
Noncompaction cardiomyopathy (NCCM) is characterised by hypertrabeculation and deep 
intertrabecular recesses of the left ventricular myocardium, reminiscent of the embryonic stages 
of cardiac development.1, 2 Cardiac symptoms include heart failure, lethal arrhythmias and/or 
thrombo-embolic complications. Initially, NCCM was perceived to be an extremely rare disease 
with a poor prognosis and an estimated prevalence of 0.045% to 0.14%.3, 4 Recent studies 
report a prevalence up to 5% depending on the study population and stringency of diagnostic 
criteria.5, 6 In childhood, NCCM is the most commonly observed cardiomyopathy after 
hypertrophic (HCM) and dilated cardiomyopathy (DCM).7 The echocardiographic as well as MRI 
diagnostic NCCM criteria presented in recent years are under discussion.2, 8-11 However, the 
diagnostic criteria as proposed by Jenni and co-workers remain most widely used.2 
Whether NCCM should be regarded as a separate cardiomyopathy has not yet been 
established. After the initial WHO official classification of cardiomyopathies12, the latest 
classification updates from the American Heart Association (AHA)13 and the European Society 
of Cardiology (ESC)14 hold different views on NCCM. The ESC classification considers NCCM 
unclassified since there is currently no consensus whether NCCM is a separate 
cardiomyopathy or a morphological trait occurring separately or in combination with another 
cardiomyopathy or congenital cardiac malformations.14 The AHA regards NCCM as a separate 
primary genetic cardiomyopathy since the disease predominantly involves the myocardium and 
has a genetic aetiology.13  
Rare genetic defects associated with NCCM include mutations in taffazin (TAZ), Cypher/ZASP 
(LDB3) and Lamin A/C (LMNA). 
The first sarcomeric NCCM mutations were reported in the β-myosin heavy chain (MYH7) gene 
in two families with isolated NCCM.15 Subsequent studies confirmed the role of MYH7 defects 
in the aetiology of NCCM and also implicated sarcomeric cardiac troponin T (TNNT2) and 
cardiac actin (ACTC1) as disease genes in NCCM.16-18 However, a genetic classification for 
NCCM is currently lacking. 
The goal of this study was to establish a genetic classification for NCCM. This is important 
because a classification including the frequencies of genetic causes and the mutation spectrum 
is instrumental in directing diagnostic screening efforts, facilitate genotype-phenotype analyses 
and may contribute to the elucidation of the pathophysiology of this currently not fully 
understood disease. 
We therefore performed a complete analysis of 17 genes, including six genes previously 
associated with NCCM, in a cohort of 56 unrelated NCCM patients. Because familial 
aggregation of NCCM, HCM and DCM suggests a shared genetic susceptibility for these forms 
of cardiomyopathy, eleven additional HCM and DCM genes were selected and analysed as 
NCCM candidate genes, although such a selection can neither be objective nor complete. Most 
known sarcomeric cardiomyopathy genes were included and, in addition, some known 
cardiomyopathy genes from the Z-disc and calcium-handling system were analysed. 
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Methods 
Patients 
The study population comprised 56 unrelated patients with isolated NCCM. Coronary artery 
disease and hypertension were excluded in all patients. Patients were diagnosed from 2005-
2008 at the Thorax centre of the Erasmus MC Rotterdam, a tertiary cardiology referral centre 
and fulfilled all four echocardiographic diagnostic Jenni criteria for NCCM: a) excessively 
thickened LV myocardial wall with a two-layered structure comprising a compact epicardial 
layer (C) and a noncompacted endocardial layer (NC) of prominent trabeculations and deep 
intertrabecular recesses; b) maximal end-systolic NC/C ratio > 2 measured at the parasternal 
short axis; c) colour-Doppler evidence of deep perfused intertrabecular recesses; d) absence of 
coexisting cardiac anomalies.2 All patients were referred for genetic counselling, DNA analysis 
and to initiate family studies. The study was approved by the institutional ethics committee and 
all subjects gave informed consent. 
 
Genetic analysis 
Complete sequence analysis of all coding regions and intron-exon boundaries of the following 
genes was performed: 
 Sarcomeric genes: β-myosin heavy chain (MYH7; NM_000257.2), myosin binding protein 
C (MYBPC3; NM_000256.3), cardiac troponin C (TNNC1; NM_003280.1), cardiac troponin 
T (TNNT2; NM_000364.2), cardiac troponin I (TNNI3; NM_000363.4), cardiac-regulatory 
myosin light chain (MYL2; NM_000432.3), cardiac-essential myosin light chain (MYL3; 
NM_000258.2), cardiac α-actin (ACTC1; NM_005159.4), α-tropomyosin (TPM1; 
NM_000366.5). 
 Calcium-handling genes: calsequestrin (CASQ2; NM_001232.3), calreticulin (CALR3; 
NM_145046.3) and phospholamban (PLN; NM_002667.3). 
 Z-disc genes: cysteine- and glycine-rich protein (CSRP3; NM_003476.2), theletonin 
(TCAP; NM_003673.2) and LIM domain binding 3/Cypher/ZASP (LDB3; NM_007078.2 and 
NM_001080116.1) 
 Other: taffazin (TAZ; NM_000116.2) and lamin A/C (LMNA; NM_170707.2 and 
NM_005572.3). 
 
Sequence analysis was carried out on an ABI3730xl capillary sequencer using Big-Dye 
Terminator v 3.1 chemistry (Applied Biosystems). (Details of methods and primer sequences 
available on request.) Analysis of sequence data was performed using SeqScape analysis 
software (v2.5, Applied Biosystems). Unknown missense variants were considered a mutation 
when they segregated with disease in a family and were not present on 384 healthy ethnically 
matched control chromosomes and were pathogenic according to prediction software.19, 20 
Although this does not formally prove pathogenicity, these three criteria combined were thought 
to provide the best evidence for pathogenicity. In case of isolated mutations, segregation with 
Disease genes in NCCMg 121
disease could not be used as a criterion. DNA variants not fulfilling these criteria were labelled 
unclassified variants (UV). 
 
Prognostic classification 
The prognosis in families was classified based on the family history at the time of diagnosis.21 
Probands were excluded from the analysis. Prognosis was considered malignant when two or 
more major cardiac events (MCE, i.e. sudden cardiac death (SCD), stroke, resuscitation or 
appropriate discharge of an intracardial defibrillator (ICD)), before the age of 60 years were 
confirmed in a family. One documented MCE in a family led to a classification of intermediate 
prognosis. Without confirmed familial MCE, prognosis was considered to be benign. 
Results 
The complete coding sequences of 17 genes; six genes previously associated with NCCM and 
11 NCCM candidate genes, were analysed in a cohort of 56 unrelated NCCM patients: 48 
adults and 8 children. Disease causing mutations were identified in 23 (41%) patients. Five of 
these 23 patients (22%) had multiple mutations. 
Twenty-nine NCCM mutations, including 21 novel ones, were identified in 11 different genes 
(Figure 1): MYH7, MYBPC3, TNNT2, TNNI3, ACTC1, TPM1, CASQ2, PLN, LMNA, LDB3 and 
TAZ. No mutations were observed in the MYL2, MYL3, TNNC1, CSRP3, TCAP and CALR3 
genes. Twenty-two (76%) of the identified mutations were found in sarcomeric genes and seven 
mutations (24%) were present in genes of the Z-disc, Calcium-handling system and nuclear and 
mitochondrial lamina (Table 1). 
The most frequently involved gene 
was MYH7, mutated in 11/56 (20%) 
patients demonstrating that this gene 
is the sole most important genetic 
factor thus far for NCCM (Figure 1). 
The MYBPC3 gene was mutated in 3 
patients (5%). Mutations in LDB3, 
CASQ2, TNNT2 and TPM1 each 
occurred in 2 patients (4%). 
Mutations in TNNI3, ACTC1, LMNA, 
PLN and TAZ were the least frequent in NCCM (2%). As a consequence of complex genotypes, 
twenty-one mutations were identified in seventeen adult patients and eight mutations were 
found in six children. The relative contribution of each disease gene to NCCM was analysed by 
looking at the distribution of the 29 identified mutations in 23 patients (Table 1). Thirty-eight 
(11/29) percent of the mutations were observed in MYH7. Among the patients with an MYH7 
mutation, no complex genotypes were observed. Fourteen percent (4/29) of the mutations were 
found in MYBPC3 and 10% of the mutations were in TNNT2. Seven percent of the mutations 
were found in TPM1, CASQ2 and LDB3 respectively. 
Figure 1. Genetic NCCM in 56 patients 
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Table 1. Distribution of mutations in 23 genotyped NCCM patients. 
Number of mutations found in: Protein 
function Gene Adults 
(n = 17) 
Children 
(n = 7) 
Single 
Genotype 
Complex 
Genotype 
Novel 
mutations 
Total 
mutations 
Sacromere MYH7 9 2 11  10 11 (38%) 
 MYBPC3 2 2 2 2 2 4 (14%) 
 TNNT2 3   3 3 3 (10%) 
 TNNI3  1  1 1 1 (3%) 
 ACTC1  1 1  1 1 (3%) 
 TPM1  2 1 1 2 2 (7%) 
Ca-handling CASQ2 2  1 1 1 2 (7%) 
 PLN 1  1   1 (3%) 
Z-disc LDB3 2   2  2 (7%) 
Nuclear 
membrane LMNA 1   1  1 (3%) 
Mitochondria TAZ 1  1  1 1 (3%) 
Total Mutations 20 9 18 11 21 29 
 
Three percent of the mutations were present in TNNI3, ACTC1, PLN, LMNA and TAZ. 
Mutations in TNNT2, TNNI3, LDB3, LMNA and TAZ were only observed in complex genotypes. 
The six children with a mutation all had a sarcomeric mutation. Non-sarcomeric mutations were 
only detected in adult NCCM patients (Table 1). The complex genotypes in adult patients 
comprised combinations of sarcomeric mutations and mutations in non-sarcomeric genes. 
 
NCCM mutations in sarcomere genes 
Twenty-two of the 29 (76%) mutations were found in sarcomeric genes (Tables 1 and 2) 
(Families 1-10, 13-15 and 18-23 of the addendum of chapter 3). Analysis of MYH7 resulted in 
the identification of eleven mutations including ten new mutations. Seven MYH7 mutations were 
missense mutations. In addition, one previously described double-missense mutation 
(p.Asp545Asn/p.Asp955Asn in cis, Table 3)15, a splice-site mutation (c.732+1G>A), a single 
amino acid deletion (p.Glu1350del) and a nonsense mutation (p.Tyr266X) were detected. The 
p.Tyr266X mutation is predicted to lead to a severely truncated MYH7 protein of 265 amino 
acids. Alternatively, the mechanism of nonsense mediated decay may interfere with MYH7 
protein formation from the mutated allele.22 
Four MYH7 mutations, c.732+1G>A, p.Tyr266X, p.Leu301Gln and p.Arg369Gln, cluster in the 
ATP-ase active site of the globular head-region on the amino-terminal part of MYH7 (Figure 2). 
Mutations in this region were recently associated with NCCM with or without Ebstein 
anomaly.16, 17 The four MYH7 mutations p.Glu1350del, p.Tyr1488Cys, p.Asn1918Lys and 
p.Arg1925Gly, were found in the carboxy-terminal rod-region of the MYH7 protein which is 
normally relatively void of cardiomyopathy mutations. The p.Arg1925Gly mutation was recently 
also seen in an apparently unrelated NCCM patient, diagnosed after completion of this study. 
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Table 2. NCCM mutations and unclassified variants in sarcomeric genes. 
Gene  Nucleotide Protein Consequence No. of patients Ref. 
ACTC1 c.811A>G p.Met271Val Missense 1  
 *22C>T  (3'UTR) rs28730667 1  
MYBPC3 c.442G>A p.Gly148Arg Missense 1  
 c.646G>A p.Ala216Thr Missense  1  
 c.2373dupG p.Gly791fs Truncating  2 23 
MYH7 c.732+1G>A  Splice-donor site 1  
 c.798T>A p.Tyr266X Nonsense 1  
 c.902T>A  p.Leu301Gln Missense 1 15 
 c.1106G>A p.Arg369Gln Missense 1  
 c.1633G>A and c.2863G>A in cis 
p.Asp545Asn and 
p.Asp955Asn in cis Missense 1 
15 
 c.1972C>G p.Leu658Val Missense 1  
 c.2453T>A p.Ile818Asn Missense 1  
 c.4048_4050delGAG p.Glu1350del Amino-acid deletion 1  
 c.4463A>G p.Tyr1488Cys Missense 1  
 c.5754C>G  p.Asn1918Lys Missense 1  
 c.5773C>G p.Arg1925Gly Missense 1  
TNNI3 c.539A>G p.Asp180Gly Missense 1  
TNNT2 c.260C>T p.Pro87Leu Missense 1  
 c.482G>A p.Arg161His Missense 1  
 c.673G>T p.Val225Leu Missense 1  
TPM1 c.241-12_241-11delinsTG  Splice-acceptor site 1  
 c.479G>A p.Arg160His Missense 1  
Legend. Sarcomeric NCCM mutations and unclassified variants identified in this study. Novel 
mutations are in bold. Unclassified variants are in italics. 
 
 
Table 3. Sarcomeric NCCM mutations reported in previous studies. 
Gene  Nucleotide Protein Consequence Ref. 
ACTC1 c.478G>A p.Glu101Lys  17, 18 
MYH7 c.801_803delGAC p.Asp239del  17 
 c.814G>A p.Arg243His  17 
 c.818+1G>A   17 
 c.818+3G>C   17 
 c.842G>C p.Arg281Thr  16 
 c.840T>C p.Phe252Leu  17 
 c.902T>A  p.Leu301Gln  15 
 c.1633G>A and c.2863G>A in cis p.Asp545Asn and p.Asp955Asn in cis  
15 
 c.4161C>T p.Arg1359Cys  17 
 c.5382G>A p.Ala1766Thr  17 
TNNT2 c.450C>T p.Arg131Trp  16 
 
MYBPC3 mutations were identified in three patients, including the Dutch c.2373dupG founder 
mutation in two patients.23 One had the p.Gly148Arg mutation on the other MYBPC3 allele. The 
Glycine residue at position 148 is conserved in mammals. The MYBPC3 p.Ala216Thr mutation 
was identified in another patient. The Alanine residue at position 216 is conserved in most 
mammal species. 
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 Figure 2. Currently identified NCCM mutations in MYH7. 
 
Mutations identified in this study are in bold. AAS: ATPase active site; ELC: myosin essential light chain 
binding site. 
 
Three TNNT2 mutations were identified in two NCCM patients. One NCCM patient had the 
p.Pro87Leu mutation. The Proline at position 87 is conserved up to nematode C. elegans. The 
other patient had two TNNT2 mutations, the p.Arg161His mutation and p.Val225Leu. We were 
unable to determine the phase of the two TNNT2 variants since no relatives were available for 
testing. P.Arg161His is likely pathogenic because the Arginine at 161 is highly conserved up to 
fruit fly and a mutation affecting the same amino acid has been reported (rs45608937; 
c.481C>T, p.Arg161Cys). The p.Val225Leu mutation affects the relatively weakly conserved 
Valine residue at position 225 and is predicted to be non-pathogenic.19, 20 
TPM1 mutations were identified in two patients. The p.Arg160His mutation was identified as de 
novo mutation in a 16-year old NCCM patient who received a heart-transplant at age 17. The 
Arginine residue at position 160 is conserved in all mammals. The other TPM1 mutation c.241-
12_241-11delinsTG was found in combination with the TNNI3 mutation p.Asp180Gly in a four 
months old patient. The TNNI3 mutation p.Asp180Gly affects the Aspartic acid residue at 
position 180 which is conserved up to Platypus. 
The ACTC1 mutation p.Met271Val was found in a child that was diagnosed with NCCM one 
month after birth. The mutation was de novo in her father who was diagnosed with a dilated left 
and right ventricle without evident crypts on echocardiography. Most ACTC1 amino acid 
substitutions are poorly tolerated and overall cross-species conservation of protein sequence is 
one of the highest known. The Methionine at position 271 is conserved up to C. elegans. 
 
NCCM mutations in non-sarcomere genes 
Seven of the 29 (24%) mutations were found in non-sarcomeric genes (Tables 1 and 4) 
(Families 11, 12, 14-17, A, B and C of the addendum of Chapter 3). Analysis of Calcium-
handling genes resulted in the identification of p.Arg14del in the phospholamban (PLN) gene in 
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an adult NCCM patient. This mutation was previously associated with hereditary heart failure 
and dilated cardiomyopathy.24, 25 CASQ2 DNA variants were found in four NCCM patients. Two 
had the p.Asp398del variant, which removes an Aspartic acid residue at the C-terminal part of 
the CASQ2 protein. This variant was not found in control chromosomes. Although p.Asp398 is 
part of a conserved stretch of 5 Aspartic acid residues, this part of the CASQ2 protein is weakly 
conserved between species. This variant did not segregate with disease in the two families of 
the patients, contesting its pathogenicity. 
 
Table 4. NCCM mutations and unclassified variants in sarcomeric genes. 
Gene  Nucleotide Protein Consequence No. of patients Ref. 
CASQ2 c.731A>G p.His244Arg Missense rs28730716 2  
 c.1194_1196delTGA p.Asp398del Amino-acid deletion 2  
PLN c.40_42delAGA p.Arg14del Amino-acid deletion 1 24, 25 
CSRP3 c.*12G>A  (3'UTR) rs45607943 1  
LMNA 1608+5G>C  Splice-donor site disruption 1 26 
 1968+26A>G  Splice-acceptor site? 2  
LDB3 c.349G>A p.Asp117Asn (Isoform 4) 2 27 
 c.352G>A p.Val118Met (isoform 1) rs35507268 1  
 c.611A>G p.Lys204Arg (Isoform 4) rs34423165 1 27 
 c.549-4A>G  (Isoform 4) rs45529531 1  
TAZ c.383T>C p.Phe128Ser Missense 1  
Legend. Non-sarcomeric NCCM mutations and unclassified variants identified in this study. Novel 
mutations are in bold. Unclassified variants are in italics. 
 
Two NCCM patients had the p.His244Arg mutation in CASQ2. The Histidine at position 244 lies 
in the thioredoxin-like fold of CASQ2 and is highly conserved up to birds. The substitution for 
Arginine at this position is predicted to be pathogenic.19, 20 The PLN and CASQ2 mutations are 
the first mutations in Calcium-handling genes reported to be associated with NCCM. Analysis of 
LMNA resulted in the identification of c.1608+5G>C in a patient with relatives diagnosed with 
NCCM or DCM. This mutation was associated with limb girdle muscular dystrophy with 
cardiologic involvement (LGMD1B).26 In two other NCCM patients, the LMNA variant 
c.1968+26A>G was detected which is predicted to lead to an aberrant splice-acceptor site. 
Since this variant was also observed twice in control chromosomes it was considered a UV. 
Analysis of LDB3 resulted in the identification of the p.Asp117Asn mutation in two unrelated 
NCCM patients. This mutation was previously shown to be present in cardiac specific 
Cypher/ZASP isoforms and have a disturbing effect on cellular architecture in transfected 
C2C12 cells.27 A taffazin gene (TAZ) mutation, p.Phe128Ser, was detected in a 57 years old 
female patient. There is a large physicochemical difference (‘Grantham distance’) between 
Phenylalanine and Serine residues and this mutation was not observed on 384 control 
chromosomes. Previously reported non/sarcomeric ]nccm mutations are listed in Table 5. 
 
Paediatric patients  
Eight (14%) of the 56 patients were diagnosed in childhood (<18 years). Six (75%) of these 
paediatric patients had a sarcomeric mutation, including four single mutations and two complex 
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sarcomeric genotypes (Tables 1 and 6). Two patients aged four and 10 years had an MYH7 
mutation, one six-weeks old patient had an ACTC1 mutation and one 16-year-old patient had a 
TPM1 mutation.  
 
Table 5. Previously reported non-sarcomeric NCCM mutations. 
Gene  Nucleotide Protein Consequence Reference 
DTNA c.362C>T p.Pro121Leu  31, 34 
LMNA c.368C>T p.Arg109Trp  30 
LDB3 c.349G>A p.Asp117Asn Disruption cytoarchitecture 27 
 c.587C>T p.Ser196Leu  27 
 c.1876G>A p.Asp626Asn Altered PKC binding affinity 34, 35 
TAZ c.157dupC p.Leu53fs  34 
 c.352C>T p.Cys118Arg  31, 36 
 c.589G>A p.Gly197Arg  37 
 c.647-1G>C  Exon 9 skipping 34, 38 
 c.777+2T>A  Exon 10 skipping 31, 32, 36 
 
Complex genetic status 
Multiple mutations were observed in five of the 23 genotyped NCCM patients: one had three 
mutations and four patients had two mutations. In addition, two patients had a mutation in 
combination with a UV (Table 6). One patient had the p.Asp545Asn and p.Asp955Asn MYH7 
mutations. Since these mutations were previously shown to be allelic, the patient was not 
considered to be of complex genetic status.15 One paediatric patient had the MYBPC3 
c.2373dupG mutation on one and the p.Gly148Arg mutation on the other MYBPC3 allele. We 
have recently found p.Gly148Arg associated with the MYBPC3 p.Ser311X nonsense mutation 
in trans in two sisters with early onset HCM (onset ~16 years). One patient, diagnosed at the 
age of 3 months who died at the age of four years, had the TPM1 mutation c.241-12_241-
11delinsTG in combination with the TNNI3 mutation p.Asp180Gly. 
One patient presenting with peripartum cardiomyopathy had two TNNT2 mutations, 
p.Arg160His and p.Val225Leu, in combination with a third mutation, the CASQ2 mutation 
p.His244Arg. One adult patient had the TNNT2 p.Pro87Leu mutation and the LDB3 mutation 
p.Asp117Asn. An unrelated NCCM patient from a family with LGMD1B had the same LDB3 
mutation p.Asp117Asn in addition to the LMNA mutation c.1608+5G>C. His brother, who had 
ECG abnormalities but no signs of NCCM on echocardiography or MRI, also had these two 
mutations. Other relatives diagnosed with DCM or LGMD1B had only the LMNA mutation. 
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Prognosis 
Ascertainment of family histories allowed us to investigate prognosis in 55 families stratified for 
genotype including a sub classification in MYH7 and other mutations (Table 7). Sixty-eight 
percent of non-genotyped families had a benign prognosis and 22% had a malignant prognosis. 
In contrast, 27% of the genotyped MYH7 families had a benign prognosis and 45% had a 
malignant prognosis. Families with non-MYH7 mutations showed intermediate results, 58% had 
a benign prognosis and 33% a malignant prognosis. These results indicate that in families with 
a malignant prognosis the chance to identify a pathogenic (MYH7) mutation is increased 
compared to families with a less severe prognosis. Pathogenic MYH7 mutations are associated 
with a more malignant prognosis than mutations in other genes or NCCM caused by yet 
unidentified causes (non-genotyped) (p=0.112). 
 
Table 7. Prognosis and genotype in NCCM families. 
Prognosis 
Genotype Total probands n (%)* Benign 
n(%)* 
Intermediate 
n(%)* 
Malignant 
n(%)* 
MYH7 11 (20) 3 (10, 27) 3 (37, 27) 5 (31, 45) 
Other genes 12 (21) 7 (23, 55) 1 (13, 8) 4 (25,33) 
Non-genotyped 32 (58) 21 (68, 66) 4 (50, 13) 7 (44,22) 
Total 55† 31 8 16 
Legend. Prognosis was determined by the number of major cardiac events (MCE) before the age of 60 
yrs in the family. * (% of column, % of row). † Prognosis was not determined in the family of one 
proband.  
Discussion 
To establish a genetic classification and enhance molecular diagnosis for NCCM, a complete 
analysis of 17 cardiomyopathy genes was performed in a cohort of 56 isolated NCCM patients. 
Mutations were found in the MYH7, MYBPC3, TNNT2, TNNI3, ACTC1, TPM1, CASQ2, PLN, 
LDB3, LMNA and TAZ genes. MYBPC3, TNNI3, TPM, PLN and CASQ2 were identified as new 
NCCM genes. This is the first report associating the Calcium-handling system genes PLN and 
CASQ2 with NCCM. Disease causing mutations were identified in 41% of the patients (in 35% 
of adult patients and 75% of children), making this the highest reported percentage of 
genotyped NCCM thus far. This is also the first genetic study of NCCM in childhood, indicating 
that childhood NCCM is predominantly a sarcomeric disease. 
Hypertrophic cardiomyopathy is mainly caused by mutations in genes encoding sarcomeric 
proteins. In large patient series, a pathogenic mutation is identified in up to 65% of the HCM 
patients by screening the same nine sarcomeric genes that were analysed in this study.21 The 
most prevalent disease genes in HCM are MYBPC3 and MYH7, each accounting for 
approximately 40% of the mutations.21, 28 The genetic basis of DCM is more heterogeneous and 
includes, in addition to sarcomeric mutations, mutations in genes encoding proteins of 
intracellular and extracellular matrix as well as the nuclear and mitochondrial lamina. Extensive 
molecular analysis in patients reveals a defect in approximately only 30% of DCM.29 The 
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present study shows that NCCM, HCM and DCM share a number of genetic causes. Extensive 
genetic screening results in the identification of a mutation in 41% of the patients, an MYH7 
mutation in half of these patients and only a modest contribution of the other disease genes. 
Previously described non-sarcomeric genetic causes for NCCM include mutations in the TAZ, 
LMNA and LDB3 genes.27, 30, 31 Mutations in these genes have however been shown to be only 
rare causes of NCCM and their relevance is mostly limited to single families.32 After the initial 
report associating sarcomeric MYH7 mutations with isolated NCCM15, the importance of MYH7 
mutations was confirmed and the ACTC1 and TNNT2 genes were implicated in the aetiology of 
NCCM.16-18 Klaasen et al., identified a sarcomeric MYH7, TNNT2 or ACTC1 mutation in 17% of 
NCCM patients.17 The higher percentage (41%) of genotyped NCCM patients in the present 
study may partially be explained by the larger number of genes analysed (17 vs. 6) and a 
higher percentage of paediatric patients in this study. The percentages of MYH7 mutations in 
the study of Klaassen et al. and the present study (13% and 20% respectively), indicate that 
MYH7 is the most important genetic cause for isolated NCCM in adults as well as in children.17 
MYH7 mutations are common in familial forms of cardiomyopathy, including HCM, DCM, RCM 
and distal myopathies with cardiac involvement. Most mutations leading to the different 
cardiomyopathies are located in the head and neck regions, much more than in the rod region. 
Remarkably, 50% (10/20, Figure 2) of the MYH7 mutations currently associated with NCCM, 
cluster in the ATPase active site in the head region of MYH7. This is an evolutionary well-
conserved region of MYH7. As the ATPase active site is required for normal force production, 
impaired force generation might play a role in the aetiology of NCCM. Six other MYH7 
mutations (30%) associated with NCCM were located in the rod domain of the protein. This light 
meromyosin (LMM) part of the protein adopts an α-helical coiled coil-structure that forms the 
core of the thick filament. Mutations in this domain could perturb thick filament assembly which 
may also be important in the aetiology of NCCM.33 
Five patients (21%) had multiple mutations. Two patients with complex genetic status were 
diagnosed in childhood and had a severe presentation. These findings indicate that, especially 
in patients with a severe presentation and/or early onset of disease, performing a complete 
molecular screening of all NCCM genes even when a pathogenic mutation has been found is 
recommended. Ascertainment of complex genetic status is important to determine risk for 
relatives and may help to understand genotype-phenotype relations. Our results confirm that 
mutations in non-sarcomeric genes, including mutations in the TAZ, LMNA and LDB3 genes, 
are relatively infrequent genetic causes for NCCM.27, 30, 31  Absence of a mutation after genetic 
screening in approximately half of NCCM could be explained by involvement of other yet 
unidentified disease genes, undetected mutations in non-analysed gene sequences, diagnostic 
errors or incomplete sensitivity of the methods used. Alternatively, the possibility of non-genetic 
forms of NCCM or the involvement of somatic mutations cannot be excluded. 
We found that in families of patients in which we identified a mutation, genotype-positive NCCM 
was associated with a less favourable prognosis. This finding was not statistically significant 
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due to limited patient numbers. The observation could partly be explained by the presence of 
non-genetic forms of NCCM among the genotype-negative patients. 
Similar to the other cardiomyopathies, NCCM is mainly caused by mutations in genes that 
encode various structural cardiac proteins. Rather than being a separate disease entity, this 
study demonstrates that NCCM genetically classifies in the aetiologic spectrum of 
cardiomyopathies also including HCM and DCM since, sometimes identical, mutations in 
shared disease genes can lead to these different phenotypes. HCM and NCCM are primarily 
diseases of the sarcomere but the relative importance of disease genes differs between these 
two diseases and NCCM mutations are also found in disease genes previously only associated 
with DCM. The large number of genetic defects identified thus far in isolated NCCM may lead to 
inclusion of NCCM as a genetic cardiomyopathy in future cardiomyopathy classifications as 
suggested by the AHA.33 
In conclusion, we report a systematic molecular genetic screen in a large cohort of isolated 
NCCM patients. NCCM is predominantly a genetic disease with NCCM associated disease 
seen in families of 67% of NCCM patients (Chapter 3). Like HCM, NCCM is primarily a disease 
of the sarcomere. Extensive genetic screening may lead to the identification of a molecular 
defect in 41% of isolated NCCM patients and in half of these patients an MYH7 mutation is 
found. Other disease genes have a relatively modest contribution to the disease. These results 
indicate that in NCCM, like in the other cardiomyopathies, genetic analysis is recommended. 
Initial screening of the MYH7 gene in NCCM patients should be considered as an initial 
approach, possibly followed by the analysis of the other genes of the NCCM spectrum. In 
paediatric patients, sarcomeric gene analysis is warranted given the high percentage of 
sarcomeric mutations in these patients. The identification of genetic causes of NCCM could 
enhance diagnosis, risk assessment and counselling in NCCM families. 
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Abstract 
Introduction 
Noncompaction cardiomyopathy (NCCM), characterised by localised endocardial thickening 
consisting of a meshwork of trabecularisation of the left ventricular wall, can present with heart 
failure, thombo-embolism and sudden death. The majority of NCCM is isolated and 
predominantly familial. NCCM was associated with defects in sarcomere genes, particularly the 
ß-Myosin Heavy Chain (MYH7) gene. 
 
Methods and results 
We report the first two individual cases of prenatally diagnosed NCCM caused by a mutation in 
the MYH7 gene. Biventricular cardiomegaly led to the diagnosis of NCCM at 31 and at 23 
weeks of pregnancy respectively. The parents were unaware of familial cardiomyopathy. 
However, subsequent cardiologic family screening and molecular diagnostics identified MYH7 
cardiomyopathy in several members in both families. 
 
Conclusions 
Prenatal NCCM with biventricular enlargement may occur in familial MYH7 cardiomyopathy. In 
accordance with previous reports, the prognosis of prenatally diagnosed NCCM predominantly 
depends on cardiac function and may improve after birth. Since MYH7 mutations may present 
with prenatal onset, prenatal ultrasound of pregnancies at risk for MYH7 cardiomyopathy is 
recommended. Familial disease may initially present with a prenatal onset, molecular 
diagnostics and cardiologic screening of first-degree relatives are therefore necessary even in 
absence of a family history of cardiomyopathy. 
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Introduction 
Noncompaction of the left ventricle or noncompaction cardiomyopathy (NCCM) was first 
described by Feldt et al in 1969.1 It is characterised by a prominent trabecular meshwork and 
deep intertrabecular recesses communicating with the left ventricular (LV) cavity, 
morphologically reminiscent of early cardiac development. Therefore NCCM was thought to be 
caused by an arrest of normal embryogenesis of the myocardium.2, 3 NCCM, alternatively 
referred to as left ventricular noncompaction (LVNC) in the literature, is the third most prevalent 
cardiomyopathy in childhood after hypertrophic (HCM) and dilated cardiomyopathy (DCM), with 
an estimated prevalence of 9% in paediatric cardiomyopathies.4 
NCCM can present at all ages with heart failure, (potentially lethal) arrhythmia or stroke. A large 
proportion of NCCM in adults is asymptomatic and is diagnosed by chance at routine medical 
screening or by family studies with cardiologic or molecular screening, following the diagnosis 
of cardiomyopathy in a relative. The majority of NCCM diagnosed in adults is isolated. Non-
isolated forms of NCCM are more frequent in childhood and co-occur with congenital heart 
malformations, neurological disorders, as part of a malformation or chromosomal syndrome, or 
are caused by metabolic or mitochondrial defects.5 In the majority of patients NCCM, isolated 
and non-isolated, is hereditary. NCCM appears to be genetically heterogeneous, and is 
predominantly caused by sarcomere gene defects. A recent study showed that 75% of children 
diagnosed with isolated NCCM had a mutation in sarcomere genes that are also involved in 
HCM, DCM and restrictive cardiomyopathy (RCM). Similar to other sarcomere 
cardiomyopathies, in NCCM genetic and cardiac screening of first-degree relatives is therefore 
recommended. Absence of a known genetic defect does not preclude a genetic cause of 
NCCM. In approximately half of familial isolated NCCM diagnosed in adults the genetic defect 
remains unknown. Shared sarcomere defects and the occurrence of HCM and DCM in families 
of NCCM patients indicate that, at least some forms of NCCM are part of a broader 
cardiomyopathy spectrum. 
A review of the literature of prenatal diagnosis of NCCM is presented in this study and indicates 
that none of the previous cases had been genotyped.6-20 We report the first two prenatal 
diagnosis of NCCM caused by a sarcomere gene defect. 
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Patient 1 
A 30-year-old healthy Caucasian woman, was referred in her first pregnancy for prenatal 
ultrasound to the Department of Obstetrics and Prenatal Medicine at our hospital because her 
husband had been diagnosed with a then unspecified childhood heart condition. He had been 
discharged from cardiologic follow-up at the age of 14 years. He performed his military service 
and had a full-time job without suffering from a heart condition. 
 
Prenatal examination 
Ultrasound at 20 weeks’ gestation revealed a normal four-chamber view of the heart with no 
evidence of structural or functional abnormalities of the heart (Figure 1). According to protocol a 
repeat scan was performed at 
31 weeks’ gestation and 
showed a severe cardiomegaly 
with extensive mitral and 
tricuspid regurgitation. The 
cardiac-thoracic ratio was 0.7 
(>>P95).21 Both ventricles and 
atria were enlarged, the right 
ventricle was more dilated than 
the left ventricle and cardiac 
contractility was impaired. The 
myocardium was hypertrophic 
and showed a spongiform aspect (Figure 2). Amniocentesis was performed and chromosome 
analysis showed a normal female karyotype; FISH-analysis excluded a 22q11 deletion. There 
were no signs of intra-uterine infection: screening for TORCH, parvovirus B19, enterovirus, 
coxackievirus and parechovirus was negative. At repeated examinations at 35+6 weeks of 
gestation the hypertrophic and spongiform aspect was predominantly localized in the 
myocardial apex; tricuspid regurgitation had increased and was more severe than mitral 
regurgitation. 
Figure 1. Prenatal ultrasound of patient 1 at 20 weeks’ 
gestation. 
A. Normal four-chamber view of the heart.  
B. Normal aspect of the left ventricle and aorta. 
 
 
 
 
 
 
 
 
B A 
 Figure 2. Prenatal ultrasound of patient 1 at 31 weeks’ gestation  
A. Enlarged heart with hypertrophic and spongy myocardium, particularly in the left apex (arrow).   B. Colour Doppler image of severe regurgitation over tricuspid and mitral valve.  
 C. Pulsed Doppler image of severe tricuspid regurgitation (> 200 cm/sec) 
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Postnatal period 
Labour was induced at 38+2 weeks’ gestation 
due to a deteriorating foetal condition. A girl 
was delivered with a birth weight of 2990 g 
(P25) and Apgar scores of 6 and 9 after one 
and five minutes. Postpartum 
echocardiography con-firmed noncompaction 
cardiomyopathy (apical and lateral wall) with 
biventricular dilatation, impaired left 
ventricular function (shortening fraction (SF) 
of 20%), moderate mitral and severe 
tricuspid regurgitation (Figure 3). The child 
was treated with continuous positive airway 
pressure for a few hours and was discharge
condition. During the following weeks she developed feeding problems and was hospitalised for 
congestive heart failure at the age of three months with severe mitral valve regurgitation, mild 
mitral valve stenosis, substantial left atrial dilatation and secondary pulmonary hypertension, 
reactive to oxygen and nitric oxide. Surgical mitral valvoplasty was performed at four months of 
age. There was a grade III residual mitral regurgitation one week after the procedure requiring 
additional intervention. In a third operation a mechanical valve (St. Jude, 17 mm) was implanted 
in mitral position. Thrombosis of one of the valve leafs necessitated another intervention. LV 
function gradually improved to near-normal levels after implanting the mechanical valve and 
increasing ACE-inhibitor and β-blocker medication. Her cardiac situation remains stable at age 
three years and nine months, still requiring partial tube feeding. 
 
Figure 3. Postnatal echocardiography of patient 1. 
ouF
located in the left ventricular apex 
r-chamber view with evident noncompaction 
(arrows). 
d from hospital after 14 days in good clinical 
ardiologic family study (Figure 4)C  
wed that he suffered of 
showed no abnormalities. 
Medical records of the father sho
MYH7 +/-
DCM
MYH7 -/- MYH7 -/-
ND MYH7 -/-
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tachypnoea at the age of three months. At the age of six 
months, he was diagnosed with a dilated LV and mitral valve 
regurgitation. Differential diagnosis for his dilated LV then 
included subendocardial fibroelastosis and myocarditis. He 
was treated with digitalis and prednisone. His condition 
improved and he was discharged from cardiologic follow up 
when chest X-ray showed a normal heart-thoracic index and 
he was without symptoms at age 14 years. Cardiologic 
screening of the asymptomatic father at age 36 years showed 
dilated cardiomyopathy (DCM) LV end diastolic diameter 76 
mm) with an ejection fraction (EF) of 40%. Cardiologic 
screening of the paternal grandparents and the mother 
Figure 4. Pedigree of family 1. 
The arrow indicates the proband. 
ND: not determined. 
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Molecular testing 
DNA analysis in the father identified mutation p.Cys905Arg in the ß-Myosin Heavy Chain gene 
Patient 2 
woman, gravida 6, para 2, of Turkish descent, was referred at 23 weeks’ 
renatal examination
(MYH7). This mutation was postnatally confirmed in his affected daughter. P.Cys905Arg is a 
novel MYH7 mutation (i.e. has not been described previously) and is  expected to be 
pathogenic because a pathogenic mutation p.Cys905Phe has been described on the same 
amino acid location.22 The unaffected paternal grandparents did not carry the p.Cys905Arg 
mutation in the MYH7 gene confirming that the mutation occurred de novo in the affected 
father. 
 
A 33-year-old 
gestation to our hospital for advanced prenatal imaging after a routine anomaly scan detected a 
foetal cardiomegaly with increased ventricular wall thickness. 
 
P  
s’ gestation confirmed biventricular cardiomegaly with a cardio-thoracic Ultrasound at 23 week
ratio >P95 21, decreased contractility and increased apical myocardial wall thickness. Doppler 
ultrasound of the tricuspid, mitral, pulmonary valves and aorta did not reveal functional 
insufficiency. Cardiac structural defects were excluded. Maternal TORCH, parvovirus B19, 
adenovirus and enterovirus screening was negative. The patient declined amniocentesis. 
Ultrasound examinations at 28 and 32 weeks’ gestation showed a slight decrease in 
cardiomegaly, unchanged decreased contractility but no evidence of insufficient blood flow. At 
36 weeks’ gestation signs of noncompaction became visible in the apex (Figure 5). 
 
Figure 5. Prenatal ultrasound of patient 2  
A. Four-chamber view of the heart at 23 weeks’ gestation with increased apical myocardial thickness. 
B. Colour Doppler ultrasound of the apical right ventricular wall at 36 weeks’ gestation shows filling of 
the non-compacted myocardium.  
C. Graph of cardiothoracic (CT) ratio indicating decrease of cardiomegaly during gestation. 
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Postnatal period 
Labour was induced at 37 weeks and 4 
days due to foetal heart rate decelerations. 
A boy was delivered with a birth weight of 
2700 g (>P10), Apgar scores were 9, 10 
and 10 after one, five and 10 minutes 
respectively. Echocardiography showed 
NCCM of the apex and lateral wall (NC/C 
ratio 4.4 / 1.8) with cardiomegaly, without 
impairment of the left ventricular function 
(SF 30%) (Figure 6). The infant was 
discharged from hospital on day one after 
delivery. Cardiologic follow up at three 
months showed normal cardiac function 
and dimensions with unchanged NCCM. 
He was feeding well and growing accordingly. 
Figure 6. Postnatal echocardiography of patient 2 
Four-chamber view with evident thickened endocardium 
with noncompaction located in the left ventricular apex 
(arrow). 
 
Cardiologic family study 
Subsequent cardiologic screening of the non-consanguineous parents identified NCCM in the 
34-year-old father and the 10-year-old asymptomatic brother of the index. The father suffered 
from exercise dyspnoea. His EF was 36%. The mother, a 14-year-old brother and two paternal 
aunts were cardiologically unaffected. The paternal grandmother had been diagnosed with 
NCCM shortly before, at age 62 years after having experienced chest pain. She had an NC/C 
ratio of 2.1 in the posterolateral, lateral and apical regions of the LV, EF of 23% and left atrial 
enlargement of 183 ml. One of her sisters suffered a sudden cardiac death at the age of 38 
years. The pedigree of this family is depicted in Figure 7. 
 
Molecular testing 
A pathogenic MYH7 splice-site mutation (c.732+1G>A) and a cardiac Myosin Binding Protein 
C3 gene (MYBPC3) unclassified variant (UV) (p.Gln1142Pro) were identified in the affected 
father. DNA analysis showed the MYH7 mutation and the MYBPC3 UV in the index and his 
affected brother. The MYH7 mutation was excluded in two unaffected paternal aunts (one had 
the MYBPC3 UV) and in an unaffected maternal cousin of the father. 
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Figure 7. Pedigree of family 2. 
The arrow indicates the proband. MYBPC3 = cardiac Myosin Binding Protein C3 gene; MYH7 = ß-Myosin 
Heavy Chain gene; ND = not determined; SD = Sudden death; SVES = Supra Ventricular Extra Systole. 
 
Discussion 
We describe the first two prenatal ultrasound diagnosis of NCCM associated with pathogenic 
mutations in the gene coding for heavy chain sarcomere protein MYH7. Sarcomere mutations 
are important causes for HCM, DCM, RCM and NCCM in adults and children. However, to our 
knowledge, prenatal presentation of NCCM, HCM, DCM, or RCM in families with an MYH7 or 
other sarcomere mutation have not yet been reported. 
MYH7 mutations are the most common genetic cause for NCCM and show – like other 
sarcomere cardiomyopathies – variability in age at diagnosis including NCCM diagnosed in 
childhood. As this report indicates, MYH7 mutations may also present with prenatal 
cardiomyopathy. For that reason prenatal ultrasound of pregnancies at risk for cardiomyopathy 
in families with MYH7 mutations is recommended, allowing optimal peripartum care in favour of 
an affected child. Because familial disease may initially present with a prenatal onset, molecular 
diagnostics and cardiologic screening of first-degree relatives are recommended even in 
absence of a family history of cardiomyopathy. This way cardiologic surveillance and – if 
necessary treatment – can be offered during pregnancy in order to reduce risks of peripartum 
cardiomyopathy in the mother. 
Whether prenatal onset of cardiomyopathy in familial NCCM is specific for MYH7 mutations or 
whether other sarcomere related cardiomyopathies may also present with prenatal 
cardiomegaly, arrhythmia or decreased cardiac function has yet to be established. 
Previous reports of prenatal diagnosed NCCM illustrate that this diagnose is possible from the 
20th week of gestation (Table 1). The majority of the cases were diagnosed between 20 and 26 
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weeks of gestation (mean 26, median 25 weeks). The first case presented in this paper had 
normal findings at 20 weeks gestation, indicating that in pregnancies at risk for genetic NCCM, 
ultrasound should be repeated in the third trimester. 
Most cases (17/32) had biventricular involvement; the RV was often more affected than the LV, 
possibly because of the haemodynamics of the foetal circulation, with a dominant RV. After 
birth the LV becomes the systemic ventricle, pumping against high pressure, whereas the RV 
pumps against low pressures after birth. Gradual diminishing of noncompaction of the RV after 
birth suggests certain reversibility to alterations in haemodynamic conditions. Hypothetically, 
NCCM may be explained by remodelling of the myocardial tissue, adjusting itself to different 
circumstances. According to the diagnostic criteria (Jenni) for NCCM, only signs of left 
ventricular noncompaction are characteristic for NCCM. And although there are no diagnostic 
criteria for right ventricular involvement in noncompaction cardiomyopathy, right ventricular 
noncompaction in adults were observed in as much as 38-41% of adult NCCM.23, 24  
As the review of the literature of prenatally diagnosed NCCM in Table 1 shows, a large 
proportion of the 32 reported cases were detected in initially diagnosed structural heart defects 
(16/32). In NCCM families congenital heart defects appear to be more prevalent than in the 
normal population. So far no aetiological association has been established. Nevertheless, it 
suggests that further considerations are necessary whether absence of congenital heart defects 
should remain one of the diagnostic criteria of NCCM. 
Arrhythmia (mainly bradycardia), hydrops and reduced foetal movement were among the other 
indications for advanced ultrasound between 20 - 34 weeks’ gestation, leading to the diagnosis 
of NCCM, indicating that NCCM should be considered in these prenatal conditions. 
Genetic risk for cardiomyopathy was the initial reason for prenatal ultrasound in four cases from 
literature. The importance of screening for cardiomyopathy in parents and siblings was 
illustrated before: in eleven families of the reported prenatal NCCM cases cardiologic screening 
of parents and/or siblings was performed showing familial cardiomyopathy in six families (eight 
cases)10, 12-14 These results clearly endorse the high prevalence of genetic cardiomyopathy in 
prenatal NCCM. Molecular diagnostics may explain approximately half of familial postnatal 
NCCM and - as our report shows - may also find the cause of prenatal NCCM. For that reason 
DNA testing of NCCM related sarcomere genes is recommended in prenatally diagnosed 
NCCM, by means of amniocentesis, postnatal blood sampling or, in case of a lethal outcome, at 
autopsy. 
Detection of a molecular defect in NCCM is important because it allows more accurate 
identification of relatives at risk for cardiomyopathy than cardiologic screening, since a 
proportion of at risk relatives may show age-dependent penetrance or non-penetrance. 
The outcome of prenatal NCCM in previous cases is variable. In complex NCCM, nine of 16 
patients died (two terminations of pregnancy; three foetal demises and four neonatal deaths); 
survival up to four years was described. In isolated NCCM eight of 16 patients died (five 
terminations; one foetal demise; and two neonatal deaths); survival was described up to three 
years of age. 
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Table 1. Part 1. Overview of 32 patients prenatally diagnosed with noncompaction cardiomyopathy, 
including our two cases. 
Involvement 
Patient 
GA at 
diagnosis 
(weeks) LV RV 
Congenital 
Heart 
disease 
Arrhythmia / 
conduction 
abnormalities 
Other features 
1 (M) 20 + +   Hydrops 
2 (F) 20 +  VSD, ASD SVT Mild motor development delay 
3 (M) 20 + - Ao-LV tunnel  AoR 
4 (M) 21   AVSD, DORV, TGV, PS Heart block AVVR; heterotaxy; hydrops 
5 (F) 21   
AVSD, DORV, 
TGV, PS, 
PAPVR 
Heart Block Heterotaxy; hydrops 
6 (F) 21 + + Dextroposition 3
d-degree 
AVB 
Omphalocele; polysplenia;  
clubfeet; systemic venous   
abnormalities 
7 (F) 22 + +  Bradycardia, SVT Hydrops 
8 (M)# 22 - +   TR 
9 (M) 22 + +    
10 (M) 22 +  VSD, ASD  
Corpus callosum agenesis; 
Arnold Chiari malformation;  
facial dysmorphism 
11 (M) 23   AVSD, DORV, TGV Heart block Heterotaxy; hydrops 
12 (M) 23.4 + +    
13 (F) 24  + +   TR; single umbilical artery 
14 (F) 24 +  PS  TR 
15 (M)# 25 - +   MR, TR, Hydrops 
16 (F) 25 + +    
17 (M) 26 + +  SVT Microcephaly; growth retardation; dysmorhic features 
18 (M) 26 + + AoCo Bradycardia Low-set ears 
19 (F) 27 + +  Complete heart block Multicystic kidney; hydrops 
20 (M) 27 + - Ebstein, SA    
21 (M) 28   AVSD, DORV  Heart block AVVR; heterotaxy; hydrops 
22 28 - +  1
st-degree 
AVB, LQT  
23 (F) 29.6 + +  Bradycardia 
MR; TR; omphalocele; absent 
gallbladder; extrabiliary atresia;  
enlarged liver; hydronephrosis 
24 (M) 30   AVSD, DORV, PA, PAPVR Bradycardia AVVR; heterotaxy 
25 (M)* 31 + +   Hydrops 
Legend. AoCo = aortic coarctation; AoR = aortic regurgitation; ASD = atrial septal defect; 
AVB = atrioventricular block; AVSD = atrioventricular septal defect; 
AVVR; atrioventricular valve regurgitation; DA = ductal aneurysm; 
DORV = double outlet right ventricle; F = female; GA = gestational age; 
LQT = long QT segment; LV = left ventricle; M = male; 46XX / 47XX,+22 = Mosaic trisomy 22; 
MR = mitral regurgitation; MVS = mitral valve stenosis; 
MYH7 = ß-Myosin Heavy Chain gene; Nt = not tested. 
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Referral due to 
 
Outcome 
 
Familial Genetic defect Ref. 
Poor ventricular function Stable at age 2 yrs -  13 
Abnormal cardiac anatomy Mild decrease in LVF at age 2 yrs +  13 
Abnormal cardiac anatomy Stable at age 2 yrs -  13 
Bradycardia; hydrops; 
abnormal foetal heart Termination Nt  
20 
Bradycardia; hydrops; 
abnormal foetal heart 
 
Neonatal death 
 
Nt  
20 
 
Bradycardia 
 
Foetal demise Nt  
7, 20 
Foetal arrhythmia; abnormal 
ventricular contraction Termination Nt  
19 
Family history Termination +  14 
Foetal hydrops Termination Nt  9 
 
RV hypoplasia 
 
Stable at age 4 yrs -  
13 
Bradycardia; hydrops; abnormal 
foetal heart Termination Nt  
20 
Hypertrophic aspect myocardium Stable at 7 months + MYH7 This study 
Abnormal foetal heart; single 
umbilical artery Stable at age 3 yrs -  
14 
Maternal DCM; foetal hydrops Neonatal death +  12 
Abnormal foetal heart Termination +  14 
Cardiac enlargement Stable -  13 
Pericardial effusion 
 Termination Nt  
14 
Reduced foetal movements Foetal demise Nt  8 
Foetal hydrops; bradycardia 
 Neonatal death Nt  
11 
Increased foetal heart rate; 
dilated LV Stable at 3.5 yrs Nt  
18 
Bradycardia; hydrops; abnormal 
foetal heart Neonatal death Nt  
20 
Foetal arrhythmia Pacemaker; stable at 5 months Nt  
6 
Omphalocele Stable Nt 
 
 
 
11 
Bradycardia; hydrops; abnormal 
foetal heart Live birth Nt  
20 
Family screening? Foetal demise +  10 
Legend. PA = pulmonary atresia; PAPVR = partial anomalous pulmonary venous return; 
PDA = patent ductus arteriosus; PS = pulmonic stenosis; RV = right ventricle; 
SA = septal aneurysm; SubAoS = subaortic stenosis; SVT = supraventricular tachycardia; 
TGV = transposition of the great vessels; TR = tricuspid regurgitation; US = ultrasound; 
VSD = ventricular septal defect; 
# patient 8 and 15 are brothers; 
* patient 25 and 31 are half-brother and sister. 
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Table 1. Part 2. 
Involvement 
Patient 
GA at 
diagnosis 
(weeks) LV RV 
Congenital 
Heart 
disease 
Arrhythmia / 
conduction 
abnormalities 
Other features 
26 (F) 31.2 + + MVS  MR, TR 
27 (M) 31.5 + +   Dysmorhpic features 
28 32   VSD, SubAoS Heart block Heterotaxy; hydrops 
29 (F) 33 + -  Bradycardia Hydrops 
30  34 + + VSD Bradycardia Hydrops 
31 (F)* 34 + +  Bradycardia, complete AVB  
32 (F) 35 + + ASD, PDA, DA  TR; dysmorphic features 
Legend. AoCo = aortic coarctation; AoR = aortic regurgitation; ASD = atrial septal defect; 
AVB = atrioventricular block; AVSD = atrioventricular septal defect; 
AVVR; atrioventricular valve regurgitation; DA = ductal aneurysm; 
DORV = double outlet right ventricle; F = female; GA = gestational age; 
LQT = long QT segment; LV = left ventricle;M = male; 46XX / 47XX,+22 = Mosaic trisomy 22; 
MR = mitral regurgitation; MVS = mitral valve stenosis; 
MYH7 = ß-Myosin Heavy Chain gene; Nt = not tested. 
 
The difference in gestational age at ultrasound diagnosis of NCCM may depend on late onset of 
NCCM features, like in our first case, or alternatively reflect technical difficulties envisioning the 
fine noncompacted structure of the heart for instance in case of severe dilatation of the 
ventricles. 
Prognosis of prenatal NCCM seems highly variable, even in cases of isolated prenatal NCCM, 
ranging from severe progressive disease to postnatal improvement or stabilization of clinical 
features in asymptomatic infants. This is also illustrated by our two cases, where patient 1 had 
several interventions, and patient 2 hardly experienced any problems after birth so far. 
Counselling and making decisions concerning continuation or termination of pregnancy is 
difficult. In this process, cardiac functioning, presence of additional congenital malformations, 
family history of cardiomyopathy and if available the molecular defect identified in the family, 
may all play a role. 
 
In summary, this report endorses that prenatal diagnosis of NCCM may be possible as early as 
the 20th week of gestation although in some cases NCCM may only become visible later in 
pregnancy. Prenatal NCCM may be biventricular and prognosis is variable depending among 
others on cardiac functioning. Prenatal onset of NCCM may be caused by MYH7 gene 
mutations and may be the initial presentation of familial cardiomyopathy, therefore warranting 
molecular testing and also cardiologic (and molecular) screening of the parents especially in 
case of isolated prenatal NCCM. 
 
 
 
 
Prenatal MYH7 NCCMg 145
 
Referral due to Outcome Familial Genetic defect 
 
Ref. 
 
Family history Stable at at 3 yrs + MYH7 This study 
Routine 3d trimester US Stable at 10 months Nt  16 
Bradycardia; hydrops; abnormal 
foetal heart Neonatal death Nt  
20 
Reduced foetal movements; 
uterine contractions Stable at 2 yrs Nt  
15 
Moderate foetal hydrops Foetal demise Nt  10 
Bradycardia 
 Neonatal death +
  10 
? ? Nt 46, XX / 47XX,+22 
17 
Legend. PA = pulmonary atresia; PAPVR = partial anomalous pulmonary venous return; 
PDA = patent ductus arteriosus; PS = pulmonic stenosis; RV = right ventricle; 
SA = septal aneurysm; SubAoS = subaortic stenosis; SVT = supraventricular tachycardia; 
TGV = transposition of the great vessels; TR = tricuspid regurgitation; US = ultrasound; 
VSD = ventricular septal defect; 
# patient 8 and 15 are brothers; 
* patient 25 and 31 are half-brother and sister. 
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Abstract 
Background 
Noncompaction cardiomyopathy (NCCM) is a genetically heterogeneous cardiomyopathy 
characterised by left ventricular (LV) prominent trabeculations and deep intertrabecular 
recesses that communicate with the LV cavity. NCCM in children and adults has been 
associated predominantly with mutations in sarcomere genes. In approximately half of familial 
NCCM the genetic defect remains unknown. 
 
Methods and results 
Cardiological examination of 20 individuals from an extended Dutch family identified nine 
patients with NCCM and one patient with dilated cardiomyopathy (DCM). To identify a genetic 
cause for NCCM in this family we performed a genome-wide linkage analysis using 300K SNP 
arrays. A maximum LOD score of 3.02 on chromosome 4p15.3 was obtained. The inclusion of a 
patient that shares a common ancestor with the index case seven generations ago allowed the 
identification of a small candidate region. This area comprised 5.47 Mb (10.03-15.5 Mb, marker 
CGR525 until D4S419) on chromosome 4p15.3 and contains 25 genes. 
 
Conclusions 
We have mapped a new locus for autosomal dominant NCCM to a 5.47 Mb region on 
chromosome 4p15.3. Identification of the novel disease gene will facilitate genetic screening 
and provide fundamental insight into the understanding of NCCM pathogenesis. 
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Introduction 
Noncompaction of the left ventricle or noncompaction cardiomyopathy (NCCM) is a relatively 
new cardiomyopathy, first described by Feldt in 1969.1 It is characterized by left ventricular (LV) 
prominent trabeculations and deep intertrabecular recesses that communicate with the LV 
cavity.2, 3 Morphologically NCCM resembles the myocardium during its early cardiac 
development; it is therefore thought to be caused by an arrest of normal myocardial 
embryogenesis.4 Congestive heart failure, thrombo-embolic events and arrhythmias, including 
sudden cardiac death (SCD), may be the initial presentation. Like other hereditary 
cardiomyopathies, NCCM shows inter- and intrafamilial variability, ranging from asymptomatic 
disease in adults to severe congenital forms.5-7 The majority of NCCM diagnosed in adults is 
isolated, as defined in the fourth criterion stated by Jenni et al.8 Non-isolated forms of NCCM 
are more frequent in childhood and may co-occur with congenital heart malformations, or may 
be part of a malformation or chromosomal syndrome.7 
The majority of NCCM is hereditary and appears to be genetically heterogeneous.9, 10 An 
important proportion of isolated NCCM in children and adults has been associated with 
mutations in sarcomere genes.9, 11 Rare genetic defects include mutations in Tafazzin (TAZ), α-
dystrobrevin (DTNA), Cypher/ZASP (LDB3) and Lamin A/C (LMNA). Absence of a genetic 
defect does not preclude a genetic cause of NCCM. In approximately half of familial NCCM the 
genetic defect remains unknown.10 
To identify new genetic causes for NCCM we performed linkage analysis in a large NCCM 
family, linked together through genealogic analysis. 
 
Methods 
Clinical studies 
This study was performed in the proband and his relatives as depicted in Figure 1. Cardiologic 
analysis of participating relatives of the proband (VIII:2) was performed at the Cardiogenetic 
outpatient clinic of the Erasmus Medical Centre in Rotterdam, the department of Cardiology of 
the Antonius Hospital in Sneek, the department of Cardiology of the Medical Centre Alkmaar 
and the department of Cardiology of the Isala Clinics in Zwolle, the Netherlands and consisted 
of echocardiography, electrocardiography (ECG) and physical examination. Additionally 24-
hours ambulatory ECG monitoring and exercise ECG were performed in affected relatives. All 
imaging data were reviewed by KC and MM at the Erasmus Medical Centre. Diagnosis of 
NCCM was made when the noncompacted endocardial layer to compacted epicardial layer 
ratio (NC/C) was equal to or larger than two, without structural heart defects, and Colour 
Doppler imaging visualised blood flow within the intertrabecular recesses. 
VI:6 was independently identified as an NCCM patient, she came from the same village as the 
mother of the proband and could be linked to the NCCM family by genealogical analysis.  
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I:1 I:2
 
Genealogic analysis 
Dutch Civil Registry records publicly available through Genlias (www.genlias.nl), records 
available on the internet from Frisian archives (www.allefriezen.nl) and private genealogic 
databases were used for the genealogic study. The resulting pedigree was displayed using 
Cyrillic 2.1.3 (Cherwell Scientific Publishing Ltd 1997, Oxford, UK). 
 
Molecular studies 
Genomic DNA was isolated from peripheral blood using the Puregene DNA purification kit 
(Gentra Systems) following standard procedures. The genome wide search was conducted 
using DNA from 12 members of the family including nine patients: eight patients with NCCM 
(VII:6, VII:8, VII:9, VII:14, VIII:2, VIII:3, VIII:4, VIII:5) and one with dilated cardiomyopathy 
(VII:12). The Human CytoSNP12 arrays containing 299,671 genome wide tag SNPs were used. 
Samples were processed according to the manufacturer’s instructions (Infinium DNA analysis 
BeadChip kits, Illumina). The GenomeStudio Data Analysis software (Genotyping module) was 
used for genotype calling, quality control and to export the data. 
 
II:1
† 86 yrs
II:4
† 69 yrs
II:2 II:3
† 69 yrs
III:1 III:2
† 68 yrs
III:3
† 76 yrs
III:4
† 47 yrs
IV:1
† 73 yrs
IV:2 IV:3
† 72 yrs
IV:4
† 63 yrs
V:1
† 100 yrs
V:2
† 62 yrs
VI:2
† 86 yrs
VI:1
† 76 yrs
VII:1 VII:3
?
VII:4 VII:6 VII:8 VII:9 VII:10 VII:11 VII:12 VII:14 VII:15VII:5
VIII:2 VIII:3 VIII:4
VII:7
VIII:5
VII:13
?
VIII:6
V:4
† 84 yrs
V:3
† 72 yrs
VI:3
† 54 yrs
VI:4
† 34 yrs
VI:6VI:5
VII:2 VII:16
† 33 yrs
VIII:1 VIII:7 VIII:8
Figure 1. Pedigree. Genealogy identified a shared ancestor seven generations before the proband.  
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Micro-satellite markers 
Micro-satellite markers mapping to the identified genomic regions were selected. Polymerase 
chain reaction (PCR) products were run on an ABI Prism 3130xl genetic sequencer (Applied 
Biosystems) and analyzed using the GeneMapper software v.3.0 (Applied Biosystems).  DNAs 
from 22 available family members were investigated including the newly identified patient, 
linked through genealogy (VI:6). 
 
Linkage analysis and loci identification 
The statistical package EasyLinkage Plus v5.08 12 designed to perform automated linkage 
analyses using large-scale SNP data, was used to perform all analyses. All SNPs showing 
inconsistency in transmission were removed from further analyses. Allegro v1.2c software 
(incorporated in the EasyLinkage Plus v5.08 package) was used to perform fully automated 
single point and multipoint linkage analysis. LOD scores were obtained using a dominant model 
of inheritance, with a penetrance of 90% and a disease allele frequency of 1:1000. A 
phenocopy rate of 1% was considered. Allele frequencies of genotyped SNPs were set to co-
dominant. Map order and inter-SNPs distances were taken from the Illumina website.  
Since closely spaced SNP markers were used for the linkage analysis, the genome analyses 
were performed with predefined spacing of 0.3 to 0.1 centiMorgan (cM), in blocks of 90 and 100 
SNPs. Then, single chromosomes showing positive linkage signals were independently 
analysed under the same conditions and haplotypes were constructed. 
The analysis of the micro-satellite data was performed with Merlin (v1.01) to allow the use of an 
extended genealogical tree that included patient VI:6, (Figure 1) assuming a common ancestor 
that lived four generations ago. 
Graphical visualization of haplotypes to facilitate inspection and analyses was performed with 
HaploPainter v029.5 13; a tool for drawing pedigrees with complex haplotypes. 
 
Results 
Clinical studies 
VIII:2 
The proband was a 36-year-old man without a previous history of cardiac disease, who suffered 
a sudden cardiac arrest while running a marathon. He was successfully resuscitated and trans-
oesophageal and trans-thoracic echocardiography showed moderate LV dysfunction with 
typical abnormal trabeculation, consistent with noncompaction cardiomyopathy with a NC/C 
ratio of 2.5 and an ejection fraction (EF) of 45%. ECG showed sinus rhythm of 84 beats per 
minute and borderline LV hypertrophy pattern with repolarisation abnormalities in anterolateral 
and inferior leads. Coronary angiography showed no occlusions. He received an implantable 
cardioverter defibrillator (ICD) for secondary prophylaxis and was treated with an ACE-inhibitor 
and a β-blocker. His systolic function steadily improved and after three years of follow-up he 
gChapter 6 152 
remains asymptomatic. No ICD discharges or anti-tachypacing was reported. He is now a father 
of a healthy girl and boy, they didn’t show any abnormalities at prenatal advanced ultrasound; 
the parents refused cardiologic screening after birth. 
 
VII:6 
The mother of the proband had a transient ischaemic attack at the age of 59 years, for which 
she was evaluated. Duplex of the carotic arteries was normal. Cardiac screening at that time 
showed a moderately severe LV dysfunction, with an EF of 34% and mild mitral valve 
insufficiency due to mitral valve prolaps. Repeated echocardiographic screening at the age of 
65 years, after her son’s cardiac arrest, showed slightly dilated LV (end-diastolic dimension 65 
mm and end-systolic dimension of 54 mm) with a fractional shortening (FS) of 17%. Distinct 
trabeculations were visible in the left ventricular apical, lateral and distal inferior and anterior 
segments with a NC/C ratio of 3.5 (19/5.5), resembling NCCM.  ECG showed sinus rhythm of 
68 beats per minute with mild intraventricular conduction abnormalities (QRS width of 110 
msec, and a QTc of 421 msec). She experienced fatigue and dyspnea after walking two flights 
of stairs (NYHA class II) but had no complaints of palpitations or chest pain. Coronary 
angiography was normal. She received an ICD for prophylactic purposes. 
 
VIII:3 
A 33-year-old sister of the proband had a history of arrhythmia and palpitations since the age of 
28 years and was diagnosed with mitral valve prolaps. Cardiac evaluation after her brother’s 
sudden cardiac arrest revealed typical features of NCCM with a NC/C ratio of 2.3 and abnormal 
trabeculations in the left ventricular apical, inferior, inferolateral and posterior segments. EF was 
51%. ECG showed sinus bradycardia of 52 beats per minute with normal conduction 
parameters and repolarisation pattern. Her exercise ECG was normal, but her 24-hour Holter 
revealed three non-sustained ventricular tachycardia’s (VT’s). Therefore an invasive 
electrophysiological study was done for risk stratification; no ventricular arrhythmias could be 
induced. She was then empirically treated with a β-blocker. After 2.5 years follow up, she was 
no longer experiencing palpitations and was completely asymptomatic. 
 
VIII:4 
A 32-year-old asymptomatic sister of the proband was also diagnosed abnormal trabeculations 
in the apical, inferior and lateral LV walls, with a maximal NC / C ratio of 2,0. Her EF on MRI 
was 49%. Her ECG was normal. 
 
VII:8 
Of an asymptomatic maternal aunt, aged 64 years, echocardiography showed mildly prominent 
left ventricular trabeculations with a maximal NC/C ratio of 1.5. MRI showed a NC/C ratio of 1.8 
with an EF of 48%. ECG showed no abnormalities. 
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VIII:5 
The daughter of patient VII:8 presented with palpitations at the age of 27 years and was 
diagnosed with paroxysmal AV-nodal re-entry tachycardia and supraventricular tachycardia 
(SVT). Echocardiography at that time showed no signs of cardiomyopathy. She was treated 
with cryo-ablation of the slow pathway twice; afterwards tachycardia could not be induced. After 
five years of follow up, she had palpitations again, with frequent irregular heart beats. After 
sudden cardiac arrest of her cousin she was admitted for cardiac re-evaluation. There were 
prominent trabeculations in the posterior and apical segments. NC/C ratio on echocardiography 
was 1.5; on MRI it was 1.8 with an EF of 53%. Palpitations were treated with β-blockage 
therapy. 
 
VII:9 
This 59 year old maternal uncle had atypical chest pain and mild hypertension. His ECG 
showed a left bundle branch block with ventricular extra-systoles. Echocardiography revealed 
segmental wall motion irregularities inferior, inferoseptal, and anteroseptal. There was 
hypertrabeculation of the apical and anterior wall, with a NC/C ratio < 2. LVEF was 49%. There 
was a mild central mitral insufficiency. Follow-up was advised. 
 
VII:12 
At the age of 55 years an asymptomatic paternal uncle was diagnosed with dilated 
cardiomyopathy (DCM) at family screening. Echocardiography showed borderline hypertrophy 
of the intraventricular septum (12.2 mm) as well as a dilated left ventricle (59 mm) with a mildly 
impaired function. There are no signs of NCCM. ECG is aberrant showing sinus rhythm with a 
prolonged QRS duration of 180 ms due to a right bundle branch block and left posterior 
hemiblock. Stress testing revealed an excellent exercise capacity (116% of expected) in the 
absence of complaints or arrhythmias. Twenty-four-hour ambulatory ECG was normal. On MRI 
both ventricles were dilated. LVEF was 45% with an end diastolic volume of 242 ml; RVEF is 
33% with an EDV of 231 ml. Because of the normal exercise capacity and the absence of 
complaints it was decided to postpone invasive diagnostics. Treatment was started with ACE 
inhibition and follow-up was advised. 
 
VII:14 
Family screening showed excessive trabeculations in the apical region, with a NC/C ratio < 2 in 
another 53 year old paternal uncle. ECG showed no significant abnormalities. The patient was 
asymptomatic. Follow-up was advised. 
 
VI:6 
Patient 10 was cardiologically examined at the age of 76 years after the sudden cardiac death 
of two of her brothers (aged 54 and 34 years respectively) and of her 33-year-old son. She was 
asymptomatic. Echocardiography showed noncompaction localised at the anterior wall, septal 
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and apical regions with a NC/C ratio of 2.5; LVEF was normal. ECG showed normal sinus 
rhythm with normal conduction and without ST segment abnormalities. She was born in the 
same small village of approximately 2000 inhabitants as VII:6. Genealogic studies showed the 
family ties between VI:6 and VII:6 (Figure 1).  
 
VII:4 
A 67-year-old maternal aunt with palpitations did not show any abnormalities on her ECG, 24-hr 
Ambulatory monitoring showed SVT’s; her echocardiogram showed some apical trabeculations, 
with a NC/C ratio <2. 
 
VIII:6 
The eldest son of patient VII:11 was asymptomatic. Echocardiography at age 26 years did not 
show any abnormalities. His ECG showed sinus rhythm with normal PR time and a delayed 
ventricular activation. QRS width is 95 ms. There was an early repolarisation pattern. 
VII:1 (age 69 years); VII:3 (age 68 years); VII:10 (age 58 years); VII:11 (age 56 years); VII:15 
(age 60 years); VIII:1 (age 44 years); VIII:7 (age 22 years) and III:8 (age 16 years) were also 
examined but had no cardiac abnormalities. 
 
Molecular studies 
Genome wide linkage analysis (GWLA) 
No mutations were found in any of the most prevalent HCM genes (MYH7, MYBPC3, TNNC1, 
TNNT2, TNNI3, ACTC1, MYL2, MYL3, TPM1, CSRP3, TCAP, LDB3, CASQ2, CALR3, PLN, 
TAZ and LMNA) in the proband. A genome wide search using 300k SNP arrays was performed. 
Because incomplete and age-dependent penetrance are common features in most genetic 
cardiomyopathies, family members with a normal cardiological examination were included in the 
analysis as “diagnosis unknown”. 
The linkage analysis revealed linkage to two genomic regions; on chromosome 4p15.3 and 
chromosome 5 with a multipoint LOD score of 2.1 for each locus. The border of the candidate 
regions were defined using the SNPs data. On chromosome 4p recombinations observed in 
patients VIII:2 (upper border) and VIII:4 (lower border) determined the region extending from 
rs10938692 to rs758327 (8.2-15.5 Mb, NCBI build 37.1). On chromosome 5, the candidate 
region extended from rs10805760 until rs168825 (24.3-31.7 Mb), based on recombinations 
observed in patients VII:9 (upper border) and VII:12 (lower border).  
We then tested 23 micro-satellite markers mapping to chromosome 4 (3-28 Mb) and 
chromosome 5 (16-34 Mb) and included the new patient (VI:6, 11th degree relative of the 
proband). The linkage analysis yielded a maximum LOD score of 3.02 for the locus on 
chromosome 4 while on chromosome 5 the LOD score was negative (LOD=-0.5). 
Haplotype analysis confirmed that all 10 patients were sharing a haplotype on chromosome 4 
from marker CGR525 until D4S2960 (Figure 2). The maximum candidate region after  
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combining with the SNP data was reduced to 5.47 Mb (10.03-15.5 Mb) and contained 25 genes 
from which 13 genes have a “hypothetical or predicted” status with no reference sequence or 
are pseudogenes (NCBI build 37.1).  From the 12 remaining genes, the RAB28, CC2D2A, 
SLC2A9, WDR1 and NKX3.2 gene are considered candidate genes, either because of their 
expression in the heart or because of their function. Sequence analysis of all these genes is 
ongoing. 
The region on chromosome 5 could not be excluded; we observed allele sharing among the 
patients in a small region comprising only two markers (D5S502-D5S419, Figure 3). 
Considering the SNP and micro-satellite data, the maximum region comprised only 1.8 Mb 
(25.6-27.4 Mb) and 5 genes, the majority are of them also “predicted” or pseudogenes. 
Discussion 
NCCM is a heterogeneous disorder, so far 14 genes and 2 loci were identified.5, 9, 11, 14-21 Here 
we performed a genome wide linkage analysis in a family with autosomal dominant NCCM and 
identified a novel locus on chromosome 4p15.3 with a maximum LOD score of 3.02. Due to 
software limitations the linkage analysis was performed assuming that the newly identified 
patient was sharing a common ancestry only four generation ago. The calculated 3.02 LOD 
score is therefore lower than the actual LOD score. 
We performed extensive haplotype analysis in this genomic area and identified allele sharing 
among all patients in a region that extended 4.57 Mb and five consecutive microsatellite 
markers. However, from patient VI:6 no first-degree relatives were available to determine 
whether these alleles are on the same (maternal) chromosome. On chromosome 5, allele 
sharing with patient VI:6 was less evident, comprising only two markers. Until the actual 
segregation of the alleles is confirmed by genotyping of first-degree relatives, the locus on 
chromosome 5 cannot be excluded. From the known or predicted genes located within the 
5.47-Mb disease gene interval on chromosome 4, RAB28, CC2D2A, and SLC2A9 were 
considered candidate genes for NCCM because of their cardiac expression, NKX3.2 and 
WDR1 were considered candidate genes because of their function. 
RAS-associated protein 28 (RAB28), member of the RAS oncogene family, is a RAS-related 
GTPase that operates signalling pathways in cell growth, metabolism and organelle 
trafficking.22 Mutations in other RAS oncogene family members cause Noonan, Leopard, 
Costello and cardio-facio-cutaneous (CFC) syndrome and neurofibromatosis (PTPN11, KRAS, 
RAF1, SOS1, BRAF, MAP2K1, MAP2K2 and NF1). In all these syndromes hypertrophic 
cardiomyopathy has been identified, making RAB28 an excellent candidate gene. 
Coiled-Coil and C2 Domains-containing protein 2A (CC2D2A) is expressed in both foetal and 
adult heart. Its function is cilia-related.23 Homozygous mutations in this gene have been 
associated with Meckel and with Joubert syndrome and with mental retardation in combination 
with retinitis pigmentosa. Solute carrier family 2 (SLC2A9) is a urate transporter mainly 
expressed in the kidney, and is important for renal urate reabsorption.24 Lower expression 
levels were seen in the heart. Mutations in this gene have been associated with hypo-uricemia 
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and a strong association with serum uric acid concentration was found.25 There are studies in 
the literature showing a correlation between increased serum urate and blood pressure, 
coronary artery disease, and metabolic disorders.26-28 
WD repeat domain 1 (WDR1) or actin-interacting protein 1 (AIP1) is a gene encoding for a 
protein with 9 WD repeats. WD domains are involved in protein-protein interactions. In C. 
elegans AIP1 synergistically promotes sarcomeric actin organisation in striated muscle cells.29 
It is therefore a good candidate gene. 
NK3 homeobox 2 (NKX3.2) is a member of the homeobox family and is expressed in embryonic 
tissue. It is associated with skeletal dysplasia.30 Nishida et al identified NKX3.2 expression in 
arterial smooth muscle cells of chicken.31 Perhaps this gene plays a role in the pathogenesis of 
NCCM by faulty expression in coronary arteries. Furthermore, another member of the 
homeobox family, NKX2.5, has been shown to be associated with congenital heart disease.32 
Therefore the NKX3.2 should also be considered. 
Similar to other heart muscle disorders, NCCM shows extensive genetic heterogeneity, with 
sarcomere and Z-disc genes and mutations in TAZ, LMNA and DTNA have been reported.5, 9, 
11, 14-19 Linkage analysis in the extended family with autosomal dominant NCCM identified one 
putative NCCM locus. All patients presented with isolated NCCM without congenital heart 
defects. Four patients did not fulfil all diagnostic criteria established for isolated NCCM because 
the ratio of noncompacted to compacted myocardium (NC/C ratio) was did not reach the 
established value for diagnosis. However, there is no mechanical or haemodynamic explanation 
for the development of NCCM in these patients, there weren’t any left ventricular inflow and/or 
outflow tract abnormalities. It is very likely that the cause of their slight NCCM is genetic, 
indicating that further studies of NCCM criteria for relatives at risk are needed, similar to HCM.33 
In conclusion, we have mapped a locus for autosomal dominant NCCM to chromosome 4p15.3 
and narrowed the critical region to 5.47 Mb. Sequence analysis of all genes located on this 
locus is ongoing as is cardiologic family screening of first-degree relatives of patient VI:6. 
These findings confirm the genetic heterogeneity of this disorder. Identification of the disease-
causing gene will allow genetic screening and provide new insights into the pathogenic 
mechanism of NCCM development. 
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Abstract 
Aims 
Familial hypertrophic cardiomyopathy is usually caused by autosomal dominant mutations in 
genes encoding sarcomeric cardiac muscle proteins. The disease mainly affects adults, but 
young children with severe hypertrophic cardiomyopathy have been reported. We describe here 
two unrelated neonates with a severe form of hypertrophic cardiomyopathy, and performed 
molecular studies to identify the genetic defect. 
 
Methods and results 
Two unrelated neonates with lethal cardiomyopathy were studied at the clinical, pathological 
and molecular level. Both patients were compound heterozygous for two common loss-of-
function mutations in the MYBPC3 gene. One of the patients also presented with a ventricular 
septal defect, whereas the other patient had an atrial septal defect. 
 
Conclusions 
Whereas heterozygous mutations in sarcomeric protein genes usually lead to hypertrophic 
cardiomyopathy with clinical symptoms starting in child- or adulthood, homozygousity or 
compound heterozygousity for two truncating mutations in the MYBPC3 gene can cause severe 
neonatal cardiomyopathy with features of left ventricular noncompaction. Furthermore, 
mutations in sarcomeric protein genes seem also to be implicated in congenital heart 
malformations. 
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Introduction 
Hypertrophic cardiomyopathy (HCM) is a major cause of sudden cardiac death in people 
younger than 35 years of age under physical stress, and a major cause of mortality and 
morbidity in the elderly, with an estimated prevalence of 1 in 500 individuals according to 
echocardiographic criteria. In approximately 60% of cases a mutation in one of the sarcomeric 
contractile protein genes is found.1, 2 Familial HCM is usually transmitted as an autosomal 
dominant condition due to heterozygous gene mutations with incomplete penetrance. After the 
identification in 1990 of HCM-causing mutations in the cardiac -myosin heavy chain gene 
(MYH7).3, 4 mutations in genes encoding proteins involved in the sarcomere, cytoskeleton and 
Z-disc, calcium handling, mitochondrial and lysosomal functions have been associated with 
HCM.5, 6 More than 400 different mutations have been found in the genes that encode 
sarcomeric proteins, such as ß-cardiac myosin heavy chain (MYH7), cardiac myosin-binding 
protein-C (MYBPC3), α-cardiac myosin heavy chain (MYH6), regulatory myosin light chain 
(MYL2), essential myosin light chain (MYL3), cardiac troponin T (TNNT2), cardiac troponin I 
(TNNI3), tropomyosin (TPM1), cardiac actin (ACTC1), and titin (TTN) (see: 
http://cardiogenomics.med.harvard.edu). 
Partly due to the genetic heterogeneity, interfamilial clinical variability in HCM is high. Also 
intrafamilial variability is considerable, and it has proven difficult to establish good genotype-
phenotype correlations in HCM. In addition to the primary genetic defect, the effects of modifier 
genes or additional mutations in other sarcomeric genes may contribute to the phenotypic 
expression of HCM.7 Childhood-onset cardiac hypertrophy is also genetically determined in the 
majority of cases, and two thirds of familial cases of childhood-onset cardiac hypertrophy are 
caused by a mutation in one of the sarcomeric protein genes.8 Here we describe two unrelated 
children with severe cardiomyopathy, ventricular noncompaction and septal defects, due to 
compound heterozygousity for truncating mutations in MYBPC3, resulting in neonatal death. 
Methods 
Clinical diagnosis 
Two unrelated families with an index patient with severe neonatal cardiomyopathy were studied 
after informed consent at the clinical, pathological and molecular level. Clinical evaluation 
included clinical history and physical examination, electrocardiography (ECG) and 2D and M-
mode echocardiography. Noncompaction of the left ventricle was diagnosed based upon three 
echocardiographic criteria defined by Jenni et al.9 including i) a thick non-compacted (NC) 
endocardial layer in end systole at the parasternal short-axis views (ratio NC/C >2) with 
numerous, excessively prominent trabeculations and deep intertrabecular recesses, ii) that are 
perfused on colour Doppler studies and iii) predominantly apical localisation. 
 
Pathologic studies 
Microscopic examination and electron microscopy of cardiac autopsy material of patient 1 was 
performed with standard techniques. 
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Molecular analysis 
Genomic DNA of the patients was isolated from blood samples. All coding regions and intron-
exon boundaries of the MYBPC3 gene were analysed by direct sequence analysis. Sequence 
analysis of M13-tagged PCR products was carried out on an ABI3730xl capillary sequencer 
using Big-Dye Terminator v 3.1 chemistry (Applied Biosystems). (Details of methods and primer 
sequences are available on request.) Analysis of sequence data was performed using 
SeqScape analysis software (v2.5, Applied Biosystems). In addition to sequence analysis, 
MLPA analysis of the MYBPC3 gene was carried out (MRC Holland SALSA MLPA kit P100) to 
detect possible genomic rearrangements. Exons of the MYBPC3 gene were numbered 1-34 
according to international standards with the Adenine of the translation initiation start site (ATG) 
numbered +1 and the ATG in exon 1 (www.HGVS.org). Subsequently, using the same 
techniques, the complete coding regions and intron-exon boundaries of eight other sarcomeric 
genes (MYH7, TNNT2, TNNI3, MYL2, MYL3, TNNC, TPM1 and ACTC1) were analysed to 
exclude that additional pathogenic mutations in these genes contributed to the phenotype 
observed in the patients. 
Results 
Patient 1 
This male patient was born after an uncomplicated pregnancy at 40 weeks gestation with a birth 
weight of 3110 grams and Apgar scores of 9/9. He was the second child of healthy Dutch non-
consanguineous parents. At the age of one week cyanosis was noticed during crying and the 
child experienced feeding difficulties. At the age of five weeks he was hospitalised because of 
feeding problems, perspiration and facial cyanosis. X-thorax showed a grossly enlarged heart. 
Echocardiography revealed a moderately dilated left ventricle with severe systolic dysfunction. 
The apical wall of the left ventricle was excessively thickened with prominent 
hypertrabeculation. The left and right atria showed mild dilatation. A small secundum atrial 
septal defect (ASD) was also present. He was treated for heart failure with Furosemide, 
Captopril, Carnitine and Digoxin. Viral serology showed no abnormalities. Metabolic screening 
of urine, including oligosaccharide spot test, was normal. Plasma carnitine and amino acid 
levels were normal. After stabilisation, the child was released from hospital, but two weeks later 
he was readmitted to the hospital presenting with a pallor colour and progressive feeding 
problems. X-thorax and echocardiography revealed further enlargement of the heart (heart-
thorax ratio ± 0.7) with severe hypertrophy with a fractional shortening of the left ventricle of 
less than 10%. The child died from cardiac failure at the age of 12 weeks. Macroscopic 
examination of the heart revealed severe cardiomegaly and dilatation with a total weight of 115 
gram (normal weight at this age: 30 gram). Right ventricular thickening was noted, especially of 
the LV posterior wall. The anterior wall of the left ventricle was also severely thickened, and 
showed abnormal trabeculation and multiple intertrabecular recesses as seen in 
noncompaction cardiomyopathy. The secundum ASD was confirmed. No other congenital 
malformations were found. Microscopic examination of cardiac tissue (Figure 1A) showed 
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myofibrillar disarray in both the ventricular septum and the left ventricular wall. No significant 
amount of interstitial fibrosis was observed. Hypertrophic myocytes with a diameter varying 
between 20 and 30 micrometers (normal 12 micrometers) and multiple vacuoles on electron 
microscopy were suggestive of a glycogenosis (Figure 1B). As the echocardiography images 
and ECG were not suggestive of Pompe disease and urine oligosaccharide analysis was 
normal, no α-glucosidase enzyme or molecular assay was performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1. Histopathology 
A. Microscopic examination of post-mortem heart muscle from patient 1. Hypertrophic myocytes with 
myofibrillar disarray typical of HCM due to sarcomeric protein mutations was present, albeit without 
significant amount of interstitial fibrosis. 
 
 
B. Electron micrograph showing a large, irregular vacuole  
Sarcomere mutation analysis was initiated by screening of the complete coding region and 
intron-exon boundaries of the MYBPC3 gene. This analysis revealed that the patient was 
compound heterozygous for the c.2373dupG mutation and the c.2827C>T (p.Arg943X) 
mutation. Mutation analysis of additional sarcomeric genes (MYH7, TNNT2, TNNI3, MYL2, 
MYL3, TNNC, TPM1 and ACTC1) did not result in the identification of additional pathogenic 
mutations. Large deletions of mitochondrial DNA, and several mitochondrial missense 
mutations associated with hypertrophic cardiomyopathy were excluded. Mutation analysis in 
both parents identified the c.2373dupG mutation in the mother and the p.Arg943X mutation in 
the father (Figure 2). 
At the time of diagnosis of cardiomyopathy in their newborn child, both parents had no cardiac 
symptoms. Echocardiography revealed no abnormalities in the mother at age 32 years and the 
father at age 31 years. ECG in the father showed mild repolarisation abnormalities (ST-
elevation of 0,5 mm in V1 followed by a negative T in V1-V4). Re-evaluation of both parents 
after seven years, revealed moderate septal hypertrophy (HCM) with an interventricular septum 
of 14 mm in the mother, and interventricular septal measurements at the upper limit of the 
normal range (12 mm) in the father. Family history indicated that there were several family 
members with cardiac symptoms, sudden death, and/or diagnosed with HCM on both sides of 
the family (Figure 2). 
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Figure 2. Pedigree of patient 1. 
 
 
Pedigree of patient 1 who had severe neonatal cardiomyopathy due to compound heterozygousity for the 
c.2373dupG and p.Arg943X mutations in the MYBPC3 gene. On both sides of the pedigree, there are 
multiple affected individuals with adult HCM that are heterozygous for one of the mutations. 
 
Patient 2 
This male patient was born at 38 weeks 
gestation with a birth weight of 3345 gr. He was 
the second child of non-consanguineous 
parents. He experienced feeding problems in 
the first weeks of life. At the age of four weeks 
dyspnoea was noticed and he was referred to 
the hospital. He was mildly hypotonic. A grossly 
enlarged heart was observed on the X-thorax 
and low oxygen saturation blood levels were 
found. He was referred to the paediatric 
cardiology centre for further evaluation. 
Echocardiography revealed moderately dilated 
ventricles with severe diastolic and systolic 
dysfunction. Hypertrabeculation with flow 
perfused intertrabecular recesses was present 
in both ventricles, including the apical walls 
(Figure 3). An apical muscular VSD was 
visualised, although deep recessal flow 
complicated interpretation of the imaging. 
Figure 3. Echocardiography of patient 2. 
Echocardiographic studies in patient 2 
showing cardiomyopathy with LV non-
compaction. The four chamber shows 
excessive trabeculation (arrows) at the 
apical right ventricular wall, whereas the left 
ventricular wall also showed numerous 
deep trabeculae and recesses. 
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A muscle CT scan showed no signs of atrophy, and a muscular biopsy revealed no congenital 
myopathy. Biochemical studies, including lactate, pyruvate, creatine kinase, amino acids, 
carnitine and sialotransferrines levels, and metabolic screening of urine, including 
oligosaccharides, were normal. Viral serology showed no abnormalities. The patient was 
treated for heart failure with Furosemide, Captopril and Digoxin. He deteriorated at the age of 
12 weeks, and died. 
The complete coding regions and intron-exon boundaries of the MYBPC3 gene were analysed. 
Compound heterozygousity for the c.2373dupG and the c.2827C>T (p.Arg943X) in the 
MYBPC3 gene was found. Molecular analyses of other sarcomeric genes (MYH7, TNNT2, 
TNNI3, MYL2, MYL3, TNNC, TPM1 and ACTC1) revealed no additional disease-causing 
mutation. The parents declined pathological studies of the heart of their deceased child, nor did 
they decide on further cardiologic evaluation for themselves or pedigree analysis. 
Discussion 
Here we describe two unrelated newborns with severe cardiomyopathy resulting in neonatal 
death due to compound heterozygousity for null mutations in the MYBPC3 gene. Although 
initially their cardiomyopathies were described as severe atypical HCM, HCM with 
noncompaction (NCCM) was considered after re-evaluation of serial ultrasounds and pathologic 
examination. NCCM is a genetically heterogeneous disease associated with mutations in 
TAZ(G4.5), DTNA, LDB3, SCN5A, and LMNA in a limited number of families.10-14 Recently, 
NCCM was shown to be due to heterozygous mutations in genes encoding sarcomeric proteins, 
including ß-cardiac myosin heavy chain (MYH7), alpha-cardiac actin (ACTC) and cardiac 
troponin T (TNNT2).15-19 Here we report that mutations in another sarcomeric protein gene 
MYBPC3 also lead to NCCM, as we previously reported.20 This suggests that NCCM, HCM, 
dilated cardiomyopathy (DCM) and restrictive cardiomyopathy (RCM) are allelic diseases that 
share similar pathophysiological mechanisms. 
In the majority of patients with familial cardiomyopathy due to a mutation in one of the genes 
encoding sarcomeric proteins, a single autosomal dominant mutation is found. In contrast our 
two patients are compound heterozygotes for two truncating MYBPC3 mutations, suggesting a 
cumulative effect of these mutations. Mutations in the MYBPC3 gene, encoding cardiac myosin 
binding protein C, are one of the most common genetic causes of HCM in many populations, 
found in approximately 20-40% of individuals with HCM.21-23 Autosomal dominant mutations in 
the MYBPC3 gene, mostly truncating mutations and sometimes missense mutations, give rise 
to HCM with an age of onset after the third decade and moderate left ventricular hypertrophy.24 
As mutations in MYBPC3 (and MYH7) are the most common genetic cause of familial HCM8, 
compound heterozygous or homozygous mutations should be considered in a neonate which 
presents with severe HCM or NCCM, even in the absence of symptoms in the parents or a 
negative family history. This is shown here where both patients with severe neonatal 
cardiomyopathy are compound heterozygotes for the two most frequent HCM mutations in the 
Netherlands, the c.2373dupG mutation and the p.Arg943X mutation. The c.2373dupG mutation 
gChapter 7 168 
alone accounts for nearly one-fourth of all HCM cases in the Netherlands, and has previously 
been shown to be an important founder mutation in the Dutch population and also to be present 
in other  populations.21, 25, 26 The mutation creates a new aberrant splice donor site leading to 
skipping of exon 24, resulting in a frame shift after p.Gln791 and a premature stop.27 No 
truncated protein product from the c.2373dupG allele could be detected in the sarcomere using 
antibodies, suggesting that the truncated protein was unstable, or the aberrant transcript was 
degraded by cell surveillance mechanisms such as nonsense mediated decay.28 The second 
mutation found in both our patients is the p.Arg943X mutation. This mutation was identified as 
an additional founder mutation in the Dutch population (Chapter 9). P.Arg943X is a nonsense 
mutation in exon 27, leading to a premature stop codon and protein truncation beyond domain 
C 7 of MYBPC3. Even in the absence of nonsense mediated decay of the mutant MYBPC3 
mRNAs the p.Arg943X mutation is thought to lead to reduction in MYBPC3 due to protein 
instability and/or loss of the C-terminus of MYBPC3 that binds myosin thick filaments and titin, 
which is required for normal MYBPC3 incorporation into the A-band of the sarcomere.29 As a 
consequence, in our patients no MYBPC3 protein is expected to be incorporated into the 
sarcomere, which might explain the early and severe presentation of the cardiomyopathy in 
both patients. 
In larger series approximately 3-5 % of HCM patients are compound or double heterozygotes 
for two disease-causing mutations in the same or different sarcomeric protein genes.21, 22  
However, most of these mutations are missense mutations of which the pathogenic nature is 
not always easy to establish. In these patients generally a more severe HCM phenotype is 
seen, characterised by an age of onset around the second decade or in childhood (Table 1).21, 
22, 30-39 In a recent study on sarcomeric protein gene mutations in childhood-onset HCM six out 
of 84 children (7%) had compound mutations.8 This suggests that a gene-dosage effect might 
be responsible for manifestations at a younger age. 
Not only clinical features such as the neonatal onset of severe symptoms, but also the 
pathology of the heart in patient 1 initially suggested a metabolic origin e.g. glycogenosis 
(Figure 1). It is known that mutations in genes regulating glycogen metabolism, including AMP-
activated protein kinase γ2 (PRKAG2) in Wolff-Parkinson-White associated cardiomyopathy, 
lysosome-associated membrane protein 2 (LAMP2) in Danon disease, α-galactosidase (GLA) in 
Fabry’s disease, and acid α-1,4-glucosidase (GAA) in Pompe’s disease can cause left 
ventricular hypertrophy that mimics HCM.40 Conversely, metabolic diseases might also be 
misdiagnosed in patients with HCM due to sarcomeric protein mutations, as shown in our 
patient. Mutations in genes regulating glycogen metabolism cause myocyte hypertrophy by 
stimulating glycogen-filled vacuoles but cause neither myocyte disarray nor interstitial fibrosis, 
which typically occur with defects of sarcomere-protein genes. 
Few neonatal cases with severe cardiomyopathy due to homozygous or compound 
heterozygous truncating mutations in MYBPC3 have previously been described.21, 34, 37, 38 A 
homozygous splice site mutation p.Asp1064GlyfsX38 in MYBPC3 (leading to a frame shift and 
premature truncation) was recently described in three neonates with severe neonatal HCM that  
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all died at the average age of 3-4 months in an inbred Old Order Amish pedigree with severe 
HCM.37 This homozygous MYBPC3 mutation was also reported in another cohort of 10 
neonates with severe infantile HCM from Old Order Amish descent, suggesting that this 
mutation is a founder mutation in the Amish.38 It is remarkable that several of the affected 
neonates from the Old Order Amish with homozygous truncating mutations in MYBPC3, 
present with septal defects including apical muscular VSD, and ASD and patent ductus 
arteriosus. Septal defects were also present in the neonates with severe HCM due to 
compound heterozygous truncating mutations described by Lekanne et al.34 and the two cases 
described here. Recently, different congenital heart malformations (septal defects, patent 
ductus arteriosus, aortic aneurysm and Ebstein anomaly) have been reported in families with 
mutations in sarcomeric protein genes, including MYBPC3, MYH6, MYH7, MYH11, and 
ACTC1.16, 19, 37, 41-43 This suggests that sarcomeric cardiac muscle proteins are not only 
involved in cardiomyopathies but also in congenital heart malformations.44 
In conclusion, the absence of functional MYBPC3 from the sarcomere can lead to a phenotype 
of severe HCM with features of ventricular noncompaction and septal defects, which appears to 
be lethal in the postnatal period. 
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Abstract 
Background 
Hypertrophic cardiomyopathy (HCM) is an autosomal dominantly inherited disease, 
characterised by incomplete penetrance and variable phenotypic expression. Mutations in 24, 
mostly sarcomeric, genes are known to cause HCM. Earlier studies have associated mutations 
in the sarcomere Myosin Binding Protein C gene (MYBPC3) with late onset benign HCM. Our 
aim was to analyse the contribution and natural history of MYBPC3-HCM in the Dutch HCM 
population. 
 
Methods and results 
We performed molecular analysis of MYBPC3 in 327 unrelated Dutch HCM index patients. A 
genetic variant was identified in 45% (148/327) of the patients. Fifty-one different variants, 
including 35 novel ones, were found. In addition to the c.2373dupG founder mutation, found in 
14.4% of the patients, we identified the two new MYBPC3 founder mutations p.Arg943X in 
6.7% and c.2864_2865delCT in 4.6% of the HCM patients. Family studies show a malignant 
prognosis in 33%, 38% and 56% of the c.2373dupG, p.Arg943X and c.2864_2865delCT 
families respectively. Identical survival estimates were computed for all three truncating 
c.2373dupG, p.Arg943X and c.2864_2865delCT founder mutations. 
 
Conclusion 
Truncating MYBPC3 founder mutations show a comparable natural history likely due to 
haploinsufficiency.  
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Introduction 
Hypertrophic cardiomyopathy (HCM) is characterised by unexplained left ventricular 
hypertrophy (LVH), myocardial fibrillar disarray and interstitial fibrosis. HCM has an estimated 
prevalence of 1:500 in the population. It is the most common cause of sudden cardiac death 
(SCD) in the young and a major cause of morbidity and mortality in the elderly.1 Approximately 
65% of HCM is hereditary, transmitted as an autosomal dominant trait with incomplete 
penetrance and high inter- and intra-familial variability.2 
Thus far 24 different genes have been associated with HCM. Over 400 different sarcomeric 
mutations have been reported3, many occurring in single families; founder effects seem to be 
exceptional.4-7 In familial HCM, mutations are most frequently observed in the -myosin heavy 
chain gene (MYH7, 30-40%) and the cardiac troponin-T gene (TNNT2, 10-20%). The reported 
prevalence of mutations in the Myosin Binding Protein C gene (MYBPC3) varies between 15-
20% 2, 8 to 38-42% 5, 9 from more recent surveys in Finland and France. Genetic defects, with a 
prevalence of less than 5% include mutations in the ACTC1, CSRP3, MYH6, MYL2, MYL3, 
TCAP, TNNC1, TNNI3, TPM1, TTN , PLN, CASQ2, MYOZ2 and CALR3 genes.2, 8, 10, 11 
Mutations in the MYH7 and TNNT2 genes are generally missense mutations and appear to be 
almost completely penetrant by the second or third decade of life. TNNT2 mutations are 
associated with a malignant form of HCM with high risk of cardiac failure and sudden death at a 
young age.12 In contrast, MYBPC3 mutations are almost invariably truncating mutations, 
reported to be associated with slowly progressive hypertrophy, late onset of clinical features 
and a benign or intermediate prognosis in 90% of the patients.4, 9, 13, 14 
Previously, the c.2373dupG mutation in the MYBPC3 gene, demonstrated to create a novel 
splice donor site within exon 24 of the MYBPC3 coding sequence,15 was identified as an 
ancient MYBPC3 founder mutation present in a large proportion of HCM patients in the 
Netherlands.15, 16 
To establish the contribution of MYBPC3 mutations in the Dutch HCM population, we performed 
MYBPC3 mutation analysis in 327 Dutch unrelated HCM probands. Two additional founder 
mutations in exon 27 of the MYBPC3 gene were identified: the p.Arg943X and 
c.2864_2865delCT mutations, present in 6.7% and 4.6% of the analysed HCM patients 
respectively. 
Although the majority of genetic causes of HCM have been identified, the molecular mediators 
determining the high inter- and intra-familial variability in clinical expression and cardiac 
phenotypes remain elusive.17 Genotype-phenotype studies have been hampered by extensive 
allelic heterogeneity and the individual nature of the causative sarcomere gene mutations, 
precluding accurate risk stratification and tailored cardiologic monitoring and management in 
HCM families. The occurrence of founder mutations in the Dutch HCM population provides the 
unique opportunity to investigate the genotype-phenotype association in groups of HCM 
patients sharing the identical molecular sarcomere defect. Clinical signs and symptoms were 
studied in families with the p.Arg943X and c.2864_2865delCT founder mutations. Prognosis 
and survival estimates were computed for all three currently known truncating founder 
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mutations in the MYBPC3 gene (c.2373dupG, p.Arg943X and c.2864_2865delCT). These 
results provide the first robust genotype-phenotype relations for individual MYBPC3 mutations. 
Methods 
Patients 
The study population comprised 327 HCM index patients from the Rotterdam area in the 
Netherlands. Patients were referred to the Department of Clinical Genetics of the Erasmus MC 
in Rotterdam, the Netherlands, for genetic counselling and molecular diagnosis of HCM.  
Family studies were initiated for all MYBPC3 mutation patients and included genetic 
counselling, cardiologic evaluation and (presymptomatic) molecular testing of first and second-
degree relatives. Following the identification of the p.Arg943X and c.2864_2865delCT founder 
mutations, evaluation of phenotypic severity in mutation carriers was performed using history of 
symptoms (fatigue, palpitations, dyspnoea, chest pain), ECG, exercise ECG, 24-hour 
ambulatory ECG monitoring, two-dimensional and Doppler echocardiography.  
We classified prognosis in families based on family history at the time of diagnosis as described 
previously.9 Prognosis was considered malignant when two or more major cardiac events 
(MCE; i.e. sudden cardiac death (SCD), cardiac-related stroke, resuscitation, appropriate 
implantable cardioverter defibrillator (ICD) discharge) were documented in a patient’s family 
before the age of 60 years (probands were excluded from the analysis). One reported MCE in 
the family led to an intermediate prognosis classification and when no MCE had taken place, 
prognosis was considered benign. In sporadic HCM patients, absence of family history 
prevented prognostic classification.  
 
Genetic testing 
Genomic DNA from 327 HCM index patients was isolated from peripheral blood samples using 
standard procedures. All coding regions and intron-exon boundaries of the MYBPC3 gene were 
analysed using direct sequence analysis (reference sequence NM_000256.3). Analysis PCR 
products was carried out on an ABI3730xl capillary sequencer using Big-Dye Terminator v 3.1 
chemistry (Applied Biosystems). (Details of methods and primer sequences are available upon 
request.) Analysis of sequence data was performed using SeqScape analysis software (v2.5, 
Applied Biosystems). To detect possible genomic rearrangements in MYBPC3, MLPA analysis 
was performed (MRC Holland kit P100). Exons of MYBPC3 were numbered 1-34 according to 
international standards with the Adenine of the translation initiation start site (ATG) numbered 1 
and the ATG in exon 1.18 In case of novel DNA variants, a panel of 384 Dutch control 
chromosomes was screened to identify common polymorphisms. Unknown missense variants 
were considered a mutation when they segregated with disease in a family and were not 
present on control chromosomes and were pathogenic according to prediction software.19, 20 
Although this does not formally prove pathogenicity, these three criteria combined were thought 
to provide the best evidence for pathogenicity. In case of isolated mutations, segregation with 
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disease could not be used as a criterion. DNA variants not fulfilling these criteria were labelled 
unclassified variants (UV). 
 
Haplotype analysis 
Extended haplotype analysis, using five intragenic SNPs and four extragenic polymorphic 
markers flanking MYBPC3 (D11S1344, D11S4137, D11S986 and D11S4109), was performed 
to construct haplotypes segregating with the p.Arg943X and c.2864_2865delCT mutations as 
described previously.16 Validity of the constructed haplotypes was checked by segregation 
analysis in families of patients whose family members were available for testing. 
 
Statistics 
Data on survival of 117 mutation carriers from 26 c.2373dupG mutation families, 50 mutation 
carriers from 16 p.Arg943X families and 62 mutation carriers from 12 c.2864_2865delCT 
mutation families were used to compute Kaplan–Meier survival curves for each founder 
mutation separately. 
Results 
Mutation analysis 
Diagnostic MYBPC3 screening in 327 independent HCM probands identified 51 different 
genetic variants, including 35 novel ones, in 148 (45%) patients (Table 1), making this the 
highest percentage of MYBPC3-HCM reported thus far. The majority of pathogenic MYBPC3 
mutations were truncating mutations (i.e. nonsense, frame shift or splice site mutations), 
predicted to lead to shortened or absent protein due to nonsense-mediated decay (NMD).21 
Only three different pathogenic missense mutations were identified in six patients. Twenty-one 
different unclassified variants (UVs) were identified, mostly missense variants predicted by in 
silico analyses to affect protein function.19, 21 Several rare and common sequence 
polymorphisms, both novel and previously published ones, were observed during this study 
(Table 2). 
Some MYBPC3 mutations were observed frequently. In 47/327 patients (14.4%) the 
c.2373dupG founder mutation was present.16 In 22 (6.7%) and 15 (4.6%) of the patients 
respectively we detected the truncating p.Arg943X (c.2827C>T) and c.2864_2865delCT 
mutations in exon 27 of MYBPC3. 
 
Haplotype analysis 
Using extended haplotype analysis, we demonstrated a founder effect for the p.Arg943X and 
c.2864_2865delCT mutations in the Dutch population; a shared haplotype was identified for the 
p.Arg943X mutation carriers analysed (Table 3). A different common haplotype segregating 
with the c.2864_2865delCT mutation was observed (Table 4). Of the 15 p.Arg943X carriers 
analysed, at least three did not share the common allele for the distal marker D11S4109 and 
one other patient did not share the common allele for the most proximal marker D11S986. This  
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Table 1. MYBPC3 pathogenic mutations and unclassified variants in 327 Dutch HCM patients. 
Exon Intron Nucleotide change Protein No. index patients Status Consequence Ref. 
3  c.312delG* p.Ala105fs 1 MUT Frameshift in exon 3  
4  c.442G>A p.Gly148Arg 2 UV Missense  
4  c.478C>G p.Arg160Gly 1 UV Missense  
4  c.481C>T p.Pro161Ser 4 MUT Missense 16 
5  c.530G>A p.Arg177His 1 UV Missense  
5  c.646G>A p.Ala216Thr 1 UV Missense  
 5 c.655+1G>A  2 MUT Affects splice donor site  
6  c.676_701dup26 p. Gly235fs 1 MUT Frameshift in exon 6  
6  c.772G>A  1 MUT Affects splice donor site 32 
 7 c.821+1G>A  1 MUT Affects splice donor site 4 
9  c.897delG p.Lys301fs 3 MUT Frameshift in exon 9  
11  c.913_914delTT p.Phe305fs 1 MUT Frameshift in exon 11  
 11 c.927-2A>G  4 MUT Affects splice acceptor site  
12  c.932C>A p.Ser311X 2 MUT Nonsense  
12  c.961G>A p.Val321Met 1 UV Missense  
12  c.977G>A p.Arg326Gln 2 UV Missense 5, 14 
12  c.989delC p.Pro330fs 1 MUT Frameshift in exon 12  
12  c.1008C>T† p.= 1 UV Silent  
 16 c.1458-1G>C  1 MUT Affects splice acceptor site  
17  c.1468G>A p.Gly490Arg 1 UV Missense 31 
17  c.1484G>A p.Arg495Gln 1 MUT Missense 14, 32 
17  c.1501T>C p.Tyr501His 1 UV Missense  
17  c.1591G>A p.Gly531Arg 1 UV Missense  
 17 c.1624+1G>A  1 MUT Affects splice donor site  
18  c.1765C>G p.Arg589Gly 1 UV Missense  
18  c.1790G>A  1 MUT Affects splice donor site  
 18 c.1791-1G>A  1 MUT Affects splice acceptor site  
19  c.1800delA p.Lys600fs 1 MUT Frameshift in exon 19 9 
19  c.1827C>G† p.= 1 UV Silent  
19  c.1831G>A p.Glu611Lys 2 UV Missense  
 22 c.2149-9C>A  1 UV Affects splice acceptor site  
 22 c.2149-2delA  2 MUT Affects splice acceptor site 15 
23  c.2164G>A p.Glu722Lys 1 UV Missense  
23  c.2308G>A  1 MUT Affects splice donor site  
23  c.2149-?_2737+?  2 MUT Deletion exons 23-26  
24  c.2346C>T† p.= 1 UV Silent  
24  c.2373dupG  47 MUT Novel splice donor in ex.24 15 
25  c.2432A>G p.Lys811Arg 1 MUT Missense 9 
25  c.2497G>A p.Ala833Thr 5 UV Missense 15, 31 
25  c.2542G>A p.Ala848Thr 1 UV Missense  
25  c.2574C>A p.Ser858Arg 1 UV Missense  
27  c.2827C>T p.Arg943X 22 MUT Nonsense 32 
27  c.2864_2865delCT p.Pro955fs 15 MUT Frameshift in exon 27 9, 32 
27  c.2869A>T p.Thr957Ser 1 UV Missense  
29  c.3181C>T p.Gln1061X 1 MUT Nonsense 5 
31  c.3332_3335dup p.Trp1112X 1 MUT Nonsense  
31  c.3392T>C p.Ile1131Thr 3 UV Missense 15, 31 
31  c.3407_3409delACT p.Tyr1136del 1 UV Single amino acid deletion  
 31 c.3490+1G>T  1 MUT Affects splice donor site  
 32 c.3628-41_3628-17del25  2 MUT Affects splice acceptor site 33 
33  c.3776delA p.Gln1259fs 5 MUT Frameshift in exon 33  
* Novel mutations, identified during this study, are in bold. 
† The silent UVs c.1008C>T, c.1827C>G and c.2346C>T likely represent rare polymorphisms, although 
pathogenic character cannot formally be excluded. 
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Table 2. MYBPC3 Polymorphisms in the Dutch population. 
Exon Intron U91629 Nucleotide change Amino acid 
RefSNP ID 
(dbSNP129) 
Allele freq. 
(total = 136) 
 2 g.2484G>C c.292+41G>C  rs3729985 <0.01 
4  g.3634G>A c.472G>A p.Val158Met rs3729986 0.05 
4  g.3654C>T c.492C>T  rs3218719 0.15 
 4 g.3712insG c.506-46insG   <0.01 
 4 g.3746insC c.506-12dupC  rs11570050 0.20 
5  g.3789C>T c.537C>T  rs11570051 0.04 
6  g.5190A>G c.706A>G p.Ser236Gly* rs3729989 0.07 
7  g.5788C>T c.786C>T  rs11570058 0.07 
 11 g.7078C>A c.926+25C>A  rs3729991 0.02 
 12 g.9994G>A c.1091-31G>A  rs7940442 <0.01 
 12 g.10001T>C c.1091-24T>C  rs2856650 0.71 
 13 g.10186G>A c.1223+29G>A  rs11570078 0.07 
 15 g.10693A>C c.1252-21A>C   <0.01 
 19 g.12559G>A c.1897+47G>A  rs11570086 0.03 
 23 g.15148C>T c.2308+18C>G  rs3729948 0.03 
25  g.16203C>T c.2547C>T  rs3729953 0.03 
 25 g.16288C>T c.2602+30C>T   <0.01 
26  g.17721G>A c.2686G>A p.Val896Met rs35078470 0.02 
 26 g.17784C>T c.2737+12C>T  rs3729936 0.02 
 26 g.17788C>G c.2737+16C>G   <0.01 
 29 g.20294A>G c.3191-21A>G  rs11570115 0.09 
30  g.20412G>A c.3288G>A  rs1052373 0.38 
31  g.20757G>A c.3413G>A p.Arg1138His  <0.01 
 31  c.3491-29dupC   † 
 33 g.21700C>T c.3815-66C>T  rs2290146 0.28 
* The p.Ser236Gly polymorphism was found in coupling with the c.786C>T and c.1223+29G>A 
polymorphisms. 
† We found every sample tested to be homozygous for c.3491-29dupC when compared to U91629, 
probably indicating a mistake in the reference sequence rather than a true polymorphism. 
 
accounts for at least three p.Arg943X haplotypes in the population for the small 0.9 cM region 
tested (Table 3). The 11 tested index patients carrying the c.2864_2865delCT mutation showed 
a similar pattern. At least three haplotypes exist for the c.2864_2865delCT mutation for the 
same region indicating a similar age as the p.Arg943X mutation in the population. The high 
frequencies of both mutations and the observed recombination frequency in the 0.9 cM region 
between polymorphic markers D11S986 and D11S4109 suggest that both founder mutations 
p.Arg943X and c.2864_2865delCT arose about 15-20 generations ago in the Dutch population 
(calculated according to Bergman et al).22 
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Clinical features of the two new MYBPC3 founder mutations 
Cardiologic evaluation of 23 mutation carriers from 16 p.Arg943X families and 20 mutation 
carriers from 12 c.2864_2865delCT families showed patients who developed atrial fibrillation 
(AF): 22% of the p.Arg943X and 30% of the c.2864_2865delCT carriers. Most of these patients 
underwent several electrical cardioversions. These numbers are comparable with previous 
reports demonstrating that AF occurs in 25% of HCM patients. A pedigree of a 
c.2864_2865delCT mutation-family is shown in Figure 1, demonstrating intrafamilial variability 
of disease. The results of the clinical evaluation of all mutation carriers are summarised in Table 
5. Post mortem molecular analysis identified the p.Arg943X mutation in two patients, who 
suffered a sudden cardiac death at age 11 years and 31 years respectively and were diagnosed 
at autopsy with severe hypertrophic cardiomyopathy. They had not been diagnosed with HCM 
during their lives. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Family with MYBPC3 mutation c.2864_2865delCT. 
 
Pedigree of a c.2864_2865delCT mutation family illustrating intrafamilial variability. The arrow indicates the 
proband. MI = Myocardial Infarction. 
Notably, there was a significant increase in echocardiographic measurements of the left atrium 
(LA) at follow-up in the p.Arg943X carriers (p=0.00097) and the c.2864_2865delCT carriers 
(p=0.004) (Table 6). This may be a reflection of increased left ventricular (LV) filling pressure 
because of LVH or decreased LV compliance. 
 
Prognosis and Survival in families with founder mutations 
Evaluation of available family histories allowed assessment of the natural history, including 
prognosis and survival, of the three c.2373dupG, p.Arg943X and c.2864_2865delCT MYBPC3 
founder mutations (Table 7). Nine out of 27 (33%) analysed c.2373dupG mutation families had 
a malignant prognosis and 12 (44%) had an intermediate prognosis. Five of 13 (38%) 
p.Arg943X families had a malignant prognosis, seven (54%) were intermediate and one was 
benign (8%). Of nine c.2864_2865delCT families five (56%) families were malignant and four 
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(44%) were intermediate. A remarkable proportion of patients was unaware of the familial 
nature of the disease at diagnosis, although SCD had sometimes occurred in one of their 
(close) relatives. 
 
Table 5. Clinical features in p.Arg943X and c.2864_2865delCT mutation carriers. 
 p.Arg943X c.2864_2865delCT 
Number of patients (index patients) 23 (16) 20 (12) 
Male / female  16 / 7 12 / 8 
Family history    
Positive for HCM  10 (63%) 9 (75%) 
Positive for SCD  9 (56%) 7 (58%) 
Ascertainment of patients    
Cardiac symptoms  16 (70%) 12 (60%) 
Family screening  5 (22%) 3 (15%) 
Asymptomatic carriers 7 (30%) 6 (30%) 
Age at diagnosis   
Mean ± SD (yrs)  35 ± 16 43 ± 15 
< 18 yrs, n  3 (13%) 0 
Follow-up duration   
Mean ± SD (yrs)  8 ± 10 12 ± 8 
Range (yrs) 0 - 28 2 - 25 
Treatment   
No medical treatment 9 (39%) 6 (30%) 
B-blocker 4 (17%) 8 (40%) 
Other 10 (44%) 6 (30%) 
Intervention   
Myectomy 3 (13%) 3 (15%) 
PTSMA* 0 (0%) 1 (5%) 
ICD 1 (4%) 0 (0%)  
NYHA class at first evaluation   
I 14 (61%) 9 (45%) 
II 5 (22%) 11 (55%) 
III 4 (17%) 0 (0%)  
IV 0 (0%) 0 (0%) 
NYHA class at follow-up   
I 10 (53%) 13 (65%) 
II 7 (37%) 6 (30%) 
III 2 (10%) 1 (5%) 
IV 0 (0%) 0 (0%) 
Complications   
Atrial fibrillation (AF) 5 (22%) 6 (30%) 
Mean age AF (+/- SD) 57 (+/- 6.4) 56 (+/- 15.6) 
Range age AF 50-64 31-74 
Cardiac arrest survival 1 (4%) 0 (0%) 
Follow-up   
Unknown 2 (9%) 1 (5%) 
Deceased 6 (26%) 4 (20%) 
Periodic cardiologic examination 15 (65%) 15 (75%) 
Legend. * PTSMA = Percutaneous Transluminal Septal Myocardial Ablation 
† NYHA = New York Heart Association classification 
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Table 7. Prognosis in c.2373dupG, p.Arg943X and c.2864_2865delCT families. 
 Benign n (%) 
Intermediate* 
n (%) 
Malignant
n (%) 
Total families 
n 
c.2373dupG mutation 6 (22) 12 (44) 9 (33) 27 
p.Arg943X mutation 1 (8) 7 (54) 5 (38) 13 
c.2864_2865delCT mutation 0 4 (44) 5 (56) 9 
Legend. * Assessment of prognosis was made based on the occurrence of MCE in available pedigrees 
 
Kaplan-Meier survival curves were computed for all three MYBPC3 founder mutations (Figure 
2). The survival curves for all three mutations were not statistically different (p=0.119 for 
p.Arg943X and c.2373dupG; p=0.134 for c.2864_2865delCT and p.Arg943X and p=0.952 for 
c.2864_2865delCT and c.2373dupG). Remarkably, the p.Arg943X founder mutation survival 
curve showed three deaths before the age of 20 years. 
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Figure 2. Survival associated with truncating MYBPC3 mutations. 
Kaplan-Meier survival curves for a group of 117 patients from 26 c.2373dupG families, 50 patients from 16 
p.Arg943X families and 62 patients from 12 c.2864_2865delCT families. 
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Discussion 
This study describes the molecular analysis of the MYBPC3 gene in a large cohort of 327 
probands with familial or sporadic HCM followed at the adult cardiogenetic outpatient clinic of 
the Erasmus MC Rotterdam. HCM is a genetically heterogeneous autosomal dominant disease 
and familial disease is caused by a single pathogenic mutation in one of the 24 currently 
identified HCM genes. Our approach to analyse a single HCM gene in a large HCM population 
does not take into account the possibility of multiple pathogenic mutations in additional HCM 
genes. Double mutations have been reported in literature in 3 to 5 % of genotype-positive 
patients.5, 9 However, these percentages are likely to be an over-estimation since in reported 
HCM patients with double mutations it is often uncertain whether the second mutation is truely 
pathogenic. In addition, real double-mutation patients appear to have a different disease 
expression than is seen in classical HCM including very early onset and severe clinical 
presentation, making it less likely that an important proportion of our ‘adult cohort’ would 
constitute double mutation patients. 
We report the highest percentage of MYBPC3-HCM thus far, emphasising the importance of 
MYBPC3 in the aetiology of HCM.5, 9 The high percentage of MYBPC3 mutations in the 
analysed Dutch population can be explained by the presence of three founder mutations: the 
c.2373dupG, p.Arg943X and c.2864_2865delCT mutations. These founder mutations together 
are present in 84/148 (59%) of the MYBPC3-HCM patients and are found in 84/327 (26%) of 
the Dutch HCM patients. Based on a population prevalence of HCM of 0.2% it can be estimated 
that approximately 8320 HCM patients in the Netherlands carry one of the three MYBPC3 
founder mutations (population 16 million). The discovery of three highly prevalent MYBPC3-
HCM founder mutations in the Dutch population has important implications for molecular HCM 
screening in this population. The efficacy of initial MYBPC3 analysis is high, especially when 
the three founder mutations are tested first. 
Most HCM causing mutations are rare and occur in only one or a few families worldwide and 
founder effects are exceptional.4-7, 23 Only mutations that do not impose an adverse effect on 
reproduction may be transmitted repeatedly and become founder mutations. The discovery of 
strong founder effects for three MYBPC3 mutations suggest that MYBPC3-HCM does not pose 
a reproductive burden. In other HCM genes, like beta-myosin heavy chain (MYH7) and troponin 
T (TNNT2), strong founder effects are not frequently observed. This difference may be 
explained by the observation that MYBPC3 associated HCM has in general a 10-year later age-
of-onset than MYH7-HCM and TNNT2-HCM. MYH7-HCM and TNNT2-HCM may be expressed 
during the reproductive period and therefore there is evolutionary selective pressure against 
mutations in these genes. In general MYBPC3-HCM is expressed when the biological 
reproductive period is already over and therefore MYBPC3 mutations are not counter-selected 
and founder mutations in this gene are more easily tolerated. 
In most populations HCM is highly heterogeneous. Limited numbers of distinct genotypes and 
families have placed constraints on genotype-phenotype analyses. In the current study, we 
used family history to analyse clinical phenotype and prognosis associated with two new 
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founder mutations. In the current study, only 22%, 8% and none of the c.2373dupG, p.Arg943X 
and c.2864_2865delCT families respectively, were associated with a benign prognosis. 
Moreover, in 33%, 38% and 56% of the c.2373dupG, p.Arg943X and c.2864_2865delCT 
families respectively, two or more HCM associated MCE were recorded before the age of 60 
years, indicating a malignant course of the disease in these families. However, our results may 
represent an over-estimation of the malignancy of these mutations since ascertainment bias in 
patient collection may have played a role because the Erasmus MC is a tertiary referral centre. 
The three founder mutations show identical Kaplan-Meier survival estimates. This finding is 
likely explained by the suggestion from several studies that haploinsufficiency is the pathogenic 
mechanism for HCM caused by truncating MYBPC3 mutations.24-26 Therefore, we hypothesise 
that most – if not all – truncating MYBPC3 mutations will have identical survival curves and an 
identical natural history as the c.2373dupG, p.Arg943X and c.2864_2865delCT mutations. 
As reported previously, general measurements of LV function are not disturbed in HCM 
patients, whereas during clinical follow-up LV remodelling occurs.27 This is reflected in our 
study by the LA enlargement during follow-up as a sign of decreased LV compliance and by the 
high prevalence of AF in this population, reflecting both decrease of LA function and LV 
remodelling. Also, if detailed LV function measurements such as LV strain are used, it is 
expected that in mutation carriers a higher prevalence of abnormalities will be identified, 
compared to when only conventional echocardiography is performed. 
Variability in clinical features of HCM presentation is high, even within families. Both 
environmental and genetic modifying factors may contribute to the intrafamilial clinical 
variability. The assessment of the influence of possible modifying genes on development of 
heart failure has been pursued in a large number of studies, yielding contradicting results. In 
particular, the importance of the well known insertion/deletion (I/D) polymorphism in the 
angiotensin-converting enzyme (ACE) and several polymorphisms in the Renin-Angiotensin-
Aldosterone system (RAAS) have been considered as potential disease modifiers in HCM.28-31 
RAAS plays an important role in normal cardiovascular physiology and disease and the (I/D)-
ACE polymorphism has been implicated in ‘hypertension induced’ LVH and HCM. A study in 
one large family carrying the c.2373dupG mutation reported a correlation between LV mass and 
number of ‘pro-LVH’ polymorphisms present in each mutation carrier.29 However, a recent 
study failed to confirm such a general relationship in a large population of HCM patients; in 
contrast to MYH7-HCM, a significant pro-LVH effect of the DD-ACE genotype could be 
demonstrated in MYBPC3-HCM only.30 The discovery of three important founder mutations in 
the Dutch HCM population provides an opportunity to study the role of additional genetic and 
environmental modifying factors in the clinical presentation of HCM. 
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Abstract 
Background 
Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous cardiomyopathy 
characterised by unexplained left ventricular hypertrophy. HCM is mostly autosomal dominantly 
inherited and associated with defects in sarcomere and Z-disc genes. Recently, HCM was 
observed in families with X-linked myopathies caused by mutations in X-chromosomal Four-
and-a-half-LIM domains 1 (FHL1), suggesting that FHL1 may play a role in HCM. We analysed 
the FHL1 gene in a selected cohort of 86 HCM patients to investigate its role in HCM. 
 
Methods 
From a group of 260 HCM index patients, 86 HCM patients (54 men and 32 women) were 
selected because no causal HCM mutation could be identified in their HCM genes MYH7, 
MYBPC3, TNNC1, TNNT2, TNNI3, ACTC1, MYL2, MYL3, TPM1, CSRP3 and TCAP. Complete 
sequence analysis of the FHL1 gene was performed in all 86 HCM index patients. 
 
Results 
FHL1 mutations were identified in two HCM patients; a nonsense mutation in a woman with 
neuromuscular symptoms and a missense mutation in a neurologically asymptomatic man. 
Family studies showed intrafamilial variability in cardiologic and neurologic symptoms and in 
age of onset (including incomplete penetrance). 
 
Conclusion 
FHL1 mutations are an infrequent cause (<1%) of HCM, characterised by X-linked dominant 
inheritance. FHL1 analysis is recommended in male and female HCM patients, especially when 
family history shows X-linked inheritance or is positive for myopathy or muscular dystrophy. 
Absence of family history does not exclude FHL1 cardiomyopathy given the intrafamilial 
variability and incomplete penetrance of HCM and neuromuscular disease. Cardiologic family 
studies are recommended in FHL1 disease. 
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Introduction 
Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disease characterised by 
unexplained left ventricular hypertrophy. It is the most common genetic cardiac disorder with an 
estimated prevalence of 1:500 individuals. Patients can be asymptomatic, or have symptoms of 
heart failure, angina or arrhythmia. It is a major cause of sudden cardiac death in the young.1 
Numerous disease-causing mutations have been identified in 24 genes. Currently, genetic 
defects are identified in approximately 60% of HCM patients, depending on the number of 
genes analysed.2 Mutations are mainly identified in sarcomere and Z-disc genes and cause 
autosomal dominant HCM in the majority of cases. X-linked HCM or HCM phenocopies are less 
frequent and may occur in Fabry and in Danon disease.3-5 Isolated HCM has been recognised 
in female and male carriers of both Fabry and Danon disease.6-8 Fabry disease is a lysosomal 
storage disorder, caused by deficiency of Xq22 GLA-encoded α-galactosidase A with 
multisystemic involvement, including renal, neurological, ocular, skin, and cardiac 
manifestations. The classical form is characterised by early multisystemic manifestations. 
Atypical forms with late-onset isolated renal or cardiac manifestations may occur in men with 
some residual plasma enzymatic activity or in female carriers. Primary deficiency of LAMP2-
encoded lysosomal-associated membrane protein 2 on Xq24 leads to Danon disease. It is 
characterised by intracytoplasmic vacuoles containing autophagic material and glycogen in 
cardiac and skeletal muscle cells. The phenotypic expression of Danon’s disease is variable 
and includes cardiomyopathy and skeletal myopathy, sometimes with conduction defects, 
Wolff-Parkinson-White syndrome, and/or mental retardation. 
The Four-and-a-half-LIM domains 1 gene (FHL1) is located on Xq26; mutations in this Z-disc 
gene have been shown to cause a variety of X-linked myopathies like X-linked dominant 
scapuloperoneal myopathy (SPM, MIM 300695); X-linked myopathy with postural muscle 
atrophy and generalised hypertrophy (XMPMA, MIM 300696); reducing body myopathy (MIM 
300717); rigid spine syndrome (RSS) and Emery-Dreifuss muscular dystrophy (EDMD, 
MIM310300).9-13 Recently FHL1 mutations were also suggested to be associated with HCM and 
dilated cardiomyopathy (DCM).10, 12 
FHL1 consists of eight exons. Exons one and two are thought to be non-coding; the other 
exons are transcribed into three major protein isoforms. FHL1 proteins consist mainly of double 
zinc finger motifs (LIM domains), each zinc finger containing highly conserved cysteines and 
histidines which are held together by one zinc ion.14, 15 FHL1A, composed of 4.5 LIM domains, 
is the main isoform and is predominantly expressed in skeletal muscle and shows intermediate 
expression in cardiac muscle.16-18 FHL1A has been implicated in sarcomere assembly by 
interacting with myosin binding protein-C (MYBPC3).19 The two other isoforms, FHL1B and 
FHL1C, composed of 3.5 and 2.5 LIM domains respectively, expressed to a lesser extent in 
cardiac and skeletal muscles, are also expressed in brain (FHL1B) and testis (FHL1C).16, 17, 20 
To explore the role of FHL1 mutations in sporadic and familial HCM we analysed the FHL1 
gene in 86 unrelated HCM index patients in whom a causal mutation in 11 known HCM genes 
was absent. 
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Methods 
260 unrelated HCM index patients were diagnosed between 1993 and 2007 at the department 
of cardiology of the Erasmus MC in Rotterdam, the Netherlands, according to current diagnostic 
criteria by Maron et al.21 Eighty-six patients from this cohort were selected for this study 
because consecutive screening of the genes MYH7, MYBPC3, TNNC1, TNNT2, TNNI3, 
ACTC1, MYL2, MYL3, TPM1, CSRP3 and TCAP did not result in the identification of a 
causative mutation. Women were included because of the possibility of X-linked dominant 
inheritance of HCM as is seen in Fabry and Danon disease. No selection was made according 
to family history of HCM or neuromuscular disorders. Complete sequence analysis of coding 
regions in exons 3-6 and 8 (NM_001449.4) and intron-exon boundaries of the FHL1 gene was 
performed. 
Sequence analysis of M13-tagged PCR products was carried out on an ABI3730xl capillary 
sequencer using Big-Dye Terminator v 3.1 chemistry (Applied Biosystems). (Details of methods 
and primer sequences available on request.) Analysis of sequence data was performed using 
SeqScape analysis software (v2.5, Applied Biosystems). Mutations were considered pathogenic 
when they were either truncating or, alternatively, when they segregated with disease in a 
family and were not present on 279 healthy control chromosomes and were pathogenic 
according to prediction software.22, 23  
Results 
A novel FHL1 mutation was found in two of the 86 (2.3%) HCM patients, in whom causal 
mutations in 11 known HCM genes had been previously excluded (Table 1); in one woman with 
neurologic symptoms and in one cardiologically and neurologically asymptomatic male HCM 
patient. These results indicate a frequency of around 1% (2/260) in the general HCM population 
and of 1/32 (3.1%) in women and of 1/54 (1.9%) in men after exclusion of the most frequent 
genetic causes for HCM. The p.Gln270X (c.808C>T) mutation in patient 1 is a nonsense 
mutation that disrupts the second zinc finger of the fourth LIM domain (Figure 1). The 
p.Cys188Phe (c.563G>T) mutation is a missense mutation, pathogenic according to prediction 
software22, 23, that affects the first cysteine residue of the second zinc finger of the third LIM 
domain (Figure 1). This cysteine residue is conserved from humans to zebrafish (Figure 2) and 
substitution of this residue for a phenylalanine likely destabilises the structure of the third LIM 
domain. The p.Gln270X mutation affects isoform FHL1A and the p.Cys188Phe mutation affects 
isoforms FHL1A and FHL1B (Figure 3). 
Patient 1 is a female patient who was diagnosed with HCM at the age of 64 years with an 
interventricular septum (IVS) of 15 mm without signs of obstruction; diastole was pseudo-
normal and there was a mild mitral regurgitation. She was under cardiologic surveillance since 
the age of 56 years, after the sudden cardiac death (SCD) of her 18-year-old son while playing 
soccer. He was diagnosed with HCM at autopsy. She had an abnormal electrocardiogram 
(ECG) with repolarisation disturbances without echocardiographic signs of HCM. From the age 
of 37 years on she suffered from pain in her shoulders, had four operations of shoulder  
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Table 1. Clinical and molecular characteristics of two HCM patients with an FHL1 mutation. 
 Patient 1 Patient 2 
Clinical characteristics   
Sex Female Male 
Age of onset (yrs) 64 32 
Initial presentation Cardiac screening after SCD of son  Heart murmur 
NYHA II I 
IVS (mm) 15 17 
ECG Negative T in V1-3 Abnormal Q in AVL, negative T in V3-6 
24-hour ECG Short periods of atrial tachycardia np 
Neurological symptoms Shoulder pain with abduction restriction None 
 Nocturnal calf muscle cramps  
 Food passage problems  
Family history for    
HCM / SCD + / + - / - 
Neurological disease + - 
Familial disease   
Cardiologic + np 
Neurologic + np 
Molecular characteristics   
Exon 8 6 
Nucleotide c.808C>T c.563G>T 
Protein p.Gln270X p.Cys188Phe 
Consequence Nonsense, disruption fourth LIM domain. 
Missense, disruption third LIM 
domain. 
 Presumed effect on FHL1A Presumed effect on FHL1A and FHL1B 
Legend. NYHA: New York Heart Association classification; IVS: intraventricular septum; ECG: 
electrocardiography; SCD: sudden cardiac death; np: not performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The 3d and 4th LIM domain showing the positions of the identified FHL1 mutations. 
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Figure 2. Alignment of amino acids of the 3d LIM domain.  
Black background shows conservation throughout all species. The arrow shows the cysteine on position 
188.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Distribution of the HCM-related mutations along the FHL1 gene and corresponding RNA 
isoforms (adapted from Guneau et al).12 
 
 
 
 
 
 
FHL1 consists of eight exons; exons 1 and 2 are non-coding, exons 3 to 8 are alternatively spliced, giving 
rise to three isoforms: FHL1A, FHL1B and FHL1C. Translation of all three isoforms starts with ATG on 
exon 3 and ends with TAA and TGA respectively on different positions on exon 8. Exons 1, 6 and 7 are 
alternatively spliced in the different isoforms (grey). Mutation p.Cys188Phe (patient 2), located on exon 6, 
affects isoforms FHL1A and FHL1B; mutation p.Gln270X (patient 1) is located on exon 8 positioned behind 
the stop codon of the FHL1B and FHL1C isoforms and thus only affects FHL1A. Mutations in bold were 
identified during this study, dotted lines represent mutations previously reported in EDMD FHL1 families 
with isolated HCM.12 
ligaments and was eventually diagnosed with fibromyalgia. At the age of 66 years she was 
seen in the neurological outpatient clinic with difficulties of moving food from the pharynx to the 
stomach. Neurologic examination showed no weakness of facial or shoulder girdle muscles but 
a restriction in shoulder abduction at 120° at both sides was noted. There were no signs of limb 
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girdle or distal muscle weakness. Serum creatine kinase was normal. There were no signs of 
hypermobility or of skin hyperextensibility or scapular winging.  There were no chewing 
problems. During the night she had complaints of easily elicited muscle cramps in her calf 
muscles. Muscle biopsy performed from the quadriceps muscle demonstrated aspecific 
myopathic features with central nuclei and subsarcolemmal positioned vacuoles. Electron 
microscopy was not performed.  
The pedigree of family 1 is shown in Figure 4. At autopsy of IV:2 a heart weight of 760 grams 
was noted (normal ~350 grams), with hypertrophy of the left and right ventricular wall and 
asymmetric hypertrophy of the IVS. Microscopic examination of the heart demonstrated 
architectural distortion with myocyte disarray with variable hypertrophy of the cardiomyocytes 
and interstitial fibrosis (Figure 5). In DNA from post-mortem material, the p.Gln270X mutation in 
FHL1 was identified. The family history revealed HCM in IV:3 at age 28 years. A maternal uncle 
(II:3) was reported with an unspecified muscle dystrophy and was wheelchair bound from the 
age of 35 years onwards; he died from heart failure at the age of 78 years. Medical records 
were not available. Molecular analysis identified the p.Gln270X mutation in the FHL1 gene in 
IV:3, III:4, and in III:9, the 59-year-old unaffected daughter of  II:3, confirming that the uncle with 
muscular dystrophy had been an obligate carrier of the mutation. Three of her four 
asymptomatic daughters were identified as carriers. Cardiologic examination showed no signs 
of HCM at the ages of 29, 32 and 36 years respectively. The mutation was absent in the 
unaffected son of the proband (IV:1) and in a niece (IV:4). 
Patient 2 was diagnosed with HCM at the age of 32 years with an IVS of 17 mm. He was 
referred to the cardiologist because a heart murmur was detected when he suffered form 
pneumonia. The patient did not have signs of a neuromuscular disorder. Family history was 
negative for HCM and neuromuscular disorders, relatives declined cardiologic and molecular 
screening.  
Discussion 
FHL1 mutations were identified in <1% of HCM patients (2/260). In a selected cohort of 86 
HCM patients in which more prevalent genetic causes for HCM were excluded, FHL1 mutations 
were found one male and one female patient, indicating a frequency of 1/32 (3.1%) in women 
and of 1/54 (1.9%) in men in this population. Guneau et al previously showed isolated HCM in 
four EDMD families to be more frequent in female (7) than male carriers (5).12  
Since we also detected a pathogenic mutation in a woman diagnosed with HCM at age 64 
years, we conclude that FHL1 mutations are associated with X-linked dominant inheritance of 
HCM and can be distinguished from autosomal dominant HCM by the absence of father to son 
inheritance. X-linked dominant HCM is also seen in Fabry and in Danon disease. The 
prevalence of Fabry can be as high as 12% in female patients with late-onset HCM.7 Danon 
disease often presents at a young age with hypertrophic or dilated cardiomyopathy 
accompanied by skeletal myopathy and Wolff-Parkinson-White syndrome. However, isolated 
cardiomyopathy has been described in female carriers.5, 6 The difference between FHL1- HCM 
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 Figure 4. Pedigree of patient 1. 
 
 
The arrow indicates the proband. HCM: hypertrophic cardiomyopathy; FHL1: four-and-a-half LIM domains 
1 gene; IVS: interventricular septum; SCD: sudden cardiac death 
and HCM associated with Fabry and Danon 
disease is that microscopy of FHL1- HCM 
shows the typical characteristics of 
sarcomere-related autosomal dominant 
HCM, whereas Fabry and Danon disease 
patients show microscopic inclusions typically 
associated with lysosomal storage disorders. 
FHL1 codes for four-and-a-half-LIM domains 
1 which is localised in the sarcolemma, 
sarcomere and nucleus of muscle cells.16-18, 
20 FHL1 interacts with MYBPC3 and may 
compete with myosin for binding to 
MYBPC3.19 Myosin thick filament formation 
was impaired in FHL1 knockdown 
experiments in mouse myoblast cells (C2C12 
cells) and was associated with reduced incorporation of MYBPC3 into the sarcomere, 
suggesting that FHL1 has a role in sarcomere assembly.19 This could explain the 
neuromuscular disorders associated with FHL1 mutations although in EDMD patients none of 
the identified FHL1 mutations seemed to have an impact on sarcomere formation in 
myoblasts.12 Human cardiac muscle tissue has not been studied so far. Cardiac FHL1 
Figure 5. Post-mortem microscopy of relative IV:2 
of patient 1. 
Note the myocyte disarray, with oblique and 
sometimes perpendicular orientation of the 
cardiomyocytes, interstitial fibrosis and irregular, 
polymorphic and hyperchromatic nuclei. 
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deficiency in knockout mice resulted in a blunted hypertrophic response to biomechanical 
stress.24 The discrepancy between the weakened hypertrophic reaction in FHL1 knockout mice 
and HCM in human FHL1 mutation carriers might be explained by differences in FHL1 
expression in human and mouse cardiac muscle. All mutations identified in FHL1 so far are 
unique mutations that may have different effects on FHL1 function, similar to different mutations 
in the N2-B region of titin / connectin leading to either an increase of titin-FHL2 interaction 
causing HCM, or a decrease in titin-FHL2 interaction causing dilated cardiomyopathy.25 Since 
there are three FHL1 isoforms, differences in expression or function between the three isoforms 
may also play a role in the different observed phenotypes. In addition, truncated FHL1 proteins 
may act as poison-polypeptides and cause HCM through a dominant-negative effect. 
Functional studies on human cardiac tissue might establish which mechanism leads to HCM in 
FHL1 mutations carriers. 
Mutations that have previously been identified in EDMD (missense, truncating and suppression 
of stopcodon) were located on exons 5, 6 and 8; seven of the eight EDMD mutations affect the 
FHL1A isoform, four also affect the FHL1B isoform, two also affect FHL1C and one mutation 
solely affects FHL1C.12 Mutations described in reducing body myopathy, XMPMA, SPM and 
RSS are missense mutations often affecting highly conserved cysteines and are mainly located 
in exon 5 and to a lesser extent in exon 4, affecting all three isoforms. One mutation in XMPMA 
is located on exon 6 and affects the FHL1A and FHL1B isoforms.9-11, 13 Cardiac involvement in 
FHL1 mutation carriers has been seen in both women and men and consists of HCM and DCM 
with or without arrhythmia. Isolated cardiac disease without neuromuscular involvement in both 
women and men has been described in EDMD families by Gueneau et al. 12 The mutations in 
these families are located on exon 5 (frameshift), exon 6 (missense) and exon 8 (one frameshift 
and one missense mutation) (Figure 3). No specific genotype-phenotype relationships can be 
established yet, based on the present knowledge. Family studies are therefore recommended in 
all FHL1 families, especially since FHL1 mutations have been associated with an increased risk 
of SCD, as demonstrated in family 1 and in previous studies.12 Molecular and cardiologic family 
screening allows accurate identification of relatives at risk of developing HCM and/or SCD. In 
relatives who refuse DNA analysis, neurological evaluation may establish their risk-status, even 
in the absence of a cardiac phenotype.  
Neurological family studies of FHL1 HCM families are necessary to establish whether FHL1 is 
linked to isolated HCM without neuromuscular disease. For now cardiologic and neurologic 
examinations remain recommended in FHL1 families. 
In summary, FHL1 mutations are an infrequent cause of HCM with cardiologic and neurologic 
intrafamilial variability and incomplete penetrance. When X-linked dominant inheritance is 
suspected, the chance of finding FHL1 defects may be higher, especially when family history is 
positive for myopathy or muscular dystrophy. In these cases FHL1 analysis is recommended. 
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Abstract 
Background 
Hypertrophic cardiomyopathy (HCM) is the most common inheritable cardiac disorder and is 
characterised by marked genetic and clinical heterogeneity. Genotype-phenotype studies have 
been hampered by the genetic heterogeneity of HCM and uniqueness of HCM mutations. 
Disease variability is expected to be partially explained by the effect of additional mutations in 
sarcomere genes. 
 
Methods and results 
To analyse whether a complex genotype is an important modifier of disease severity we 
completely analysed nine sarcomere HCM genes (MYH7, MYBPC3, MYL2, MYL3, TNNT2, 
TNNI3, TNNC1, ACTC1, TMP1) in 87 subjects carrying truncating MYBPC3 founder mutations 
as primary genetic HCM defect. The subjects were clinically diagnosed as either having a mild 
or severe phenotype based on age of diagnosis, maximal wall thickness, left ventricular outflow 
tract obstruction, positive family history of sudden cardiac death and the necessity for septal 
reduction therapy or an implantable cardioverter defibrillator. 
No additional mutations were seen in the group with a severe phenotype compared to the group 
with a mild phenotype. 
 
Conclusion 
The severity of phenotypic expression of HCM in subjects with a truncating MYBPC3 mutation 
is not primarily dependent on the modifying effects of secondary sarcomere mutations. 
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Introduction 
Hypertrophic cardiomyopathy (HCM) is the most common inheritable cardiac disorder with a 
phenotypic prevalence of 1:500. It is defined by the presence of left ventricular hypertrophy in 
the absence of loading conditions (hypertension, valve disease) sufficient to cause the 
observed abnormality. Hundreds of mutations scattered among at least 24 putative HCM 
susceptibility genes encoding various sarcomere, Z-disc, calcium-handling, and mitochondrial 
proteins are known to cause HCM and are found in up to 60% of cases.1-5 The genetic 
heterogeneity of HCM together with the fact that most HCM mutations are unique and occur in 
single families, have hampered studies establishing genotype-phenotype relations. The 
observed variability in disease severity may be partially explained by complex genotypes i.e. 
the effect of additional mutations in sarcomere genes.6-9 
In the Netherlands, approximately one third of all HCM cases are caused by the truncating 
c.2373dupG, p.Arg943X and c.2864_2865delCT founder mutations in the myosin binding 
protein C gene (MYBPC3).10 These mutations lead to haploinsufficiency and are thought to be 
functionally identical.11 We completely analysed nine sarcomere genes in 87 patients from this 
group, homogeneous with respect to the primary HCM defect, to analyse whether a complex 
sarcomere genotype is a modifier of disease severity in MYBPC3 associated HCM. 
Methods 
Subjects 
Subjects were selected from our cohort of carriers of Dutch founder mutations (c.2373dupG, 
p.Arg943X and c.2864_2865delCT in MYBPC3), including probands as well as family 
members. All subjects in the cohort were clinically diagnosed as either having “mild” or “severe” 
phenotype based on the following criteria: age at diagnosis < 25 years, maximal wall thickness 
(MWT) ≥ 30 mm, left ventricular outflow tract obstruction (LVOTO) > 30 mmHg, sudden cardiac 
death (SCD) ≥ 2 first-degree family member < 40 years and the necessity for septal reduction 
therapy or an implantable cardioverter defibrillator (ICD) for primary or secondary prevention of 
SCD. A mild phenotype was defined as the absence of any of these criteria and a severe 
phenotype was defined as the presence of ≥ 2 criteria. Based on these definitions 87 subjects, 
from 52 different families, were included in the current study. For the diagnosis of HCM in family 
members the published diagnostic criteria for HCM in adult members of affected families were 
used.12 
 
Genetic analysis 
Complete DNA sequence analysis was performed of all coding regions of nine HCM genes; β-
myosin heavy chain (MYH7; NM_000257.2), myosin binding protein C (MYBPC3; 
NM_000256.3), cardiac troponin C (TNNC1; NM_003280.1), cardiac troponin T (TNNT2; 
NM_000364.2), cardiac troponin I (TNNI3; NM_000363.4), cardiac-regulatory myosin light chain 
(MYL2; NM_000432.3), cardiac-essential myosin light chain (MYL3; NM_000258.2), cardiac α-
actin (ACTC1; NM005159.4), α-tropomyosin (TPM1; NM_000366.5). 
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Sequence analysis was carried out on an ABI3730xl capillary sequencer using Big-Dye 
Terminator v 3.1 chemistry (Applied Biosystems). (Details of methods and primer sequences 
are available on request.) Analysis of sequence data was performed using SeqScape analysis 
software (v2.5, Applied Biosystems). All identified sequence variations were subjected to 
statistical analysis. 
Nomenclature for the description of sequence variants was used according to the 
recommendations of the Human Genome Variation Society (www.HGVS.org). 
 
Statistical methods  
All statistics were performed using the SPSS 16 for Windows (SPSS Inc, Chicago, IL, USA). 
Descriptive data were computed as a mean value  SD. Variables among the groups were 
compared by ANOVA. Statistical significance was defined by P  0.05. 
Results 
HCM mutation carriers  
The descriptives of the study population are displayed in Table 1. A total of 87 subjects were 
included in the study; 44 had a mild phenotype and 43 a severe phenotype. The group with the 
severe phenotype was diagnosed at a significantly younger age. In this group MWT was 
significantly thicker and the gradient in the LVOT was significantly higher compared to the 
group with a mild phenotype. By definition a positive family history for SCD, septal reduction 
therapy or ICD implantation were absent in the group with a mild phenotype. There was no 
significant difference in gender or in the presence of the three founder mutations between the 
two groups. 
 
Table 1. Subject characteristics. 
 Total group Mild phenotype 
Severe 
phenotype P-value 
Number patients 87 44 43  
Men (n, %) 48 (55%) 25 (57%) 23 (53%) 0.5 
HCM diagnosis (n, %) 65 (75%) 22 (50%) 43 (100%) 0.001 
Age at diagnosis (yrs, mean ± SD) (range) 38.4 ± 13.5 (11 - 68) 
44.7 ± 10.9 
(29 – 64) 
35.7 ± 13.7 
(11 – 65) 0.006 
MWT (mm, mean ± SD) (range) 18.7 ± 7.2 (7 - 40) 
15.1 ± 5.9 
(7 - 29) 
23.8 ± 5.3 
(15 – 40) 0.001 
LVOT (mmHg, mean ± SD) (range) 32.7 ± 37.7 (3 – 130) 
8.6 ± 5.4 
(3 – 29) 
57.9 ± 39.7 
(5 – 130) 0.001 
Family history SCD (n, %) 18 (21%) 0 (0%) 18 (41%) 0.001 
Septal reduction therapy (n, %) 26 (30%) 0 (0%) 26 (59%) 0.001 
ICD (n, %) 9 (10%) 0 (0%) 9 (20%) 0.001 
c.2373dupG (p.Trp792fs) (n, %) 47 (54%) 22 (50%) 25 (58%) 0.5 
c.2827C>T (p.Arg943X) (n, %) 24 (28%) 12 (27%) 12 (28%) 0.5 
c.2864_2865delCT (p.Pro955fs) (n, %) 16 (18%) 10 (23%) 6 (14%) 0.3 
Legend. HCM = hypertrophic cardiomyopathy; MWT = maximal wall thickness; LVOT = left ventricular 
outflowtract; SCD = sudden cardiac death; ICD = implantable cardioverter defibrillator 
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DNA sequence analysis 
Complete sequence analysis of nine sarcomere genes in 87 subjects with a truncating 
MYBPC3 mutation resulted in the identification of 68 different sequence variations (Table 2). 
Forty-seven different sequence variations were found in the MYBPC3 and MYH7 genes. No or 
only a single sequence variant was observed in the TNNC1, MYL3 and ACTC1 genes. 
Except for the c.2373dupG, p.Arg943X and c.2864_2865delCT founder mutations in MYBPC3, 
no additional clearly pathogenic mutation was found in the nine HCM genes. Fifty-nine variants 
were identified that were either in intronic sequences or did not have an effect on protein 
composition (i.e. ‘silent variants’). For none of these 59 variants a significant difference in 
distribution could be demonstrated between the mildly affected group and the severely affected 
group (Table 2). 
A total of nine different missense variants (i.e. variants with an effect on protein composition) 
were identified. Missense variants are of interest because of their potential modifying effect on 
protein function and disease expression in HCM. In total, six missense variants were identified 
in MYBPC3, one missense variant in MYH7 and 2 missense variants in TNNT2. The missense 
variants were analysed using the SIFT and PolyPhen prediction algorithms13, 14. The predictions 
by SIFT were mostly of low confidence and the predictions of PolyPhen suggested seven 
missense variants to be benign and not have an adverse effect on protein function. Only the 
p.His1039Tyr and p.Ile1131Thr variants in the MYBPC3 gene, observed in a mildly affected and 
a severely affected subject respectively were predicted by PolyPhen to have a deleterious 
effect on protein function. 
There was no significant difference between the total number of missense variants (10) in the 
severely affected group and the total number of missense variants (15) in the mildly affected 
group (p=0.389). When the frequent polymorphism p.Ser236Gly in MYBPC3, present in equal 
numbers in both groups, is excluded from the analysis the difference remains non-significant 
(p=0.249). 
The heterozygous p.Val158Met variant in the MYBPC3 gene was found six times in the group 
with the mild phenotype and was absent in the group with severe phenotype (p=0.029). 
However, after correction for multiple testing this difference was found to be non-significant. 
Discussion 
Secondary sarcomere mutations did not explain the difference in disease severity in this cohort 
of HCM subjects with a truncating MYBPC3 founder mutation. No additional pathogenic 
mutations were found and the identified sarcomere sequence variations could not be 
associated with a mild or a severe phenotype. We therefore conclude that severity of 
phenotypic expression of HCM is not primarily dependent on the modifying effects of a 
secondary sarcomere mutation or sequence variant on top of the primary genetic defect. HCM 
is characterised by phenotypic heterogeneity; some carriers do not develop cardiomyopathy, in 
others negligible to extreme hypertrophy, absent or severe left ventricular outflow tract 
obstruction, normal longevity or premature sudden cardiac death occurs, even in patients carry- 
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ing the same pathogenic HCM mutation.15 According to literature compound or double 
heterozygotes are detected in 3 - 5% of genotype-positive patients.6-8 These patients appear to 
have a more severe phenotype and an increased incidence of SCD, suggesting a gene-dose 
effect might contribute to disease severity.7, 16 Compound heterozygousity for truncating 
MYBPC3 mutations causes severe neonatal HCM leading to death in the first weeks or months 
of life.17 This is probably the result of the lack of functional MYBPC3 protein (i.e. human 
MYBPC3 knockouts). Since the youngest patient in our cohort was 11 years old it is not 
surprising that we did not find compound heterozygousity for two truncating mutations in 
MYBPC3. Double heterozygousity, when two pathogenic mutations in two different genes are 
present and at least one functional copy of the MYBPC3 gene is still active, has been described 
in adult patients without being responsible for a lethal phenotype at a young age.6, 8 In a large 
cohort from the Mayo Clinic, patients with two mutations in different genes were significantly 
younger at diagnosis, had the most hypertrophy, and the highest incidence of myectomy and 
ICD placement compared to patients with one mutation.7 Based on these data additional 
analysis of sarcomere genes in the presence of a severe phenotype was recommended, posing 
important implications for genetic counselling and pre-symptomatic testing of family members.8 
However, the current study suggests otherwise for specific MYBPC3 founder mutations, unless 
severe hypertrophy or end stage heart failure is present at a young age. It remains to be 
established whether these findings extend to other MYBPC3 and sarcomere mutations. 
All three described Dutch founder mutations are functionally identical truncating mutations, 
leading to haploinsufficiency, and have identical Kaplan-Meier survival estimates (Chapter 9).11 
The result of our study illustrates that the clinical heterogeneity of HCM is in this group is more 
likely to be modified by environmental factors as well as by other non-sarcomere genetic factors 
than by multiple mutations in sarcomere genes.18-20  The most important subgroup of non-
sarcomere polymorphisms studied to date involve the major components of the renin-
angiotensin-aldosteron system (RAAS). The RAAS system contributes to ventricular 
hypertrophy through effects mediated by circulating angiotensin as well as local activation of 
RAAS in the myocardium.21 Polymorphisms in the RAAS pathway appear to influence the 
severity of LVH in HCM patients carrying MYBPC3 mutations.18, 22 Proteins involved in 
hypertrophic pathways or mediators of calcium signalling in cardiomyocytes are other promising 
candidates as modifier genes.23-25 Further studies are needed to identify modifier genes in HCM 
and to elucidate the molecular mechanisms by which they influence cardiac hypertrophy; as this 
could possibly lead to new prognostic markers and new therapeutic targets for HCM. 
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General Discussion 
The aim of this dissertation was to investigate the genetics of cardiomyopathies, in particular 
noncompaction cardiomyopathy (NCCM) and hypertrophic cardiomyopathy (HCM). With 
cardiologist Dr. Folkert ten Cate’s experience in HCM of many years’ standing, the Thorax 
Centre outpatient-clinic of the Erasmus Medical Centre in Rotterdam became a tertiary referral 
centre for HCM with renowned expertise in natural history and treatment of HCM patients. The 
large “Rotterdam” HCM population provided the opportunity to start the research projects 
described in this dissertation, and to identify a new HCM gene and investigate genotype-
phenotype relationships. Interest in cardiomyopathies further extended to NCCM, and the 
relatively large number of NCCM patients referred nationwide to cardiologist Kadir Caliskan 
allowed establishing a genetic classification for NCCM.  
Funding by the Dutch Health Insurances (“Locale component”) enabled to achieve a 
multidisciplinary cardiogenetic out-patient clinic, where cardiologist and clinical geneticists work 
together to facilitate genetic diagnosis, genetic counselling and family screening. In the mean 
time a growing number of genetic causes for cardiomyopathies were identified, improving 
molecular diagnostics. The first part of this thesis focused on the genetic aspects of NCCM, the 
second part concerned HCM. 
NCCM 
Since NCCM is a relatively newly discovered cardiomyopathy, little was known of the genetic 
origin and aetiology of NCCM. The first objective of the NCCM study was to investigate the 
prevalence of genetic NCCM by extensive cardiologic family studies of NCCM probands and 
simultaneous molecular analysis of 17 genes (MYH7, MYBPC3, TNNC1, TNNT2, TNNI3, 
ACTC1, MYL2, MYL3, TPM1, CSRP3, TCAP, LDB3, CASQ2, CALR3, PLN, TAZ and LMNA) in 
the probands. This way we identified genetic NCCM in the majority of cases (67%; 39/58). In 
thirty-two probands (16 with a genetic defect, 15 without a genetic defect and one in whom no 
genetic analysis was performed) cardiologic family studies identified cardiologically affected 
relatives, indicating genetic NCCM. Additionally, one proband had a de novo mutation, three 
had a mutation without any affected relatives and three had a mutation but cardiologic 
screening of relatives did not take place. Approximately half of the probands with familial 
disease did not report familial disease prior to the cardiologic family study (47%). Therefore, 
ascertainment of family history alone proved to be insufficient to detect familial disease. 
Although our estimates of the role of genetics in NCCM are higher than in previous report, 
underestimation of the true proportion of genetic disease may have occurred. There are four 
possible causes for underestimation of familial disease in our cardiologic family study. First, 
compliance in the family study of first-degree relatives was 52%; of the 277 first-degree 
relatives identified to be possibly at risk for NCCM, 145 participated in the cardiologic study. 
Since our study showed that the majority of affected relatives was asymptomatic, and family 
history cannot reliably detect familial disease, relatives will have to be examined by a 
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cardiologist to establish whether they are affected. Screening more relatives will most likely lead 
to detection of more cases of familial NCCM. Secondly, some families were small with few first-
degree relatives to include in our study. Perhaps the proband in these families had a genetic 
form of NCCM but the relatives did not have the genetic defect and were therefore unaffected. 
When the family is larger, chances of finding an affected relative are higher. Thirdly, we 
encountered 20 relatives with clinical features not meeting current diagnostic criteria for NCCM 
as stated by Jenni.1 Neither did they fulfil criteria for HCM or DCM.2 We could not include these 
relatives as affected, neither were they unaffected. These relatives may have reduced 
penetrance or an early stage of cardiomyopathy that eventually might develop into NCCM, 
HCM or DCM. Revised criteria for diagnosis in relatives, as those proposed for HCM, 
distinguishing major and minor diagnostic criteria for NCCM are needed for accurate family 
screening.3 Follow-up studies of these probably affected relatives are necessary to validate the 
significance of minor abnormalities. Fourthly, non penetrance was observed in eight unaffected 
carriers of a familial mutation. It is possible that similar to HCM and DCM, late-onset NCCM 
may occur in relatives. Follow-up studies of unaffected and possibly-affected relatives will 
determine whether they will develop NCCM. 
Taking into account the compliance of relatives, the “affected” relatives not fulfilling NCCM 
criteria, non-penetrance and possible age-dependent penetrance, the actual percentage of 
familial disease in NCCM may be even higher than the 67% we reported. In literature previous 
studies reported 33% - 44% familial disease.4-10 Careful evaluation of the methodology of these 
studies may explain why there are such substantial differences. Our results originate from a 
combined cardiologic and molecular family study. None of the previous studies performed 
cardiologic screening of relatives as systematically and as extensively as in our study, nor did 
they perform extensive molecular studies.4-10 One study did not present the proportion of 
probands where family screening revealed familial NCCM; instead the proportion of affected 
relatives was presented (25%).4 Another study used questionnaires reporting 44% familial 
disease.7 Other studies relied on retrospective review of medical records of probands to assess 
occurrence of familial disease, which is very likely to lead to under-ascertainment. As our study 
showed, at least 47% of the probands is unaware of familial disease. One study that did 
perform molecular analysis (in six sarcomere genes: MYH7, TNNT2, TNNI3, ACTC1, MYL2 and 
MYL3) identified mutations in 17% but did not perform family studies.11 It is therefore difficult to 
compare the results of our study with the previous reports. 
The next objective of this study was to establish a genetic classification for NCCM by identifying 
the genes associated with isolated NCCM. Since different phenotypes (NCCM, HCM and DCM) 
may occur within one family and mutations in some sarcomere genes can cause HCM as well 
as DCM, our hypothesis was that genes involved in HCM / DCM may also play a role in NCCM. 
For that reason extended molecular diagnostics of 17 genes previously associated with NCCM 
and/or with HCM and DCM, were performed systematically in 48 unrelated adults and eight 
children with NCCM. This way the molecular genetic cause for NCCM was identified in 23 
patients (41%). The MYH7 gene is the most prevalent genetic cause for NCCM identified so far, 
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accounting for 20% of all tested probands (11) and for 48% of the probands in whom a mutation 
was identified. Apart from MYH7, mutations were also identified in MYBPC3 in three patients 
(four mutations), TNNT2 in two patients (three mutations), TPM1 in two patients, TNNI3 in one 
patient who also had a TPM1 mutation, ACTC1 in one patient, CASQ2 in two patients (one in 
combination with two TNNT2 mutations), PLN in one patient, TAZ in one patient, LDB3 in two 
patients, (once combined with a TNNT2 mutation, once with an LMNA mutation). Single 
mutations were identified in 18 patients; complex genotypes, identified in adults and in children, 
consisted of two mutations in four patients and three mutations in one patient. In addition to 
these genes we also identified a new locus associated with NCCM on chromosome 4. We can 
conclude that genetics play an important role in NCCM. By finding 11 genes associated with 
NCCM and identifying a new NCCM locus, a large step has been taken in identifying the 
genetic causes of NCCM. These genes are mainly of the sarcomere and Z-disc, similar to the 
genes associated with HCM. Establishing the genetic causes facilitates accurate identification 
of relatives who are at risk of developing NCCM or a related cardiomyopathy. 
Combining the results of the family and molecular studies showed that the majority of NCCM, 
with or without a mutation, is inherited in an autosomal dominant mode and that clinical features 
and age at onset in NCCM are highly variable, even within families. One of the most important 
findings was that the majority of relatives diagnosed with NCCM by family screening was 
asymptomatic (63%). In addition we observed non-penetrance in eight cardiologically 
unaffected mutation carriers (age range 12 - 72 years). These observations have major 
implications for recommendations for follow-up of relatives and for cardiologic family screening. 
In families without a mutation, asymptomatic relatives can only be identified as affected through 
cardiologic examination. However, in case of non-penetrance, continuation of follow-up of 
unaffected relatives is necessary and further family screening is recommended (as depicted in 
flow chart in Chapter 3). If a molecular defect is found in a family, predictive molecular testing 
will identify the asymptomatic relatives at risk for cardiomyopathy, and may exclude those who 
do not need cardiologic screening. Asymptomatic disease seems to occur frequently in adults 
with NCCM, and was also found in probands (20%). These probands were diagnosed by 
chance for instance during pre-operative screening or after an X-ray due to persistent coughing 
revealed an enlarged heart. Apparently it is possible to have a cardiomyopathy without any 
symptoms. It is likely that relatives with symptoms of cardiomyopathy are picked up earlier 
when they seek medical care. 
 
Phenotypic variability in NCCM 
In our family study we identified NCCM at all ages; even prenatal presentation was seen in two 
cases (Chapter 5). Disease severity was also variable; some patients died at a young age, 
some required heart transplants and some patients were coincidentally diagnosed and 
completely asymptomatic. Phenotypic variability can even be so extreme that a mutation carrier 
might not even develop a cardiomyopathy at all. For this phenomenon there is no good 
explanation, there are only theories. Numerous additional modifying factors, either genetic or 
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environmental or both, probably play a role in phenotype development. Some modifying factors 
may have a protective effect, others may cause more damage. Currently there is not enough 
evidence that additional genetic factors play a large role in the variability of the severity of 
NCCM and HCM. In our NCCM study five patients with a complex genetic status all presented 
with NYHA classification II or higher, whereas some patients with a single mutation were 
asymptomatic. Two of the multiple mutation patients presented at a young age (four months 
and seven years respectively); nevertheless in single mutation patients, four patients presented 
at an early age (ranging from one month to 17 years). According to these data a second (and 
third) mutation does not necessarily lead to early-onset disease nor is a second mutation 
always identified in early-onset disease. Numbers of this study are too small too draw any final 
conclusions on genotype-phenotype relationships in NCCM, especially since most mutations 
are unique. Similarly, there was no evidence for additional genetic factors playing a role in 
disease severity in our HCM double heterozygousity study (Chapter 11). Limitations of these 
studies are that we cannot actually exclude a second or third genetic factor, since we did not 
sequence the whole genome. Perhaps even a non-coding part of the DNA will be of importance 
as was recently established in coronary artery disease in mice.12 
 
Congenital heart defects and NCCM 
In our NCCM study we identified structural heart defects in eight families, in families with as well 
as in families without a mutation. Some of the relatives with a structural heart defect also had 
NCCM. In congenital heart disease over 25 genes have been identified, such as ligands-
receptor genes (e.g. NOTCH1, JAG1 and PTPN11), transcription factor genes (e.g. GATA4, 
NKX2.5, TBX1) and also several sarcomere genes (ACTC1, MYBPC3, MYH6, MYH7 and 
MYH11).13-19 Because of the typical trabecularisation reminiscent of early embryological cardiac 
development, it has been suggested that NCCM is caused by an arrest of normal 
embryogenesis of the myocardium.5, 20 Identifying sarcomere defects in NCCM as well as in 
structural heart disease may indicate that NCCM indeed has its origins in defective myocardial 
embryogenesis. This may also explain the co-occurrence of structural heart defects in NCCM. 
Possible late-onset disease however, as seen in HCM, will be more difficult to explain if this 
hypothesis is correct. Evidence for late-onset NCCM has not been established yet. Non-
penetrance however, as observed in our study population indicates otherwise. We also do not 
know if patients who are diagnosed in adulthood had NCCM in their early infancy. Follow-up of 
unaffected relatives is needed to establish the occurrence of late-onset NCCM. 
HCM 
HCM is one of the most prevalent genetic cardiac disorders, in adults and children, affecting 
approximately 1 in 500 people. In the last decade, more than 24 genes involved in HCM have 
been identified, accounting together for approximately 60 - 70% of HCM patients. The MYBPC3 
and the MYH7 gene are the most prevalent causes for autosomal dominantly inherited HCM. X-
linked forms of HCM or phenocopies of HCM have been described, for instance in Fabry and 
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Danon disease. The frequency of Fabry in the HCM population is currently investigated. The 
highest prevalence reported so far was 12% in female patients with late-onset HCM.21 
In some patients HCM occurs as a part of a complex syndrome, especially in childhood. Among 
these complex causes are malformation syndromes, neurological, mitochondrial and metabolic 
disease and chromosomal defects (as listed in Table 10-12 of chapter 1). Systematic research 
of the prevalence of non-sarcomere causes of HCM in adults is currently lacking. 
The presently known 24 genes do not explain HCM in 30 - 40% of the patients. Some of these 
patients show evident familial disease, others may display sporadic HCM. In this thesis we 
describe the identification of a novel genetic cause for HCM. New candidate genes for HCM 
may be found in sarcomere and Z-disc genes that have not been tested in an HCM population 
yet. One of these genes is the FHL1 gene, a Z-disc gene located on the X-chromosome. 
Additional to this gene being a Z-disc gene, the FHL1 gene has been implicated in several 
neuromuscular disorders, some of these patients also displayed cardiomyopathy.22 Family 
studies even revealed isolated HCM without neuromuscular disease in male and female 
relatives in these families.22 The FHL1 gene was therefore an excellent candidate, so we 
analysed this gene and identified mutations in the FHL1 gene as a new genetic cause for HCM. 
Since HCM was also present in women with an FHL1 mutation we can conclude that this type 
of HCM inherits as an X-linked dominant trait. Although the exact frequency of FHL1-associated 
HCM remains to be established, in a family with X-linked inheritance (no father to son 
transmission), especially combined with presence of neuromuscular disease, it is advisory to 
sequence the FHL1 gene.  
 
Founder mutations 
In the Netherlands genetic HCM features the presence of three founder mutations in the 
MYBPC3 gene (c.2373dupG; p.Arg943X and c.2864_2865delCT), causing approximately 25% 
of Dutch HCM and thus making the MYBPC3 gene the most prevalent HCM-causing gene in 
the Netherlands. The three founder mutations are all truncating mutations, most likely causing 
haploinsufficiency. The genetically homogenous HCM population provides an excellent 
opportunity to evaluate genotype phenotype correlation and investigate the role of potential 
genetic modifiers on the variability of the phenotype.  
 
Genotype - phenotype correlation in HCM 
Our study showed a similar natural history of founder-mutation-related HCM in the Netherlands, 
with a malignant prognosis in 33-56% of the founder mutation families and almost identical 
survival estimates (Chapter 9). Early diagnosis of HCM may prevent a malignant course of the 
disease, it is therefore important to perform family studies (cascade screening). Naturally, 
careful genetic counselling is required in order to inform each relative before DNA analysis, so 
they can make in informed decision concerning presymptomatic testing. 
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Modifiers in the founder population  
Variability in disease severity and age of onset is observed within and between families. 
Modifying factors may explain this variability. In order to identify possible modifiers, we 
analysed 87 HCM patients with an MYBPC3 founder mutation for additional defects in 11 HCM 
genes (ACTC1, CSRP3, MYBPC3, MYH7, MYL2, MYL3, TCAP, TNNI3, TNNC1, TNNT2 and 
TPM1) to analyse whether a complex genotype plays a role in disease variability. We did not 
find additional defects in the group of more severely affected HCM patients. Nevertheless, the 
co-occurrence of two truncating mutations in the MYBPC3 gene, resulting in a human MYBPC3 
knockout, does constitute a very severe phenotype with death in early infancy, as shown in the 
two cases in Chapter 7 and also in literature.23 We cannot exclude that other, yet unknown, 
genetic causes of cardiomyopathy, play a role in the observed variability within the founder 
population. 
 
Other HCM modifiers 
To determine whether aldosterone is a modifying factor in HCM we studied the influence of the 
C-344T polymorphism in aldosterone synthase (CYP11B2) on left ventricular mass index 
(LVMI) and intraventricular septum (IVS) thickness in 79 unrelated HCM patients. In male HCM 
patients LVM and IVS increased with presence of the T-allele in CYP11B2 (p-value 0.06 and 
0.01 respectively). This effect was not seen in women; since the very small number of women 
without a T-allele no definite conclusions about the gender difference should be made.  
Overlapping features of NCCM and HCM 
The cardiologic NCCM family study revealed that in eight of the 50 screened families, NCCM as 
well as HCM and DCM were diagnosed in relatives of NCCM probands. HCM and DCM 
occurred in families with an identified genetic defect and in families without such a defect. This 
may be coincidental but previous studies also identified different cardiomyopathies within one 
family, indicating that NCCM belongs to a spectrum of cardiomyopathies with HCM and DCM.15, 
24-26 This observation raises the question, why does one person develop NCCM and another 
HCM or DCM? We observed that even the same mutation in a gene may result in different 
phenotypes within one family. Most NCCM mutations that were identified are unique. Except for 
the identification of a Dutch MYBPC3 founder mutation in our NCCM cohort: we identified the 
c.2373dupG mutation twice in our NCCM cohort, once as a single mutation in an adult and 
once in combination with another MYBPC3 (p.Gly148Arg) mutation in a 7-year-old girl. As 
previously mentioned, the MYBPC3 c.2373dupG mutation is the most prevalent disease-
causing mutation in the Dutch HCM population (14.4%, Chapter 9); approximately 4600 Dutch 
HCM patients carry the c.2373dupG mutation (population 16 million, HCM prevalence 0.2%). 
Despite this high prevalence of c.2373dupG patients, NCCM was not reported in c.2373dupG 
carriers so far. It is possible, that the p.Gly148Arg mutation in MYBPC3 in the girl with two 
mutations attributes to the NCCM phenotype; her father carried the p.Gly148Arg and had 
NCCM whereas her mother, carrying the c.2373dupG mutation, did not show a cardiomyopathy 
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phenotype (yet); the maternal grandfather carried the c.2373dupG mutation as well and he was 
diagnosed with HCM. In the adult NCCM patient with only the c.2373dupG mutation we were 
unable to identify a second genetic defect, however it can not be excluded that she carries a 
second mutation in a currently unknown NCCM gene. 
Similar to the MYBPC3 c.2373dupG mutation being identified in NCCM and HCM, the MYH7 
p.Asp545Asn and p.Asp955Asn in cis mutations were recently identified in a DCM family in 
Groningen and in a DCM family in Amsterdam. It is highly probable that these families are 
distantly related, because the odds of developing two identical MYH7 missense mutations in cis 
in three independent families seem slim. So far we were not able to link these three families by 
genealogy. 
For now there is no explanation for the difference in phenotypes in patients carrying the exact 
same mutations. Nevertheless, it seems likely that additional genetic factors do play a role. 
Given the fact that quite a large proportion of NCCM and a smaller proportion of HCM are 
currently still genetically unexplained, perhaps the unidentified genetic factors in these patients 
also play a role as second genetic defect in families where a causative mutation has already 
been identified. 
 
Molecular mechanisms of the NCCM – HCM spectrum 
Different mutations in the same genes may lead to different phenotypes, because they may 
involve different pathogenic pathways. It is likely that the nature and location of the specific 
mutation dictates phenotypic variability. The most frequently mutated gene in NCCM was the 
MYH7 gene with 11 mutations and this gene is the second most frequent cause for HCM in the 
Netherlands. Therefore the MYH7 gene is suitable for having a closer look at the different 
nature and locations of the mutations. In our study, seven of the MYH7 mutations identified in 
NCCM patients were missense mutations; additionally a double missense-mutation, a slice-site 
mutation, a single amino-acid deletion and a nonsense mutation were identified. Four MYH7 
mutations (the splice-site, the nonsense and two missense mutations) are located in the ATP-
ase active site of the globular head-region on the amino-terminal part of the MYH7 protein. Of 
all NCCM-related MYH7 mutations that have been identified, half are located in this region.11, 16 
Four other MYH7 mutations in our study (three missense mutations and the single amino-acid 
deletion) were found in the carboxy-terminal rod-region of the MYH7 protein. In this region few 
cardiomyopathy mutations have been identified. However, MYH7 mutations associated with 
HCM are mainly missense mutations and have been identified throughout the MYH7 gene.27 In 
conclusion, the current insight of pathogenetic mechanisms of specific mutations in the MYH7 
gene is insufficient to explain phenotypic variability. Clinical and molecular data support that 
NCCM, HCM and DCM belong to a cardiomyopathy spectrum. However, insight into the genetic 
and / or other factors playing a role in phenotype differences remains scant. Understanding of 
the pathogenetic mechanisms that lead to NCCM, HCM and DCM may help in identifying these 
additional modifying factors. 
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Heterogeneity of NCCM and HCM  
Isolated forms of NCCM and HCM are genetically heterogeneous, and since these clinically 
distinct forms of cardiomyopathy share a number of disease-causing genes, mainly coding for 
sarcomere and Z-disc proteins, overlapping pathophysiological mechanisms are suspected. 
Figure 1 clearly demonstrates the heterogeneity of NCCM and HCM and the shared genetic 
causes. Members of the same family of genes (for instance sarcomere or Z-disc genes) will 
most likely share common pathways leading to cardiomyopathy. NCCM and HCM may also 
occur as part of genetic neuromuscular diseases or malformation syndromes. The RAS 
pathway seems to play an important role in syndromal HCM and NCCM (Noonan, Leopard, 
Costello, cardio-facio-cutaneous syndrome and neurofibromatosis). Apparently there are 
different pathways leading to cardiomyopathy. 
In some of the (rare) complex disorders NCCM and HCM may occur in different patients, 
suggesting an aetiologic overlap, also between complex forms of NCCM and HCM. However a 
more prevalent genetic cause for NCCM and HCM involved in the occurrence of 
cardiomyopathy in complex disease cannot be excluded. For instance, one patient in our study 
was a girl with Down syndrome and NCCM who was diagnosed with an MYH7 mutation 
(p.Ala326Pro). She could not be included in Chapter 3 and 4 since she didn’t fulfil the fourth 
Jenni criterion of absence of co-existing cardiac anomalies because she had an atrioventricular 
septal defect, as often seen in Down syndrome. It is very well possible that NCCM or HCM in 
some of the syndromes listed in Figure 1 are caused by a gene defect in an additional 
(sarcomere or Z-disc) gene, unrelated to the syndrome. Obviously, a search for a 
cardiomyopathy-related gene defect may not be performed when a structural heart defect or an 
evident syndromal cause is present, assuming that the cardiomyopathy is secondary. In this 
way, a diagnosis of genetic familial cardiomyopathy may be overlooked. 
We may conclude that even in the presence of structural heart defects, a syndrome or other 
disorders, separate molecular diagnostics for cardiomyopathy may be appropriate, especially 
when there is a family history of cardiac symptoms. 
 
Sarcomere and Z-disc 
The sarcomere is the contractile unit of muscle cells and contains different filament protein 
complexes. The thick filament system, composed of myosin heavy chain and myosin essential 
and regulatory light chain, is connected from the M-line to the Z-disc by giant filament titin 
(Figure 2). Intermediate filament myosin-binding protein C binds the thick filament to thin 
filament component actin. The thin filament is formed by actin monomers that bind to nebulin; 
troponin C, troponin I, troponin T and tropomyosin complete the thin filament. Titin is present in 
both thick and thin filament and gives stability and structure to the sarcomere. The main 
component of the Z-disc is α-actinin 2, other Z-disc proteins are cysteine-and-glycine-rich 
protein, LIM domain-binding 3, four-and-a-half-LIM domains 1, myozenin 2, telethonin and 
vinculin/metavinculin. 
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Figure 1. Heterogeneity and overlap of disease-causing genes in HCM and NCCM and in 
neuromuscular and syndromal disease. Red displays sarcomere genes, blue Z-disc genes and green 
calcium-handling genes. ACTA1: α-Skeletal actin; ACTC1: α-Cardiac actin; ACTN2: α-Actinin 2; AMPD1: 
Adenosine monophosphate deaminase 1; ANKRD1: Cardiac ankyrin repeat protein; ARX: Aristaless-
related homeobox; BRAF: V-RAF murine sarcoma viral oncogene homolog B1; CALR3: Calreticulin; 
CASQ2: Calsequestrin; CAV3: Caveolin; CDKN1C: Cyclin-dependent kinase inhibitor 1C; CRYAB: α-B 
Crystallin; CSRP3: Cysteine and glycine rich protein; DES: Desmin; DMD: Dystrophin; DMPK: Dystrophia 
myotonica protein kinase, DTNA: α-Dystrobrevin; EYA1: Eyes absent 1; FBN2: Fibrillin 2; FHL1: Four-an-
a-half LIM domains; FLNA: Filamin A; FXN: Frataxin; GPC3: Glypican 3; HCCS: Holocytochorme C 
synthase; HRAS: V-HA-RAS Harvey rat sarcoma viral oncogene homolog; H19: H19 gene; JPH2: 
Junctophilin 2; KCNH2: Potassium channel, voltage-gated, subfamily H, member 2; KCNQ10T1: KCNQ1-
overlapping transcript 1; KRAS: V-KI-RAS2 Kirsten sarcoma viral oncogene homolog; LDB3: LIM domain-
binding 3; LMNA: Lamin A/C; LMX1B: LIM homeobox transcription factor 1; MEK1: Mitogen-activated 
potein kinase kinase 1; MEK2: Mitogen-activated potein kinase kinase 2; MYBPC3: Cardiac myosin-
binding protein C; MYH6: α-Myosin heavy chain; MYH7: β-Myosin heavy chain; MYL2: Ventricular 
regulatory myosin light chain; MYL3: Ventricular essential myosin light chain; MYLK2: Myosin light chain 
kinase 2; MYO6: Myosin VI; MYOZ2: Myozenin 2; NF1: Neurofibromatosis 1; NIPBL: Nipped-B-like; 
NR0B1: Nuclear receptor subfamily 0, group B, member 1; NSD1: Nuclear receptor-binding Su-var, 
enhancer of zeste, and trithorax domain protein 1; PAHX: Phytanoyl-CoA hydroxylase; PEX7: Peroxisome 
biogenesis factor 7; PLN: Phospholamban; PMP22: Peripheral myelin protein 22; PTPN11: Protein-tyrosin 
phophatase, nonreceptor-type 11; RAF1: V-RAF-1 Murine leukemia viral oncogene homolog 1; SCN5A: 
Sodium channel, voltage-gated, type V, α-subunit; SEPN1: Selenoprotein N1; SOS1: Son of sevenless, 
drosophila homolog 1; TAZ: Taffazin; TCAP: Telethonin; TNNC1: Cardiac troponin C; TNNI3: Cardiac 
troponin I; TNNT2: Cardiac troponin T; TPM1: α-Tropomyosin; TTN: Titin; VCL: Vinculin/metavinculin; 
ZNF: Zinc finger protein. 
gChapter 13 242 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2
and ban
. The sarcomere and its proteins. Z, I, A and M represent corresponding sarcomere zones 
ds. 
Reproduced with permission from: “Diagnostic yield, interpretation and clinical utility of mutation screening 
coding genes in Danish hypertrophic cardiomyopathy patients and relatives; Andersen et 
on 2009;30:363-370”  
 
of sarcomere en
al; Human Mutati
Contraction occurs after release of calcium into the cardiomyocyte, after which the thick 
filament slides in between the thin filaments. In almost all sarcomere and in many Z-disc genes 
mutations causing cardiomyopathy have been identified. Several mechanisms have been 
suggested through which cardiomyopathy occurs in patients with such a gene defect. The 
defective allele may act as a poisonous peptide, interfering with the normal allele. Alternatively 
a gain of function dominates normal function. A third mechanism is haploinsufficiency, in which 
the remaining normal allele provides insufficient protein to perform the function required. 
Hypertrophy or noncompaction may be compensatory reactions to one of these mechanisms. 
Daily practice  
Although many questions currently remain unsolved, identifying genetic defects in NCCM and 
HCM is important enabling family studies and accurate identification of who is at risk for NCCM 
or HCM and, equally important, who can be excluded from cardiologic follow-up. 
In NCCM the MYH7 gene is the most frequently mutated gene, our recommendation is to 
analyse this gene first. Additionally MYBPC3, TPM1, TNNT2, TNNI3, ACTC1, CASQ2, PLN, 
TAZ, LDB3 and LMNA sequencing gives a yield of approximately 40%. In HCM in the 
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Netherlands it is recommended to screen for the Dutch founders c.2373dupG, p.Arg943X and 
c.2864-2865delCT in the MYBPC3 gene first since approximately 25% of the Dutch HCM 
population carries one of these three founder mutations. When no founder mutation is identified 
the rest of MYBPC3 should be sequenced, followed by MYH7 and TNNT2. Screening of 
additional sarcomere and Z-disc genes will lead to a total yield of approximately 60-70%. When 
family history indicates X-linked inheritance and/or when family history is positive for 
neurological disease, the FHL1 gene should be sequenced. 
When no mutation can be established in the NCCM or HCM proband, periodic cardiologic 
family screening is recommended to identify relatives at risk. Identifying new affected relatives 
in its turn will help facilitate future linkage studies in order to find novel genetic causes for 
cardiomyopathy. 
 
Future studies 
To establish whether NCCM may develop at a later age, similar to HCM and DCM, follow-up of 
unaffected relatives in NCCM families is necessary, especially in mutation carriers without a 
phenotype. NCCM was thought to originate from an arrest in embryonic development since the 
phenotype is very similar to embryonic cardiac development. Establishing late onset NCCM and 
non-penetrance of NCCM may invalidate this theory, at least in some cases. Follow-up is 
equally important to establish whether currently “affected” relatives not fulfilling diagnostic 
criteria will eventually develop NCCM or another cardiomyopathy. Knowledge regarding this 
special group of neither affected nor unaffected relatives will be invaluable to determine reliable 
diagnostic NCCM criteria for relatives. Thirdly, follow-up will help to establish accurate risk 
stratification. 
With new molecular techniques (e.g. next generation sequencing) to identify mutations more 
unclassified variants will be exposed. This will pose a problem since it is difficult to establish 
whether an unclassified variant is pathogenic or not. Conservation throughout different species, 
prediction programs and segregation with disease are easily available. Nevertheless, they are 
not always conclusive. RNA studies in splice-site mutations may give us more insight in those 
mutations. For missense mutations such techniques are not readily available. Since the majority 
of NCCM and HCM patients does not provide us with cardiac tissue, functional studies of 
specific mutations will currently only be possible in patients who had a heart transplantation or a 
biopsy. 
In search of new candidate genes for NCCM and HCM additional sarcomere and z-disc genes 
should be sequenced. Genes important for cytoarchitecture, nuclear envelope structure and 
cardiac ion-channel genes (“DCM-genes”) might add to the genetic classification. Additionally 
linkage studies may reveal different associated genes and array-CGH may detect 
submicroscopic genomic aberrations. No doubt in the future sequencing of the whole genome 
of the patient will become possible, technically and financially. This will shift genetics from 
monogenetic disease to genetically more complex aetiologies, and will possibly help to unravel 
the protective effects that cause non-penetrance in familial disease. 
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Finally, the MYBPC3 founder mutation population is extremely valuable in the search for 
genetic modifiers. However, it will take a joint effort of the different cardiogenetic clinics in the 
Netherlands to detect all approximately 4600 c.2373dupG mutation carriers and to perform a 
large-scale research, with sufficient statistical power to detect associations with modifiers. The 
Dutch GENCOR database (www.gencor.nl) will play a major role in national research. 
GENCOR was developed in 2004 by the Interuniversity Cardiology Institute of the Netherlands 
(ICIN) to establish a national registry for patients (and their affected relatives) with familial heart 
diseases such as cardiomyopathies and channelopathies, in whom a causative mutation was 
identified; to facilitate prevalence studies of hereditary heart diseases in the Netherlands and to 
promote research and improve diagnostics and therapeutic possibilities. This database will be 
invaluable in the search for all Dutch founder mutation carriers and will facilitate large-scale 
modifying factor studies. Identifying novel genetic causes and modifiers will give a better 
understanding of pathogenesis and may lead to new therapeutic strategies for NCCM and 
HCM. 
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Summary 
In 1949 the first report of familial cardiomegaly appeared. Over 60 years later, insight in the 
aetiology, especially the genetics of cardiologic disorders, has increased tremendously. With 
the discovery of many genes involved in (mostly autosomal dominantly inherited) familial 
cardiomyopathies, arrhythmias, congenital heart disease and cardiovascular disorders the 
cardiogenetic field is rapidly expanding. These discoveries offer increasing understanding of 
pathogenesis. But above all, this knowledge is of importance for patients and their families, 
enabling accurate identification of relatives at risk of developing a cardiogenetic disorder. 
Subsequently, an increasingly large number of patients, and their relatives, are currently 
referred for genetic counselling and DNA diagnostics. At present the most frequently counselled 
cardiogenetic disorders in Rotterdam are the cardiomyopathies, mainly hypertrophic 
cardiomyopathy (HCM) and noncompaction cardiomyopathy (NCCM). The focus of this thesis 
lies on genetic and family studies of NCCM, in the first part, and HCM, in the second part of this 
thesis. 
 
Chapter 1 presents a general overview of the prevalence, clinical features, clinical and 
molecular diagnostics of these cardiomyopathies and describes the goal of this study: 
identification of familial NCCM and its genetics causes, finding additional genes involved in 
hypertrophic cardiomyopathy en establishing genotype-phenotype relationships. The first part of 
this chapter describes NCCM, a relatively newly classified (by the American Heart Association 
and the European Society of Cardiology) and genetically heterogeneous cardiomyopathy. It is 
characterised by a two-layered structure of the myocardium, with a thin compact epicardial 
layer and a thickened endocardial layer (at least twice as thick as the epicardial layer) with 
prominent trabeculations. Clinical presentation varies among patients. In some (asymptomatic) 
patients NCCM is detected by chance, other patients may present with (aborted) sudden 
cardiac death.  Prognosis is also variable, from slow progression to rapidly developing severely 
disabling cardiac failure. Treatment consists of medication to improve cardiac function (mainly 
β-blockers and ACE-inhibitors). Non-penetrance may occur in carriers of disease causing 
mutations. The clinical features of NCCM may occur at all ages, even prenatally. In adults the 
majority of NCCM is isolated. In childhood, the course of the disease is often more severe and 
NCCM is frequently associated with congenital heart defects, metabolic or neuromuscular 
disease or chromosomal aberrations. In isolated NCCM molecular testing may yield a genetic 
defect, mostly in sarcomere genes, responsible for the production of sarcomere proteins. 
Sarcomere proteins play an important role in myocardial contraction. 
The second part of the first chapter describes HCM, the most frequent cardiogenetic disorder. 
HCM is characterised by left ventricular hypertrophy (left ventricular wall thickness ≥ 15 mm) 
and is mostly asymmetric with hypertrophy of the intraventricular septum. HCM displays a high 
intra- and interfamilial variability. It can present with (symptoms of) heart failure or arrhythmias 
and even SCD. A substantial proportion of HCM patients however, is asymptomatic. HCM 
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occurs at all ages, from prenatal presentation to onset at a high age. HCM is genetically 
heterogeneous. In up to 70% of HCM molecular testing may yield a genetic defect, mostly in the 
MYBPC3 and MYH7 genes. In part of familial HCM no genetic defect can be detected with 
current knowledge. Genetic counselling and (predictive) molecular analysis and/or cardiac 
evaluation of patients and their relatives is important. Figure 14 of chapter 1 shows the process 
of genetic counselling and family studies in HCM. 
HCM may also be caused by mitochondrial defects and is associated with several syndromes 
and neuromuscular disorders. HCM can have important clinical consequences and may lead to 
premature death in some patients while a normal life expectancy is reached by many other 
patients, having mild or no disability. Not all HCM patients require treatment, their prognosis is 
favourable. When treatment is needed, pharmacological therapy is the first option, followed by 
myectomy or PTSMA when medication is insufficient to relieve symptoms. To prevent sudden 
cardiac death adequate risk stratification and subsequent management is important. 
 
In chapter 2 we describe the first two families with pathogenic mutations in the sarcomeric 
cardiac β-myosin heavy chain gene (MYH7) causing autosomal-dominant NCCM. This is the 
first report of the association of MYH7 with NCCM. The MYH7 gene is one of the most frequent 
causes of HCM worldwide and has also been associated with restricted cardiomyopathy (RCM), 
and dilated cardiomyopathy (DCM). These results confirm that the genetic heterogeneity of 
NCCM includes MYH7-associated disease, and suggest that MYH7-associated NCCM may be 
part of a cardiomyopathy spectrum with HCM, RCM, and DCM. 
 
Chapter 3 describes the results of the cardiogenetic family study in a cohort of 58 consecutively 
diagnosed unrelated patients with isolated NCCM (49 adults and nine children). Combined 
molecular testing and cardiologic family screening revealed that in at least 67% NCCM is 
genetic. Cardiologic screening with electrocardiography (ECG) and echocardiography of 194 
relatives from 50 unrelated NCCM probands revealed familial cardiomyopathy in 32 families 
(64%), including NCCM, HCM and DCM. Molecular diagnostics, described in more detail in the 
next paragraph, identified a pathogenic mutation in half of the patients with familial NCCM. The 
majority (63%) of the relatives newly diagnosed with cardiomyopathy in this study was 
asymptomatic. Of 17 asymptomatic relatives with a mutation, nine had NCCM, and in eight 
relatives non-penetrance was observed, explaining that 44% (14/32) of familial disease 
remained undetected by ascertainment of family history prior to cardiologic family screening. In 
41% of the tested probands molecular screening of 17 genes identified mutations in 11 genes. 
In 50% (16/32) of familial NCCM the genetic defect remained inconclusive. In conclusion, we 
identified that NCCM is predominantly a genetic cardiomyopathy with variable presentation. 
Since early diagnosis in (asymptomatic) relatives may be important, NCCM requires genetic 
counselling, DNA diagnostics and cardiologic family screening. A flow chart for this purpose is 
presented in Figure 1. 
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In chapter 4 extensive molecular studies provided a genetic classification of NCCM. Seventeen 
genes (MYH7, MYBPC3, TNNC1, TNNT2, TNNI3, ACTC1, MYL2, MYL3, TPM1, CSRP3, 
TCAP, LDB3, CASQ2, CALR3, PLN, TAZ and LMNA) were completely analysed in a cohort of 
56 unrelated NCCM patients (48 adults and eight children). These genes encode proteins of the 
sarcomere, Z-disc, Calcium-handling system and cellular matrix which, which had all previously 
been associated with other genetic forms of cardiomyopathies. Twenty-nine mutations, 
including 21 new ones, were identified in 23 (41%) of the patients. The MYH7 gene was the 
most prevalent genetic cause for NCCM identified so far, accounting for 11 (20%) of all tested 
probands and for 48% of the probands in whom a mutation was identified. Mutations in 
MYBPC3 were identified in four patients (7%), TNNT2 in three (5%), TPM1, CASQ2 and LDB3 
in two patients each (4%) and TNNI3, ACTC1, PLN, TAZ, and LMNA in one patient each (2%). 
Thirty-five percent of the adult patients had a mutation and 75% percent of the paediatric 
patients had a sarcomeric mutation. Mutations previously associated with cardiomyopathy 
(NCCM, HCM or DCM) were regarded as pathogenic. Novel mutations were considered 
pathogenic when they were either truncating, splice-site or de novo mutations or fulfilled the 
following three criteria: segregation with disease in a family; absence on 384 ethnically matched 
healthy control chromosomes; likely pathogenic according to prediction software (SIFT and 
PolyPhen). Eighteen probands had a single mutation and five patients had a complex genotype. 
MYBPC3, TNNI3, TPM1, PLN and CASQ2 were identified as novel NCCM genes. These 
results showed that genetically, NCCM primarily classifies as a sarcomeric disease and is part 
of a sarcomere gene-associated spectrum including hypertrophic and dilated cardiomyopathy. 
Furthermore, investigating prognosis in families with an identified mutation indicated that in 
families with an identified mutation the prognosis was worse compared to non-genotyped 
families. In conclusion the high frequency of mutations in adult- and childhood-onset NCCM 
confirms the importance of molecular analysis in NCCM. Starting with the most frequent genetic 
cause, the MYH7 gene, is recommended.  
 
Chapter 5 reports on the first two cases of prenatal ultrasound diagnosis of MYH7-associated 
NCCM. Prenatal ultrasound examinations revealed biventricular cardiomegaly leading to the 
diagnosis of NCCM at 31 and at 23 weeks of pregnancy respectively. There was no family 
history of cardiomyopathy in the two families, although one of the fathers was reported with an 
unspecified cardiac condition in childhood, he had been discharged from follow-up at the age of 
14 years. Since maternal cardiomyopathy may require special measures during delivery and to 
identify the cause of the prenatal cardiomyopathy, both parents were cardiologically screened 
and molecularly analysed. In both families MYH7 cardiomyopathy was identified. Subsequent 
family studies identified more affected relatives, who were mostly asymptomatic. Post partum 
follow up of the two prenatal cases and a review of the literature showed that prognosis of 
prenatally diagnosed NCCM predominantly depends on cardiac function and may improve after 
birth. We concluded that MYH7 mutations may present with prenatal onset with biventricular 
enlargement and therefore prenatal ultrasound of pregnancies at risk for MYH7-NCCM is 
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recommended. Since familial disease may initially present with a prenatal onset, molecular 
diagnostics and cardiologic screening of first-degree relatives is necessary even in absence of 
a family history of cardiomyopathy. 
 
Currently, the genetic defect in approximately half of familial NCCM is unknown. In chapter 6 a 
large multi-generation family with an autosomal dominantly inherited cardiomyopathy 
presenting alternatively with NCCM and DCM is described. Cardiological examination of 20 
individuals from this Frisian family identified nine patients with NCCM and one patient with 
DCM. No causative genetic defect was identified by sequencing the 17 cardiomyopathy genes 
as described in chapter 4. To identify the genetic cause for NCCM / DCM in this family a 
genome-wide linkage analysis was performed using 300K SNP arrays. A maximum LOD score 
of 3.02 on chromosome 4p15.3 was obtained. The inclusion of the tenth patient that shares a 
common ancestor with the index case seven generations ago allowed the identification of a 
small candidate region, leading to the mapping of a new locus for autosomal dominant NCCM 
to a 5.47 Mb region on chromosome 4p15.3. Identification of the novel disease gene is ongoing 
and will facilitate genetic screening in this family and provide fundamental insight into the 
understanding of NCCM pathogenesis. 
 
Chapter 7 describes the clinical, pathological and molecular findings of two unrelated neonates 
with complex cardiac pathology, including noncompaction cardiomyopathy. These two patients 
were compound heterozygous for two loss-of-function mutations in the MYBPC3 gene (founder 
mutations) that are common in the Dutch HCM population (the founder mutations are described 
in more detail in chapters 9 and 10). One of the patients had a ventricular septal defect, 
whereas the other patient had an atrial septal defect. Heterozygous mutations in sarcomeric 
protein genes usually lead to hypertrophic cardiomyopathy with clinical symptoms starting in 
child- or adulthood. Homozygousity or compound heterozygousity for two truncating mutations 
in the MYBPC3 gene can cause severe neonatal cardiomyopathy with features of left 
ventricular noncompaction.  
 
Chapter 8 presents the experience with genetic testing and cardiac screening of HCM patients 
and their relatives at the cardiogenetic outpatient clinic at the Erasmus MC. A flowchart for 
clinical and genetic diagnosis and family screening of HCM is included. This chapter discusses 
the importance of identifying autosomal dominantly inherited genetic defects in HCM, thus 
allowing accurate identification of at-risk relatives and effective screening of relatives of HCM 
patients. It focuses in particular on the phenotypic variability including non-penetrance and late 
onset of HCM symptoms demanding repeated cardiac screening of adults at risk for HCM, 
whether they are carriers of a known mutation or relatives of families without an identified 
genetic defect. 
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Previous studies have associated mutations in the sarcomere Myosin Binding Protein C gene 
(MYBPC3) with late onset benign HCM. In chapter 9 molecular analysis of MYBPC3 was 
performed in 327 unrelated Dutch HCM index patients, leading to the identification of a genetic 
variant in 45% of the patients. In addition to the c.2373dupG founder mutation, that was present 
in 14.4% of the patients, two new Dutch MYBPC3 founder mutations were identified: p.Arg943X 
in 6.7% and c.2864_2865delCT in 4.6% of the HCM patients. Family studies showed a 
malignant prognosis in 33%, 38% and 56% of the c.2373dupG, p.Arg943X and 
c.2864_2865delCT families respectively. Estimates of survival were similar for these three 
truncating founder mutations, suggesting a comparable natural history most likely due to 
haploinsufficiency of the three truncating MYBPC3 founder mutations. 
 
HCM often is an autosomal dominantly inherited disorder caused by defects in sarcomere and 
Z-disc genes. Recently, HCM was observed in families with X-linked myopathies caused by 
mutations in X-chromosomal Z-disc gene Four-and-a-half-LIM domains 1 (FHL1), suggesting 
that FHL1 may play a role in HCM. Chapter 10 describes complete sequence analysis of the 
FHL1 gene in 86 HCM patients to investigate the role of FHL1 in HCM. From a group of 260 
HCM index patients, 86 HCM patients (54 men and 32 women) were selected because no 
causal HCM mutation had been identified in MYH7, MYBPC3, TNNC1, TNNT2, TNNI3, ACTC1, 
MYL2, MYL3, TPM1, CSRP3 and TCAP. FHL1 mutations were identified in two HCM patients; 
a nonsense mutation in a woman with subtle neuromuscular symptoms (muscle biopsy 
revealed aspecific myopathic changes) and a missense mutation in a neurologically 
asymptomatic man. Family history was positive for sudden cardiac death and HCM in the 
female patient. Subsequent family studies showed intrafamilial variability in cardiologic and 
neurologic symptoms and in age of onset and included incomplete penetrance in the family of 
the female HCM patient. No family studies of the male patients were performed (yet). These 
results showed that FHL1 mutations are an infrequent cause (<1%) of HCM. FHL1 associated 
HCM is characterised by X-linked dominant inheritance. For that reason FHL1 analysis is 
recommended in male and in female HCM patients, especially when family history suggests an 
X-linked inheritance pattern or when family history is positive for myopathy or muscular 
dystrophy. Absence of a positive family history does not exclude FHL1 cardiomyopathy given 
the intrafamilial variability and incomplete penetrance of HCM and neuromuscular disease, 
family studies are therefore recommended. 
 
Intrafamilial variability of disease severity and age of onset is characteristic for HCM but its 
cause remains unknown. It has been hypothesised that additional genetic or environmental 
factors play a role in HCM phenotype. Additional risk factors are difficult to determine because 
of the unique status the identified mutations. The high prevalence of three truncating founder 
mutations in MYBPC3 in the Netherlands provided an opportunity to investigate the cause of 
variability in disease severity among carriers of identical genetic defects. Chapter 11 describes 
the results of the study on the effect of additional mutations in sarcomere genes on disease 
llSummary 254 
variability in carriers of founder mutations. In order to analyse whether a complex genotype is 
an important modifier of disease severity nine sarcomere HCM genes (MYH7, MYBPC3, MYL2, 
MYL3, TNNT2, TNNI3, TNNC1, ACTC1 and TPM1) were sequenced in 87 HCM patients with a 
previously identified truncating MYBPC3 founder mutation as their primary genetic HCM defect. 
The HCM patients were clinically categorised with a mild or severe phenotype based on age of 
diagnosis, maximal wall thickness, left ventricular outflow tract obstruction, positive family 
history of sudden cardiac death and the necessity for septal reduction therapy or an implantable 
cardioverter defibrillator. There was no difference in the number of additional mutations in the 
group with a severe phenotype compared to the group with a mild phenotype. Therefore we 
concluded that the severity of phenotypic expression of HCM in subjects with a truncating 
MYBPC3 mutation does not primarily depend on the modifying effects of secondary sarcomere 
mutations. Other, yet unknown, genetic causes of cardiomyopathy playing a role in the 
observed variability within the founder population cannot be excluded. 
 
In chapter 12 the role of aldosterone as a modifying factor in HCM was investigated. Cardiac 
and / or plasma aldosterone were measured in 79 genetically independent HCM patients and in 
12 organ donors without cardiac pathology. The effect of the aldosterone synthase (CYP11B2) 
C-344T polymorphism on LV mass index (LVMI) and intraventricular septal thickness (IVS) was 
determined the HCM patients. Aldosterone in HCM hearts and plasma of eight HCM patients 
was similar to that in normal hearts and plasma. In HCM women, no associations between 
CYP11B2 genotype and any of the measured parameters were observed, whereas in HCM 
men, LVMI increased with the presence of the T allele. Similar T allele-related increases were 
observed for the IVS. Multiple regression analysis revealed that the T allele-related effect on 
IVS occurred independently of renin, the ACE I/D polymorphism, the AT1-receptor A/C1166 
polymorphism and the AT2-receptor A/C3123 polymorphism. In conclusion, circulating and 
cardiac aldosterone are normal in HCM, thereby arguing against selectively increased cardiac 
aldosterone production in HCM. Thus, the association between the CYP11B2 C-344T 
polymorphism and hypertrophy in HCM most likely relates to the T allele-related increases in 
circulating aldosterone. This finding raises the need for studies determining the benefit of 
aldosterone blockade in HCM. 
 
In the general discussion in chapter 13 the results of this thesis and comments on their 
significance and implications for daily clinical practice are presented. NCCM and HCM are two 
highly heterogeneous forms of cardiomyopathy that partly share their genetic aetiology. In 
NCCM the MYH7 gene is the most frequently mutated gene, our recommendation is to analyse 
this gene first. Additionally MYBPC3, TPM1, TNNT2, TNNI3, ACTC1, CASQ2, PLN, TAZ, LDB3 
and LMNA sequencing gives a yield of approximately 40%. For HCM in the Netherlands it is 
recommended to screen for the Dutch founders c.2373dupG, p.Arg943X and c.2864-
2865delCT in the MYBPC3 gene first since approximately 25% of the Dutch HCM population 
carries one of these three founder mutations. If this analysis does not reveal a pathogenic 
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mutation, the rest of the MYBPC3 gene should be sequenced, followed by MYH7 and TNNT2. 
Screening of additional sarcomere and Z-disc genes will lead to a total yield of approximately 
60-70%. When family history indicates X-linked inheritance and / or when family history is 
positive for neurological disease, the FHL1 gene should be sequenced. Approximately half of 
familial NCCM and a third of HCM are currently still genetically unexplained. Establishing the 
genetic causes facilitates accurate identification of relatives who are at risk of developing 
NCCM, HCM or a related cardiomyopathy and is therefore important. Carriers of a pathogenic 
mutation or relatives from NCCM or HCM families without an identified genetic defect are 
advised to undergo periodic cardiologic examinations to establish an early diagnosis and start 
necessary therapy, striving to diminish the risk of serious complications within cardiomyopathy 
families. New candidate genes may be found in sarcomere and Z-disc genes that have not 
been tested in NCCM and HCM. Genes involved in DCM, coding for proteins involved in 
nuclear envelope structure, cytoarchitecture and cardiac ion-channels, may also play a role in 
NCCM and DCM. New molecular techniques will make simultaneous sequencing of great 
numbers of genes possible at relatively low costs and may lead to the identification of novel 
genetic defects in NCCM and HCM, adding the challenge of determining whether these variants 
are pathogenic or represent unclassified variants with an unknown effect. Novel genetic defects 
will give more insight into the involved pathways in the pathogenesis of cardiomyopathies. 
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In 1949 verscheen de eerste publicatie over het familiair voorkomen van een vergrote hartspier. 
Nu, meer dan 60 jaar later, is het inzicht in de erfelijkheid van cardiomyopathieën enorm 
toegenomen. Vele genen werden inmiddels ontdekt, die betrokken zijn bij het optreden van – 
voornamelijk autosomal dominant overervende – vormen van cardiomyopathie en 
hartritmestoornissen. Deze ontdekkingen bieden in toenemende mate inzicht in de 
ontstaanswijze. Maar bovenal zijn de ontdekkingen van belang omdat deze de mogelijkheid van 
gerichte en nauwkeurige diagnostiek bij patiënten bieden, waarna op betrouwbare wijze kan 
worden vastgesteld welke familieleden een verhoogd risico lopen op de betreffende 
aandoening. De kennis over de erfelijkheid van de hartziekten heeft ertoe geleid dat steeds 
meer cardiologische patiënten en hun familieleden worden verwezen voor 
erfelijkheidsonderzoek, erfelijkheidsadvisering en DNA diagnostiek. Nu zijn de 
cardiomyopathieën de meest voorkomende erfelijke cardiologische aandoeningen waarvoor 
erfelijkheidsadvisering plaatsvindt in Rotterdam met in het bijzonder de hypertrofische 
cardiomyopathie (HCM) en de noncompaction cardiomyopathie (NCCM). Het eerste deel van 
deze dissertatie beschrijft de resultaten van de onderzoeken naar de erfelijkheid van NCCM en 
het tweede deel gaat over de genetische onderzoeken van HCM. 
 
Hoofdstuk 1 is de algemene inleiding van de dissertatie en beschrijft het doel van de studie: 
het identificeren van familiaire NCCM en de genetische oorzaken, het vinden van additionele 
genen die betrokken zijn bij het ontstaan van HCM en het vaststellen van verhoudingen tussen 
genotype en fenotype. Daarna volgt een overzicht van de prevalentie, de klinische en 
moleculaire (DNA) diagnostiek van NCCM en vervolgens HCM. 
NCCM is een relatief recent door de American Heart Association en de European Society of 
Cardiology geclassificeerde cardiomyopathie waarvan al enkele, voornamelijk zeldzame, 
erfelijke oorzaken bekend waren. NCCM wordt gekenmerkt door een twee-lagige structuur van 
de hartspier, waarbij de buitenste laag dun en compact is en de binnenste laag verdikt is 
(minimaal twee maal zo dik als de compacte laag) met het voorkomen van trabekels. De 
klinische presentatie van NCCM kan van patiënt tot patiënt verschillen. Bij sommige patiënten 
wordt NCCM bij toeval bij een medische keuring of preoperatief onderzoek ontdekt, zonder dat 
er hartklachten zijn. Maar NCCM kan ook een hartstilstand of ernstig hartfalen tot gevolg 
hebben. Ook het beloop van NCCM kan sterk verschillen: van niet of langzaam progressief tot 
een snelle achteruitgang. De behandeling bestaat uit medicijnen die de pompfunctie van het 
hart ondersteunen (voornamelijk β-blockers en ACE-remmers). NCCM komt op alle leeftijden 
voor en kan zelfs al voor de geboorte worden vastgesteld met echografisch onderzoek. Bij 
volwassenen komt NCCM meestal geïsoleerd voor, dat wil zeggen zonder andere (aangeboren 
hart-) afwijkingen. Bij kinderen met NCCM zijn er vaker complexe ziektebeelden; zoals het 
voorkomen van NCCM samen met een aangeboren hartafwijking, of een erfelijke 
stofwisselingsziekte, een neuromusculaire ziekte of een chromosoomafwijking. Bij patiënten 
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met een geïsoleerde NCCM wordt vaker een ziekteveroorzakende (pathogene) mutatie in een 
sarcomeer gen gevonden (zie hoofdstuk 2-4), genen die verantwoordelijk zijn voor de productie 
van sarcomeer eiwitten. Deze eiwitten spelen een belangrijke rol in het samentrekken van het 
hart.  
Het tweede deel van hoofdstuk 1 beschrijft HCM, de meest voorkomende erfelijke hartziekte. 
HCM is een, meestal asymmetrische, verdikking van de hartspier (≥ 15 mm), vooral het 
tussenschot tussen de twee hartkamers is verdikt. Binnen en tussen HCM families is een grote 
variabiliteit in ernst van het ziektebeeld. HCM kan aanleiding geven tot klachten van hartfalen of 
hartritmestoornissen en zelfs plotse dood. Een aanzienlijk deel van de HCM patiënten heeft 
echter geen klachten. HCM komt op alle leeftijden voor, prenatale presentatie als ene uiterste 
en het ontstaan van HCM op hoge leeftijd als andere uiterste zijn mogelijk. Ook HCM is 
genetisch heterogeen. Tegenwoordig kan in ongeveer 70% van de HCM patiënten een 
genetisch defect worden aangetoond, voornamelijk in sarcomeer genen MYBPC3 en MYH7. Bij 
een deel van de familiare vormen van HCM kan momenteel nog geen gen defect worden 
aangetoond. Erfelijkheidsvoorlichting en -onderzoek bij HCM patiënten en hun familieleden, die 
in aanmerking komen voor diagnostisch of voorspellend DNA en / of cardiologisch onderzoek, 
is belangrijk. De werkwijze voor een dergelijk erfelijkheids- en familieonderzoek wordt 
weergegeven in Figuur 14 van hoofdstuk 1. 
HCM kan ook veroorzaakt worden door defecten in de mitochondrieën. Tevens kan HCM 
voorkomen bij verscheidene syndromen en spierziekten. HCM kan belangrijke klinische 
consequenties hebben en kan leiden tot vroegtijdig overlijden, terwijl andere patiënten een 
normale levensverwachting bereiken zonder of met weinig lichamelijke beperkingen. Niet alle 
HCM patiënten hebben therapie nodig, deze patiënten hebben een gunstige prognose. 
Wanneer wel therapie noodzakelijk is, is medicatie de eerst aangewezen optie, indien nodig 
gevolgd door een open hart operatie waarbij een stukje van de verdikking wordt weggesneden 
(myectomie) of een alcohol-ablatie, waarbij door middel van het inspuiten van alcohol lokaal 
een klein hartinfarct wordt opgewekt in de verdikte hartspier, opdat dit stukje hartspierweefsel 
afsterft en de hartspier dunner wordt. Om plotse dood te voorkomen is adequate risico 
stratificatie nodig om te bepalen wie hier een hoog risico op heeft opdat deze patiënten tijdig 
behandeld kunnen worden. 
 
In hoofdstuk 2 beschrijven we de eerste twee families waarin pathogene mutaties in het 
sarcomeer gen β-myosine zware keten (MYH7) autosomaal dominant overervende NCCM 
veroorzaken. Dit was de eerste keer dat MYH7 mutaties met NCCM in verband werden 
gebracht. Mutaties in het MYH7 gen zijn de meest frequente oorzaken van HCM wereldwijd en 
kunnen ook dilaterende en restrictieve cardiomyopathie (DCM, RCM) veroorzaken. Deze 
resultaten geven aan dat de genetische heterogeniteit van NCCM MYH7- geassocieerde ziekte 
omvat en suggereert dat MYH7-geassocieerde NCCM deel uit maakt van een cardiomyopathie 
spectrum met HCM, RCM en DCM.  
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In hoofdstuk 3 staan de resultaten van het cardiogenetische familie onderzoek in een cohort 
van 58 patiënten met geïsoleerde NCCM (49 volwassenen en negen kinderen). Met het 
toepassen van gecombineerd moleculair onderzoek en cardiologisch familieonderzoek vonden 
wij dat in minimaal 67% van de patiënten NCCM genetisch was. Voor het cardiologische 
familieonderzoek werd een cardiologisch onderzoek met elektrocardiografie (ECG of 
hartfilmpje) en echocardiografie verricht van 194 familieleden van 50 NCCM index patiënten. 
Hierbij werd in 32 families (64%) een familiaire vorm van hartspierziekte (NCCM, HCM en 
DCM) aangetoond. Met moleculair onderzoek, dat in de volgende paragraaf in meer detail 
beschreven wordt, werd in de helft van de patiënten met familiaire NCCM een pathogene 
mutatie gevonden. Het merendeel (63%) van de familieleden, die een cardiomyopathie bleken 
te hebben, had geen hartklachten. Door het combineren van voorspellend DNA onderzoek en 
cardiologisch onderzoek van de familieleden kon worden vastgesteld dat van 17 
asymptomatische volwassen dragers er negen NCCM hadden en acht geen tekenen van 
cardiomyopathie hadden (non-penetrantie). Het hoge percentage asymptomatische dragers in 
de families kan verklaren waarom bij 44% (14/32) van de familiaire vormen van NCCM de 
familiegeschiedenis die werd afgenomen voorafgaand aan het cardiologische familieonderzoek 
negatief of niet informatief was. Concluderend kunnen we vaststellen dat NCCM overwegend 
een genetische cardiomyopathie is met een variabele presentatie. Omdat vroeg diagnostiek 
van (asymptomatische) familieleden belangrijk kan zijn is erfelijkheidsadvisering en -onderzoek 
voor de NCCM patiënten en hun familie nodig. In dit hoofdstuk wordt een stroomdiagram 
gepresenteerd voor de genetische en cardiologische diagnostiek in NCCM families en wordt 
besproken wat de voor- en nadelen van voorspellend onderzoek bij familieleden kunnen zijn en 
dat het van belang is dat de familie daarover ingelicht worden. 
 
Hoofdstuk 4 geeft de genetische classificatie van NCCM op basis van uitgebreide moleculaire 
studies Zeventien genen (MYH7, MYBPC3, TNNC1, TNNT2, TNNI3, ACTC1, MYL2, MYL3, 
TPM1, CSRP3, TCAP, LDB3, CASQ2, CALR3, PLN, TAZ en LMNA) werden volledig 
geanalyseerd in een cohort van 56 NCCM patiënten (48 volwassenen en acht kinderen). Deze 
genen coderen voor sarcomeer en Z-disk eiwitten, Calcium regulerende eiwitten en eiwitten die 
een functie hebben in de cellulaire matrix; al deze genen werden eerder al geassocieerd met 
(andere) genetische hartspierziekten. Negenentwintig mutaties, inclusief 21 nieuwe, werden 
geïdentificeerd in 23 (41%) van de onderzochte NCCM patiënten. Erfelijke veranderingen in het 
MYH7 gen waren de meest frequente genetische oorzaak voor NCCM en werden vastgesteld 
in 11 (20%) van alle geteste index patiënten en in 48% van de patiënten bij wie een mutatie 
werd vastgesteld. Mutaties in MYBPC3 werden in vier patiënten aangetoond (7%), TNNT2 in 
drie (5%), TPM1, CASQ2 en LDB3 elk in twee patiënten (4%) en TNNI3, ACTC1, PLN, TAZ, en 
LMNA elk in één patiënt (2%). Bij 35% van de volwassen patiënten werd een mutatie 
vastgesteld. Bij 75% van de kinderen werd een sarcomeer mutatie aangetoond. Mutaties die 
eerder geassocieerd werden met hartspierziekten (hetzij NCCM, hetzij HCM of DCM) werden 
als ziekteveroorzakend beschouwd. Nieuwe mutaties werden als ziekteveroorzakend 
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beschouwd wanneer ze tot een ingekort (truncerend) eiwit leiden of aanleiding geven tot 
veranderingen in de opbouw van het eiwit, wanneer ze de novo waren (nieuw ontstaan in de 
patiënt) of wanneer ze voldeden aan de volgende drie criteria: segregatie met het ziektebeeld 
binnen een familie, afwezigheid in een controle panel van 384 gezonde controle chromosomen 
en voorspeld pathogeen waren volgens predictie programma’s SIFT en PolyPhen. Achttien 
index patiënten hadden een enkele mutatie, in vijf patiënten werd een complex genotype 
aangetoond (meerder mutaties al dan niet in hetzelfde gen). De genen MYBPC3, TNNI3, 
TPM1, PLN en CASQ2 werden voor het eerst geassocieerd met NCCM. Deze resultaten laten 
zien dat NCCM voornamelijk een ziekte is die veroorzaakt wordt door veranderingen in 
sarcomeer eiwitten en daarmee behoort tot het spectrum sarcomeer - geassocieerde 
cardiomyopathieën waartoe ook een deel van de erfelijke vormen van HCM en DCM behoren. 
Tevens werd onderzocht of er een verschil is in prognose in families met een aangetoond gen 
defect en de families waarin (nog) geen erfelijke aanleg kon worden aangetoond. Hieruit bleek 
dat het ziektebeloop in families met een aangetoonde mutatie ongunstiger was. Concluderend 
kunnen we stellen dat de hoge mutatie frequentie in volwassenen en kinderen met NCCM het 
belang van moleculaire diagnostiek bij NCCM bevestigt. Het verdient aanbeveling om met het 
analyseren van de meest frequente oorzaak voor NCCM, het MYH7 gen, te beginnen. 
 
Hoofdstuk 5 beschrijft de eerste twee patiënten bij wie de diagnose MYH7-geassocieerde 
NCCM prenataal door middel van een echo werd vastgesteld. Prenataal echo onderzoek 
toonde biventriculaire cardiomegalie (vergroting van zowel de linker als de rechter hartkamer) 
en noncompaction bij een zwangerschapsduur van respectievelijk 31 en 23 weken. 
Aanvankelijk was niet bekend of er cardiomyopathie in de families voorkwam, hoewel bij een 
van de vaders op jonge leeftijd een aspecifieke hartaandoening werd vastgesteld, waarvoor hij 
sinds zijn 14e jaar uit cardiologische controle was ontslagen. Om te weten of de moeders een 
cardiomyopathie hadden, waarvoor bij de bevalling speciale maatregelen nodig zouden zijn, en 
om de oorzaak voor het optreden van de prenatale cardiomyopathie te vinden, werden de beide 
ouders cardiologisch onderzocht en werd er een DNA onderzoek bij de ouders verricht. Uit 
deze onderzoeken bleken dat in beide families een MYH7 cardiomyopathie voorkwam. 
Uitbreiding van het familieonderzoek toonde later aan dat er nog meer aangedane familieleden 
waren die veelal asymptomatisch waren. Vervolgonderzoek na de geboorte van de twee 
patiënten en een overzicht van de literatuur geven aan dat de prognose van prenataal 
vastgestelde NCCM voornamelijk afhankelijk is van de pompfunctie van het hart en dat deze na 
de geboorte kan verbeteren. We concluderen dat MYH7 mutaties zich prenataal kunnen 
presenteren met biventriculaire noncompaction cardiomyopathie. Daarom wordt prenataal echo 
onderzoek in zwangerschappen met een risico op MYH7-geassocieerde NCCM geadviseerd. 
Anderzijds is, aangezien familiaire ziekte zich initieel prenataal kan presenteren, DNA en 
cardiologisch onderzoek geïndiceerd van eerstegraads familieleden wanneer er bij een 
prenataal echo onderzoek NCCM wordt ontdekt, ook als de familieanamnese blanco is voor 
cardiomyopathie. 
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Momenteel wordt in ongeveer de helft van de familiaire vormen van NCCM geen gendefect 
aangetoond. In hoofdstuk 6 wordt een grote familie met een autosomaal dominant 
overervende cardiomyopathie beschreven die voornamelijk bestaat uit NCCM maar waar ook 
DCM is vastgesteld. Cardiologisch onderzoek van 20 familieleden uit deze Friese familie 
toonde negen patiënten aan met NCCM en één patiënt met DCM. Er werd geen erfelijke aanleg 
aangetoond in de 17 cardiomyopathie genen zoals beschreven in hoofdstuk 4. Om de 
genetische oorzaak voor NCCM / DCM in deze familie te identificeren werd een genoom-breed 
koppelingsonderzoek uitgevoerd met 300K SNP arrays. Aanvankelijk werd een maximale LOD 
score van 3.02 verkregen op chromosoom 4p15.3. De inclusie van de tiende patiënt die een 
gemeenschappelijke voorouder deelt met de index patiënt zeven generaties terug leidde tot de 
identificatie van een kleine kandidaat regio. Zo werd een nieuw gebied voor autosomaal 
dominante NCCM vastgesteld met een grootte van 5.47 Mb op chromosoom 4p15.3. Analyses 
ter identificatie van het nieuwe ziekte gen worden momenteel uitgevoerd. Identificatie van het 
gendefect maakt genetisch testen van familieleden binnen deze familie mogelijk en zal nieuwe 
inzichten in de ontstaanswijze van NCCM geven. 
 
Hoofdstuk 7 beschrijft de klinische, pathologische en moleculaire bevindingen van twee 
pasgeborenen met een structurele hartafwijking en NCCM. Deze twee patiënten hadden allebei 
twee verschillende mutaties in het MYBPC3 gen: de zogenaamde founder mutaties voor HCM, 
die in meer detail in de hoofdstukken 9 en 10 worden besproken. Eén van de patiënten had een 
ventrikel septum defect; de ander had een atrium septum defect. Een enkele erfelijke 
verandering in een gen dat codeert voor een sarcomeer eiwit (heterozygote mutatie) leidt 
meestal tot hypertrofische cardiomyopathie waarbij de klachten en klinische kenmerken zowel 
op kinderleeftijd als op volwassen leeftijd kunnen ontstaan. Twee dezelfde (homozygotie) of 
twee verschillende truncerende mutaties (compound heterozygotie) in het MYBPC3 gen 
kunnen ernstige cardiomyopathie met tekenen van noncompaction veroorzaken die zich op 
zeer jonge leeftijd (neonataal) presenteert.  
 
In hoofdstuk 8 wordt de ervaring van de cardiogenetica polikliniek van het Erasmus MC met 
het genetisch testen en cardiologisch onderzoek in HCM families beschreven. Een 
stroomdiagram voor het stellen van de klinische en genetische diagnose en het 
daaropvolgende familieonderzoek wordt gepresenteerd. In dit hoofdstuk wordt het belang van 
het identificeren van een autosomaal dominante erfelijke aanleg voor HCM besproken. Het 
vaststellen van een erfelijke aanleg maakt identificatie van familieleden die risico lopen mogelijk 
en faciliteert een effectieve screening van familieleden. Tevens worden de variabiliteit in het 
ziektebeeld, inclusief non-penetrantie, (hierbij heeft de erfelijke aanleg niet tot het ziektebeeld 
geleid) en het ontstaan van HCM op latere leeftijd en de consequenties daarvan voor het 
screenen besproken. Omdat een betrouwbare risico classificatie voor asymptomatische 
familieleden ontbreekt en HCM ook op latere leeftijd nog kan ontstaan is het van belang om 
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cardiologisch onderzoek periodiek te laten plaatsvinden, zowel voor mutatie dragers als voor 
familieleden van HCM patiënten bij wie geen pathogene mutatie kan worden vastgesteld.  
 
In eerdere studies werd beschreven dat bij mutaties in het sarcomeer gen Myosine Bindend 
Proteïne C gen (MYBPC3) HCM op latere leeftijd ontstaat en relatief mild kan verlopen. In 
hoofdstuk 9 worden de resultaten van moleculaire analyse van het MYBPC3 gen in 327 
Nederlandse HCM index patiënten beschreven. Bij 45% van de patiënten werd een verandering 
in het MYBPC3 gen aangetoond waaronder de al bekende c.2373dupG founder mutatie, in 
14,4% van de patiënten. Ook  werden twee nieuwe Nederlandse MYBPC3 founder mutaties 
geïdentificeerd: de p.Arg943X mutatie in 6,7% en de c.2864_2865delCT in 4,6% van de HCM 
patiënten. Het opnemen van de familiegeschiedenissen met de prognose en overleving in de 
families met deze drie founder mutaties toonde dat in 33%, 38% en 56% van de respectievelijk 
c.2373dupG, p.Arg943X en c.2864_2865delCT families de prognose slecht was. 
Overlevingscurves van deze drie truncerende founder mutaties waren nagenoeg identiek, 
suggererend dat er een vergelijkbaar natuurlijk beloop is dat waarschijnlijk veroorzaakt wordt 
door haplo-insufficiëntie (onvoldoende eiwit productie, met verlies van functie als gevolg). 
 
HCM erft vaak autosomaal dominant over er wordt voornamelijk veroorzaakt door mutaties in 
sarcomeer en Z-disk genen. Recentelijk werd HCM ook vastgesteld in families met X-gebonden 
spierziekten veroorzaakt door mutaties in het Z-disk gen, gelegen op het X-chromosoom, Four-
and-a-half-LIM domains 1 (FHL1). Deze bevindingen suggereren een rol voor het FHL1 gen in 
het ontstaan van HCM. Hoofdstuk 10 beschrijft de resultaten van onderzoek naar de rol van 
het FHL1 gen in HCM. Voor dat doel werd DNA analyse van het FHL1 gen in 86 HCM patiënten 
(54 mannen en 32 vrouwen) verricht. Deze patiënten werden geselecteerd uit een groep van 
260 HCM index patiënten omdat bij hen geen pathogene mutatie werd aangetoond in de HCM 
genen (MYH7, MYBPC3, TNNC1, TNNT2, TNNI3, ACTC1, MYL2, MYL3, TPM1, CSRP3 en 
TCAP). FHL1 mutaties werden vastgesteld in twee HCM patiënten; een nonsens mutatie 
(leidend tot een getrunceerd eiwit) in een vrouw die achteraf ook subtiele spierklachten had en 
bij wie een spierbioptie aspecifieke myopathische veranderingen aantoonde. De 
familiegeschiedenis van deze patiënte was positief voor plotse hartdood en HCM. Cardiologisch 
en neurologisch familieonderzoek toonde variabiliteit van symptomen en leeftijd waarop de 
klachten begonnen aan. Ook waren er dragers in de familie die (nog) geen HCM hadden. De 
andere patiënt, een man zonder neuromusculaire klachten, had een missense mutatie (een 
enkele aminozuurverandering in het eiwit). In de familie van de mannelijke HCM patiënt werd 
(nog) geen familie onderzoek verricht. De resultaten laten zien dat FHL1 mutaties een 
zeldzame oorzaak (<1%) van HCM zijn. FHL1 geassocieerde HCM wordt gekenmerkt door X-
gebonden dominante overerving. Analyse van het FHL1 gen wordt dan ook geadviseerd in 
zowel mannen als vrouwen met HCM, zeker wanneer de familie geschiedenis doet vermoeden 
dat de aandoening X-gebonden is (er is dan geen overerving van vader op zoon) en/of wanneer 
er neuromusculaire problemen in de familie voorkomen. Afwezigheid van een familie 
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geschiedenis van HCM of spierziekte sluit een FHL1 cardiomyopathie niet uit gezien de 
incomplete penetrantie van HCM en neuromusculaire klachten. Familie onderzoek wordt 
daarom ook aanbevolen bij deze geslachtsgebonden erfelijke vorm van HCM. 
 
Het verschil in ernst en in leeftijd waarop klachten optreden in HCM families is karakteristiek 
voor deze ziekte en de oorzaak hiervoor is onbekend. De hypothese is dat er naast de 
pathogene mutaties andere genetische of omgevingsinvloeden een rol spelen bij het optreden 
van HCM. Deze additionele risicofactoren zijn moeilijk te onderzoeken omdat de mutaties in de 
meeste families uniek zijn. Het vaak voorkomen van drie truncerende MYBPC3 founder 
mutaties in Nederland biedt de gelegenheid om in grotere genetisch homogene 
patiëntengroepen naar de modificerende risicofactoren onderzoek te doen. In hoofdstuk 11 
worden de resultaten van onderzoek naar het effect van additionele mutaties in sarcomeer 
genen op de ernst van het ziektebeeld bij dragers van een founder mutatie beschreven. Om te 
analyseren of een complex genotype een invloed heeft op de ernst van HCM werden negen 
sarcomeer genen (MYH7, MYBPC3, MYL2, MYL3, TNNT2, TNNI3, TNNC1, ACTC1 and TPM1) 
onderzocht in 87 HCM patiënten bij wie eerder een truncerende MYBPC3 founder mutatie als 
primair genetisch HCM defect werd vastgesteld. De HCM patiënten werden op grond van 
klinische kenmerken geclassificeerd in een mild of in een ernstig fenotype gebaseerd op leeftijd 
van diagnose, maximale wand dikte, obstructie van linker kamer uitstroombaan, een positieve 
familie geschiedenis voor plotse hartdood en de noodzaak voor een operatie of ablatie of het 
implanteren van een inwendige defibrillator. Wij vonden geen verschil in het aantal additionele 
mutaties in de groep met een ernstig ziektebeeld in vergelijking met de groep met een mild 
ziektebeeld. De ernst van het ziektebeeld in HCM patiënten met een truncerende MYBPC3 
mutatie wordt niet beïnvloed door een modificerend effect van een tweede sarcomeer mutatie. 
Andere, momenteel nog onbekende, genetische oorzaken van cardiomyopathie kunnen 
mogelijk de variabiliteit binnen de founder HCM populatie verklaren. 
 
In hoofdstuk 12 wordt de rol van aldosteron als modificerende factor in HCM onderzocht. In dit 
onderzoek werden de concentraties van cardiaal en / of plasma aldosteron vergeleken in 79 
HCM patiënten en in 12 orgaan donoren zonder cardiale pathologie. Ook werd het effect van 
het aldosteron synthase (CYP11B2) polymorfisme (een niet-pathogene variatie in het DNA) C-
344T op de linker kamer massa index (LVMI) en de dikte van het tussenschot tussen de 
hartkamers (intraventriculair septum of IVS) onderzocht. Het aldosteron in de harten en het 
plasma van acht HCM patiënten was vergelijkbaar met dat in de harten en plasma van de 
personen zonder cardiomyopathie. In vrouwen met HCM was er geen verband tussen het 
CYP11B2 genotype en de cardiomyopathie parameters. Mannelijke HCM patiënten met dit T 
allel hadden een hogere LVMI en een dikker tussenschot. Multipele regressie analyse toonde 
aan dat het T allel - gerelateerde effect op het tussenschot onafhankelijk was van renine, het 
ACE I/D polymorfisme, het AT1-receptor A/C1166 polymorfisme and the AT2-receptor A/C3123 
polymorfisme. Circulerend en cardiaal aldosteron zijn normaal in HCM, wat pleit tegen een 
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selectief verhoogde cardiale aldosteron productie in HCM patiënten. Het verband tussen het 
CYP11B2 C-344T polymorfisme en hypertrofie in HCM heeft waarschijnlijk te maken met de T 
allel - gerelateerde verhoging in circulerend aldosteron. Deze bevindingen geven de noodzaak 
aan van aanvullende studies naar de gunstige uitwerking van aldosteron blokkade als therapie 
in HCM patiënten. 
 
In de algemene discussie in hoofdstuk 13 worden de resultaten van dit proefschrift besproken 
en wordt aangegeven wat het belang is van de bevindingen en hoe ze in de praktijk te 
gebruiken zijn. NCCM en HCM zijn twee heterogene vormen van cardiomyopathie, met een 
gedeeltelijk overlappende genetische etiologie. In NCCM is het MYH7 gen het meest frequent 
gemuteerde gen. Daarom geldt het advies dit gen het eerst te analyseren. Aansluitend DNA 
onderzoek van de genen MYBPC3, TPM1, TNNT2, TNNI3, ACTC1, CASQ2, PLN, TAZ, LDB3 
en LMNA leidt tot het vinden van een erfelijke oorzaak voor NCCM in ongeveer 40% van de 
patiënten. Wat betreft HCM in Nederland wordt aanbevolen eerst de Nederlandse founder 
mutaties c.2373dupG, p.Arg943X en c.2864_2865delCT in het MYBPC3 gen te analyseren 
aangezien ongeveer 25% van de Nederlandse HCM populatie één van deze drie pathogene 
founder mutaties heeft. Indien deze analyse geen pathogene mutatie aantoont wordt 
aansluitend geadviseerd de rest van het MYBPC3 gen te onderzoeken, gevolgd door MYH7 en 
TNNT2. Screenen van additionele sarcomeer en Z-disk genen zal een uiteindelijke opbrengst 
leveren van ongeveer 60 tot 70%. Als de familiegeschiedenis past bij een X - gebonden 
overerving en / of wanneer er neuromusculaire ziekten in de familie voorkomen wordt 
geadviseerd het FHL1 gen te onderzoeken. 
Ongeveer de helft van NCCM en een derde van HCM kunnen momenteel nog niet moleculair 
verklaard worden. Identificatie van een pathogene mutatie in een familie maakt een 
nauwkeurige identificatie van familieleden die risico hebben op NCCM en / of HCM mogelijk. Bij 
personen die drager zijn van een pathogene mutatie of bij personen uit families met NCCM of 
HCM waarin geen genetisch defect kan worden vastgesteld, wordt periodiek cardiologisch 
onderzoek geadviseerd teneinde een eventuele cardiomyopathie tijdig te diagnosticeren en, 
indien noodzakelijk, te behandelen. Hiermee wordt getracht het risico op ernstige complicaties 
binnen cardiomyopathie families te verkleinen. 
Het ligt in de lijn van de verwachtingen dat er over niet al te lange tijd nieuwe cardiomyopathie 
genen zullen worden gevonden bijv. in andere dan tot nu toe onderzochte sarcomeer en Z-disk 
genen. Genen die betrokken zijn bij het ontstaan van DCM zouden ook een rol kunnen spelen 
in het ontstaan van NCCM en HCM. De snelle introductie van nieuwe moleculaire technieken, 
waarmee grote aantallen genen tegelijkertijd gescreend kunnen worden tegen relatief lage 
kosten zullen leiden tot het identificeren van nieuwe genetische defecten in NCCM en HCM, 
maar er zullen ook een heleboel varianten ontdekt worden waarvan de betekenis niet duidelijk 
is. Het zal een uitdaging zijn deze varianten te classificeren en erachter te komen welke 
pathways betrokken zijn bij het ontstaan van cardiomyopathieën. 
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ter 1: Figure 1 
 
NCCM gross pathology with a variety of NCCM patterns:                                                                      
 
A. Anastomosing broad trabeculae 
B. Coarse trabeculae resembling multiple papillary muscles 
C. Interlacing smaller muscle bundles resembling a sponge 
D. Trabeculae viewed en face 
E. Subtle NCCM on gross section, requires histological confirmation 
 
Reproduced with permission from “Left ventricular noncompaction: a pathological study of 14 cases; 
Burke et al; Human Pathology 2005;36;403-411” 
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 Chapter 1: Figure 2  
  
Histological features in NCCM:   
 The ratio of noncompact versus compact myocardium is larger 
than two.  
A. Relatively smooth endocardial surface (left) with 
anastomosing broad trabeculae  
 B. Polypoid pattern of trabeculae; prominent fibrous band 
separating the noncompact from the compact myocardium   
 Reproduced with permission from:  “Left ventricular 
noncompaction: a pathological study of 14 cases; Burke et al; 
Human Pathology 2005;36;403-411” 
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 Chapter 1: Figure 3  
  
 Human embryos at Carnegie stage 16 (A), stage 18 (B) 
and after closing of the embryonic interventricular 
foramen (C)  
  
During development there is an extensive trabecular layer 
forming the greater part of the ventricular wall thickness 
compared to the extent of the compact layer. The trabecular 
layer becomes compacted and forms the papillary muscles of 
the atrioventricular valves (*). 
 
 
 
  
 Reproduced with permission from: 
 “The morphological spectrum of ventricular noncompaction; 
Freedom et al; Cardiology in the Young 2005;15:345-364”  
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 Chapter 1: Figure 10  
  
HCM gross pathology (Source: univadis.nl)  
 
 
 
 
 
 
 278 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B
DC 
Chapter 1:  Figure 11  E  
Myocyte disarray in HCM 
Myocytes are arranged obliquely and perpen-
dicularly around foci of interstitial collagen in a: 
A. pinwheel or;  
B. herringbone pattern; 
C. increased interstitial fibrosis (Modified M
D. Hypertrop
asson’s); 
hy and distinct nuclear changes   
ia) 
rganization and intersecting of 
tain). 
(hypertrophy, pleomorphism and hyperchromas
of the myocytes;  
E. Myofibrillar diso
myofibrils within individual myocytes 
(Phosphotungstic acid haematoxylin s
Reproduced with permission from: “The pathology of hypertrophic cardiomyopathy; Hughes; 
Histopathology  
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Chapter 1: Figure 12  
 
Intramural coronary artery dysplasia in HCM 
 
There is marked medial hypertrophy and narrowing of the 
lumen of the intramural coronary arteries with associated 
myocardial fibrosis (Elastic van Gieson). 
 
Reproduced with permission from: 
“The pathology of hypertrophic cardiomyopathy; 
Hughes; Histopathology 2004; 44; 412-427.” 
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Chapter 2: Figure 2 
 
Schematic diagram showing 
chromosome 14 with the location 
of the MYH7 gene (14q12) 
  
Mutations were identified on one 
allele of the MYH7 gene in exons 11 
and 16/23 in families A and B 
respectively. Sequence traces show 
the mutations identified in families A 
and B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ActinAAS ELC Coiled-coilActin
p.Asp545Asn
p.Arg369Gln
p.Asp955Asn
p.Glu1350del p.Tyr1488Cys
p.Ala326Pro
p.Ile818Asn
p.Leu658Val p.Arg1925Gly
p.Leu301Gln
p.Tyr266X
p.Asn1918Lys
p.Asp239del
p.Arg281Thr
p.Arg1359Cys
p.Arg243His
p.Phe252Cys
p.Ala1766Thr
c.818+3G>C
c.818+1G>A
c.732+1G>A
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Chapter 4: Figure 2    
 Currently identified LVNC mutations in MYH7 
 The mutations identified in this study are in bold. AAS: ATPase active site; ELC:  myosin essential light 
chain binding site.  
 
Colour figures g 281
 
 
 
 
 
 
 
 
B A 
 
Chapter 5: Figure 2  
 
 Prenatal ultrasound of patient 1 at 31 weeks’ gestation  A. Enlarged heart with hypertrophic and spongy myocardium, particularly in the left apex (arrow).  
 B. Colour Doppler image of severe regurgitation over tricuspid and mitral valve.  
 C. Pulsed Doppler image of severe tricuspid regurgitation (> 200 cm/sec) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: Figure 5 
 
 Prenatal ultrasound of patient 2  A. Four-chamber view of the heart at 23 weeks’ gestation with increased apical myocardial thickness. 
Color Doppl B. er ultrasound of the apical right ventricular wall at 36 weeks’ gestation shows filling of 
C. ndicating decrease of cardiomegaly during gestation. 
the non-compacted myocardium.  
Graph of cardiothoracic (CT) ratio i 
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 Chapter 7: Figure 1 Histopathology A. Microscopic examination of postmortem heart muscle from patient 1. Hypertrophic myocytes with 
myofibrillar disarray typical of HCM due to sarcomeric protein mutations, was present, albeit without 
significant amount of interstitial fibrosis. 
 
 
B. Electron micrograph showing a large, irregular vacuole 
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Chapter 9: Figure 2 
 
Survival associated with truncating MYBPC3 mutations. 
Kaplan-Meier survival curves for a group of 117 patients from 26 c.2373dupG families, 50 patients from 
16 p.Arg943X families and 62 patients from 12 c.2864_2865delCT families. 
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Chapter 10: Figure 5  
 
Post-mortem microscopy of relative IV:2 of patient 1. 
 
Note the myocyte disarray, with oblique and sometimes perpendicular 
orientation of the cardiomyocytes, interstitial fibrosis and irregular, polymorphic 
and hyperchromatic nuclei. 
Chapter 10: Figure 1  
 
The 3d and 4th LIM domain showing the positions of the identified FHL1 mutations. 
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Chapter 13: Figure 1 
 
 
 
Hetero
s
geneity and overlap of disease-causing genes in HCM and NCCM and in neuromuscular a
yndromal disease.  
nd 
 
 Red displays sarcomere genes, blue Z-disc genes and green calcium-handling genes. ACTA1: α-Skeletal ACTC1: α-Cardiac actin; ACTN2: α-Actinin 2; AMPD1: Adenosine monophosphate deaminase 1; 
 
 
actin; 
ANKRD1: Cardiac ankyrin repeat protein; ARX: Aristaless-related homeobox; BRAF: V-RAF murine 
og B1; CALR3: Calreticulin; CASQ2: Calsequestrin; CAV3: Caveolin; 
: Cyclin-dependent kinase inhibitor 1C; CRYAB: α-B Crystallin; CSRP3: Cysteine and glycine 
DES: Desmin; DMD: Dystrophin; DMPK: Dystrophia myotonica protein kinase, DTNA: α-
strobrevin; EYA1: Eyes absent 1; FBN2: Fibrillin 2; FHL1: Four-an-a-half LIM domains; FLNA: Filamin 
sarcoma viral oncogene homol
 
 
CDKN1C
rich protein; 
Dy
 A; FXN: Frataxin; GPC3: Glypican 3; HCCS: Holocytochorme C synthase; HRAS: V-HA-RAS Harvey rat ncogene homolog; H19: H19 gene; JPH2: Junctophilin 2; KCNH2: Potassium channel, 
 H, member 2; KCNQ10T1: KCNQ1-overlapping transcript 1; KRAS: V-KI-RAS2 
LDB3: LIM domain-binding 3; LMNA: Lamin A/C; LMX1B: LIM 
x transcription factor 1; MEK1: Mitogen-activated potein kinase kinase 1; MEK2: Mitogen-
kinase kinase 2; MYBPC3: Cardiac myosin-binding protein C; MYH6: α-Myosin heavy 
MYH7: β-Myosin heavy chain; MYL2: Ventricular regulatory myosin light chain; MYL3: Ventricula
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NSD1: Nuclear receptor-binding Su-var, enhancer of zeste, and trithorax domain protein 1; PAHX: 
ytanoyl-CoA hydroxylase; PEX7: Peroxisome biogenesis factor 7; PLN: Phospholamban; PMP22: 
yelin protein 22; PTPN11: Protein-tyrosin phophatase, nonreceptor-type 11; RAF1: V-RAF-1 
SCN5A: Sodium channel, voltage-gated, type V, α-subunit; 
: Selenoprotein N1; SOS1: Son of sevenless, drosophila homolog 1; TAZ: Taffazin; TCAP: 
Telethonin; TNNC1: Cardiac troponin C; TNNI3: Cardiac troponin I; TNNT2: Cardiac troponin T; TPM1: α-
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Dankwoord 
Als ik iets geleerd heb tijdens mijn promotie onderzoek dan is het wel dat het leven vol 
uitdagingen zit. Grote uitdagingen en kleine uitdagingen… Zie hier mijn laatste uitdaging, het 
dankwoord, misschien wel het belangrijkste en mogelijk het meest gelezen deel van mijn 
proefschrift… 
 
Ten eerste wil ik alle patiënten en familieleden hartelijk danken voor hun medewerking en de 
getoonde interesse voor mijn onderzoek. Zonder u had dit proefschrift er niet gelegen. 
 
Dan mijn co-promotoren: Danielle Majoor – Krakauer en Dennis Dooijes. Beste Danielle, jouw 
grenzeloze inzet is van onschatbare waarde geweest, van de aanvraag voor de subsidie van de 
Hartstichting tot de laatste bladzijde van mijn proefschrift ben je ongelofelijk betrokken geweest. 
Bovendien heb je de structuur voor de cardiomyopathie counseling en het familieonderzoek 
vorm gegeven. Hartelijk dank voor al je inspanningen! Beste Dennis, je hebt de 
cardiogenetische DNA diagnostiek in Rotterdam op de kaart gezet. Dankzij jouw inspanningen 
was de uitgebreide diagnostiek van de cardiomyopathie patiënten mogelijk. Met je vertrek naar 
Utrecht heb je zo een grote nalatenschap in Rotterdam achtergelaten, waar niet alleen ik, maar 
het hele cardiogenetica team je dankbaar voor is. De discussies, onder andere over diagnostiek 
en etiologie, zijn uitermate leerzaam geweest voor mijn academische vorming. Dank voor al je 
hulp! 
 
Mijn promotoren: Prof.dr. Oostra, beste Ben, de begeleiding van de laatste loodjes was zeer 
waardevol. Ik heb bewondering voor de rust waarmee je me altijd onmiddellijk te woord stond in 
tijden van nood en ik wil je ook nog graag expliciet bedanken voor het vertrouwen dat alle 
deadlines daadwerkelijk gehaald zouden worden en dat mijn boekje op tijd af zou komen. 
Prof.dr. Simoons, beste Maarten, hartelijk dank voor uw tijd en het meegaan in de in uw ogen 
wellicht wat onorthodoxe manier van het afronden van mijn proefschrift. 
 
De leden van de leescommissie, Prof. van Langen, Dr. Balk en prof. Wilde. Beste Irene, Aggie 
en Arthur, maar liefst ruim een week voor de deadline kreeg ik bericht dat mijn proefschrift 
goedgekeurd was. Hartelijk dank voor deze snelle beslissing en de genomen moeite. 
 
Op één been kun je niet lopen… Zo heeft ook dit proefschrift twee benen (nee, geen poten), de 
afdelingen cardiologie en klinische genetica. 
 
Te beginnen met het linkerbeen, de cardiologie. Mijn onderzoek was niet mogelijk geweest 
zonder de inspanningen van de cardiologen met wie ik nauw samen gewerkt heb. Geachte Dr. 
ten Cate, beste Folkert, de huidige opzet van de cardiogenetica poli was nooit zonder u 
ontstaan. Met uw uitgebreide ervaring in de diagnostiek en behandeling van HCM is het Thorax 
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Centrum van het Erasmus MC een tertiair verwijs centrum voor HCM geworden, wat heeft 
geleid tot de grote huidige Rotterdamse HCM populatie. Beste Kadir Caliskan, ik kende je al 
vanuit je laatste jaar in opleiding, toen je me uitlegde hoe ik een ECG moest beoordelen. Het 
lijkt allemaal zo lang geleden… Zonder jouw verwijzingen waren er in ieder geval geen NCCM 
patiënten voor mij. Samen hebben we er toch maar een mooi cohort van gemaakt! Beste 
Michelle Michels, je bent altijd snel in je antwoord, altijd bereid om een CD-tje van elders te 
(her)beoordelen. Fijn dat je Kadir kon helpen met het zien van de vele NCCM familieleden en 
dank voor de snelle berichtgeving in Elpado en je inspanningen voor de modifier paper! Beste 
Tjebbe Galama, dank voor de ruimte die de klinische genetica op de poli kreeg. Jan Res, 
Agnes Muskens, Eric Sijbrands en Janneke Langendonk, zonder jullie is de cardiogenetica 
bespreking op vrijdag niet meer compleet! Eric, dank je wel voor je steun en interesse in mijn 
onderzoek en mijn presentaties. Alhoewel ik de cursus kritisch literatuur lezen helaas niet 
volledig heb kunnen volgen was het zeer waardevol. Prof. Roos – Hesselink, beste Jolien, dank 
voor je getoonde interesse in mijn onderzoek en voor de fijne samenwerking bij mijn niet - 
cardiomyopathie patiënten. Wim Vletter, hartelijk dank voor het maken van de vele echo’s. 
Kitty, altijd behulpzaam, dank voor het inplannen van alle patiënten. Celeste, bij afwezigheid 
van Kitty kon ik altijd bij jou terecht. De dames van de functie en de Holter afdeling: Cindy 
Macnack, Anouschka van Moorselaar, Irma den Adel, Conny de Ruiter, Istrelia Duijzer, 
Memento Almeida, Mariette Mijnlieff, Ramona Beversluis, Donna Bode, Lenne Stok – 
Hoogerwerf, Angela Peterse, Petra de Haan en Jeanette Steenhorst, hartelijk dank voor het 
bloed prikken, het afnemen van fietstesten en het aanhangen van Holters bij de vele 
cardiomyopathie patiënten en hun familieleden. Ook de dames achter de balie op de poli 
cardiologie: Corrie Scheepers, Rina de Kruijff, Anita van der Jagt, Henny Kroos, Hanneke van 
der Most, Miriam van der Hoeven, Conny Roos en Marianne Grauss, dank voor jullie 
hartelijkheid, gezelligheid en medeleven. Tijdens mijn jaar op de poli cardiologie heb ik lief en 
leed gedeeld met Susan Valk, Lucia Jewbali, Tabitha Valentijn, Natascha Rabatic, Raemon 
Baak, Jawed Polad en Chris van der Lee. Bedankt hiervoor! Hartfalenverpleegkundigen Ellen 
Klaassen en Ymkje Hendriksma, bedankt voor jullie blijvende interesse en voor jullie hulp in het 
“vangen van Kadir”. Ron van Domburg, hartelijk dank voor je hulp bij het last-minute statistiek 
werk! Beste Willeke van der Bent, mijn promotie moet een ware nachtmerrie voor je zijn 
geweest, zonder de gebruikelijke structuur van een cardiologische promotie. Tirza Springeling, 
bedankt voor het leveren van de plaatjes voor mijn kaft. 
 
Ook de kindercardiologen waren van groot belang in mijn onderzoek. Beste Ingrid Frohn – 
Mulder, Michiel Dalinghaus, Lennie van Osch – Gevers, Wim Helbing, Frederik du Plessis en 
(inmiddels overgestapt naar de congenitale poli bij de volwassenen) Maarten Witsenburg, dank 
voor het beoordelen van de kinderen die verwezen werden en dank voor het verwijzen van de 
kinderen bij wie als eerste in hun familie een NCCM werd vastgesteld. Ingrid en Michiel, 
hartelijk dank voor jullie tijd en hulp met het schrijven van de artikelen. Ingrid, je kwam er zelfs 
voor op je vrije woensdag naar het ziekenhuis, helemaal geweldig! 
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Daar ik zelf rechtsbenig ben, betreft het rechterbeen van mijn proefschrift de klinische genetica. 
Beste Fred Petrij, niet alleen vroeg je me regelmatig hoe het onderzoek ging, je vroeg ook hoe 
het met mij ging. Die vraag was zelden een overbodige luxe, dank voor je luisterend oor. Beste 
Anneke Maat – Kievit, ook van jouw kant regelmatig vragen van interesse, of alles volgens 
planning en naar wens liep. Dank ook voor de ruimte die ik kreeg sinds het begin van mijn 
opleiding voor het afronden van de “laatste loodjes”. Ook de andere stafleden wil ik graag 
bedanken voor hun begrip en steun, Jeanette Hoogeboom, Grazia Mancini, Marleen Simon, 
Alice Brooks, Margriet Collée, Anja Wagner, Rogier Oldenburg, Grétel Oudesluijs, Marieke van 
Dooren (je was zo trots toen ik de wetenschapsdag gewonnen had…), Marieke Joosten (ja, je 
staat nu ook in het rijtje bazen…), Robert-Jan Galjaard, Lutgarde Govaerts (dank voor je 
voortdurende interesse in mijn onderzoek) en natuurlijk Yolande van Bever, dank je voor de 
ruimte die je voor me hebt gecreëerd en dat je mijn mentor wilde zijn. Beste Marja Wessels, 
dank voor het meedenken en schrijven, ik heb de samenwerking altijd als prettig ervaren. Ingrid 
van de Laar, je had een belangrijke bijdrage in de eerste NCCM familie bij wie we een mutatie 
vonden, dank hiervoor! Fijn dat je na je opleiding als staflid aan de slag kon op de afdeling, je 
bent een aanwinst voor het cardiogenetica team! 
Ook de artsen op de afdeling wil ik graag bedanken voor hun steun en interesse. Beste Lieke 
Berger, Marije Meeuwissen, Renske Oegema, Laura van Loon, Danielle Bosch en Shimriet 
Zeidler, dank voor jullie betrokkenheid. Dan mijn kamergenoten, wat zou ik zonder jullie 
gemoeten hebben. Wanneer tot 10 tellen niet genoeg was leerden jullie me nog een keer tot 10 
te tellen. Beste Rogier Kersseboom, je bent de nodige Y-factor tussen al die X-factors… Beste 
Karin Diderich, tijdens je zwangerschapsverlof is het wel erg stil op onze kamer… Beste Judith 
Verhagen, ook jij bent een ware aanwinst voor het cardio-team, met jou kan ik lachen en 
huilen… Beste Anja Kattentidt, dank voor de gezelligheid in Liverpool en Bologna! En natuurlijk 
Esther de Theije – Kors, wat een krachtige vrouw ben jij! De hele afdeling put moed uit jouw 
positieve instelling. Ik blijf hopen op een medisch wonder… 
Inmiddels vertrokken maar tegelijk met mij begonnen in Rotterdam, Nienke Verbeek, je was 
een fijne collega, jammer dat je niet in Rotterdam bent gebleven! Ook Ingrid Krapels, met roots 
in Rotterdam, jij bent in Maastricht ook de cardio ingerold en dat heeft je geen windeieren 
gelegd! Dank je wel voor je interesse in mijn onderzoek. Eveneens vertrokken maar van vitaal 
belang geweest voor mijn carrière, Hanne Meijers – Heijboer, nu professor aan de VU in 
Amsterdam, je nam me aan voor de cardiogenetica, dank zij jou raakte de bal aan het rollen. 
Hartelijk dank hiervoor! 
Alle genetisch consulenten, Annemarieke Otto, Charlotte Castenmiller (je trouwjurk poll houdt 
de hele afdeling bezig), Desiree de Jongh, Ingrid van Kessel, José van Montfoort – Kroes, 
Judith Prins – Cornelisse, Lydia Overbeek en Margreethe van Vliet, dank voor jullie steun en 
interesse. Conny van de Meer, je hebt een hoop productie gedraaid in de cardiogenetica, het is 
fijn samenwerken met je! Judith Phefferkorn, hoe kan ik jou ooit genoeg bedanken! Je bent mijn 
steun en toeverlaat. Het lijkt wel gisteren dat je je in de cardio-wereld stortte, inmiddels ben je 
de spil van de cardiomyopathie counselingen geworden. In de loop van de jaren hebben we 
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een hoop meegemaakt met toch wel als hoogtepunt het congres in Florence, waar je de schrik 
van je leven kreeg toen ik je bij kaarslicht iets wilde vragen… …of je mijn paranimf wilde zijn! Je 
zei (natuurlijk) ja en daar ben ik erg blij mee. Dank je wel voor alles! 
Samantha Riedijk, super dat iedereen, patiënt en counselor, bij jou terecht kan! Je bent een 
enorme motivator en weet iedereen enthousiast te krijgen. Dank je wel voor wie je bent! 
Uiteraard vullen Prof. Tibben en Kathleen Vanheusden het psychologen team perfect aan. Aad, 
altijd de rust zelve en Kathleen, jammer dat je weggaat! 
Het datateam, Aart Leegwater, Anja Nieuwlaat, Mayra de Man en, inmiddels ook vertrokken, 
Sintyha Buddha. Wat een luxe dat jullie de cardio-stambomen maken en updaten. Anja, de 
database die je hebt gemaakt is van groot wetenschappelijk belang, hieruit kunnen we in de 
toekomst nog eindeloos putten! Sintyha, jammer dat je wegging, je inzet was reuze en het was 
altijd gezellig met jou! Aart, je bent altijd lekker snel met de stambomen, dank je wel hiervoor! 
Mayra, ik ga je kiprecept echt een keer uitproberen, waarschijnlijk als dit oeuvre dan eindelijk bij 
de drukker ligt… 
Beste Marlies Veldhuizen, Liesbeth Middelkoop – Joppe, Marjolijn de Jonge, Gisla Damrie, 
Isabel Abazie – van de Boogert, Wilma Verbrugh (dank je wel voor het bloedprikken bij de 
patiënten), Joke Kruithof – van de Bergen, Agnes Jansen – Spelt, Daphne ‘t Hart, Hellen de 
Bruin – van de Wende, Ruud Voorburg, Gulay Aydogan, Dilek Gönül – Sever en Elly 
Kranendonk, zonder jullie ligt de hele sectie counseling stil! Beste Gisla, altijd bereid toch nog 
even dat spoedje weg te werken, ik wil je graag hartelijk bedanken voor je inzet! Hans 
Blanksma, je bent al weer een tijdje bij ons weg, hopelijk heb je het naar je zin op je nieuwe 
plek. In ieder geval bedankt voor je hulp. De poli-dames, Corry van de Weegen – Pompstra en 
Serena Rosman, jullie maken het verschil op de Westzeedijk! Corry, je bent een ware 
moederkloek die haar weidse vleugels als een warme deken over de afdeling legt! Serena, ik 
heb bewondering voor jouw levensinstelling en kan alleen maar tegen je zeggen: “hand in 
hand, kameraden!!!” 
Ellen Crepin en Elisabeth Huijskens, op de Westzeedijk zaten we nog op dezelfde kamer, het 
was gezellig met jullie. Esther Buunk, ook jij bedankt voor je interesse. 
Marjoleine van Berckel Bik, wat een aardverschuiving toen jij wegging! Gelukkig ben je niet 
helemaal weg, hartelijk dank voor al je regelwerk op de afdeling. 
Technische ondersteuning is ook geen overbodige luxe op de afdeling, als de V-schijf er weer 
eens uit ligt of Thunderbird moeilijk doet. Om de een of andere reden lijkt dat vaker op een 
maandag voor te komen (is hier sprake van het “maandag-syndroom”?), maar Ton Verkerk, 
Mario Redeker en Pim Visser staan altijd klaar om het euvel te verhelpen. Dank hiervoor! En 
natuurlijk Tom de Vries Lentsch, ondanks je vele bezigheden vond je altijd de tijd om “nog 
even” een figuur voor me aan te passen of een poster of de kaft van dit proefschrift in elkaar te 
zetten. Je tips en hulp bij de lay-out van dit boekje waren heel welkom! Ruud Koppenol, dank 
voor je hulp bij het verwerken van alle foto’s, je geduld wordt zeer gewaardeerd! Ook wil ik 
graag de altijd vrolijke Jane Pique bedanken voor het schoonhouden van onze werkplekken, 
zelfs als heel schoonmakend Nederland staakt! 
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Naast (de omvangrijke) sectie counseling bestaat de afdeling klinische genetica natuurlijk ook 
uit de diagnostische laboratoria. Zonder DNA diagnostiek had ik niet zulke mooie resultaten 
behaald. Marjon van Slegtenhorst, fijn dat jij de cardio diagnostiek voor je rekening hebt 
genomen nadat Dennis wegging. Het is goed zaken doen met je (en ook altijd weer gezellig), je 
bent altijd zo snel in het antwoorden van je mail. Martina Wilke, als kamergenoot van Marjon 
moest je me vaak tolereren, sorry voor de vele onderbrekingen! Hetzelfde geldt voor Dr. Halley, 
beste Dicky, toen je nog met Dennis een kamer deelde op de 24e heb ik ook jou meerdere 
malen moeten storen. Dank je wel voor je geduld en voor je interesse. Beste Marianne van 
Tienhoven, gedeelde smart is halve smart! Dank je wel voor je altijd snelle reactie als ik 
overzichtsgegevens nodig had en bedankt voor je hulp met het maken van de figuren. Onze 
lunches zijn altijd om naar uit te kijken! Raoul van de Graaf, dank je wel voor je waardevolle 
hulp met de diagnostiek. Wilma Mouthaan, dank je wel voor je vrolijkheid en je 
behulpzaamheid, we zullen je allemaal missen. 
Ook op het research lab werd hard meegewerkt aan mijn proefschrift. Dear Aida Bertoli – 
Avella, thank you for all your time and patience and for our always enjoyable meetings. Lilian 
Parsaulian, thank you so much for your valuable work on the linkage study. Hetzelfde geldt 
uiteraard voor Christan Rohe, hartelijk dank! Beste Jeanette Lokker, hartelijk dank voor al je 
hulp rondom alle promotie bureaucratie! Het uitprinten van mijn proefschrift was een hele klus, 
dank hiervoor! 
 
Natuurlijk was er ook samenwerking met andere afdelingen. Beste Titia Cohen – Overbeek en 
Ernst Schoonderwaldt, dank voor jullie hulp, ik heb veel van jullie geleerd over prenatale 
cardiomyopathieën. René de Coo, dank voor je neurologische inzichten en de informatieve 
tramritjes. Joanne Verheij, veel dank voor je snelle hulp en de prachtige PA-plaatjes! Prof. 
Danser, beste Jan, dank voor je betrokkenheid. David Alexander, thank you for your 
inspirational course, I hope you will not be too disappointed by my writing… 
 
Cardiogenetisch Nederland is klein, maar stiekem groeit deze groep heel hard. Teveel mensen 
om allemaal apart te noemen, dus dank ik de hele ICIN werkgroep voor erfelijke hartziekten 
hartelijk. Elke vergadering is weer een bron van inspiratie. Een aantal mensen wil ik graag apart 
noemen. Uit Groningen: Peter van Tintelen en Rina Keupink hartelijk dank voor jullie 
enthousiasme en de bergen werk die jullie verzet hebben in de linkage studie! Ook Paul van 
Haelst verdient een zeer eervolle vermelding! Zonder jou had ik niet afgeweten van dat verre 
familielid! Uit Utrecht: Jasper van der Smagt, ook jij bent altijd enthousiast geweest over mijn 
onderzoek en stuurde patiënten in. Helaas werd je getroffen door een ernstige ziekte, veel 
sterkte in het herstel! Eveneens uit Utrecht: Bert Baars, dank voor het getoonde vertrouwen om 
mij een hoofdstuk te laten verzorgen in het cardiogenetica boek, ik ben erg benieuwd naar het 
totale resultaat. Uit Nijmegen: Carlo Marcelis, toen ik wegging uit Nijmegen gaf je me een heel 
pakket cardiogenetische literatuur mee, dat was mijn initiatie… Dank je wel! Uit Leiden: Anneke 
van Mil, die gezamenlijke familie die we hebben is helaas nog niet opgelost, maar we gaan 
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dapper verder! Uit Amsterdam: Imke Christiaans, jij mag een dag voor mijn verdediging de hete 
kastanjes vast uit het vuur halen. Veel succes met jouw verdediging! Wanda Hermans – van 
Ast, dank voor je hulp met de ICIN adressen! 
 
Dan zijn we nu aangekomen bij het hart van mijn dankwoord. Het is maar goed dat het 
promoveren zelf niet door een medisch-ethische commissie getoetst hoeft te worden. Gezien 
de sociale deprivatie die kenmerkend is voor het leven van een promovendus zou het 
promoveren al gauw verboden worden… Bij deze dan ook eerst mijn welgemeende excuses 
aan familie en vrienden voordat ik met mijn dankwoord verder ga… 
 
Lieve Eddy, wat heb je allemaal moeten doorstaan? Ik heb je tot wanhoop en zelfs tot (letterlijk) 
koken gedreven (het was heel goed te eten, misschien voor herhaling vatbaar?)… Ik ben je 
ongelofelijk dankbaar voor je steun, voor het geven van perspectief en voor je nuchtere kijk op 
de wetenschappelijke wereld. Dat je zoveel tijd hebt gestoken in de lay-out van mijn boekje 
geeft duidelijk je betrokkenheid aan. Te quiero mucho, met jou wil ik oud en rimpelig worden! 
 
Lieve pap en mam, mijn dankbaarheid is eindeloos. Voor jullie stimulatie, steun en begrip, voor 
jullie medeleven en meedenken. Niet alleen in mijn promotie traject, maar in mijn hele leven. 
Voor wie jullie zijn, voor wat jullie van mij gemaakt hebben (zowel nature als nurture…) en voor 
wat jullie allemaal voor mij gedaan hebben. Jullie zijn er altijd voor me geweest, ik kan altijd op 
jullie rekenen. Miljoenen schapen (nee, dat is niet overdreven…) zijn onvoldoende om mijn 
liefde en dankbaarheid uit te drukken! 
 
Lieve Lilian, mijn grote zus… Dank je wel voor je andere kijk, voor je betrokkenheid en voor je 
zeer rustgevende massages! Je betekent veel voor mij! En samen met Stefan heb je toch maar 
even twee prachtige meiden op de wereld gezet. Lieve Sara en Eva, ik zie jullie veel te weinig 
naar mijn zin, maar geniet met volle teugen van elke keer. Hoogste tijd voor een nieuw dagje 
Rotterdam met jullie! 
 
Lieve Miriam. Mijn jongste zusje… mijn paranimf (je moet toch wat bij gebrek aan behoefte aan 
een ceremoniemeester…). Je bent geweldig! Zo sterk, zo kordaat. Hoogzwanger met een man 
uitgezonden naar Afghanistan, petje af! Don, dank je wel dat je uit de buurt van de 
bermbommen bent gebleven en heelhuids terug kwam! Ook jullie hebben samen voor een 
prachtige uitbreiding van de familie gezorgd. Lieve Nynke, je bent nog klein maar het is nu al 
alsof je er altijd al was. Je glimlach is er een uit duizenden! Jou de fles geven was een zegen in 
hectische tijden… 
 
Lieve Mariska, beste Peter. Wat een geluk dat jullie onze buren zijn. Maris, je bent altijd erg 
betrokken geweest. Dank je wel voor je meedenken en voor je luisterend oor en natuurlijk voor 
je paella! 
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Bao Chau en Louis, Judith en Koen en Hilde en Robert, dank je wel voor jullie begrip. Ik ben 
ernstig in gebreke gebleven maar kom zeker alsnog op kraambezoek! 
 
Elly en Jork en Karin en Erik, dank jullie voor jullie interesse en steun. Elly en Jork, bedankt 
voor de MSN-sessies, altijd net op het moment dat ik het nodig had! Karin, je ging me voor… 
Als eerste in onze generatie van de familie promoveerde je. Dank je wel voor het delen van je 
ervaringen. 
 
Dan is het nu tijd om het humane achter me te laten en nog een paar speciale exemplaren uit 
het dierenrijk te bedanken… Guusje, als ik jou aai daalt mijn bloeddruk spontaan! Je voorliefde 
voor riet is op zijn zachtst gezegd vreemd te noemen maar wel uiterst vermakelijk! Sukke, je 
bent zo lekker zacht, en met je geklets maak je er een vrolijke boel van. Ondanks jullie voorkeur 
voor mijn toetsenbord kan ik me geen andere katten wensen. Fokke, ik mis je… En wie het 
kleine niet eert… ook de eendjes in de sloot wil ik graag bedanken. Voor de welkome rust die 
jullie me gaven als ik jullie hele broden toe wierp. 
 
Toch nog even terug naar de mensenwereld, last but not least: Eduard Douwes Dekker. Zelfs je 
pseudoniem is mooi, Multatuli. Uitkijkend over de van Oldenbarneveltstraat in het centrum van 
Rotterdam, hebben zijn wijze woorden mij zeer aangesproken: “Van de maan af gezien zijn we 
allen even groot”. Woorden die ik zowel letterlijk als figuurlijk heb geïnterpreteerd en waar een 
grote troostende waarde vanuit gaat. 
 
 
